U.S. patent application number 16/968899 was filed with the patent office on 2022-01-13 for novel cas9 orthologs.
This patent application is currently assigned to PIONEER HI-BRED INTERNATIONAL, INC.. The applicant listed for this patent is PIONEER HI-BRED INTERNATIONAL, INC.. Invention is credited to GIEDRIUS GASIUNAS, ZHENGLIN HOU, VIRGINIJUS SIKSNYS, JOSHUA K YOUNG.
Application Number | 20220010293 16/968899 |
Document ID | / |
Family ID | |
Filed Date | 2022-01-13 |
United States Patent
Application |
20220010293 |
Kind Code |
A1 |
HOU; ZHENGLIN ; et
al. |
January 13, 2022 |
NOVEL CAS9 ORTHOLOGS
Abstract
Compositions and methods are provided for novel Cas9 orthologs,
including, but not limiting to, novel guide polynucleotide/Cas9
endonucleases complexes, single or dual guide RNAs, guide RNA
elements, and Cas9 endonucleases. The present disclosure also
describes methods for creating a double strand break in a target
polynucleotide, methods for genome modification of a target
sequence under various in vivo and in vitro conditions, in the
genome of a cell, for gene editing, and for inserting a
polynucleotide of interest into the genome of a cell. Also provided
are nucleic acid constructs and cells having a modified target site
or altered polynucleotide of interest produced by the methods
described herein.
Inventors: |
HOU; ZHENGLIN; (ANKENY,
IA) ; YOUNG; JOSHUA K; (JOHNSTON, IA) ;
GASIUNAS; GIEDRIUS; (VILNIUS, LT) ; SIKSNYS;
VIRGINIJUS; (VILNIUS, LT) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
PIONEER HI-BRED INTERNATIONAL, INC. |
JOHNSTON |
IA |
US |
|
|
Assignee: |
PIONEER HI-BRED INTERNATIONAL,
INC.
JOHNSTON
IA
|
Appl. No.: |
16/968899 |
Filed: |
February 22, 2019 |
PCT Filed: |
February 22, 2019 |
PCT NO: |
PCT/US19/19086 |
371 Date: |
August 11, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62634257 |
Feb 23, 2018 |
|
|
|
62651991 |
Apr 3, 2018 |
|
|
|
International
Class: |
C12N 9/22 20060101
C12N009/22; C12N 15/11 20060101 C12N015/11; C12N 15/90 20060101
C12N015/90; C12N 15/10 20060101 C12N015/10; C12N 9/78 20060101
C12N009/78 |
Claims
1. A synthetic composition comprising a heterologous component and
a Cas endonuclease, wherein the Cas endonuclease comprises at least
one amino acid feature selected from the group consisting of: (a)
Isoleucine (I) at position 13, (b) Isoleucine (I) at position 21,
(c) Leucine (L) at position 71, (d) Leucine (L) at position 149,
(e) Serine (S) at position 150, (f) Leucine (L) at position 444,
(g) Threonine (T) at position 445, (h) Proline (P) at position 503,
(i) F (Phenylalanine) at position 587, (j) A (Alanine) at position
620, (k) L (Leucine) at position 623, (l) T (Threonine) at position
624, (m) I (Isoleucine) at position 632, (n) Q (Glutamine) at
position 692, (o) L (Leucine) at position 702, (p) I (Isoleucine)
at position 781, (q) K (Lysine) at position 810, (r) L (Leucine) at
position 908, (s) V (Valine) at position 931, (t) N/Q (Asparagine
or Glutamine) at position 933, (u) K (Lysine) at position 954, (v)
V (Valine) at position 955, (w) K (Lysine) at position 1000, (x) V
(Valine) at position 1100, (y) Y (Tyrosine) at position 1232, and
(z) I (Isoleucine) at position 1236; wherein the position numbers
are determined by sequence alignment against SEQID NO: 1125.
2. The synthetic composition of claim 1, wherein the Cas
endonuclease shares at least 90% identity with a sequence selected
from the group consisting of: SEQID NOs:86-170 and 511-1135.
3. The synthetic composition of claim 1, wherein the Cas
endonuclease comprises a domain sharing 90% or greater identity
with any of SEQID NOs: 1136-1730.
4. The synthetic composition of claim 1, wherein the Cas
endonuclease is fused to a heterologous polypeptide.
5. The synthetic composition of claim 4, wherein the heterologous
polypeptide comprises nuclease activity.
6. The synthetic composition of claim 4, wherein the heterologous
polypeptide is a deaminase.
7. The synthetic composition of claim 1, further comprising a guide
polynucleotide with which the polypeptide forms a complex.
8. The synthetic composition of claim 2, wherein the guide
polynucleotide is a single guide comprising a sequence selected
from the group consisting of SEQID NOs: 426-510.
9. The synthetic composition of claim 2, wherein the guide
polynucleotide comprises a tracrRNA comprising a sequence selected
from the group consisting of SEQID NOs: 341-425.
10. The synthetic composition of claim 2, wherein the guide
polynucleotide comprises a crRNA comprising a sequence selected
from the group consisting of SEQID NOs: 171-255.
11. The synthetic composition of claim 2, wherein the guide
polynucleotide comprises an anti-repeat sequence comprising a
sequence selected from the group consisting of SEQID NOs:
256-340.
12. The synthetic composition of claim 2, wherein the guide
polynucleotide guide comprises DNA.
13. The synthetic composition of claim 1 that selectively
hybridizes with a PAM sequence consensus listed in Tables 4-83.
14. A Cas endonuclease or deactivated Cas endonuclease that
recognizes a PAM selected from the group consisting of: NAR
(G>A)WH (A>T>C)GN (C>T>R), N (C>D)V (A>S)R
(G>A)TTTN (T>V), NV (A>G>C)TTTTT, NATTTTT, NN
(H>G)AAAN (G>A>Y)N, N (T>V)NAAATN, NAV
(A>G>C)TCNN, NN (A>S>T)NN (W>G>C)CCN (Y>R),
NNAH (T>M)ACN, NGTGANN, NARN (A>K>C)ATN, NV
(G>A>C)RNTTN, NN (A>B)RN (A>G>T>C)CCN, NN
(A>B)NN (T>V)CCH (A>Y), NNN (H>G)NCDAA, NN (H>G)D
(A>K)GGDN (A>B), NNNNCCAG, NNNNCTAA, NNNNCVGANN, N
(C>D)NNTCCN, NNNNCTA, NNNNCYAA, NAGRGNY, NNGH (W>C)AAA,
NNGAAAN, NNAAAAA, NTGAR (G>A)N(A>Y>G)N(Y>R), N
(C>D)H (C>W)GH (Y>A)N(A>B)AN(A>T>S), NNAAACN,
NNGTAM (A>C)Y, NH (A>Y)ARNN (C>W>G)N, B
(C>K)GGN(A>Y>G)N NN, N (T>C>R)AGAN (A>K>C)NN,
NGGN (A>T>G>C)NNN, NGGD (A>T>G)TNN,
NGGAN(T>A>C>G)NN, CGGWN (T>R>C)NN, NGGWGNN, N
(B>A)GGNN (T>V)NN, NNGD (A>T>G)AY (T>C)N, N
(T>V)H(T>C>A)AAAAN, NRTAANN, N (H>G)CAAH
(Y>A)N(Y>R)N, NATAAN (A>T>S)N, NV (A>G>C)R
(A>G)ACCN, CN (C>W>G)AV (A>S)GAC, NNRNCAC, N(A>B)GGD
(W>G)D (G>W)NN, BGD (G>W)GTCN(A>K>C), NAANACN,
NRTHAN(A>B)N, BHN (H>G)NGN(T>M)H(Y>A),
NMRN(A>Y>G)AH(C>T>A)N, NNNCACN, NARN(T>A>S)ACN,
NNNNATW, NGCNGCN, NNNCATN, NAGNGCN, NARN(T>M>G)CCN, NATCCTN,
NRTAAN(T>A>S)N, N(C>T>G>A)AAD (A>G>T)CNN,
NAAAGNN, NNGACNN, N(T>V)NTAAD (A>T>G)N, NNGAD (G>W)NN,
NGGN(W>S)NNN, N(T>V)GGD(W>G)GNN,
NGGD(A>T>G)N(T>M>G)NN, NNAAAGN,
N(G>H)GGDN(T>M>G)NN, NNAGAAA, NN(T>M>G)AAAAA,
N(C>D)N(C>W>G)GW(T>C)D(A>G>T)AA, NAAAAYN,
NRGNNNN, NATGN (H>G)TN, NNDATTT, and
NATARCN(C>T>A>G).
15. The synthetic composition of claim 1 that is identified from an
organism listed in Table 1.
16. The synthetic composition of claim 1, selected from the group
consisting of SEQID NOs: 86-170.
17. The synthetic composition of claim 1, wherein the target
cell-optimized polypeptide lacks endonuclease activity.
18. The synthetic composition of claim 1, wherein the target
cell-optimized polypeptide is capable of nicking a single stranded
target polynucleotide.
19. The synthetic composition of claim 1, wherein the target
cell-optimized polypeptide is capable of cleaving a double stranded
target polynucleotide.
20. The synthetic composition of claim 1, further comprising a
donor DNA molecule.
21. The synthetic composition of claim 1, further comprising repair
template DNA molecule.
22. The synthetic composition of claim 1, wherein the heterologous
composition is selected from the group consisting of: a
heterologous polynucleotide, a heterologous polypeptide, a
particle, a solid matrix, an antibody, a buffer composition, Tris,
EDTA, dithiothreitol (DTT), phosphate-buffered saline (PBS), sodium
chloride, magnesium chloride, HEPES, glycerol, bovine serum albumin
(BSA), a salt, an emulsifier, a detergent, a chelating agent, a
redox reagent, an antibody, nuclease-free water, a viscosity agent,
and a Histidine tag.
23. The synthetic composition of claim 22, further comprising an
additional heterologous composition.
24. The synthetic composition of claim 1, further comprising a
cell.
25. The synthetic composition of claim 24, wherein the cell is
obtained or derived from an organism selected from the group
consisting of: human, non-human primate, mammal, animal, archaeal,
bacterial, protist, fungal, insect, yeast, non-conventional yeast,
and plant.
26. The synthetic composition of claim 25, wherein the plant cell
is obtained or derived from maize, rice, sorghum, rye, barley,
wheat, millet, oats, sugarcane, turfgrass, switchgrass, soybean,
canola, alfalfa, sunflower, cotton, tobacco, peanut, potato,
tobacco, Arabidopsis, vegetable, or safflower.
27. The synthetic composition of claim 25, wherein the animal cell
is selected from the group consisting of: haploid cells, diploid
cells, reproductive cells, neurons, muscle cells, endocrine or
exocrine cells, epithelial cells, muscle cells, tumor cells,
embryonic cells, hematopoietic cells, bone cells, germ cells,
somatic cells, stem cells, pluripotent stem cells, induced
pluripotent stem cells, progenitor cells, meiotic cells, and
mitotic cells.
28. A polynucleotide encoding the polypeptide of claim 1.
29. The polynucleotide of claim 28, wherein in the polynucleotide
is comprised within a vector that further comprises at least one
heterologous polynucleotide.
30. A kit comprising the synthetic composition of claim 1 or the
polynucleotide of claim 28.
31. The synthetic composition of claim 1, wherein the polypeptide
is in a liquid formulation.
32. The synthetic composition of claim 1, wherein the polypeptide
is in a lyophilized composition.
33. The synthetic composition of claim 1, wherein the polypeptide
is in a substantially endotoxin-free formulation.
34. The synthetic composition of claim 1, wherein the polypeptide
is in a formulation with a pH of between 1.0 and 14.0, between 2.0
and 13.0, between 3.0 and 12.0, between 4.0 and 11.0, between 5.0
and 10.0, between 6.0 and 9.0, between 7.0 and 8.0, between 4.5 and
6.5, between 5.5 and 7.5, or between 6.5 and 7.5.
35. The synthetic composition of claim 1, wherein the polypeptide
is stored or incubated at a temperature of at least minus 200
degrees Celsius, at least minus 150 degrees Celsius, at least minus
135 degrees Celsius, at least minus 90 degrees Celsius, at least
minus 80 degrees Celsius, at least minus 20 degrees Celsius, at
least 4 degrees Celsius, at least 17 degrees Celsius, at least 20
degrees Celsius, at least 25 degrees Celsius, at least 30 degrees
Celsius, at least 35 degrees Celsius, at least 37 degrees Celsius,
at least 39 degrees Celsius, at least 40 degrees Celsius, at least
45 degrees Celsius, at least 50 degrees Celsius, at least 55
degrees Celsius, at least 60 degrees Celsius, at least 65 degrees
Celsius, at least 70 degrees Celsius, or greater than 70 degrees
Celsius.
36. The synthetic composition of claim 1, wherein the polypeptide
is attached to a solid matrix.
37. The synthetic composition of claim 36, wherein the solid matrix
is a particle.
38. A method of detecting a target polynucleotide sequence,
comprising: (a) obtaining the target polynucleotide, (b) combining
a Cas endonuclease, a guide polynucleotide, and said target
polynucleotide in a reaction vessel, (c) incubating the components
of step (b) at a temperature of at least 10 degrees Celsius for at
least 1 minute, (d) sequencing the resulting polynucleotide(s) in
the reaction mixture, and (e) characterizing the sequence of the
target polynucleotide of step (a) that was identified by the Cas
endonuclease and the guide polynucleotide; (f) wherein said guide
polynucleotide comprises a polynucleotide sequence that is
substantially complementary to the sequence of the target
polynucleotide; wherein the Cas endonuclease comprises at least one
amino acid feature selected from the group consisting of: (i)
Isoleucine (I) at position 13, (ii) Isoleucine (I) at position 21,
(iii) Leucine (L) at position 71, (iv) Leucine (L) at position 149,
(v) Serine (S) at position 150, (vi) Leucine (L) at position 444,
(vii) Threonine (T) at position 445, (viii) Proline (P) at position
503, (ix) F (Phenylalanine) at position 587, (x) A (Alanine) at
position 620, (xi) L (Leucine) at position 623, (xii) T (Threonine)
at position 624, (xiii) I (Isoleucine) at position 632, (xiv) Q
(Glutamine) at position 692, (xv) L (Leucine) at position 702,
(xvi) I (Isoleucine) at position 781, (xvii) K (Lysine) at position
810, (xviii) L (Leucine) at position 908, (xix) V (Valine) at
position 931, (xx) N/Q (Asparagine or Glutamine) at position 933,
(xxi) K (Lysine) at position 954, (xxii) V (Valine) at position
955, (xxiii) K (Lysine) at position 1000, (xxiv) V (Valine) at
position 1100, (xxv) Y (Tyrosine) at position 1232, and (xxvi) I
(Isoleucine) at position 1236; wherein the position numbers are
determined by sequence alignment against SEQID NO: 1125.
39. A method of binding a Cas endonuclease and guide polynucleotide
complex to a target polynucleotide, comprising: (a) obtaining the
sequence of said target polynucleotide, (b) combining a Cas
endonuclease, a guide polynucleotide, and said target
polynucleotide in a reaction vessel, (c) incubating the components
of step (b) at a temperature of at least 10 degrees Celsius for at
least 1 minute; wherein said guide polynucleotide comprises a
polynucleotide sequence that is substantially complementary to the
target polynucleotide sequence of the target polynucleotide;
further comprising detecting the Cas endonuclease and guide
polynucleotide complex bound to the target polynucleotide; and
wherein the Cas endonuclease comprises at least one amino acid
feature selected from the group consisting of: (i) Isoleucine (I)
at position 13, (ii) Isoleucine (I) at position 21, (iii) Leucine
(L) at position 71, (iv) Leucine (L) at position 149, (v) Serine
(S) at position 150, (vi) Leucine (L) at position 444, (vii)
Threonine (T) at position 445, (viii) Proline (P) at position 503,
(ix) F (Phenylalanine) at position 587, (x) A (Alanine) at position
620, (xi) L (Leucine) at position 623, (xii) T (Threonine) at
position 624, (xiii) I (Isoleucine) at position 632, (xiv) Q
(Glutamine) at position 692, (xv) L (Leucine) at position 702,
(xvi) I (Isoleucine) at position 781, (xvii) K (Lysine) at position
810, (xviii) L (Leucine) at position 908, (xix) V (Valine) at
position 931, (xx) N/Q (Asparagine or Glutamine) at position 933,
(xxi) K (Lysine) at position 954, (xxii) V (Valine) at position
955, (xxiii) K (Lysine) at position 1000, (xxiv) V (Valine) at
position 1100, (xxv) Y (Tyrosine) at position 1232, and (xxvi) I
(Isoleucine) at position 1236; wherein the position numbers are
determined by sequence alignment against SEQID NO: 1125.
40. A method of creating a double strand break in a target
polynucleotide, comprising: (a) obtaining the sequence of said
target polynucleotide, (b) combining a Cas endonuclease
polypeptide, a guide polynucleotide, and said target polynucleotide
in a reaction vessel, (c) incubating the components of step (b) at
a temperature of at least 10 degrees Celsius for at least 1 minute;
wherein said guide polynucleotide comprises a polynucleotide
sequence that is substantially complementary to the target
polynucleotide sequence of the target polynucleotide; further
comprising detecting the Cas endonuclease and guide polynucleotide
complex bound to the target polynucleotide; and wherein the Cas
endonuclease comprises at least one amino acid feature selected
from the group consisting of: (i) Isoleucine (I) at position 13,
(ii) Isoleucine (I) at position 21, (iii) Leucine (L) at position
71, (iv) Leucine (L) at position 149, (v) Serine (S) at position
150, (vi) Leucine (L) at position 444, (vii) Threonine (T) at
position 445, (viii) Proline (P) at position 503, (ix) F
(Phenylalanine) at position 587, (x) A (Alanine) at position 620,
(xi) L (Leucine) at position 623, (xii) T (Threonine) at position
624, (xiii) I (Isoleucine) at position 632, (xiv) Q (Glutamine) at
position 692, (xv) L (Leucine) at position 702, (xvi) I
(Isoleucine) at position 781, (xvii) K (Lysine) at position 810,
(xviii) L (Leucine) at position 908, (xix) V (Valine) at position
931, (xx) N/Q (Asparagine or Glutamine) at position 933, (xxi) K
(Lysine) at position 954, (xxii) V (Valine) at position 955,
(xxiii) K (Lysine) at position 1000, (xxiv) V (Valine) at position
1100, (xxv) Y (Tyrosine) at position 1232, and (xxvi) I
(Isoleucine) at position 1236; wherein the position numbers are
determined by sequence alignment against SEQID NO: 1125.
41. The method of claim 39 or claim 40, further comprising at least
one additional target site.
42. A method for editing the genome of a cell, the method
comprising providing to the cell: (a) at least one Cas endonuclease
comprises at least one amino acid feature selected from the group
consisting of: (i) Isoleucine (I) at position 13, (ii) Isoleucine
(I) at position 21, (iii) Leucine (L) at position 71, (iv) Leucine
(L) at position 149, (v) Serine (S) at position 150, (vi) Leucine
(L) at position 444, (vii) Threonine (T) at position 445, (viii)
Proline (P) at position 503, (ix) F (Phenylalanine) at position
587, (x) A (Alanine) at position 620, (xi) L (Leucine) at position
623, (xii) T (Threonine) at position 624, (xiii) I (Isoleucine) at
position 632, (xiv) Q (Glutamine) at position 692, (xv) L (Leucine)
at position 702, (xvi) I (Isoleucine) at position 781, (xvii) K
(Lysine) at position 810, (xviii) L (Leucine) at position 908,
(xix) V (Valine) at position 931, (xx) N/Q (Asparagine or
Glutamine) at position 933, (xxi) K (Lysine) at position 954,
(xxii) V (Valine) at position 955, (xxiii) K (Lysine) at position
1000, (xxiv) V (Valine) at position 1100, (xxv) Y (Tyrosine) at
position 1232, and (xxvi) I (Isoleucine) at position 1236; wherein
the position numbers are determined by sequence alignment against
SEQID NO: 1125; and (b) a guide polynucleotide with which the Cas
endonuclease forms a complex; wherein the complex is capable of
recognizing, binding to, and optionally nicking or cleaving a
target polynucleotide sequence; and identifying at least one cell
that has a modification in a genomic DNA sequence of the cell,
wherein the modification is selected from the group consisting of:
an insertion, a deletion, a substitution, and the addition or
association of an atom or molecule to an existing nucleotide.
43. A method of modulating the expression of a gene in a cell, the
method comprising providing to the cell: (a) at least one Cas
endonuclease comprises at least one amino acid feature selected
from the group consisting of: (i) Isoleucine (I) at position 13,
(ii) Isoleucine (I) at position 21, (iii) Leucine (L) at position
71, (iv) Leucine (L) at position 149, (v) Serine (S) at position
150, (vi) Leucine (L) at position 444, (vii) Threonine (T) at
position 445, (viii) Proline (P) at position 503, (ix) F
(Phenylalanine) at position 587, (x) A (Alanine) at position 620,
(xi) L (Leucine) at position 623, (xii) T (Threonine) at position
624, (xiii) I (Isoleucine) at position 632, (xiv) Q (Glutamine) at
position 692, (xv) L (Leucine) at position 702, (xvi) I
(Isoleucine) at position 781, (xvii) K (Lysine) at position 810,
(xviii) L (Leucine) at position 908, (xix) V (Valine) at position
931, (xx) N/Q (Asparagine or Glutamine) at position 933, (xxi) K
(Lysine) at position 954, (xxii) V (Valine) at position 955,
(xxiii) K (Lysine) at position 1000, (xxiv) V (Valine) at position
1100, (xxv) Y (Tyrosine) at position 1232, and (xxvi) I
(Isoleucine) at position 1236; wherein the position numbers are
determined by sequence alignment against SEQID NO: 1125, and (b) a
guide polynucleotide with which the Cas endonuclease forms a
complex; wherein the complex is capable of recognizing, binding to,
and optionally nicking or cleaving a target polynucleotide sequence
in the cell; and identifying at least one cell that has a modulated
gene expression as compared to a cell that did not have the Cas
endonuclease introduced.
44. The method of claim 42 or claim 43, further comprising
providing to the cell a donor DNA molecule.
45. The method of claim 42 or claim 43, further comprising
providing to the cell a template DNA molecule.
46. The method of claim 42 or claim 43, wherein the method confers
a benefit to the cell or to an organism that comprises the
cell.
47. The method of claim 41, wherein the benefit is selected from
the group consisting of: improved health, improved growth, improved
fertility, improved fecundity, improved environmental tolerance,
improved vigor, improved disease resistance, improved disease
tolerance, improved tolerance to a heterologous molecule, improved
fitness, improved physical characteristic, greater mass, increased
production of a biochemical molecule, decreased production of a
biochemical molecule, upregulation of a gene, downregulation of a
gene, upregulation of a biochemical pathway, downregulation of a
biochemical pathway, stimulation of cell reproduction, and
suppression of cell reproduction.
48. The method of claim 42 or claim 43, wherein the cell is
heterologous to the organism from which the Cas endonuclease was
derived, and is selected from the group consisting of: a human,
non-human primate, mammal, animal, archaeal, bacterial, protist,
fungal, insect, yeast, non-conventional yeast, and plant cell.
49. The method of claim 48, wherein the plant cell is obtained or
derived from maize, rice, sorghum, rye, barley, wheat, millet,
oats, sugarcane, turfgrass, switchgrass, soybean, canola, alfalfa,
sunflower, cotton, tobacco, peanut, potato, tobacco, Arabidopsis,
vegetable, or safflower.
50. The method of claim 48, wherein the cell is a plant cell, and
the benefit is the modulation of a trait of agronomic interest of a
plant comprising said cell or a progeny cell thereof, selected from
the group consisting of: disease resistance, drought tolerance,
heat tolerance, cold tolerance, salinity tolerance, metal
tolerance, herbicide tolerance, improved water use efficiency,
improved nitrogen utilization, improved nitrogen fixation, pest
resistance, herbivore resistance, pathogen resistance, yield
improvement, health enhancement, improved fertility, vigor
improvement, growth improvement, photosynthetic capability
improvement, nutrition enhancement, altered protein content,
altered oil content, increased biomass, increased shoot length,
increased root length, improved root architecture, modulation of a
metabolite, modulation of the proteome, increased seed weight,
altered seed carbohydrate composition, altered seed oil
composition, altered seed protein composition, altered seed
nutrient composition; as compared to an isoline plant not
comprising said target site modification or as compared to the
plant prior to the modification of said target site in said plant
cell.
51. The method of claim 48, wherein the animal cell is selected
from the group consisting of: haploid cells, diploid cells,
reproductive cells, neurons, muscle cells, endocrine or exocrine
cells, epithelial cells, muscle cells, tumor cells, embryonic
cells, hematopoietic cells, bone cells, germ cells, somatic cells,
stem cells, pluripotent stem cells, induced pluripotent stem cells,
progenitor cells, meiotic cells, and mitotic cells.
52. The method of claim 48, wherein the cell is an animal cell, and
the benefit is the modulation of a phenotype of physiological
interest of an organism comprising the animal cell, or a progeny
cell thereof, selected from the group consisting of: improved
health, improved nutritional status, reduced disease impact,
disease stasis, disease reversal, improved fertility, improved
vigor, improved mental capacity, improved organism growth, improved
weight gain, weight loss, modulation of an endocrine system,
modulation of an exocrine system, reduced tumor size, reduced tumor
mass, stimulated cell growth, reduced cell growth, production of a
metabolite, production of a hormone, production of an immune cell,
and stimulation of cell production.
53. A method of editing at least one base of a target
polynucleotide, comprising: (a) contacting the target
polynucleotide with: i. a deaminase, ii. a Cas endonuclease capable
of selective hybridization with a PAM sequence consensus listed in
Tables 4-83, wherein the Cas endonuclease has been modified to lack
nuclease activity, and iii. a guide polynucleotide that shares
complementarity with a sequence of the target polynucleotide,
wherein the Cas endonuclease and the guide RNA form a complex that
recognizes and binds to the target polynucleotide; and (b)
detecting at least one modification at the DNA target site.
54. A method of editing a plurality of bases of a target
polynucleotide, comprising: (a) contacting the target
polynucleotide with: i. at least one deaminase, ii. a plurality of
Cas endonucleases, each capable of selective hybridization with a
PAM sequence consensus listed in Tables 4-83, wherein the Cas
endonucleases have been modified to lack nuclease activity, and
iii. a guide polynucleotide that shares complementarity with a
sequence of the target polynucleotide, wherein the Cas endonuclease
and the guide RNA form a complex that recognizes and binds to the
target polynucleotide; and (b) detecting at least one modification
at the DNA target site.
55. A method of optimizing the activity of a Cas molecule
comprising introducing at least one nucleotide modification to a
sequence that comprises at least one amino acid feature selected
from the group consisting of: (a) Isoleucine (I) at position 13,
(b) Isoleucine (I) at position 21, (c) Leucine (L) at position 71,
(d) Leucine (L) at position 149, (e) Serine (S) at position 150,
(f) Leucine (L) at position 444, (g) Threonine (T) at position 445,
(h) Proline (P) at position 503, (i) F (Phenylalanine) at position
587, (j) A (Alanine) at position 620, (k) L (Leucine) at position
623, (l) T (Threonine) at position 624, (m) I (Isoleucine) at
position 632, (n) Q (Glutamine) at position 692, (o) L (Leucine) at
position 702, (p) I (Isoleucine) at position 781, (q) K (Lysine) at
position 810, (r) L (Leucine) at position 908, (s) V (Valine) at
position 931, (t) N/Q (Asparagine or Glutamine) at position 933,
(u) K (Lysine) at position 954, (v) V (Valine) at position 955, (w)
K (Lysine) at position 1000, (x) V (Valine) at position 1100, (y) Y
(Tyrosine) at position 1232, and (z) I (Isoleucine) at position
1236; wherein the position numbers are determined by sequence
alignment against SEQID NO: 1125; and identifying at least one
improved characteristic as compared to the molecule prior to
nucleotide modification.
56. A method of optimizing the activity of a Cas9 molecule by
subjecting a parental Cas9 molecule to at least one round of
stochastic protein shuffling, and selecting a resultant molecule
that has at least one characteristic not present in the parental
Cas9 molecule; wherein the parental Cas9 molecule comprises at
least one amino acid feature selected from the group consisting of:
(a) Isoleucine (I) at position 13, (b) Isoleucine (I) at position
21, (c) Leucine (L) at position 71, (d) Leucine (L) at position
149, (e) Serine (S) at position 150, (f) Leucine (L) at position
444, (g) Threonine (T) at position 445, (h) Proline (P) at position
503, (i) F (Phenylalanine) at position 587, (j) A (Alanine) at
position 620, (k) L (Leucine) at position 623, (l) T (Threonine) at
position 624, (m) I (Isoleucine) at position 632, (n) Q (Glutamine)
at position 692, (o) L (Leucine) at position 702, (p) I
(Isoleucine) at position 781, (q) K (Lysine) at position 810, (r) L
(Leucine) at position 908, (s) V (Valine) at position 931, (t) N/Q
(Asparagine or Glutamine) at position 933, (u) K (Lysine) at
position 954, (v) V (Valine) at position 955, (w) K (Lysine) at
position 1000, (x) V (Valine) at position 1100, (y) Y (Tyrosine) at
position 1232, and (z) I (Isoleucine) at position 1236; wherein the
position numbers are determined by sequence alignment against SEQID
NO: 1125.
57. A method of optimizing the activity of a Cas9 molecule by
subjecting a parental Cas9 molecule to at least one round of
non-stochastic protein shuffling, and selecting a resultant
molecule that has at least one characteristic not present in the
parental Cas9 molecule; wherein the parental Cas9 molecule
comprises a motif selected from the group consisting of comprises
at least one amino acid feature selected from the group consisting
of: (a) Isoleucine (I) at position 13, (b) Isoleucine (I) at
position 21, (c) Leucine (L) at position 71, (d) Leucine (L) at
position 149, (e) Serine (S) at position 150, (f) Leucine (L) at
position 444, (g) Threonine (T) at position 445, (h) Proline (P) at
position 503, (i) F (Phenylalanine) at position 587, (j) A
(Alanine) at position 620, (k) L (Leucine) at position 623, (l) T
(Threonine) at position 624, (m) I (Isoleucine) at position 632,
(n) Q (Glutamine) at position 692, (o) L (Leucine) at position 702,
(p) I (Isoleucine) at position 781, (q) K (Lysine) at position 810,
(r) L (Leucine) at position 908, (s) V (Valine) at position 931,
(t) N/Q (Asparagine or Glutamine) at position 933, (u) K (Lysine)
at position 954, (v) V (Valine) at position 955, (w) K (Lysine) at
position 1000, (x) V (Valine) at position 1100, (y) Y (Tyrosine) at
position 1232, and (z) I (Isoleucine) at position 1236; wherein the
position numbers are determined by sequence alignment against SEQID
NO: 1125.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a 371 National Stage Entry of PCT Patent
Application No. PCT/US2019/019086 filed on 23 Feb. 2019, which
claims the benefit of U.S. Provisional Application No. 62/634,257
filed on 23 Feb. 2018 and of U.S. Provisional Application No.
62/651,991 filed on 3 Apr. 2018, all of which are incorporated by
reference herein in their entirety.
FIELD OF THE INVENTION
[0002] The disclosure relates to the field of molecular biology, in
particular to compositions of guide polynucleotide/endonuclease
systems, and compositions and methods for modifying a
polynucleotide sequence, including the genome of a cell.
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[0003] The official copy of the sequence listing is submitted
electronically via EFS-Web as an ASCII formatted sequence listing
with a file named RTS26814AUSPCT_SequenceListing_ST25.txt created
on 4 Jun. 2020 and having a size of 8663 KB and is filed
concurrently with the specification. The sequence listing comprised
in this ASCII formatted document is part of the specification and
is herein incorporated by reference in its entirety.
BACKGROUND
[0004] Recombinant DNA technology has made it possible to insert
DNA sequences at targeted genomic locations and/or modify specific
endogenous chromosomal sequences. Site-specific integration
techniques, which employ site-specific recombination systems, as
well as other types of recombination technologies, have been used
to generate targeted insertions of genes of interest in a variety
of organism. Genome-editing techniques such as zinc finger
nucleases (ZFNs), transcription activator-like effector nucleases
(TALENs), or homing meganucleases, are available for producing
targeted genome perturbations, but these systems tend to have low
specificity and employ nucleases that need to be redesigned for
each target site, which renders them costly and time-consuming to
prepare.
[0005] Newer technologies utilizing archaeal or bacterial adaptive
immunity systems have been identified, called CRISPR (Clustered
Regularly Interspaced Short Palindromic Repeats), which comprise
different domains of effector proteins that encompass a variety of
activities (DNA recognition, binding, and optionally cleavage).
[0006] Despite the identification and characterization of some of
these systems, there remains a need for identifying novel effectors
and systems, as well as demonstrating activity in eukaryotes,
particularly animals and plants, to effect editing of endogenous
and previously-introduced heterologous polynucleotides, as well as
in vitro polynucleotide binding and/or modification. Most CRISPR
gene editing is based almost entirely the Cas9 system derived from
Streptococcus pyogenes (Barrangou and Doudna, 2016), which leaves a
blunt-end overhang and effects gene editing via the recognition of
a Protospacer Adjacent Motif (PAM) sequence of "NGG" on the target
polynucleotide. A greater diversity of Cas9 proteins with different
biophysical and biochemical characteristics, including different
PAM recognition sequences, is desirable.
SUMMARY
[0007] Compositions and methods are provided for novel Cas
polynucleotides and cas polypeptides.
[0008] In some aspects, the invention provides a synthetic
composition comprising a heterologous component and a
polynucleotide selected from the group consisting of: a
polynucleotide sharing at least 80%, between 80% and 85%, at least
85%, between 85% and 90%, at least 90%, between 90% and 95%, at
least 95%, at least 96%, at least 97%, at least 98%, at least 99%,
at least 99.5%, or greater than 99.5% identity with at least 50,
between 50 and 100, at least 100, between 100 and 150, at least
150, between 150 and 200, at least 200, between 200 and 250, at
least 250, between 250 and 300, at least 300, between 300 and 350,
at least 350, between 350 and 400, at least 400, between 400 and
450, at least 500, between 500 and 550, at least 550, between 550
and 600, at least 600, between 600 and 650, at least 650, between
650 and 700, at least 700, between 700 and 750, at least 750,
between 750 and 800, at least 800, between 800 and 850, at least
850, between 850 and 900, at least 900, between 900 and 950, at
least 950, between 950 and 1000, at least 1000, or even than 1000
contiguous nucleotides of any of: SEQID NO:1-85, a functional
variant of any of SEQID NO:1-85, a functional fragment of any of
SEQID NO:1-85, a gene encoding a Cas endonuclease selected from the
group consisting of: SEQID NO:86-171 and 511-1135, a gene encoding
a Cas endonuclease that recognizes a PAM sequence listed in any of
Tables 4-83, and a gene encoding a Cas endonuclease identified,
derived, or isolated from an organism selected from the group
consisting of Acetobacter aceti, Acetobacter sp. CAG:977,
Acholeplasma palmae, Acidaminococcus sp.,
Acidaminococcus_intestini_RyC-MR95, Acidothermus cellulolyticus,
Acidovorax avenae, Acidovorax ebreus, Acidovorax sp. MR-S7,
Actinobacillus capsulatus, Actinobacillus minor, Actinobacillus
succinogenes, Actinobacillus suis, Actinomyces coleocanis,
Actinomyces georgiae, Actinomyces meyeri, Actinomyces naeslundii,
Actinomyces odontolyticus, Actinomyces sp. ICM47, Actinomyces sp.
oral taxon 175, Actinomyces sp. oral taxon 180, Actinomyces sp.
oral taxon 181, Actinomyces sp. oral taxon 848, Actinomyces sp.
S6-Spd3, Afipia sp. P52-10, Akkermansia muciniphila, Alcanivorax
pacificus, Alicycliphilus, Alicyclobacillus hesperidum,
Aliiarcobacter faecis, Alistipes ihumii, Alistipes shahii,
Alkaliflexus imshenetskii, Alloprevotella tannerae, Alloscardovia
omnicolens, alpha proteobacterium AAP38, alpha proteobacterium
AAP81b, Anaerococcus tetradius, Anaeromusa acidaminophila,
Anoxybacillus sp. P3H1B, Aquabacterium parvum, Asinibacterium sp.
or53, Azospirillum halopraeferens, Azospirillum sp. B510, Bacillus
cereus, Bacillus cytotoxicus, Bacillus niameyensis, Bacillus
okhensis, Bacillus pseudalcaliphilus, Bacillus smithii, bacterium
BRH c32, bacterium LF-3, bacterium P3, Bacteroidales bacterium CF,
Bacteroides, Bacteroides coprophilus, Bacteroides coprosuis,
Bacteroides faecis, Bacteroides fluxus, Bacteroides fragilis,
Bacteroides pectinophilus, Bacteroides propionicifaciens,
Bacteroides pyogenes, Bacteroides sp. 14(A), Bacteroides
timonensis, Bacteroides vulgatus, Bacteroidetes oral taxon 274,
Barnesiella viscericola, Bdellovibrio exovorus, Belliella baltica,
Bibersteinia trehalosi, Bifidobacterium angulatum, Bifidobacterium
bifidum, Bifidobacterium bombi, Bifidobacterium callitrichos,
Bifidobacterium longum, Bifidobacterium merycicum, Bifidobacterium
thermophilum, Bifidobacterium tsurumiense, Blastopirellula marina,
Bordetella pseudohinzii, Brevibacillus laterosporus, Bryobacter
aggregatus, Burkholderiales bacterium GJ-E10, Butyrivibrio
hungatei, Butyrivibrio sp. AC2005, Butyrivibrio sp. NC3005,
Caenispirillum salinarum, Campylobacter coli, Campylobacter jejuni,
Campylobacter peloridis, Campylobacter subantarcticus, candidate
division TA06 bacterium 32_111, Candidatus Brocadia sinica,
Candidatus hepatoplasma crinochetorum Av, Candidatus micropelagos
thuwalensis, Candidatus symbiothrix dinenymphae, Capnocytophaga
canis, Capnocytophaga cynodegmi, Capnocytophaga ochracea,
Capnocytophaga sp. CM59, Capnocytophaga sp. oral taxon 329,
Carnobacterium funditum, Carnobacterium gallinarum, Carnobacterium
sp. ZWU0011, Caviibacter abscessus, Chitinophagaceae bacterium
PMP191F, Chlamydia trachomatis, Chlorobi bacterium NICIL-2,
Chryseobacterium gallinarum, Chryseobacterium indologenes,
Chryseobacterium sp. CF314, Chryseobacterium sp. ERMR1:04,
Chryseobacterium sp. FH2, Chryseobacterium sp. Hurlbut01,
Chryseobacterium sp. Leaf201, Chryseobacterium sp. Leaf394,
Chryseobacterium sp. StRB126, Chryseobacterium sp. YR485,
Chryseobacterium tenax, Cloacibacillus evryensis, Clostridium
beijerinckii, Clostridium botulinum, Clostridium perfringens,
Clostridium sp. CAG:230, Clostridium sp. CAG:433, Clostridium
spiroforme, Collinsella sp. CAG:289, Comamonadaceae bacterium
CCH4-05, Comamonas granuli, Coprobacter fastidiosus, Coprobacter
secundus, Coprococcus catus GD/7, Coriobacteriales bacterium
DNF00809, Coriobacterium glomerans, Coriobacterium_glomerans_PW2,
Corynebacterium, Corynebacterium accolens, Corynebacterium
camporealensis, Corynebacterium caspium, Corynebacterium
diphtherias, Corynebacterium falsenii, Corynebacterium lactis,
Corynebacterium pseudodiphtheriticum, Corynebacterium vitaeruminis,
Croceitalea dokdonensis, Cytophagales bacterium B6, Dechloromonas
denitrificans, Defluviimonas, Demequina sediminicola, Desulfovibrio
termitidis, Devosia sp. Root635, Dielma fastidiosa, Dinoroseobacter
shibae, Dorea longicatena, Dysgonomonas sp. HGC4, Eggerthella sp.
YY7918, Eggerthella sp. YY7918, Eggerthellaceae bacterium AT8,
Elizabethkingia anophelis, Elizabethkingia meningoseptica,
Elusimicrobium minutum, Empedobacter brevis, Empedobacter falsenii,
Endomicrobium proavitum, Enterococcus canis, Enterococcus cecorum,
Enterococcus dispar, Enterococcus faecalis, Enterococcus faecalis
OG1RF, Enterococcus faecium, Enterococcus hirae, Enterococcus
italicus, Enterococcus massiliensis, Enterococcus mundtii,
Enterococcus phoeniculicola, Enterococcus pseudoavium, Enterococcus
thailandicus, Environmental metagenome, Eubacterium dolichum,
Eubacterium ramulus, Eubacterium rectale, Eubacterium sp.,
Eubacterium sp. CAG:251, Eubacterium ventriosum, Eubacterium yurii
subsp. margaretiae ATCC 43715, Facklamia hominis, Fibrobacter
succinogenes, Filifactor alocis, Finegoldia magna, Finegoldia magna
ATCC 29328, Firmicutes bacterium M10-2, Flavobacterium
akiainvivens, Flavobacterium branchiophilum, Flavobacterium
columnare, Flavobacterium daejeonense, Flavobacterium filum,
Flavobacterium frigidarium, Flavobacterium psychrophilum,
Flavobacterium sp. 83, Flavobacterium sp. ACAM 123, Flavobacterium
sp. TAB 87, Flavobacterium suncheonense, Fluviicola taffensis,
Francisella hispaniensis, Francisella philomiragia, Francisella
tularensis, Fructobacillus ficulneus, Fructobacillus fructosus,
Fructobacillus sp. EFB-N1, Fusobacterium necrophorum, Fusobacterium
nucleatum, Fusobacterium periodonticum, Galbibacter marinus,
Gallibacterium anatis, gamma proteobacterium HdN1, gamma
proteobacterium HTCC5015, Gardnerella vaginalis, Gemella bergeri,
Gemella cuniculi, Gemella haemolysans, Geobacillus sp.,
Globicatella sanguinis, Gluconacetobacter diazotrophicus,
Gordonibacter pamelaeae, Granulicatella, Haemophilus, Haemophilus
parainfluenzae, Haemophilus sputorum, Helcococcus sueciensis,
Helicobacter apodemus, Helicobacter canadensis, Helicobacter
cinaedi, Helicobacter fennelliae, Helicobacter muridarum,
Helicobacter mustelae, Helicobacter pametensis, Helicobacter
rodentium, Helicobacter typhlonius, Hugenholtzia roseola,
Hyphomonas, Ignavibacterium album, Ilyobacter polytropus,
Indibacter alkaliphilus, Jejuia pallidilutea, Jeotgalibaca
dankookensis, Joostella marina, Kandleria vitulina, Kingella
kingae, Kiritimatiella glycovorans, Kordia algicida, Kordia
jejudonensis, Kurthia huakuii, Lachnobacterium bovis, Lachnospira
multipara, Lachnospiraceae bacterium AC2029, Lachnospiraceae
bacterium MA2020, Lachnospiraceae bacterium NK4A179, Lacinutrix
jangbogonensis, Lactobacillus, Lactobacillus acidifarinae,
Lactobacillus agilis, Lactobacillus animalis, Lactobacillus
animalis KCTC 3501, Lactobacillus apodemi, Lactobacillus brevis,
Lactobacillus buchneri, Lactobacillus cacaonum, Lactobacillus
casei, Lactobacillus ceti, Lactobacillus ceti DSM 22408,
Lactobacillus composti, Lactobacillus concavus, Lactobacillus
coryniformis, Lactobacillus curvatus, Lactobacillus delbrueckii,
Lactobacillus diolivorans, Lactobacillus farciminis, Lactobacillus
fermentum, Lactobacillus floricola, Lactobacillus florum,
Lactobacillus fuchuensis, Lactobacillus futsaii, Lactobacillus
gastricus, Lactobacillus gorillae, Lactobacillus graminis,
Lactobacillus hammesii, Lactobacillus heilongjiangensis,
Lactobacillus hordei, Lactobacillus finers, Lactobacillus jensenii,
Lactobacillus kefiri, Lactobacillus kunkeei, Lactobacillus
lindneri, Lactobacillus mali, Lactobacillus melliventris,
Lactobacillus mindensis, Lactobacillus mucosae, Lactobacillus
namurensis, Lactobacillus nodensis, Lactobacillus oligofermentans,
Lactobacillus otakiensis, Lactobacillus ozensis, Lactobacillus
paracasei, Lactobacillus paracollinoides, Lactobacillus
paragasseri, Lactobacillus pentosus, Lactobacillus plantarum,
Lactobacillus psittaci, Lactobacillus rennini, Lactobacillus
reuteri, Lactobacillus rhamnosus, Lactobacillus rossiae,
Lactobacillus ruminis, Lactobacillus saerimneri, Lactobacillus
sakei, Lactobacillus salivarius, Lactobacillus sanfranciscensis,
Lactobacillus saniviri, Lactobacillus senmaizukei, Lactobacillus
shenzhenensis, Lactobacillus sp., Lactobacillus sp. wkB8,
Lactobacillus tucceti, Lactobacillus versmoldensis, Lactobacillus
wasatchensis, Lactobacillus zymae, Lactobacillus_rhamnosus_LOCK900,
Lagierella massiliensis, Lawsonella clevelandensis, Legionella
pneumophila, Leptotrichia sp. oral taxon 215, Leuconostoc gelidum,
Limnohabitans planktonicus, Listeria fleischmannii, Listeria
ivanovii, Listeria monocytogenes, Listeria monocytogenes Lm_1880,
Listeria seeligeri, Lunatimonas lonarensis, Lutibacter profundi,
Mannheimia, Mannheimia massilioguelmaensis, Mannheimia sp.
USDA-ARS-USMARC-1261, Massilibacterium senegalense, Megasphaera sp.
UPII 135-E, Mesorhizobium sp., Mesorhizobium sp. LC103,
Methylocystis sp. ATCC 49242, Methylophilus sp. 5, Methylophilus
sp. OH31, Methylosinus, Methylovulum miyakonense, Mobiluncus
curtisii, Mucilaginibacter paludis, Mucinivorans hirudinis,
Mucispirillum schaedleri, Mycoplasma arginini, Mycoplasma canis,
Mycoplasma dispar, Mycoplasma gallisepticum, Mycoplasma
hyosynoviae, Mycoplasma mobile, Mycoplasma ovipneumoniae,
Mycoplasma synoviae, Mycoplasma_gallisepticum_CA06, Myroides
odoratus, Necropsobacter massiliensis, Neisseria arctica, Neisseria
bacilliformis, Neisseria meningitidis, Neisseria sp., Neisseria sp.
74A18, Neisseria wadsworthii, Niabella soli, Nitratifractor
salsuginis, Nitrosomonas sp. AL212, Novosphingobium sp. MD-1,
Oceanivirga salmonicida, Oceanobacillus manasiensis, Odoribacter
laneus, Oenococcus kitaharae DSM 17330, Oligella urethralis,
Olsenella profusa, Olsenella sp. DNF00959, Olsenella uli,
Ornithobacterium rhinotracheale, Ottowia sp. oral taxon 894,
Pannonibacter phragmitetus, Parabacteroides johnsonii DSM 18315,
Parabacteroides sp., Parabacteroides sp. D26, Parasutterella
excrementihominis, Parvibaculum lavamentivorans, Parvimonas sp.
KA00067, Pasteurella multocida, Pediococcus acidilactici,
Pediococcus damnosus, Pediococcus inopinatus, Pediococcus parvulus,
Pediococcus pentosaceus, Pediococcus stilesii, Pedobacter
glucosidilyticus, Pelomonas sp. Root1237, Peptoniphilus duerdenii,
Peptoniphilus obesi, Peptoniphilus sp. oral taxon 386,
Peptostreptococcus anaerobius CAG: 621, Phascolarctobacterium
succinatutens, Planococcus antarcticus, Porphyromonas catoniae,
Porphyromonas gingivalis, Porphyromonas somerae, Porphyromonas sp.
oral taxon 278, Prevotella amnii, Prevotella aurantiaca, Prevotella
baroniae, Prevotella bivia, Prevotella buccalis, Prevotella
corporis, Prevotella denticola, Prevotella disiens, Prevotella
histicola, Prevotella intermedia, Prevotella loescheii, Prevotella
melaninogenica, Prevotella nanceiensis, Prevotella nigrescens,
Prevotella orails, Prevotella pleuritidis, Prevotella ruminicola,
Prevotella saccharolytica, Prevotella sp. C561, Prevotella sp.
DNF00663, Prevotella sp. HJM029, Prevotella sp. HUN102, Prevotella
sp. MSX73, Prevotella sp. oral taxon 306, Prevotella sp. oral taxon
317, Prevotella sp. P5-119, Prevotella stercorea, Propionimicrobium
lymphophilum, Pseudaminobacter salicylatoxidans, Pseudomonas
aeruginosa, Pseudomonas lini, Psychroflexus torquis, Psychroserpens
sp. Hel_I_66, Ralstonia solanacearum, Rhodobacteraceae bacterium
HLUCCA08, Rhodobacteraceae bacterium HLUCCA12, Rhodospirillum
rubrum, Rhodovulum sp. PH10, Riemerella anatipestifer, Rikenella
microfusus, Rikenellaceae sp., Rodentibacter pneumotropicus,
Roseburia intestinalis, Roseburia sp. CAG:197, Rothia aeria, Rothia
dentocariosa, Rothia mucilaginosa, Rubritepida flocculans,
Rugosibacter aromaticivorans, Ruminiclostridium cellulolyticum,
Ruminococcus albus, Ruminococcus flavefaciens, Ruminococcus
lactaris, Saccharibacter sp. AM169, Salegentibacter sp. Hel_I_6,
Salinispira pacifica, Salinivirga cyanobacteriivorans,
Salsuginibacillus kocurii, Scardovia inopinata, Scardovia wiggsiae,
Schleiferia thermophila, Sedimenticola thiotaurini,
Sediminibacterium sp. C3, Sharpea azabuensis, Shimia marina,
Simonsiella muelleri, Skermanella aerolata, Solobacterium moorei,
Sphaerochaeta globosa, Sphingobacterium spiritivorum, Sphingobium
baderi, Sphingobium sp. AP49, Sphingobium sp. C100, Sphingomonas,
Sphingomonas changbaiensis, Sphingomonas sanxanigenens,
Sphingomonas sp. Leaf412, Sphingomonas sp. MM-1, Sphingomonas sp.
SR52, Spiroplasma apis, Spiroplasma litorale, Spiroplasma
turonicum, Sporocytophaga myxococcoides, Sporolactobacillus vineae,
Staphylococcus agnetis, Staphylococcus haemolyticus, Staphylococcus
hominis, Staphylococcus lugdunensis, Staphylococcus microti,
Staphylococcus pasteuri, Staphylococcus pseudintermedius,
Staphylococcus schleiferi, Staphylococcus simulans, Staphylococcus
sp. CAG:324, Streptobacillus fells, Streptobacillus moniliformis,
Streptococcus, Streptococcus agalactiae, Streptococcus anginosus,
Streptococcus canis, Streptococcus constellatus, Streptococcus
dysgalactiae, Streptococcus equi, Streptococcus equinus,
Streptococcus gallolyticus, Streptococcus gordonii, Streptococcus
henryi, Streptococcus infantarius, Streptococcus iniae,
Streptococcus macacae, Streptococcus macedonicus, Streptococcus
marimammalium, Streptococcus massiliensis, Streptococcus mitis,
Streptococcus mutans, Streptococcus oralis, Streptococcus orails
subsp. tigurinus AZ_3a, Streptococcus orisasini, Streptococcus
orisratti, Streptococcus ovis, Streptococcus parasanguinis,
Streptococcus plurextorum, Streptococcus pseudopneumoniae,
Streptococcus pseudoporcinus, Streptococcus pyogenes, Streptococcus
ratti, Streptococcus sanguinis, Streptococcus sinensis,
Streptococcus sobrinus, Streptococcus
sp. C150, Streptococcus sp. C300, Streptococcus sp. HSISB1,
Streptococcus sp. I-G2, Streptococcus suis, Streptococcus
thermophilus, Streptococcus varani, Streptococcus agalactiae
NEM316, Streptococcus_dysgalactiae_subsp._equisimilis_AC-2713,
Streptococcus_gallolyticus_subsp._gallolyticus_ATCC_43143,
Streptococcus_gordonii_str._Challis_substr._CH1,
Streptococcus_mutans_GS-5, Streptococcus_salivarius_JIM8777,
Streptococcus_suis_D9, Streptococcus_thermophilus_LMG_18311,
Subdoligranulum sp. 4_3_54A2FAA, Sulfitobacter donghicola,
Sulfuritalea hydrogenivorans, Sulfurospirillum sp.,
Sulfurospirillum sp. SCADC, Sulfurovum lithotrophicum, Sutterella
wadsworthensis, Tamlana sedimentorum, Tannerella forsythia,
Tenacibaculum maritimum, Thermithiobacillus tepidarius,
Thermophagus xiamenensis, Thioalkalivibrio, Tissierellia bacterium
KA00581, Tissierellia bacterium S5-A11, Tistrella mobilis,
Treponema denticola, Treponema maltophilum, Treponema pedis,
Treponema putidum, Treponema socranskii, Treponema denticola ATCC
35405, Turicibacter sp., uncultured Termite group 1 bacterium,
Ureibacillus thermosphaericus, Urinacoccus massiliensis,
Veillonella atypica, Veillonella magna, Veillonella parvula,
Veillonella parvula ATCC 17745, Veillonella sp. 6_1_27, Veillonella
sp. AS16, Veillonella sp. CAG:933, Veillonella sp. DNF00869,
Veillonella sp. DorA_A_3_16_22, Verminephrobacter aporrectodeae,
Verminephrobacter eiseniae, Verrucomicrobia bacterium IMCC2613,
Virgibacillus senegalensis, Weeksella massiliensis, Weeksella
virosa, Weissella halotolerans, Weissella kandleri, Wolinella
succinogenes, Woodsholea maritima, Yoonia vestfoldensis, and
Zunongwangia profunda.
[0009] In some aspects, the invention provides a synthetic
composition comprising a heterologous component and a polypeptide
selected from the group consisting of: a polypeptide sharing at
least 80%, between 80% and 85%, at least 85%, between 85% and 90%,
at least 90%, between 90% and 95%, at least 95%, at least 96%, at
least 97%, at least 98%, at least 99%, at least 99.5%, or greater
than 99.5% identity with at least 50, between 50 and 100, at least
100, between 100 and 150, at least 150, between 150 and 200, at
least 200, between 200 and 250, at least 250, between 250 and 300,
at least 300, between 300 and 350, at least 350, between 350 and
400, at least 400, between 400 and 450, at least 500, between 500
and 550, at least 550, between 550 and 600, at least 600, between
600 and 650, at least 650, between 650 and 700, at least 700,
between 700 and 750, at least 750, between 750 and 800, at least
800, between 800 and 850, at least 850, between 850 and 900, at
least 900, between 900 and 950, at least 950, between 950 and 1000,
at least 1000, or even than 1000 contiguous amino acids of any of
any of: SEQID NO:86-171 and 511-1135; a functional variant of any
of SEQID NO:86-171 and 511-1135; a functional fragment of any of
SEQID NO:86-171 and 511-1135; a Cas endonuclease encoded by a
polynucleotide selected from the group consisting of: SEQID
NO:1-85; a Cas endonuclease that recognizes a PAM sequence listed
in any of Tables 4-83; a Cas endonuclease that recognizes a PAM
sequence selected from the group consisting of: NAR (G>A)WH
(A>T>C)GN (C>T>R), N (C>D)V (A>S)R (G>A)TTTN
(T>V), NV (A>G>C)TTTTT, NATTTTT, NN (H>G)AAAN
(G>A>Y)N, N (T>V)NAAATN, NAV (A>G>C)TCNN, NN
(A>S>T)NN (W>G>C)CCN (Y>R), NNAH (T>M)ACN,
NGTGANN, NARN (A>K>C)ATN, NV (G>A>C)RNTTN, NN
(A>B)RN (A>G>T>C)CCN, NN (A>B)NN (T>V)CCH
(A>Y), NNN (H>G)NCDAA, NN (H>G)D (A>K)GGDN (A>B),
NNNNCCAG, NNNNCTAA, NNNNCVGANN, N (C>D)NNTCCN, NNNNCTA,
NNNNCYAA, NAGRGNY, NNGH (W>C)AAA, NNGAAAN, NNAAAAA, NTGAR
(G>A)N(A>Y>G)N(Y>R), N (C>D)H (C>W)GH
(Y>A)N(A>B)AN(A>T>S), NNAAACN, NNGTAM (A>C)Y, NH
(A>Y)ARNN (C>W>G)N, B (C>K)GGN(A>Y>G)N NN, N
(T>C>R)AGAN (A>K>C)NN, NGGN (A>T>G>C)NNN, NGGD
(A>T>G)TNN, NGGAN(T>A>C>G)NN, CGGWN (T>R>C)NN,
NGGWGNN, N (B>A)GGNN (T>V)NN, NNGD (A>T>G)AY (T>C)N,
N (T>V)H(T>C>A)AAAAN, NRTAANN, N (H>G)CAAH
(Y>A)N(Y>R)N, NATAAN (A>T>S)N, NV (A>G>C)R
(A>G)ACCN, CN (C>W>G)AV (A>S)GAC, NNRNCAC, N(A>B)GGD
(W>G)D (G>W)NN, BGD (G>W)GTCN(A>K>C), NAANACN,
NRTHAN(A>B)N, BHN (H>G)NGN(T>M)H(Y>A),
NMRN(A>Y>G)AH(C>T>A)N, NNNCACN, NARN(T>A>S)ACN,
NNNNATW, NGCNGCN, NNNCATN, NAGNGCN, NARN(T>M>G)CCN, NATCCTN,
NRTAAN(T>A>S)N, N(C>T>G>A)AAD (A>G>T)CNN,
NAAAGNN, NNGACNN, N(T>V)NTAAD (A>T>G)N, NNGAD (G>W)NN,
NGGN(W>S)NNN, N(T>V)GGD(W>G)GNN,
NGGD(A>T>G)N(T>M>G)NN, NNAAAGN,
N(G>H)GGDN(T>M>G)NN, NNAGAAA, NN(T>M>G)AAAAA,
N(C>D)N(C>W>G)GW(T>C)D(A>G>T)AA, NAAAAYN,
NRGNNNN, NATGN (H>G)TN, NNDATTT, and NATARCN(C>T>A>G);
a Cas endonuclease that is capable of recognizing a PAM sequence
that is one, two, three, four, five, six, seven, eight, nine, or
ten nucleotides in length; a Cas endonuclease that comprises a
domain at least 80%, between 80% and 85%, at least 85%, between 85%
and 90%, at least 90%, between 90% and 95%, at least 95%, at least
96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or
greater than 99.5% identity with any of: SEQID NOs:1136-1730; a Cas
endonuclease that has an activity score, according to the identical
or similar method of Example 9 or summations of position scores of
the amino acid table of Table 86A, of at least 1.0, between 1.0 and
2.0, at least 2.0, between 2.0 and 3.0, at least 3.0, between 3.0
and 4.0, at least 4.0, between 4.0 and 5.0, at least 5.0, between
5.0 and 6.0, at least 6.0, between 6.0 and 7.0, at least 7.0,
between 7.0 and 8.0, at least 8.0, between 8.0 and 9.0, at least
9.0, between 9.0 and 10.0, at least 10.0, or even greater than
10.0; a Cas endonuclease comprising one, two, three, four, five,
six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen,
fifteen, sixteen, seventeen, eighteen, nineteen, twenty,
twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, or
twenty-six of the signature amino acids identified in Table 86B, as
compared to an alignment with the relative sequence position
numbers of SEQID NO:1125; and a Cas endonuclease that is capable of
forming a complex with a guide polynucleotide comprising any one of
SEQID NOs: 426-510, 341-425, 141-255, or 256-340. In some aspects,
the Cas9 polynucleotide has a plurality of the previously listed
features.
[0010] In some aspects, the invention provides guide
polynucleotide(s) and/or component(s) that is(are) capable of
forming a complex with a Cas endonuclease to recognize, bind to,
and optionally nick or cleave a target polynucleotide. In some
aspects, the guide polynucleotide comprises a sequence at least
80%, between 80% and 85%, at least 85%, between 85% and 90%, at
least 90%, between 90% and 95%, at least 95%, at least 96%, at
least 97%, at least 98%, at least 99%, at least 99.5%, or greater
than 99.5% identity with any of SEQID NOs: 426-510, 341-425,
171-255, or 256-340.
[0011] In some aspects, the invention provides a Cas endonuclease
that is capable of creating a single strand break, or a nick in a
double-stranded target polynucleotide. In some aspects, the Cas
endonuclease is capable of creating a sticky-end overhang double
strand break. In some aspects, the Cas endonuclease is capable of
creating a blunt-end double strand break.
[0012] In some aspects, said heterologous component is selected
from the group consisting of: a cell, a heterologous
polynucleotide, a donor DNA molecule, a repair template
polynucleotide, a heterologous polypeptide, a deaminase, a
heterologous nuclease, a particle, a solid matrix, an antibody, a
buffer composition, Tris, EDTA, dithiothreitol (DTT),
phosphate-buffered saline (PBS), sodium chloride, magnesium
chloride, HEPES, glycerol, bovine serum albumin (BSA), a salt, an
emulsifier, a detergent, a chelating agent, a redox reagent, an
antibody, nuclease-free water, a viscosity agent, and a Histidine
tag. In some aspects, said heterologous polypeptide comprises a
nuclease domain, a transcriptional activator domain, a
transcriptional repressor domain, an epigenetic modification
domain, a cleavage domain, a nuclear localization signal, a
cell-penetrating domain, a deaminase domain, a base editing domain,
a translocation domain, a marker, and a transgene. In some aspects,
said heterologous polynucleotide is selected from the group
consisting of: a guide polynucleotide, a chimeric guide
polynucleotide, a chemically modified guide polynucleotide, a guide
polynucleotide comprising both DNA and RNA, a noncoding expression
element, a gene, a marker, and a polynucleotide encoding a
plurality of Histidine residues. In some aspects, the synthetic
composition comprises at least two, at least three, at least four,
at least five, or even greater than five heterologous components.
In some aspects, there is a plurality of different heterologous
components. In some aspects, there is a plurality of heterologous
components of the same type. In some aspects, there is a plurality
of identical heterologous components.
[0013] In some aspects, the pH of the synthetic composition is
between 1.0 and 14.0, between 2.0 and 13.0, between 3.0 and 12.0,
between 4.0 and 11.0, between 5.0 and 10.0, between 6.0 and 9.0,
between 7.0 and 8.0, between 4.5 and 6.5, between 5.5 and 7.5, or
between 6.5 and 7.5. In some aspects, the Cas9 ortholog has an
activity optimum at a pH between 1.0 and 14.0, between 2.0 and
13.0, between 3.0 and 12.0, between 4.0 and 11.0, between 5.0 and
10.0, between 6.0 and 9.0, between 7.0 and 8.0, between 4.5 and
6.5, between 5.5 and 7.5, or between 6.5 and 7.5.
[0014] In some aspects, said Cas9 ortholog has an activity optimum
at a temperature between 0 degrees Celsius and 100 degrees Celsius,
between at least 0 degrees Celsius and 10 degrees Celsius, between
at least 10 degrees Celsius and 20 degrees Celsius, between at
least 20 degrees Celsius and 25 degrees Celsius, between at least
25 degrees Celsius and 30 degrees Celsius, between at least 30
degrees Celsius and 40 degrees Celsius, between at least 40 degrees
Celsius and 50 degrees Celsius, between at least 50 degrees Celsius
and 60 degrees Celsius, between at least 60 degrees Celsius and 70
degrees Celsius, between at least 70 degrees Celsius and 80 degrees
Celsius, between at least 80 degrees Celsius and 90 degrees
Celsius, between at least 90 degrees Celsius and 100 degrees
Celsius, or greater than 100 degrees Celsius.
[0015] In some aspects, the synthetic composition is stored or
incubated at a temperature of at least minus 200 degrees Celsius,
at least minus 150 degrees Celsius, at least minus 135 degrees
Celsius, at least minus 90 degrees Celsius, at least minus 80
degrees Celsius, at least minus 20 degrees Celsius, at least 4
degrees Celsius, at least 17 degrees Celsius, at least 25 degrees
Celsius, at least 30 degrees Celsius, at least 35 degrees Celsius,
at least 37 degrees Celsius, at least 39 degrees Celsius, or
greater than 39 degrees Celsius.
[0016] In some aspects, any of the synthetic compositions may be in
a substantially nuclease-free environment. In some aspects, any of
the synthetic compositions may be in a substantially endotoxin-free
environment. In some aspects, any of the synthetic compositions may
be in a substantially nuclease-free and endotoxin-free environment.
In some aspects, any of the synthetic compositions may be
lyophilized. In some aspects, any of the synthetic compositions may
exist in an aqueous solution. In some aspects, any of the synthetic
compositions may exist in a non-aqueous solution.
[0017] In one aspect, the invention provides a method of modulating
target polynucleotide specificity of a Cas9 ortholog/guide
polynucleotide complex as compared to its wild type activity, by
changing a parameter selected from the group consisting of: guide
polynucleotide length, guide polynucleotide composition, length of
PAM recognition sequence, composition of the PAM recognition
sequence, and affinity of the Cas9 molecule with the target
polynucleotide backbone; and assessing the target polynucleotide
specificity of the complex with the changed parameter, and
comparing it to the activity of a complex with wild type
parameters. In some embodiments, target polynucleotide specificity
may be increased with a longer PAM recognition sequence. In some
embodiments, target polynucleotide specificity may be decreased
with a shorter PAM recognition sequence. In some embodiments,
target polynucleotide specificity may be modulated by engineering a
non-naturally occurring PAM recognition sequence.
[0018] In one aspect, the invention provides a method of optimizing
the activity of a Cas9 molecule by subjecting a parental Cas9
molecule to at least one round of stochastic protein shuffling or
molecular evolution, and selecting a resultant molecule that has at
least one characteristic not present in the parental Cas9 molecule.
In some embodiments, multiple rounds may be performed.
[0019] In one aspect, the invention provides a method of optimizing
the activity of a Cas9 molecule by subjecting a parental Cas9
molecule to at least one round of non-stochastic protein shuffling
or molecular evolution, and selecting a resultant molecule that has
at least one characteristic not present in the parental Cas9
molecule. In some embodiments, multiple rounds may be
performed.
[0020] In one aspect, the invention provides, using any of the
compositions provided herein or any composition derived from the
compositions provided herein or any composition identified using
any of the methods provided herein, methods of effecting a
single-strand nick or a double-strand break of a target
polynucleotide, methods of modifying an isolated or genomic
polynucleotide, methods of in vitro polynucleotide modification,
methods of in vivo polynucleotide modification, methods of editing
one or more bases of a polynucleotide, methods of modulating the
expression of an endogenous or transgenic polynucleotide in a cell,
or methods of conferring a benefit to a cell, tissue, or organism
to which the composition has been introduced.
[0021] Methods of genomic modification provided herein include the
insertion of at least one nucleotide, the deletion of at least one
nucleotide, the modification of at least one nucleotide, the swap
of at least one nucleotide, the chemical alteration of at least one
nucleotide, the deamination of at least one nucleotide, or any
combination of the preceding.
[0022] In some aspects, the Cas endonuclease has been modified to
alter its wild type activity, to cleave a target polynucleotide
with greater frequency, to cleave a polynucleotide with less
frequency, or to reduce or eliminate nuclease activity.
[0023] In some aspects, the Cas endonuclease is combined with
another polypeptide to create a fusion protein, for example with a
deaminase or a heterologous nuclease.
[0024] In any aspect of the methods or compositions provided
herein, the cell may be selected from the group consisting of: a
human, non-human primate, mammal, animal, archaeal, bacterial,
protist, fungal, insect, yeast, non-conventional yeast, and plant
cell. In some embodiments, the cell is heterologous to the organism
from which the Cas9 endonuclease was derived. In some embodiments,
the cell is a plant cell selected from the group consisting of a
monocot and dicot cell. In some embodiments, the cell is a plant
cell selected from the group consisting of maize, rice, sorghum,
rye, barley, wheat, millet, oats, sugarcane, turfgrass,
switchgrass, soybean, canola, alfalfa, sunflower, cotton, tobacco,
peanut, potato, tobacco, Arabidopsis, vegetable, and safflower
cell. In some embodiments, the cell is an animal cell, optionally a
mammalian cell, optionally a primate cell, or optionally a human
cell, that is selected from the group consisting of: haploid cells,
diploid cells, reproductive cells, neurons, muscle cells, endocrine
or exocrine cells, epithelial cells, muscle cells, tumor cells,
embryonic cells, hematopoietic cells, bone cells, germ cells,
somatic cells, stem cells, pluripotent stem cells, induced
pluripotent stem cells, progenitor cells, meiotic cells, and
mitotic cells.
[0025] In any aspect, a benefit is conferred to said cell, or
organism comprising said cell, or subsequent generation of cells or
organisms derived from said cell, as a result of a composition or
method provided herein. In some embodiments, the benefit is
ascertained by comparing said cell, organism comprising said cell,
or subsequent generation of cells or organisms derived from said
cell, to an isoline cell not subjected to a method provided herein,
or not comprising at least one composition provided herein. In some
embodiments, the benefit is provided as a result of a
polynucleotide modification, deletion, or, insertion. In some
embodiments, said benefit is selected from the group consisting of:
improved health, improved growth, improved fertility, improved
fecundity, improved environmental tolerance, improved vigor,
improved disease resistance, improved disease tolerance, improved
tolerance to a heterologous molecule, improved fitness, improved
physical characteristic, greater mass, increased production of a
biochemical molecule, decreased production of a biochemical
molecule, upregulation of a gene, downregulation of a gene,
upregulation of a biochemical pathway, downregulation of a
biochemical pathway, stimulation of cell reproduction, and
suppression of cell reproduction, as compared to an isoline plant
not comprising or derived from a cell comprising said donor
polynucleotide. In some embodiments, the modification of said
target site results in the modulation of a trait of agronomic
interest of a plant comprising, or derived from, said cell or a
progeny cell thereof, said trait of agronomic interest selected
from the group consisting of: disease resistance, drought
tolerance, heat tolerance, cold tolerance, salinity tolerance,
metal tolerance, herbicide tolerance, improved water use
efficiency, improved nitrogen utilization, improved nitrogen
fixation, pest resistance, herbivore resistance, pathogen
resistance, yield improvement, health enhancement, improved
fertility, vigor improvement, growth improvement, photosynthetic
capability improvement, nutrition enhancement, altered protein
content, altered oil content, increased biomass, increased shoot
length, increased root length, improved root architecture,
modulation of a metabolite, modulation of the proteome, increased
seed weight, altered seed carbohydrate composition, altered seed
oil composition, altered seed protein composition, altered seed
nutrient composition; as compared to an isoline plant not
comprising or derived from a cell comprising said donor
polynucleotide. In some embodiments, the cell is an animal cell,
wherein the modification of said target site results in the
modulation of a phenotype of physiological interest of an organism
comprising said animal cell or a progeny cell thereof, selected
from the group consisting of: improved health, improved nutritional
status, reduced disease impact, disease stasis, disease reversal,
improved fertility, improved vigor, improved mental capacity,
improved organism growth, improved weight gain, weight loss,
modulation of an endocrine system, modulation of an exocrine
system, reduced tumor size, reduced tumor mass, stimulated cell
growth, reduced cell growth, production of a metabolite, production
of a hormone, production of an immune cell, and stimulation of cell
production.
BRIEF DESCRIPTION OF THE DRAWINGS AND THE SEQUENCE LISTING
[0026] The disclosure can be more fully understood from the
following detailed description and the accompanying drawings and
Sequence Listing, which form a part of this application. The
sequence descriptions and sequence listing attached hereto comply
with the rules governing nucleotide and amino acid sequence
disclosures in patent applications as set forth in 37 C.F.R.
.sctn..sctn. 1.821 and 1.825. The sequence descriptions comprise
the three letter codes for amino acids as defined in 37 C.F.R.
.sctn..sctn. 1.821 and 1.825, which are incorporated herein by
reference.
FIGURES
[0027] FIG. 1 is a graphical representation of the phylogram
generated to identify the 12 clades described in Example 1.
[0028] FIG. 2 depicts the secondary structure diagrams of the guide
RNA molecules identified for some of the Cas9 orthologs of each of
the 12 clades described in Example 1.
[0029] FIG. 3 shows the consensus PAM sequences determined for some
of the Cas9 orthologs of each of the 12 clades described in Example
1, as detailed in Tables 4-83.
[0030] FIG. 4 shows the consensus sequence for Group I Cas9
orthologs (SEQ ID NOs: 58, 62, 64, 63, 65, 71, 69, 74, 66, 67, 70,
72, 73, 68, 83, 79, 82, 76, 78, 80, 81, 77, and 75), which were
aligned against the Staphylococcus aureus Cas9 structure PDB ID
5CZZ_A ("Crystal structure of Staphylococcus aureus Cas9",
Nishimasu, H., Cong, L., Yan, W. X., Ran, F. A., Zetsche, B., Li,
Y., Kurabayashi, A., Ishitani, R., Zhang, F., Nureki, O., (2015)
Cell 162: 1113-1126). Absolutely conserved residues are depicted in
bold, underlined text (X).
[0031] FIG. 5 shows the consensus sequence for Group III Cas9
orthologs (SEQ ID NOs: 51, 52, 53, 54, 55, 56, 57, 59, 84, 85, 86,
87, 88, 89, 90, 91, 92, 93, 94, 95, 96, and 97), which aligned
against the Streptococcus pyogenes serotype M1 structure PDB ID
4UN3_B ("Structural Basis of Pam-Dependent Target DNA Recognition
by the Cas9 Endonuclease", Anders, C., Niewoehner, O., Duerst, A.,
Jinek, M., (2014) Nature 513: 569-573). Absolutely conserved
residues are depicted in bold, underlined text (X).
[0032] FIG. 6 shows the consensus sequence for Group IV Cas9
orthologs (SEQ ID NOs: 98 and 99), which were aligned against the
Actinomyces naeslundii structure PDB ID 4OGE_A ("Structures of Cas9
endonucleases reveal RNA-mediated conformational activation",
Jinek, M., Jiang, F., Taylor, D. W., Sternberg, S. H., Kaya, E.,
Ma, E., Anders, C., Hauer, M., Zhou, K., Lin, S., Kaplan, M.,
Iavarone, A. T., Charpentier, E., Nogales, E., Doudna, J. A.,
(2014) Science 343: 1247997-1247997). Absolutely conserved residues
are depicted in bold, underlined text (X).
[0033] FIG. 7 shows the experimental approaches described in
Example 9 for testing the HDR frequency after cleavage with Cas9:
FIG. 7A depicts HDR via duplicated region of fluorescent reporter,
and FIG. 7B depicts the repair template introduced together with
Cas9.
[0034] FIG. 8 shows WebLogo comparisons for selected Cas9 orthologs
across two different methods (IVT and RNP). IVT method results were
confirmed with purified ribonucleoprotein (RNP), at several
different concentrations.
[0035] FIG. 9 shows Protospacer-adapter ligation positions where
Illumina sequences were recovered in excess resulting in a peak or
spike of read coverage over negative controls were denoted as the
cleavage position, with numerical results as fraction of adapter
ligated reads.
[0036] FIG. 9A shows the results for selected sequences of Clades
I, II, III, and V. FIG. 9B shows the results for selected sequences
of Clades VI, VII, VIII, and IX. FIG. 9C shows the results for
selected sequences of Clades X, XI, and XII.
[0037] FIG. 10A shows those Cas9 proteins that produced dominant
cleavage at a protospacer position other than just after 3 were
then re-examined by also capturing the cleavage product resulting
from cleavage, end-repair, 3' adenine addition, and adapter
ligation of protospacer side of the cleaved library target.
[0038] FIG. 10B shows the position and type of cleavage, based on
the resulting frequencies compared for both the protospacer and PAM
sides of cleavage, taking T4 DNA polymerase end-repair into
consideration, for eight of the selected Cas9 orthologs that
demonstrated sticky-end cleavage.
[0039] FIG. 11 shows in vitro cleavage data for some of the Cas9
orthologs tested with two different lengths of spacers (20
nucleotides and 24 nucleotides) in five different buffer
compositions.
[0040] FIG. 12 shows in vitro cleavage data for selected Cas9
orthologs using the S. pyogenes sgRNA.
[0041] FIG. 13 shows in vitro cleavage activity versus temperature
for one of the Cas9 orthologs, ID46, showing a wide range of
temperature activity, with optimal activity from about 15 degrees
Celsius to about 60 degrees Celsius with a 24 nucleotide spacer
length, and a narrow window of activity with a maximum at
approximately 45 degrees Celsius with a 20 nucleotide spacer
length.
[0042] FIG. 14 shows the average NHEJ frequency in maize cells two
days after transformation, with a representative number of Cas9
orthologs.
[0043] FIG. 15 shows the expected cut sites in 20 different mutants
generated by selected Cas9 orthologs. FIG. 15A shows the results
for ID33, and FIG. 15B shows the results for ID64.
[0044] FIG. 16 shows the results of two different Cas9 orthologs
(ID33 and ID64) across three different target sites (MS45, MS26,
and LIG) in maize T0 plants, as compared to control plants modified
with S. pyogenes Cas9.
[0045] FIG. 17 shows the results of selected Cas9 orthologs at the
HEK cell WTAP locus, as compared to the activity of S. pyogenes
Cas9, in cells transformed with a recombinant construct comprising
a DNA sequence encoding the respective Cas9 ortholog.
[0046] FIG. 18 shows the results of selected Cas9 orthologs at the
HEK cell RunX1 locus, as compared to the activity of S. pyogenes
Cas9, in cells transformed with a recombinant construct comprising
a DNA sequence encoding the respective Cas9 ortholog.
[0047] FIG. 19 the expected cut sites in 20 different mutants
generated by selected Cas9 orthologs. FIG. 19A shows the results
for ID46 and FIG. 19B shows the results for ID56, in maize
cells.
[0048] FIG. 20 shows the results of selected Cas9 orthologs at the
HEK cell WTAP locus, as compared to the activity of S. pyogenes
Cas9, in cells transformed with ribonucleoprotein comprising the
respective Cas9 ortholog and its appropriate guide RNA.
SEQUENCES
[0049] SEQID NOs: 1-85 are the polynucleotide sequences encoding
the Cas9 ortholog sequences SEQ IDs 86-170, respectively, with the
Cas9 Ortholog ID numbers, source organisms, and phylogeny Clades
described in Table 1.
[0050] SEQ ID NOs:86-170 and 511-1135 are polypeptide sequences
encoding the Cas9 orthologs represented in FIG. 1.
[0051] SEQ ID NOs:171-255 are the crRNA repeat sequences
corresponding to the Cas9 orthologs of SEQ IDs 86-170,
respectively.
[0052] SEQ ID NOs:256-340 are the anti-repeat sequences
corresponding to the Cas9 orthologs of SEQ IDs 86-170,
respectively.
[0053] SEQ ID NOs:341-425 are the 3' tracrRNA sequences
corresponding to the Cas9 orthologs of SEQ IDs 86-170,
respectively.
[0054] SEQ ID NOs:426-510 are the CER domains of the sgRNAs
sequences corresponding to the Cas9 orthologs of SEQ IDs 86-170,
respectively.
[0055] SEQ ID NOs:1136-1220 are the protein sequences of the REC
domains for the Cas9 ortholog ID numbers listed in Table 2B.
[0056] SEQ ID NOs:1221-1305 are the protein sequences of the RUVC1
domains for the Cas9 ortholog ID numbers listed in Table 2B.
[0057] SEQ ID NOs:1306-1390 are the protein sequences of the RUVC2
domains for the Cas9 ortholog ID numbers listed in Table 2B.
[0058] SEQ ID NOs:1391-1475 are the protein sequences of the RUVC3
domains for the Cas9 ortholog ID numbers listed in Table 2B.
[0059] SEQ ID NOs:1476-1560 are the protein sequences of the HNH
domains for the Cas9 ortholog ID numbers listed in Table 2B.
[0060] SEQ ID NOs:1561-1645 are the protein sequences of the WED
domains for the Cas9 ortholog ID numbers listed in Table 2B.
[0061] SEQ ID NOs:1646-1730 are the protein sequences of the PI
domains for the Cas9 ortholog ID numbers listed in Table 2B.
[0062] SEQID NO:1731 is the DNA sequence for Adapter A1.
[0063] SEQID NO:1732 is the DNA sequence for Adapter A2.
[0064] SEQID NO:1733 is the DNA sequence for R0 primer.
[0065] SEQID NO:1734 is the DNA sequence for C0 primer.
[0066] SEQID NO:1735 is the DNA sequence for F1 primer.
[0067] SEQID NO:1736 is the DNA sequence for R1 primer.
[0068] SEQID NO:1737 is the DNA sequence for 5' end bridge
amplification sequence.
[0069] SEQID NO:1738 is the DNA sequence for 3' end bridge
amplification sequence.
[0070] SEQID NO:1739 is the DNA sequence for F2 primer.
[0071] SEQID NO:1740 is the DNA sequence for R2 primer.
[0072] SEQID NO:1741 is the DNA sequence for C1 primer.
[0073] SEQID NO:1742 is the DNA sequence for a sequence
product.
[0074] SEQID NO:1743 is the DNA sequence for an adapter and
target.
[0075] SEQID NO:1744 is the DNA sequence for a 5' sequence upstream
of the PAM.
[0076] SEQID NOs: 1746 is the DNA target sequence for the ID33 WT
cleavage pattern.
[0077] SEQID NOs: 1747-1766 are the top 20 target sequence cleavage
patterns for ID33.
[0078] SEQID NOs: 1767 is the DNA target sequence for the ID64 WT
cleavage pattern.
[0079] SEQID NOs: 1768-1787 are the top 20 target sequence cleavage
patterns for ID64.
[0080] SEQID NOs: 1788 is the DNA target sequence for the ID46 WT
cleavage pattern.
[0081] SEQID NOs: 1789-1808 are the top 20 target sequence cleavage
patterns for ID46.
[0082] SEQID NOs: 1809 is the DNA target sequence for the ID56 WT
cleavage pattern.
[0083] SEQID NOs: 1810-1829 are the top 20 target sequence cleavage
patterns for ID56.
DETAILED DESCRIPTION
[0084] Compositions are provided for novel Cas9 systems and
elements comprising such systems, including, but not limiting to,
novel guide polynucleotide/Cas endonucleases complexes, single
guide RNAs, guide RNA elements, and Cas9 endonucleases. The present
disclosure further includes compositions and methods for genome
modification of a target sequence in the genome of a cell, for gene
editing, and for inserting a polynucleotide of interest into the
genome of a cell.
[0085] Compositions and methods are also provided for direct
delivery of endonucleases, Cas proteins, guide RNAs and guide
RNA/endonuclease complexes. The present disclosure further includes
compositions and methods for genome modification of a target
sequence in the genome of a cell, for gene editing, and for
inserting a polynucleotide of interest into the genome of a
cell.
[0086] Compositions and methods are also provided for in vitro
characterization and modification of an isolated
polynucleotide.
[0087] Given the diversity of Type II CRISPR-Cas systems (Fonfara
et al. (2014) Nucleic Acids Res. 42:2577-2590), it is plausible
that many of the Cas9 endonucleases and cognate guide RNAs may have
unique sequence recognition and enzymatic properties different from
those previously described or characterized. For example, cleavage
activity and specificity may be enhanced or proto-spacer adjacent
motif (PAM) sequence may be different leading to increased genomic
target site density. To tap into this vast unexplored diversity and
expand the repertoire of Cas9 endonucleases and cognate guide RNAs
available for genome targeting, the two components of Cas9 target
site recognition, the PAM sequence and the guide RNA (either
duplexed CRISPR RNA (crRNA) and trans-activating CRISPR RNA
(tracrRNA) or chimeric fusion of crRNA and tracrRNA (single guide
RNA (sgRNA), need to be established for each new system.
[0088] As described herein, CRISPR-Cas loci (including Cas9 genes
and open reading frames, CRISPR array and anti-repeats) from
uncharacterized CRISPR-Cas systems were identified by searching
internal Pioneer-DuPont databases consisting of microbial genomes.
The Cas9 endonuclease described herein can be expressed and
purified by methods known in the art. As described herein, the
transcriptional direction of the tracrRNA for all the CRISPR-Cas
systems can be deduced and examples of sgRNAs and its components
(Variable Targeting domain (VT)), crRNA repeat, loop, anti-repeat
and 3'tracrRNA) were identified for each new diverse CRISPR-Cas
endonuclease described herein.
[0089] Terms used in the claims and specification are defined as
set forth below unless otherwise specified. It must be noted that,
as used in the specification and the appended claims, the singular
forms "a," "an" and "the" include plural referents unless the
context clearly dictates otherwise.
Definitions
[0090] As used herein, "nucleic acid" means a polynucleotide and
includes a single or a double-stranded polymer of
deoxyribonucleotide or ribonucleotide bases. Nucleic acids may also
include fragments and modified nucleotides. Thus, the terms
"polynucleotide", "nucleic acid sequence", "nucleotide sequence"
and "nucleic acid fragment" are used interchangeably to denote a
polymer of RNA and/or DNA and/or RNA-DNA that is single- or
double-stranded, optionally comprising synthetic, non-naturally
occurring, or altered nucleotide bases. Nucleotides (usually found
in their 5'-monophosphate form) are referred to by their single
letter designation as follows: "A" for adenosine or deoxyadenosine
(for RNA or DNA, respectively), "C" for cytosine or deoxycytosine,
"G" for guanosine or deoxyguanosine, "U" for uridine, "T" for
deoxythymidine, "R" for purines (A or G), "Y" for pyrimidines (C or
T), "K" for G or T, "H" for A or C or T, "I" for inosine, and "N"
for any nucleotide.
[0091] The term "genome" as it applies to a prokaryotic and
eukaryotic cell or organism cells encompasses not only chromosomal
DNA found within the nucleus, but organelle DNA found within
subcellular components (e.g., mitochondria, or plastid) of the
cell.
[0092] "Open reading frame" is abbreviated ORF.
[0093] The term "selectively hybridizes" or "selective
hybridization" includes reference to hybridization, under stringent
hybridization conditions, of a nucleic acid sequence to a specified
nucleic acid target sequence to a detectably greater degree (e.g.,
at least 2-fold over background) than its hybridization to
non-target nucleic acid sequences and to the substantial exclusion
of non-target nucleic acids. Selectively hybridizing sequences
typically have about at least 80% sequence identity, or 90%
sequence identity, up to and including 100% sequence identity
(i.e., fully complementary) with each other.
[0094] The term "stringent conditions" or "stringent hybridization
conditions" includes reference to conditions under which a
polynucleotide/probe will selectively hybridize to its target
sequence in an in vitro hybridization assay. Stringent conditions
are sequence-dependent and will be different in different
circumstances. By controlling the stringency of the hybridization
and/or washing conditions, target sequences can be identified which
are 100% complementary to the polynucleotide/probe (homologous
probing). Alternatively, stringency conditions can be adjusted to
allow some mismatching in sequences so that lower degrees of
similarity are detected (heterologous probing). Generally, a
polynucleotide/probe is fewer than about 1000 nucleotides in
length, fewer than 500 nucleotides, fewer than 100 nucleotides,
fewer than 90 nucleotides, fewer than 80 nucleotides, fewer than 70
nucleotides, fewer than 60 nucleotides, fewer than 50 nucleotides,
fewer than 40 nucleotides, fewer than 30 nucleotides, fewer than 20
nucleotides, 10 nucleotides, or even fewer than 10 nucleotides.
Typically, stringent conditions will be those in which the salt
concentration is less than about 1.5 M Na ion, typically about 0.01
to 1.0 M Na ion concentration (or other salt(s)) at pH 7.0 to 8.3,
and at least 30.degree. C. for short polynucleotides/probes (e.g.,
10 to 50 nucleotides) and at least 60.degree. C. for long
polynucleotides/probes (e.g., greater than 50 nucleotides).
Stringent conditions may also be achieved with the addition of
destabilizing agents such as formamide. Exemplary low stringency
conditions include hybridization with a buffer solution of 30 to
35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulfate) at
37.degree. C., and a wash in 1.times. to 2.times.SSC
(20.times.SSC=3.0 M NaCl/0.3 M trisodium citrate) at 50 to
55.degree. C. Exemplary moderate stringency conditions include
hybridization in 40 to 45% formamide, 1 M NaCl, 1% SDS at
37.degree. C., and a wash in 0.5.times. to 1.times.SSC at 55 to
60.degree. C. Exemplary high stringency conditions include
hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37.degree. C.,
and a wash in 0.1.times.SSC at 60 to 65.degree. C.
[0095] By "homology" is meant DNA sequences that are similar. For
example, a "region of homology to a genomic region" that is found
on the donor DNA is a region of DNA that has a similar sequence to
a given "genomic region" in the cell or organism genome. A region
of homology can be of any length that is sufficient to promote
homologous recombination at the cleaved target site. For example,
the region of homology can comprise at least 5-10, 5-15, 5-20,
5-25, 5-30, 5-35, 5-40, 5-45, 5-50, 5-55, 5-60, 5-65, 5-70, 5-75,
5-80, 5-85, 5-90, 5-95, 5-100, 5-200, 5-300, 5-400, 5-500, 5-600,
5-700, 5-800, 5-900, 5-1000, 5-1100, 5-1200, 5-1300, 5-1400,
5-1500, 5-1600, 5-1700, 5-1800, 5-1900, 5-2000, 5-2100, 5-2200,
5-2300, 5-2400, 5-2500, 5-2600, 5-2700, 5-2800, 5-2900, 5-3000,
5-3100 or more bases in length such that the region of homology has
sufficient similarity to undergo homologous recombination with the
corresponding genomic region. "Sufficient similarity" indicates
that two polynucleotide sequences have sufficient structural
equivalency to act as substrates for a homologous recombination
reaction. The structural equivalency includes overall length of
each polynucleotide fragment, as well as the sequence similarity of
the polynucleotides. Sequence similarity can be described by the
percent sequence identity over the whole length of the sequences,
and/or by conserved regions comprising localized similarities such
as contiguous nucleotides having 100% sequence identity, and
percent sequence identity over a portion of the length of the
sequences.
[0096] As used herein, a "genomic region" is a segment of a
chromosome in the genome of a cell that is present on either side
of a target site or, alternatively, also comprises a portion of a
target site. The genomic region can comprise at least 5-10, 5-15,
5-20, 5-25, 5-30, 5-35, 5-40, 5-45, 5-50, 5-55, 5-60, 5-65, 5-70,
5-75, 5-80, 5-85, 5-90, 5-95, 5-100, 5-200, 5-300, 5-400, 5-500,
5-600, 5-700, 5-800, 5-900, 5-1000, 5-1100, 5-1200, 5-1300, 5-1400,
5-1500, 5-1600, 5-1700, 5-1800, 5-1900, 5-2000, 5-2100, 5-2200,
5-2300, 5-2400, 5-2500, 5-2600, 5-2700, 5-2800, 5-2900, 5-3000,
5-3100 or more bases such that the genomic region has sufficient
similarity to undergo homologous recombination with the
corresponding region of homology.
[0097] As used herein, "homologous recombination" (HR) includes the
exchange of DNA fragments between two DNA molecules at the sites of
homology. The frequency of homologous recombination is influenced
by a number of factors. Different organisms vary with respect to
the amount of homologous recombination and the relative proportion
of homologous to non-homologous recombination. Generally, the
length of the region of homology affects the frequency of
homologous recombination events: the longer the region of homology,
the greater the frequency. The length of the homology region needed
to observe homologous recombination is also species-variable. In
many cases, at least 5 kb of homology has been utilized, but
homologous recombination has been observed with as little as 25-50
bp of homology. See, for example, Singer et al., (1982) Cell
31:25-33; Shen and Huang, (1986) Genetics 112:441-57; Watt et al.,
(1985) Proc. Natl. Acad. Sci. USA 82:4768-72, Sugawara and Haber,
(1992) Mol Cell Biol 12:563-75, Rubnitz and Subramani, (1984) Mol
Cell Biol 4:2253-8; Ayares et al., (1986) Proc. Natl. Acad. Sci.
USA 83:5199-203; Liskay et al., (1987) Genetics 115:161-7.
[0098] "Sequence identity" or "identity" in the context of nucleic
acid or polypeptide sequences refers to the nucleic acid bases or
amino acid residues in two sequences that are the same when aligned
for maximum correspondence over a specified comparison window.
[0099] The term "percentage of sequence identity" refers to the
value determined by comparing two optimally aligned sequences over
a comparison window, wherein the portion of the polynucleotide or
polypeptide sequence in the comparison window may comprise
additions or deletions (i.e., gaps) as compared to the reference
sequence (which does not comprise additions or deletions) for
optimal alignment of the two sequences. The percentage is
calculated by determining the number of positions at which the
identical nucleic acid base or amino acid residue occurs in both
sequences to yield the number of matched positions, dividing the
number of matched positions by the total number of positions in the
window of comparison and multiplying the results by 100 to yield
the percentage of sequence identity. Useful examples of percent
sequence identities include, but are not limited to, 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or any
incremental or fractional percentage from 50% to 100%. These
identities can be determined using any of the programs described
herein.
[0100] Sequence alignments and percent identity or similarity
calculations may be determined using a variety of comparison
methods designed to detect homologous sequences including, but not
limited to, the MegAlign.TM. program of the LASERGENE
bioinformatics computing suite (DNASTAR Inc., Madison, Wis.).
Within the context of this application it will be understood that
where sequence analysis software is used for analysis, that the
results of the analysis will be based on the "default values" of
the program referenced, unless otherwise specified. As used herein
"default values" will mean any set of values or parameters that
originally load with the software when first initialized.
[0101] The "Clustal V method of alignment" corresponds to the
alignment method labeled Clustal V (described by Higgins and Sharp,
(1989) CABIOS 5:151-153; Higgins et al., (1992) Comput Appl Biosci
8:189-191) and found in the MegAlign.TM. program of the LASERGENE
bioinformatics computing suite (DNASTAR Inc., Madison, Wis.). For
multiple alignments, the default values correspond to GAP
PENALTY=10 and GAP LENGTH PENALTY=10. Default parameters for
pairwise alignments and calculation of percent identity of protein
sequences using the Clustal method are KTUPLE=1, GAP PENALTY=3,
WINDOW=5 and DIAGONALS SAVED=5. For nucleic acids these parameters
are KTUPLE=2, GAP PENALTY=5, WINDOW=4 and DIAGONALS SAVED=4. After
alignment of the sequences using the Clustal V program, it is
possible to obtain a "percent identity" by viewing the "sequence
distances" Table in the same program. The "Clustal W method of
alignment" corresponds to the alignment method labeled Clustal W
(described by Higgins and Sharp, (1989) CABIOS 5:151-153; Higgins
et al., (1992) Comput Appl Biosci 8:189-191) and found in the
MegAlign.TM. v6.1 program of the LASERGENE bioinformatics computing
suite (DNASTAR Inc., Madison, Wis.). Default parameters for
multiple alignment (GAP PENALTY=10, GAP LENGTH PENALTY=0.2, Delay
Divergen Seqs (%)=30, DNA Transition Weight=0.5, Protein Weight
Matrix=Gonnet Series, DNA Weight Matrix=IUB). Unless otherwise
stated, sequence identity/similarity values provided herein refer
to the value obtained using GAP Version 10 (GCG, Accelrys, San
Diego, Calif.) using the following parameters: % identity and %
similarity for a nucleotide sequence using a gap creation penalty
weight of 50 and a gap length extension penalty weight of 3, and
the nwsgapdna.cmp scoring matrix; % identity and % similarity for
an amino acid sequence using a GAP creation penalty weight of 8 and
a gap length extension penalty of 2, and the BLOSUM62 scoring
matrix (Henikoff and Henikoff, (1989) Proc. Natl. Acad. Sci. USA
89:10915). GAP uses the algorithm of Needleman and Wunsch, (1970) J
Mol Biol 48:443-53, to find an alignment of two complete sequences
that maximizes the number of matches and minimizes the number of
gaps. GAP considers all possible alignments and gap positions and
creates the alignment with the largest number of matched bases and
the fewest gaps, using a gap creation penalty and a gap extension
penalty in units of matched bases. "BLAST" is a searching algorithm
provided by the National Center for Biotechnology Information
(NCBI) used to find regions of similarity between biological
sequences. The program compares nucleotide or protein sequences to
sequence databases and calculates the statistical significance of
matches to identify sequences having sufficient similarity to a
query sequence such that the similarity would not be predicted to
have occurred randomly. BLAST reports the identified sequences and
their local alignment to the query sequence. It is well understood
by one skilled in the art that many levels of sequence identity are
useful in identifying polypeptides from other species or modified
naturally or synthetically wherein such polypeptides have the same
or similar function or activity. Useful examples of percent
identities include, but are not limited to, 50%, 55%, 60%, 65%,
70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or any
incremental or fractional percentage from 50% to 100%. Indeed, any
amino acid identity from 50% to 100% may be useful in describing
the present disclosure, such as 51%, 52%, 53%, 54%, 55%, 56%, 57%,
58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%,
71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%,
84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98% or 99%.
[0102] Polynucleotide and polypeptide sequences, variants thereof,
and the structural relationships of these sequences can be
described by the terms "homology", "homologous", "substantially
identical", "substantially similar" and "corresponding
substantially" which are used interchangeably herein. These refer
to polypeptide or nucleic acid sequences wherein changes in one or
more amino acids or nucleotide bases do not affect the function of
the molecule, such as the ability to mediate gene expression or to
produce a certain phenotype. These terms also refer to
modification(s) of nucleic acid sequences that do not substantially
alter the functional properties of the resulting nucleic acid
relative to the initial, unmodified nucleic acid. These
modifications include deletion, substitution, and/or insertion of
one or more nucleotides in the nucleic acid fragment, or the
association of an atom or a molecule to an existing nucleotide in a
polynucleotide (for example but not limited to: a covalent addition
of a methyl group, or an ionic interaction with a metal ion).
Substantially similar nucleic acid sequences encompassed may be
defined by their ability to hybridize (under moderately stringent
conditions, e.g., 0.5.times.SSC, 0.1% SDS, 60.degree. C.) with the
sequences exemplified herein, or to any portion of the nucleotide
sequences disclosed herein and which are functionally equivalent to
any of the nucleic acid sequences disclosed herein. Stringency
conditions can be adjusted to screen for moderately similar
fragments, such as homologous sequences from distantly related
organisms, to highly similar fragments, such as genes that
duplicate functional enzymes from closely related organisms.
Post-hybridization washes determine stringency conditions.
[0103] A "centimorgan" (cM) or "map unit" is the distance between
two polynucleotide sequences, linked genes, markers, target sites,
loci, or any pair thereof, wherein 1% of the products of meiosis
are recombinant. Thus, a centimorgan is equivalent to a distance
equal to a 1% average recombination frequency between the two
linked genes, markers, target sites, loci, or any pair thereof.
[0104] An "isolated" or "purified" nucleic acid molecule,
polynucleotide, polypeptide, or protein, or biologically active
portion thereof, is substantially or essentially free from
components that normally accompany or interact with the
polynucleotide or protein as found in its naturally occurring
environment. Thus, an isolated or purified polynucleotide or
polypeptide or protein is substantially free of other cellular
material, or culture medium when produced by recombinant
techniques, or substantially free of chemical precursors or other
chemicals when chemically synthesized. Optimally, an "isolated"
polynucleotide is free of sequences (optimally protein encoding
sequences) that naturally flank the polynucleotide (i.e., sequences
located at the 5' and 3' ends of the polynucleotide) in the genomic
DNA of the organism from which the polynucleotide is derived. For
example, in various embodiments, the isolated polynucleotide can
contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or
0.1 kb of nucleotide sequence that naturally flank the
polynucleotide in genomic DNA of the cell from which the
polynucleotide is derived. Isolated polynucleotides may be purified
from a cell in which they naturally occur. Conventional nucleic
acid purification methods known to skilled artisans may be used to
obtain isolated polynucleotides. The term also embraces recombinant
polynucleotides and chemically synthesized polynucleotides.
[0105] The term "fragment" refers to a contiguous set of
polynucleotides or polypeptides. In one embodiment, a fragment is
2, 3, 4, 5, 6, 7 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
or greater than 20 contiguous polynucleotides. In one embodiment, a
fragment is 2, 3, 4, 5, 6, 7 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, or greater than 20 contiguous polypeptides. A fragment
may or may not exhibit the function of a sequence sharing some
percent identity over the length of said fragment.
[0106] The terms "fragment that is functionally equivalent" and
"functionally equivalent fragment" are used interchangeably herein.
These terms refer to a portion or subsequence of an isolated
nucleic acid fragment or polypeptide that displays the same
activity or function as the longer sequence from which it derives.
In one example, the fragment retains the ability to alter gene
expression or produce a certain phenotype whether or not the
fragment encodes an active protein. For example, the fragment can
be used in the design of genes to produce the desired phenotype in
a modified plant. Genes can be designed for use in suppression by
linking a nucleic acid fragment, whether or not it encodes an
active enzyme, in the sense or antisense orientation relative to a
promoter sequence.
[0107] "Gene" includes a nucleic acid fragment that expresses a
functional molecule such as, but not limited to, a specific
protein, including regulatory sequences preceding (5' non-coding
sequences) and following (3' non-coding sequences) the coding
sequence. "Native gene" refers to a gene as found in its natural
endogenous location with its own regulatory sequences.
[0108] By the term "endogenous" it is meant a sequence or other
molecule that naturally occurs in a cell or organism. In one
aspect, an endogenous polynucleotide is normally found in the
genome of the cell from which it is obtained; that is, not
heterologous.
[0109] An "allele" is one of several alternative forms of a gene
occupying a given locus on a chromosome. When all the alleles
present at a given locus on a chromosome are the same, that plant
is homozygous at that locus. If the alleles present at a given
locus on a chromosome differ, that plant is heterozygous at that
locus.
[0110] "Coding sequence" refers to a polynucleotide sequence that
may be transcribed into an RNA molecule and optionally further
translated into a polypeptide. "Regulatory sequences" refer to
nucleotide sequences located upstream (5' non-coding sequences),
within, or downstream (3' non-coding sequences) of a coding
sequence, and which influence the transcription, RNA processing or
stability, or translation of the associated coding sequence.
Regulatory sequences include, but are not limited to, promoters,
translation leader sequences, 5' untranslated sequences, 3'
untranslated sequences, introns, polyadenylation target sequences,
RNA processing sites, effector binding sites, and stem-loop
structures.
[0111] A "mutated gene" is a gene that has been altered through
human intervention. Such a "mutated gene" has a sequence that
differs from the sequence of the corresponding non-mutated gene by
at least one nucleotide addition, deletion, or substitution. In
certain embodiments of the disclosure, the mutated gene comprises
an alteration that results from a guide polynucleotide/Cas
endonuclease system as disclosed herein. A mutated plant is a plant
comprising a mutated gene.
[0112] As used herein, a "targeted mutation" is a mutation in a
gene (referred to as the target gene), including a native gene,
that was made by altering a target sequence within the target gene
using any method known to one skilled in the art, including a
method involving a guided Cas endonuclease system as disclosed
herein.
[0113] The terms "knock-out", "gene knock-out" and "genetic
knock-out" are used interchangeably herein. A knock-out represents
a DNA sequence of a cell that has been rendered partially or
completely inoperative by targeting with a Cas protein; for
example, a DNA sequence prior to knock-out could have encoded an
amino acid sequence, or could have had a regulatory function (e.g.,
promoter).
[0114] The terms "knock-in", "gene knock-in, "gene insertion" and
"genetic knock-in" are used interchangeably herein. A knock-in
represents the replacement or insertion of a DNA sequence at a
specific DNA sequence in cell by targeting with a Cas protein (for
example by homologous recombination (HR), wherein a suitable donor
DNA polynucleotide is also used). Examples of knock-ins are a
specific insertion of a heterologous amino acid coding sequence in
a coding region of a gene, or a specific insertion of a
transcriptional regulatory element in a genetic locus.
[0115] By "domain" it is meant a contiguous stretch of nucleotides
(that can be RNA, DNA, and/or RNA-DNA-combination sequence) or
amino acids.
[0116] The term "conserved domain" or "motif" means a set of
polynucleotides or amino acids conserved at specific positions
along an aligned sequence of evolutionarily related proteins. While
amino acids at other positions can vary between homologous
proteins, amino acids that are highly conserved at specific
positions indicate amino acids that are essential to the structure,
the stability, or the activity of a protein. Because they are
identified by their high degree of conservation in aligned
sequences of a family of protein homologues, they can be used as
identifiers, or "signatures", to determine if a protein with a
newly determined sequence belongs to a previously identified
protein family.
[0117] A "codon-modified gene" or "codon-preferred gene" or
"codon-optimized gene" is a gene having its frequency of codon
usage designed to mimic the frequency of preferred codon usage of
the host cell.
[0118] An "optimized" polynucleotide is a sequence that has been
optimized for improved expression or function in a particular
heterologous host cell.
[0119] A "plant-optimized nucleotide sequence" is a nucleotide
sequence that has been optimized for expression or function in
plants, particularly for increased expression in plants. A
plant-optimized nucleotide sequence includes a codon-optimized
gene. A plant-optimized nucleotide sequence can be synthesized by
modifying a nucleotide sequence encoding a protein such as, for
example, a Cas endonuclease as disclosed herein, using one or more
plant-preferred codons for improved expression. See, for example,
Campbell and Gowri (1990) Plant Physiol. 92:1-11 for a discussion
of host-preferred codon usage.
[0120] A "promoter" is a region of DNA involved in recognition and
binding of RNA polymerase and other proteins to initiate
transcription. The promoter sequence consists of proximal and more
distal upstream elements, the latter elements often referred to as
enhancers. An "enhancer" is a DNA sequence that can stimulate
promoter activity, and may be an innate element of the promoter or
a heterologous element inserted to enhance the level or
tissue-specificity of a promoter. Promoters may be derived in their
entirety from a native gene, or be composed of different elements
derived from different promoters found in nature, and/or comprise
synthetic DNA segments. It is understood by those skilled in the
art that different promoters may direct the expression of a gene in
different tissues or cell types, or at different stages of
development, or in response to different environmental conditions.
It is further recognized that since in most cases the exact
boundaries of regulatory sequences have not been completely
defined, DNA fragments of some variation may have identical
promoter activity.
[0121] Promoters that cause a gene to be expressed in most cell
types at most times are commonly referred to as "constitutive
promoters". The term "inducible promoter" refers to a promoter that
selectively express a coding sequence or functional RNA in response
to the presence of an endogenous or exogenous stimulus, for example
by chemical compounds (chemical inducers) or in response to
environmental, hormonal, chemical, and/or developmental signals.
Inducible or regulated promoters include, for example, promoters
induced or regulated by light, heat, stress, flooding or drought,
salt stress, osmotic stress, phytohormones, wounding, or chemicals
such as ethanol, abscisic acid (ABA), jasmonate, salicylic acid, or
safeners.
[0122] "Translation leader sequence" refers to a polynucleotide
sequence located between the promoter sequence of a gene and the
coding sequence. The translation leader sequence is present in the
mRNA upstream of the translation start sequence. The translation
leader sequence may affect processing of the primary transcript to
mRNA, mRNA stability or translation efficiency. Examples of
translation leader sequences have been described (e.g., Turner and
Foster, (1995) Mol Biotechnol 3:225-236).
[0123] "3' non-coding sequences", "transcription terminator" or
"termination sequences" refer to DNA sequences located downstream
of a coding sequence and include polyadenylation recognition
sequences and other sequences encoding regulatory signals capable
of affecting mRNA processing or gene expression. The
polyadenylation signal is usually characterized by affecting the
addition of polyadenylic acid tracts to the 3' end of the mRNA
precursor. The use of different 3' non-coding sequences is
exemplified by Ingelbrecht et al., (1989) Plant Cell 1:671-680.
[0124] "RNA transcript" refers to the product resulting from RNA
polymerase-catalyzed transcription of a DNA sequence. When the RNA
transcript is a perfect complimentary copy of the DNA sequence, it
is referred to as the primary transcript or pre-mRNA. A RNA
transcript is referred to as the mature RNA or mRNA when it is a
RNA sequence derived from post-transcriptional processing of the
primary transcript pre-mRNA. "Messenger RNA" or "mRNA" refers to
the RNA that is without introns and that can be translated into
protein by the cell. "cDNA" refers to a DNA that is complementary
to, and synthesized from, an mRNA template using the enzyme reverse
transcriptase. The cDNA can be single-stranded or converted into
double-stranded form using the Klenow fragment of DNA polymerase I.
"Sense" RNA refers to RNA transcript that includes the mRNA and can
be translated into protein within a cell or in vitro. "Antisense
RNA" refers to an RNA transcript that is complementary to all or
part of a target primary transcript or mRNA, and that blocks the
expression of a target gene (see, e.g., U.S. Pat. No. 5,107,065).
The complementarity of an antisense RNA may be with any part of the
specific gene transcript, i.e., at the 5' non-coding sequence, 3'
non-coding sequence, introns, or the coding sequence. "Functional
RNA" refers to antisense RNA, ribozyme RNA, or other RNA that may
not be translated yet has an effect on cellular processes. The
terms "complement" and "reverse complement" are used
interchangeably herein with respect to mRNA transcripts, and are
meant to define the antisense RNA of the message.
[0125] The term "genome" refers to the entire complement of genetic
material (genes and non-coding sequences) that is present in each
cell of an organism, or virus or organelle; and/or a complete set
of chromosomes inherited as a (haploid) unit from one parent.
[0126] The term "operably linked" refers to the association of
nucleic acid sequences on a single nucleic acid fragment so that
the function of one is regulated by the other. For example, a
promoter is operably linked with a coding sequence when it is
capable of regulating the expression of that coding sequence (i.e.,
the coding sequence is under the transcriptional control of the
promoter). Coding sequences can be operably linked to regulatory
sequences in a sense or antisense orientation. In another example,
the complementary RNA regions can be operably linked, either
directly or indirectly, 5' to the target mRNA, or 3' to the target
mRNA, or within the target mRNA, or a first complementary region is
5' and its complement is 3' to the target mRNA.
[0127] Generally, "host" refers to an organism or cell into which a
heterologous component (polynucleotide, polypeptide, other
molecule, cell) has been introduced. As used herein, a "host cell"
refers to an in vivo or in vitro eukaryotic cell, prokaryotic cell
(e.g., bacterial or archaeal cell), or cell from a multicellular
organism (e.g., a cell line) cultured as a unicellular entity, into
which a heterologous polynucleotide or polypeptide has been
introduced. In some embodiments, the cell is selected from the
group consisting of: an archaeal cell, a bacterial cell, a
eukaryotic cell, a eukaryotic single-cell organism, a somatic cell,
a germ cell, a stem cell, a plant cell, an algal cell, an animal
cell, in invertebrate cell, a vertebrate cell, a fish cell, a frog
cell, a bird cell, an insect cell, a mammalian cell, a pig cell, a
cow cell, a goat cell, a sheep cell, a rodent cell, a rat cell, a
mouse cell, a non-human primate cell, and a human cell. In some
cases, the cell is in vitro. In some cases, the cell is in
vivo.
[0128] The term "recombinant" refers to an artificial combination
of two otherwise separated segments of sequence, e.g., by chemical
synthesis, or manipulation of isolated segments of nucleic acids by
genetic engineering techniques.
[0129] The terms "plasmid", "vector" and "cassette" refer to a
linear or circular extra chromosomal element often carrying genes
that are not part of the central metabolism of the cell, and
usually in the form of double-stranded DNA. Such elements may be
autonomously replicating sequences, genome integrating sequences,
phage, or nucleotide sequences, in linear or circular form, of a
single- or double-stranded DNA or RNA, derived from any source, in
which a number of nucleotide sequences have been joined or
recombined into a unique construction which is capable of
introducing a polynucleotide of interest into a cell.
"Transformation cassette" refers to a specific vector comprising a
gene and having elements in addition to the gene that facilitates
transformation of a particular host cell. "Expression cassette"
refers to a specific vector comprising a gene and having elements
in addition to the gene that allow for expression of that gene in a
host.
[0130] The terms "recombinant DNA molecule", "recombinant DNA
construct", "expression construct", "construct", and "recombinant
construct" are used interchangeably herein. A recombinant DNA
construct comprises an artificial combination of nucleic acid
sequences, e.g., regulatory and coding sequences that are not all
found together in nature. For example, a recombinant DNA construct
may comprise regulatory sequences and coding sequences that are
derived from different sources, or regulatory sequences and coding
sequences derived from the same source, but arranged in a manner
different than that found in nature. Such a construct may be used
by itself or may be used in conjunction with a vector. If a vector
is used, then the choice of vector is dependent upon the method
that will be used to introduce the vector into the host cells as is
well known to those skilled in the art. For example, a plasmid
vector can be used. The skilled artisan is well aware of the
genetic elements that must be present on the vector in order to
successfully transform, select and propagate host cells. The
skilled artisan will also recognize that different independent
transformation events may result in different levels and patterns
of expression (Jones et al., (1985) EMBO J 4:2411-2418; De Almeida
et al., (1989) Mol Gen Genetics 218:78-86), and thus that multiple
events are typically screened in order to obtain lines displaying
the desired expression level and pattern. Such screening may be
accomplished standard molecular biological, biochemical, and other
assays including Southern analysis of DNA, Northern analysis of
mRNA expression, PCR, real time quantitative PCR (qPCR), reverse
transcription PCR (RT-PCR), immunoblotting analysis of protein
expression, enzyme or activity assays, and/or phenotypic
analysis.
[0131] The term "heterologous" refers to the difference between the
original environment, location, or composition of a particular
polynucleotide or polypeptide sequence and its current environment,
location, or composition. Non-limiting examples include differences
in taxonomic derivation (e.g., a polynucleotide sequence obtained
from Zea mays would be heterologous if inserted into the genome of
an Oryza sativa plant, or of a different variety or cultivar of Zea
mays; or a polynucleotide obtained from a bacterium was introduced
into a cell of a plant), or sequence (e.g., a polynucleotide
sequence obtained from Zea mays, isolated, modified, and
re-introduced into a maize plant). As used herein, "heterologous"
in reference to a sequence can refer to a sequence that originates
from a different species, variety, foreign species, or, if from the
same species, is substantially modified from its native form in
composition and/or genomic locus by deliberate human intervention.
For example, a promoter operably linked to a heterologous
polynucleotide is from a species different from the species from
which the polynucleotide was derived, or, if from the
same/analogous species, one or both are substantially modified from
their original form and/or genomic locus, or the promoter is not
the native promoter for the operably linked polynucleotide.
Alternatively, one or more regulatory region(s) and/or a
polynucleotide provided herein may be entirely synthetic.
[0132] The term "expression", as used herein, refers to the
production of a functional end-product (e.g., an mRNA, guide RNA,
or a protein) in either precursor or mature form.
[0133] A "mature" protein refers to a post-translationally
processed polypeptide (i.e., one from which any pre- or propeptides
present in the primary translation product have been removed).
[0134] "Precursor" protein refers to the primary product of
translation of mRNA (i.e., with pre- and propeptides still
present). Pre- and propeptides may be but are not limited to
intracellular localization signals.
[0135] "CRISPR" (Clustered Regularly Interspaced Short Palindromic
Repeats) loci refers to certain genetic loci encoding components of
DNA cleavage systems, for example, used by bacterial and archaeal
cells to destroy foreign DNA (Horvath and Barrangou, 2010, Science
327:167-170; WO2007025097, published 1 Mar. 2007). A CRISPR locus
can consist of a CRISPR array, comprising short direct repeats
(CRISPR repeats) separated by short variable DNA sequences (called
spacers), which can be flanked by diverse Cas (CRISPR-associated)
genes.
[0136] As used herein, an "effector" or "effector protein" is a
protein that encompasses an activity including recognizing, binding
to, and/or cleaving or nicking a polynucleotide target. The
"effector complex" of a CRISPR system includes Cas proteins
involved in crRNA and target recognition and binding. Some of the
component Cas proteins may additionally comprise domains involved
in target polynucleotide cleavage.
[0137] The term "Cas protein" refers to a polypeptide encoded by a
Cas (CRISPR-associated) gene. A Cas protein includes but is not
limited to: the novel Cas9 orthologs disclosed herein, a Cas9
protein, a Cpf1 (Cas12) protein, a C2c1 protein, a C2c2 protein, a
C2c3 protein, Cas3, Cas3-HD, Cas 5, Cas7, Cas8, Cas10, or
combinations or complexes of these. A Cas protein may be a "Cas
endonuclease", that when in complex with a suitable polynucleotide
component, is capable of recognizing, binding to, and optionally
nicking or cleaving all or part of a specific polynucleotide target
sequence. A Cas endonuclease described herein comprises one or more
nuclease domains. A Cas protein is further defined as a functional
fragment or functional variant of a native Cas protein, or a
protein that shares at least 50%, between 50% and 55%, at least
55%, between 55% and 60%, at least 60%, between 60% and 65%, at
least 65%, between 65% and 70%, at least 70%, between 70% and 75%,
at least 75%, between 75% and 80%, at least 80%, between 80% and
85%, at least 85%, between 85% and 90%, at least 90%, between 90%
and 95%, at least 95%, between 95% and 96%, at least 96%, between
96% and 97%, at least 97%, between 97% and 98%, at least 98%,
between 98% and 99%, at least 99%, between 99% and 100%, or 100%
sequence identity with at least 50, between 50 and 100, at least
100, between 100 and 150, at least 150, between 150 and 200, at
least 200, between 200 and 250, at least 250, between 250 and 300,
at least 300, between 300 and 350, at least 350, between 350 and
400, at least 400, between 400 and 450, at least 500, or greater
than 500 contiguous amino acids of a native Cas protein, and
retains at least partial activity.
[0138] A "functional fragment", "fragment that is functionally
equivalent" and "functionally equivalent fragment" of a Cas
endonuclease are used interchangeably herein, and refer to a
portion or subsequence of the Cas endonuclease of the present
disclosure in which the ability to recognize, bind to, and
optionally unwind, nick or cleave (introduce a single or
double-strand break in) the target site is retained. The portion or
subsequence of the Cas endonuclease can comprise a complete or
partial (functional) peptide of any one of its domains such as for
example, but not limiting to a complete or functional part of a HD
domain, a complete or functional part of a helicase domain, a
complete or functional part of an endonuclease domain, a complete
or functional part of a PAM-interacting domain, a complete or
functional part of a Wedge domain, a complete or functional part of
an RuvC domain, a complete or functional part of a zinc-finger
domain, or a complete or functional part of a Cas protein (such as
but not limiting to a Cas9, Cpf1, Cas5, Cas5d, Cas7, Cas8b1, Cas1,
Cas2, Cas4, or Cas9 ortholog).
[0139] The terms "functional variant", "variant that is
functionally equivalent" and "functionally equivalent variant" of a
Cas endonuclease or Cas endonuclease, including Cas9 ortholog
described herein, are used interchangeably herein, and refer to a
variant of the Cas endonuclease disclosed herein in which the
ability to recognize, bind to, and optionally unwind, nick or
cleave all or part of a target sequence is retained.
[0140] In some aspects, a functional fragment or functional variant
retains about the same level and type (e.g., target polynucleotide
recognition, binding, and cleavage) of activity as the parental
molecule from which it was derived. In some aspects, a functional
fragment or functional variant displays improved activity of the
same type (e.g., increased specificity of target polynucleotide
recognition) as the parental molecule from which it was derived. In
some aspects, a functional fragment or functional variant displays
reduced activity of the same type (e.g., lower target
polynucleotide binding affinity) as the parental molecule from
which it was derived. In some aspects, a functional fragment or
functional variant displays partial activity (e.g. polynucleotide
recognition and binding, but not cleavage) as the parental molecule
from which it was derived. In some aspects, a functional fragment
or functional variant displays a different type of activity (e.g.,
creation of a single-strand nick on a target polynucleotide vs. a
double strand break) than the parental molecule from which it was
derived. Any similarity or difference in type or level of activity
may be chosen as a desired outcome, according to the needs of the
practitioner.
[0141] A Cas endonuclease may also include a multifunctional Cas
endonuclease. The term "multifunctional Cas endonuclease" and
"multifunctional Cas endonuclease polypeptide" are used
interchangeably herein and includes reference to a single
polypeptide that has Cas endonuclease functionality (comprising at
least one protein domain that can act as a Cas endonuclease) and at
least one other functionality, such as but not limited to, the
functionality to form a cascade (comprises at least a second
protein domain that can form a cascade with other proteins). In one
aspect, the multifunctional Cas endonuclease comprises at least one
additional protein domain relative (either internally, upstream
(5'), downstream (3'), or both internally 5' and 3', or any
combination thereof) to those domains typical of a Cas
endonuclease.
[0142] The terms "cascade" and "cascade complex" are used
interchangeably herein and include reference to a multi-subunit
protein complex that can assemble with a polynucleotide forming a
polynucleotide-protein complex (PNP). Cascade is a PNP that relies
on the polynucleotide for complex assembly and stability, and for
the identification of target nucleic acid sequences. Cascade
functions as a surveillance complex that finds and optionally binds
target nucleic acids that are complementary to a variable targeting
domain of the guide polynucleotide.
[0143] The terms "cleavage-ready Cascade", "crCascade",
"cleavage-ready Cascade complex", "crCascade complex",
"cleavage-ready Cascade system", "CRC" and "crCascade system", are
used interchangeably herein and include reference to a
multi-subunit protein complex that can assemble with a
polynucleotide forming a polynucleotide-protein complex (PNP),
wherein one of the cascade proteins is a Cas endonuclease capable
of recognizing, binding to, and optionally unwinding, nicking, or
cleaving all or part of a target sequence.
[0144] The terms "5'-cap" and "7-methylguanylate (m7G) cap" are
used interchangeably herein. A 7-methylguanylate residue is located
on the 5' terminus of messenger RNA (mRNA) in eukaryotes. RNA
polymerase II (Pol II) transcribes mRNA in eukaryotes. Messenger
RNA capping occurs generally as follows: The most terminal 5'
phosphate group of the mRNA transcript is removed by RNA terminal
phosphatase, leaving two terminal phosphates. A guanosine
monophosphate (GMP) is added to the terminal phosphate of the
transcript by a guanylyl transferase, leaving a 5'-5'
triphosphate-linked guanine at the transcript terminus. Finally,
the 7-nitrogen of this terminal guanine is methylated by a methyl
transferase.
[0145] The terminology "not having a 5'-cap" herein is used to
refer to RNA having, for example, a 5'-hydroxyl group instead of a
5'-cap. Such RNA can be referred to as "uncapped RNA", for example.
Uncapped RNA can better accumulate in the nucleus following
transcription, since 5'-capped RNA is subject to nuclear export.
One or more RNA components herein are uncapped.
[0146] As used herein, the term "guide polynucleotide", relates to
a polynucleotide sequence that can form a complex with a Cas
endonuclease, including the Cas endonuclease described herein, and
enables the Cas endonuclease to recognize, optionally bind to, and
optionally cleave a DNA target site. The guide polynucleotide
sequence can be a RNA sequence, a DNA sequence, or a combination
thereof (a RNA-DNA combination sequence).
[0147] The terms "functional fragment", "fragment that is
functionally equivalent" and "functionally equivalent fragment" of
a guide RNA, crRNA or tracrRNA are used interchangeably herein, and
refer to a portion or subsequence of the guide RNA, crRNA or
tracrRNA, respectively, of the present disclosure in which the
ability to function as a guide RNA, crRNA or tracrRNA,
respectively, is retained.
[0148] The terms "functional variant", "variant that is
functionally equivalent" and "functionally equivalent variant" of a
guide RNA, crRNA or tracrRNA (respectively) are used
interchangeably herein, and refer to a variant of the guide RNA,
crRNA or tracrRNA, respectively, of the present disclosure in which
the ability to function as a guide RNA, crRNA or tracrRNA,
respectively, is retained.
[0149] The terms "single guide RNA" and "sgRNA" are used
interchangeably herein and relate to a synthetic fusion of two RNA
molecules, a crRNA (CRISPR RNA) comprising a variable targeting
domain (linked to a tracr mate sequence that hybridizes to a
tracrRNA), fused to a tracrRNA (trans-activating CRISPR RNA). The
single guide RNA can comprise a crRNA or crRNA fragment and a
tracrRNA or tracrRNA fragment of the type II CRISPR/Cas system that
can form a complex with a type II Cas endonuclease, wherein said
guide RNA/Cas endonuclease complex can direct the Cas endonuclease
to a DNA target site, enabling the Cas endonuclease to recognize,
optionally bind to, and optionally nick or cleave (introduce a
single or double-strand break) the DNA target site.
[0150] The term "variable targeting domain" or "VT domain" is used
interchangeably herein and includes a nucleotide sequence that can
hybridize (is complementary) to one strand (nucleotide sequence) of
a double strand DNA target site. The percent complementation
between the first nucleotide sequence domain (VT domain) and the
target sequence can be at least 50%, 51%, 52%, 53%, 54%, 55%, 56%,
57%, 58%, 59%, 60%, 61%, 62%, 63%, 63%, 65%, 66%, 67%, 68%, 69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%,
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99% or 100%. The variable targeting domain can be at
least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29 or 30 nucleotides in length. In some embodiments, the
variable targeting domain comprises a contiguous stretch of 12 to
30 nucleotides. The variable targeting domain can be composed of a
DNA sequence, a RNA sequence, a modified DNA sequence, a modified
RNA sequence, or any combination thereof.
[0151] The term "Cas endonuclease recognition domain" or "CER
domain" (of a guide polynucleotide) is used interchangeably herein
and includes a nucleotide sequence that interacts with a Cas
endonuclease polypeptide. A CER domain comprises a (trans-acting)
tracrNucleotide mate sequence followed by a tracrNucleotide
sequence. The CER domain can be composed of a DNA sequence, a RNA
sequence, a modified DNA sequence, a modified RNA sequence (see for
example US20150059010A1, published 26 Feb. 2015), or any
combination thereof.
[0152] As used herein, the terms "guide polynucleotide/Cas
endonuclease complex", "guide polynucleotide/Cas endonuclease
system", "guide polynucleotide/Cas complex", "guide
polynucleotide/Cas system" and "guided Cas system"
"polynucleotide-guided endonuclease", and "PGEN" are used
interchangeably herein and refer to at least one guide
polynucleotide and at least one Cas endonuclease, that are capable
of forming a complex, wherein said guide polynucleotide/Cas
endonuclease complex can direct the Cas endonuclease to a DNA
target site, enabling the Cas endonuclease to recognize, bind to,
and optionally nick or cleave (introduce a single or double-strand
break) the DNA target site. A guide polynucleotide/Cas endonuclease
complex herein can comprise Cas protein(s) and suitable
polynucleotide component(s) of any of the known CRISPR systems
(Horvath and Barrangou, 2010, Science 327:167-170; Makarova et al.
2015, Nature Reviews Microbiology Vol. 13:1-15; Zetsche et al.,
2015, Cell 163, 1-13; Shmakov et al., 2015, Molecular Cell 60,
1-13).
[0153] The terms "guide RNA/Cas endonuclease complex", "guide
RNA/Cas endonuclease system", "guide RNA/Cas complex", "guide
RNA/Cas system", "gRNA/Cas complex", "gRNA/Cas system", "RNA-guided
endonuclease", and "RGEN" are used interchangeably herein and refer
to at least one RNA component and at least one Cas endonuclease
that are capable of forming a complex, wherein said guide RNA/Cas
endonuclease complex can direct the Cas endonuclease to a DNA
target site, enabling the Cas endonuclease to recognize, bind to,
and optionally nick or cleave (introduce a single or double-strand
break) the DNA target site. In some aspects, the components are
provided as a ribonucleoprotein complex ("RNP") of a Cas
endonuclease protein and a guide RNA.
[0154] The terms "target site", "target sequence", "target site
sequence," target DNA", "target locus", "genomic target site",
"genomic target sequence", "genomic target locus" and
"protospacer", are used interchangeably herein and refer to a
polynucleotide sequence such as, but not limited to, a nucleotide
sequence on a chromosome, episome, a locus, or any other DNA
molecule in the genome (including chromosomal, chloroplastic,
mitochondrial DNA, plasmid DNA) of a cell, at which a guide
polynucleotide/Cas endonuclease complex can recognize, bind to, and
optionally nick or cleave. The target site can be an endogenous
site in the genome of a cell, or alternatively, the target site can
be heterologous to the cell and thereby not be naturally occurring
in the genome of the cell, or the target site can be found in a
heterologous genomic location compared to where it occurs in
nature. As used herein, terms "endogenous target sequence" and
"native target sequence" are used interchangeable herein to refer
to a target sequence that is endogenous or native to the genome of
a cell and is at the endogenous or native position of that target
sequence in the genome of the cell. An "artificial target site" or
"artificial target sequence" are used interchangeably herein and
refer to a target sequence that has been introduced into the genome
of a cell. Such an artificial target sequence can be identical in
sequence to an endogenous or native target sequence in the genome
of a cell but be located in a different position (i.e., a
non-endogenous or non-native position) in the genome of a cell.
[0155] A "protospacer adjacent motif" (PAM) herein refers to a
short nucleotide sequence adjacent to a target sequence
(protospacer) that is recognized (targeted) by a guide
polynucleotide/Cas endonuclease system described herein. In some
aspects, the Cas endonuclease may not successfully recognize a
target DNA sequence if the target DNA sequence is not adjacent to,
or near, a PAM sequence. In some aspects, the PAM precedes the
target sequence (e.g. Cas12a). In some aspects, the PAM follows the
target sequence (e.g. S. pyogenes Cas9). The sequence and length of
a PAM herein can differ depending on the Cas protein or Cas protein
complex used. The PAM sequence can be of any length but is
typically 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19 or 20 nucleotides long.
[0156] An "altered target site", "altered target sequence",
"modified target site", "modified target sequence" are used
interchangeably herein and refer to a target sequence as disclosed
herein that comprises at least one alteration when compared to
non-altered target sequence. Such "alterations" include, for
example: (i) replacement of at least one nucleotide, (ii) a
deletion of at least one nucleotide, (iii) an insertion of at least
one nucleotide, or (iv) any combination of (i)-(iii).
[0157] A "modified nucleotide" or "edited nucleotide" refers to a
nucleotide sequence of interest that comprises at least one
alteration when compared to its non-modified nucleotide sequence.
Such "alterations" include, for example: (i) replacement of at
least one nucleotide, (ii) a deletion of at least one nucleotide,
(iii) an insertion of at least one nucleotide, or (iv) any
combination of (i)-(iii).
[0158] Methods for "modifying a target site" and "altering a target
site" are used interchangeably herein and refer to methods for
producing an altered target site.
[0159] As used herein, "donor DNA" is a DNA construct that
comprises a polynucleotide of interest to be inserted into the
target site of a Cas endonuclease.
[0160] The term "polynucleotide modification template" includes a
polynucleotide that comprises at least one nucleotide modification
when compared to the nucleotide sequence to be edited. A nucleotide
modification can be at least one nucleotide substitution, addition
or deletion. Optionally, the polynucleotide modification template
can further comprise homologous nucleotide sequences flanking the
at least one nucleotide modification, wherein the flanking
homologous nucleotide sequences provide sufficient homology to the
desired nucleotide sequence to be edited.
[0161] The term "plant-optimized Cas endonuclease" herein refers to
a Cas protein, including a multifunctional Cas protein, encoded by
a nucleotide sequence that has been optimized for expression in a
plant cell or plant.
[0162] A "plant-optimized nucleotide sequence encoding a Cas
endonuclease", "plant-optimized construct encoding a Cas
endonuclease" and a "plant-optimized polynucleotide encoding a Cas
endonuclease" are used interchangeably herein and refer to a
nucleotide sequence encoding a Cas protein, or a variant or
functional fragment thereof, that has been optimized for expression
in a plant cell or plant.
[0163] The term "plant" generically includes whole plants, plant
organs, plant tissues, seeds, plant cells, seeds and progeny of the
same. Plant cells include, without limitation, cells from seeds,
suspension cultures, embryos, meristematic regions, callus tissue,
leaves, roots, shoots, gametophytes, sporophytes, pollen and
microspores. A "plant element" is intended to reference either a
whole plant or a plant component, which may comprise differentiated
and/or undifferentiated tissues, for example but not limited to
plant tissues, parts, and cell types. In one embodiment, a plant
element is one of the following: whole plant, seedling,
meristematic tissue, ground tissue, vascular tissue, dermal tissue,
seed, leaf, root, shoot, stem, flower, fruit, stolon, bulb, tuber,
corm, keiki, shoot, bud, tumor tissue, and various forms of cells
and culture (e.g., single cells, protoplasts, embryos, callus
tissue). The term "plant organ" refers to plant tissue or a group
of tissues that constitute a morphologically and functionally
distinct part of a plant. As used herein, a "plant element" is
synonymous to a "portion" of a plant, and refers to any part of the
plant, and can include distinct tissues and/or organs, and may be
used interchangeably with the term "tissue" throughout. Similarly,
a "plant reproductive element" is intended to generically reference
any part of a plant that is able to initiate other plants via
either sexual or asexual reproduction of that plant, for example
but not limited to: seed, seedling, root, shoot, cutting, scion,
graft, stolon, bulb, tuber, corm, keiki, or bud. The plant element
may be in plant or in a plant organ, tissue culture, or cell
culture.
[0164] "Progeny" comprises any subsequent generation of a
plant.
[0165] As used herein, the term "plant part" refers to plant cells,
plant protoplasts, plant cell tissue cultures from which plants can
be regenerated, plant calli, plant clumps, and plant cells that are
intact in plants or parts of plants such as embryos, pollen,
ovules, seeds, leaves, flowers, branches, fruit, kernels, ears,
cobs, husks, stalks, roots, root tips, anthers, and the like, as
well as the parts themselves. Grain is intended to mean the mature
seed produced by commercial growers for purposes other than growing
or reproducing the species. Progeny, variants, and mutants of the
regenerated plants are also included within the scope of the
invention, provided that these parts comprise the introduced
polynucleotides.
[0166] The term "monocotyledonous" or "monocot" refers to the
subclass of angiosperm plants also known as "monocotyledoneae",
whose seeds typically comprise only one embryonic leaf, or
cotyledon. The term includes references to whole plants, plant
elements, plant organs (e.g., leaves, stems, roots, etc.), seeds,
plant cells, and progeny of the same.
[0167] The term "dicotyledonous" or "dicot" refers to the subclass
of angiosperm plants also knows as "dicotyledoneae", whose seeds
typically comprise two embryonic leaves, or cotyledons. The term
includes references to whole plants, plant elements, plant organs
(e.g., leaves, stems, roots, etc.), seeds, plant cells, and progeny
of the same.
[0168] As used herein, a "male sterile plant" is a plant that does
not produce male gametes that are viable or otherwise capable of
fertilization. As used herein, a "female sterile plant" is a plant
that does not produce female gametes that are viable or otherwise
capable of fertilization. It is recognized that male-sterile and
female-sterile plants can be female-fertile and male-fertile,
respectively. It is further recognized that a male fertile (but
female sterile) plant can produce viable progeny when crossed with
a female fertile plant and that a female fertile (but male sterile)
plant can produce viable progeny when crossed with a male fertile
plant.
[0169] The term "non-conventional yeast" herein refers to any yeast
that is not a Saccharomyces (e.g., S. cerevisiae) or
Schizosaccharomyces yeast species. (see "Non-Conventional Yeasts in
Genetics, Biochemistry and Biotechnology: Practical Protocols", K.
Wolf, K. D. Breunig, G. Barth, Eds., Springer-Verlag, Berlin,
Germany, 2003).
[0170] The term "crossed" or "cross" or "crossing" in the context
of this disclosure means the fusion of gametes via pollination to
produce progeny (i.e., cells, seeds, or plants). The term
encompasses both sexual crosses (the pollination of one plant by
another) and selfing (self-pollination, i.e., when the pollen and
ovule (or microspores and megaspores) are from the same plant or
genetically identical plants).
[0171] The term "introgression" refers to the transmission of a
desired allele of a genetic locus from one genetic background to
another. For example, introgression of a desired allele at a
specified locus can be transmitted to at least one progeny plant
via a sexual cross between two parent plants, where at least one of
the parent plants has the desired allele within its genome.
Alternatively, for example, transmission of an allele can occur by
recombination between two donor genomes, e.g., in a fused
protoplast, where at least one of the donor protoplasts has the
desired allele in its genome. The desired allele can be, e.g., a
transgene, a modified (mutated or edited) native allele, or a
selected allele of a marker or QTL.
[0172] The term "isoline" is a comparative term, and references
organisms that are genetically identical, but differ in treatment.
In one example, two genetically identical maize plant embryos may
be separated into two different groups, one receiving a treatment
(such as the introduction of a CRISPR-Cas effector endonuclease)
and one control that does not receive such treatment. Any
phenotypic differences between the two groups may thus be
attributed solely to the treatment and not to any inherency of the
plant's endogenous genetic makeup.
[0173] "Introducing" is intended to mean presenting to a target,
such as a cell or organism, a polynucleotide or polypeptide or
polynucleotide-protein complex, in such a manner that the
component(s) gains access to the interior of a cell of the organism
or to the cell itself.
[0174] A "polynucleotide of interest" includes any nucleotide
sequence encoding a protein or polypeptide that improves
desirability of crops. Polynucleotides of interest: include, but
are not limited to, polynucleotides encoding important traits for
agronomics, herbicide-resistance, insecticidal resistance, disease
resistance, nematode resistance, herbicide resistance, microbial
resistance, fungal resistance, viral resistance, fertility or
sterility, grain characteristics, commercial products, phenotypic
marker, or any other trait of agronomic or commercial importance. A
polynucleotide of interest may additionally be utilized in either
the sense or anti-sense orientation. Further, more than one
polynucleotide of interest may be utilized together, or "stacked",
to provide additional benefit.
[0175] A "complex trait locus" includes a genomic locus that has
multiple transgenes genetically linked to each other.
[0176] The compositions and methods herein may provide for an
improved "agronomic trait" or "trait of agronomic importance" or
"trait of agronomic interest" to a plant, which may include, but
not be limited to, the following: disease resistance, drought
tolerance, heat tolerance, cold tolerance, salinity tolerance,
metal tolerance, herbicide tolerance, improved water use
efficiency, improved nitrogen utilization, improved nitrogen
fixation, pest resistance, herbivore resistance, pathogen
resistance, yield improvement, health enhancement, vigor
improvement, growth improvement, photosynthetic capability
improvement, nutrition enhancement, altered protein content,
altered oil content, increased biomass, increased shoot length,
increased root length, improved root architecture, modulation of a
metabolite, modulation of the proteome, increased seed weight,
altered seed carbohydrate composition, altered seed oil
composition, altered seed protein composition, altered seed
nutrient composition, as compared to an isoline plant not
comprising a modification derived from the methods or compositions
herein.
[0177] "Agronomic trait potential" is intended to mean a capability
of a plant element for exhibiting a phenotype, preferably an
improved agronomic trait, at some point during its life cycle, or
conveying said phenotype to another plant element with which it is
associated in the same plant.
[0178] The terms "decreased," "fewer," "slower" and "increased"
"faster" "enhanced" "greater" as used herein refers to a decrease
or increase in a characteristic of the modified plant element or
resulting plant compared to an unmodified plant element or
resulting plant. For example, a decrease in a characteristic may be
at least 1%, at least 2%, at least 3%, at least 4%, at least 5%,
between 5% and 10%, at least 10%, between 10% and 20%, at least
15%, at least 20%, between 20% and 30%, at least 25%, at least 30%,
between 30% and 40%, at least 35%, at least 40%, between 40% and
50%, at least 45%, at least 50%, between 50% and 60%, at least 60%,
between 60% and 70%, between 70% and 80%, at least 75%, at least
80%, between 80% and 90%, at least 90%, between 90% and 100%, at
least 100%, between 100% and 200%, at least 200%, at least 300%, at
least 400%) or more lower than the untreated control and an
increase may be at least 1%, at least 2%, at least 3%, at least 4%,
at least 5%, between 5% and 10%, at least 10%, between 10% and 20%,
at least 15%, at least 20%, between 20% and 30%, at least 25%, at
least 30%, between 30% and 40%, at least 35%, at least 40%, between
40% and 50%, at least 45%, at least 50%, between 50% and 60%, at
least 60%, between 60% and 70%, between 70% and 80%, at least 75%,
at least 80%, between 80% and 90%, at least 90%, between 90% and
100%, at least 100%, between 100% and 200%, at least 200%, at least
300%), at least 400% or more higher than the untreated control.
[0179] As used herein, the term "before", in reference to a
sequence position, refers to an occurrence of one sequence
upstream, or 5', to another sequence.
[0180] The meaning of abbreviations is as follows: "sec" means
second(s), "min" means minute(s), "h" means hour(s), "d" means
day(s), "uL" means microliter(s), "mL" means milliliter(s), "L"
means liter(s), "uM" means micromolar, "mM" means millimolar, "M"
means molar, "mmol" means millimole(s), "umole" or "umole" mean
micromole(s), "g" means gram(s), "ug" or "ug" means microgram(s),
"ng" means nanogram(s), "U" means unit(s), "bp" means base pair(s)
and "kb" means kilobase(s).
Classification of CRISPR-Cas Systems
[0181] CRISPR-Cas systems have been classified according to
sequence and structural analysis of components. Multiple CRISPR/Cas
systems have been described including Class 1 systems, with
multisubunit effector complexes (comprising type I, type III, and
type IV), and Class 2 systems, with single protein effectors
(comprising type II, type V, and type VI) (Makarova et al. 2015,
Nature Reviews Microbiology Vol. 13:1-15; Zetsche et al., 2015,
Cell 163, 1-13; Shmakov et al., 2015, Molecular Cell 60, 1-13; Haft
et al., 2005, Computational Biology, PLoS Comput Biol 1(6): e60;
and Koonin et al. 2017, Curr Opinion Microbiology 37:67-78).
[0182] A CRISPR-Cas system comprises, at a minimum, a CRISPR RNA
(crRNA) molecule and at least one CRISPR-associated (Cas) protein
to form crRNA ribonucleoprotein (crRNP) effector complexes.
CRISPR-Cas loci comprise an array of identical repeats interspersed
with DNA-targeting spacers that encode the crRNA components and an
operon-like unit of cas genes encoding the Cas protein components.
The resulting ribonucleoprotein complex is called a Cascade, that
recognizes a polynucleotide in a sequence-specific manner (Jore et
al., Nature Structural & Molecular Biology 18, 529-536 (2011)).
The crRNA serves as a guide RNA for sequence specific binding of
the effector (protein or complex) to double strand DNA sequences,
by forming base pairs with the complementary DNA strand while
displacing the noncomplementary strand to form a so-called R-loop.
(Jore et al., 2011. Nature Structural & Molecular Biology 18,
529-536).
[0183] The Cas endonuclease is guided by a single CRISPR RNA
(crRNA) through direct RNA-DNA base-pairing to recognize a DNA
target site that is in close vicinity to a protospacer adjacent
motif (PAM) (Jore, M. M. et al., 2011, Nat. Struct. Mol. Biol.
18:529-536, Westra, E. R. et al., 2012, Molecular Cell 46:595-605,
and Sinkunas, T. et al., 2013, EMBO J. 32:385-394). Class 1
CRISPR-Cas systems comprise Types I, III, and IV. A characteristic
feature of Class I systems is the presence of an effector
endonuclease complex instead of a single protein. Class 2
CRISPR-Cas systems comprise Types II, V, and VI. A characteristic
feature of Class 2 systems is the presence of a single Cas protein
instead of an effector module endonuclease complex. Types II and V
Cas proteins comprise an RuvC-like endonuclease domain that adopts
the RNase H fold.
[0184] Class 2 Type II CRISPR/Cas systems employ a crRNA and
tracrRNA (trans-activating CRISPR RNA) to guide the Cas
endonuclease to its DNA target. The crRNA comprises a spacer region
complementary to one strand of the double strand DNA target and a
region that base pairs with the tracrRNA (trans-activating CRISPR
RNA) forming a RNA duplex that directs the Cas endonuclease to
cleave the DNA target. For the S. pyogenes Cas9 endonuclease, the
cleavage leaves a blunt end. Type II CRISR-Cas loci can encode a
tracrRNA, which is partially complementary to the repeats within
the respective CRISPR array, and can comprise other proteins.
Cas Endonuclease CRISPR-Cas System Components
Cas Endonucleases and Effectors
[0185] Endonucleases are enzymes that cleave the phosphodiester
bond within a polynucleotide chain. Examples of endonucleases
include restriction endonucleases, meganucleases, TAL effector
nucleases (TALENs), zinc finger nucleases, and Cas
(CRISPR-associated) effector endonucleases.
[0186] Cas endonucleases, either as single effector proteins or in
an effector complex with other components, unwind the DNA duplex at
the target sequence and optionally cleave at least one DNA strand,
as mediated by recognition of the target sequence by a
polynucleotide (such as, but not limited to, a crRNA or guide RNA)
that is in complex with the Cas endonuclease. Such recognition and
cutting of a target sequence by a Cas endonuclease typically occurs
if the correct protospacer-adjacent motif (PAM) is located at or
adjacent to the 3' end of the DNA target sequence. Alternatively, a
Cas endonuclease herein may lack DNA cleavage or nicking activity,
but can still specifically bind to a DNA target sequence when
complexed with a suitable RNA component. (See also U.S. Patent
Application US20150082478 published 19 Mar. 2015 and US20150059010
published 26 Feb. 2015).
[0187] Cas endonucleases that have been described include, but are
not limited to, for example: Cas3 (a feature of Class 1 type I
systems), Cas9 (a feature of Class 2 type II systems) and Cas12
(Cpf1) (a feature of Class 2 type V systems).
[0188] Cas9 (formerly referred to as Cas5, Csn1, or Csx12) is a Cas
endonuclease that forms a complex with a crNucleotide and a
tracrNucleotide, or with a single guide polynucleotide, for
specifically recognizing and cleaving all or part of a DNA target
sequence. The canonical Cas9 recognizes a 3' GC-rich PAM sequence
on the target dsDNA, typically comprising an NGG motif. The Cas9
orthologs described herein may recognize additional PAM sequences
and used to modify target sites with different recognition sequence
specificity.
[0189] A Cas9 protein comprises a RuvC nuclease with an HNH
(H--N--H) nuclease adjacent to the RuvC-II domain. The RuvC
nuclease and HNH nuclease each can cleave a single DNA strand at a
target sequence (the concerted action of both domains leads to DNA
double-strand cleavage, whereas activity of one domain leads to a
nick). In general, the RuvC domain comprises subdomains I, II and
III, where domain I is located near the N-terminus of Cas9 and
subdomains II and III are located in the middle of the protein,
flanking the HNH domain (Hsu et al., 2013, Cell 157:1262-1278).
Cas9 endonucleases are typically derived from a type II CRISPR
system, which includes a DNA cleavage system utilizing a Cas9
endonuclease in complex with at least one polynucleotide component.
For example, a Cas9 can be in complex with a CRISPR RNA (crRNA) and
a trans-activating CRISPR RNA (tracrRNA). In another example, a
Cas9 can be in complex with a single guide RNA (Makarova et al.
2015, Nature Reviews Microbiology Vol. 13:1-15).
[0190] Cas endonucleases and effector proteins can be used for
targeted genome editing (via simplex and multiplex double-strand
breaks and nicks) and targeted genome regulation (via tethering of
epigenetic effector domains to either the Cas protein or sgRNA. A
Cas endonuclease can also be engineered to function as an
RNA-guided recombinase, and via RNA tethers could serve as a
scaffold for the assembly of multiprotein and nucleic acid
complexes (Mali et al., 2013, Nature Methods Vol. 10: 957-963).
[0191] The Cas9 orthologs described herein further comprise
endonuclease activity.
[0192] A Cas9 ortholog protein is further defined as a functional
fragment or functional variant of a native Cas9 ortholog protein,
or a protein that shares at least 50%, between 50% and 55%, at
least 55%, between 55% and 60%, at least 60%, between 60% and 65%,
at least 65%, between 65% and 70%, at least 70%, between 70% and
75%, at least 75%, between 75% and 80%, at least 80%, between 80%
and 85%, at least 85%, between 85% and 90%, at least 90%, between
90% and 95%, at least 95%, between 95% and 96%, at least 96%,
between 96% and 97%, at least 97%, between 97% and 98%, at least
98%, between 98% and 99%, at least 99%, between 99% and 100%, or
100% sequence identity with at least 50, between 50 and 100, at
least 100, between 100 and 150, at least 150, between 150 and 200,
at least 200, between 200 and 250, at least 250, between 250 and
300, at least 300, between 300 and 350, at least 350, between 350
and 400, at least 400, between 400 and 450, at least 500, between
500 and 550, at least 550, between 550 and 600, at least 600,
between 600 and 650, at least 650, between 650 and 700, at least
700, between 700 and 750, at least 750, between 750 and 800, at
least 800, between 800 and 850, at least 850, between 850 and 900,
at least 900, between 900 and 950, at least 950, between 950 and
1000, at least 1000, or even than 1000 contiguous amino acids of
any of SEQID NO:86-170 and 511-1135, and retains at least partial
activity of the native, full-length Cas9 ortholog protein of any of
SEQID NO:86-170 and 511-1135.
[0193] In some aspects, a Cas9 ortholog may comprises a polypeptide
selected from the group consisting of: a polypeptide sharing at
least 80%, between 80% and 85%, at least 85%, between 85% and 90%,
at least 90%, between 90% and 95%, at least 95%, at least 96%, at
least 97%, at least 98%, at least 99%, at least 99.5%, or greater
than 99.5% identity with at least 50, between 50 and 100, at least
100, between 100 and 150, at least 150, between 150 and 200, at
least 200, between 200 and 250, at least 250, between 250 and 300,
at least 300, between 300 and 350, at least 350, between 350 and
400, at least 400, between 400 and 450, at least 500, between 500
and 550, at least 550, between 550 and 600, at least 600, between
600 and 650, at least 650, between 650 and 700, at least 700,
between 700 and 750, at least 750, between 750 and 800, at least
800, between 800 and 850, at least 850, between 850 and 900, at
least 900, between 900 and 950, at least 950, between 950 and 1000,
at least 1000, or even than 1000 contiguous amino acids of any of
any of: SEQID NO:86-171 and 511-1135; a functional variant of any
of SEQID NO:86-171 and 511-1135; a functional fragment of any of
SEQID NO:86-171 and 511-1135; a Cas endonuclease encoded by a
polynucleotide selected from the group consisting of: SEQID
NO:1-85; a Cas endonuclease that recognizes a PAM sequence listed
in any of Tables 4-83; a Cas endonuclease that recognizes a PAM
sequence selected from the group consisting of: NAR (G>A)WH
(A>T>C)GN (C>T>R), N (C>D)V (A>S)R (G>A)TTTN
(T>V), NV (A>G>C)TTTTT, NATTTTT, NN (H>G)AAAN
(G>A>Y)N, N (T>V)NAAATN, NAV (A>G>C)TCNN, NN
(A>S>T)NN (W>G>C)CCN (Y>R), NNAH (T>M)ACN,
NGTGANN, NARN (A>K>C)ATN, NV (G>A>C)RNTTN, NN
(A>B)RN (A>G>T>C)CCN, NN (A>B)NN (T>V)CCH
(A>Y), NNN (H>G)NCDAA, NN (H>G)D (A>K)GGDN (A>B),
NNNNCCAG, NNNNCTAA, NNNNCVGANN, N (C>D)NNTCCN, NNNNCTA,
NNNNCYAA, NAGRGNY, NNGH (W>C)AAA, NNGAAAN, NNAAAAA, NTGAR
(G>A)N(A>Y>G)N(Y>R), N (C>D)H (C>W)GH
(Y>A)N(A>B)AN(A>T>S), NNAAACN, NNGTAM (A>C)Y, NH
(A>Y)ARNN (C>W>G)N, B (C>K)GGN(A>Y>G)N NN, N
(T>C>R)AGAN (A>K>C)NN, NGGN (A>T>G>C)NNN, NGGD
(A>T>G)TNN, NGGAN(T>A>C>G)NN, CGGWN (T>R>C)NN,
NGGWGNN, N (B>A)GGNN (T>V)NN, NNGD (A>T>G)AY (T>C)N,
N (T>V)H(T>C>A)AAAAN, NRTAANN, N (H>G)CAAH
(Y>A)N(Y>R)N, NATAAN (A>T>S)N, NV (A>G>C)R
(A>G)ACCN, CN (C>W>G)AV (A>S)GAC, NNRNCAC, N(A>B)GGD
(W>G)D (G>W)NN, BGD (G>W)GTCN(A>K>C), NAANACN,
NRTHAN(A>B)N, BHN (H>G)NGN(T>M)H(Y>A),
NMRN(A>Y>G)AH(C>T>A)N, NNNCACN, NARN(T>A>S)ACN,
NNNNATW, NGCNGCN, NNNCATN, NAGNGCN, NARN(T>M>G)CCN, NATCCTN,
NRTAAN(T>A>S)N, N(C>T>G>A)AAD (A>G>T)CNN,
NAAAGNN, NNGACNN, N(T>V)NTAAD (A>T>G)N, NNGAD (G>W)NN,
NGGN(W>S)NNN, N(T>V)GGD(W>G)GNN,
NGGD(A>T>G)N(T>M>G)NN, NNAAAGN,
N(G>H)GGDN(T>M>G)NN, NNAGAAA, NN(T>M>G)AAAAA,
N(C>D)N(C>W>G)GW(T>C)D(A>G>T)AA, NAAAAYN,
NRGNNNN, NATGN (H>G)TN, NNDATTT, and NATARCN(C>T>A>G);
a Cas endonuclease that is capable of recognizing a PAM sequence
that is one, two, three, four, five, six, seven, eight, nine, or
ten nucleotides in length; a Cas endonuclease that comprises a
domain at least 80%, between 80% and 85%, at least 85%, between 85%
and 90%, at least 90%, between 90% and 95%, at least 95%, at least
96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or
greater than 99.5% identity with any of: SEQID NOs:1136-1730; a Cas
endonuclease that has an activity score, according to the identical
or similar method of Example 9 or summations of position scores of
the amino acid table of Table 86A, of at least 1.0, between 1.0 and
2.0, at least 2.0, between 2.0 and 3.0, at least 3.0, between 3.0
and 4.0, at least 4.0, between 4.0 and 5.0, at least 5.0, between
5.0 and 6.0, at least 6.0, between 6.0 and 7.0, at least 7.0,
between 7.0 and 8.0, at least 8.0, between 8.0 and 9.0, at least
9.0, between 9.0 and 10.0, at least 10.0, or even greater than
10.0; a Cas endonuclease comprising one, two, three, four, five,
six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen,
fifteen, sixteen, seventeen, eighteen, nineteen, twenty,
twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, or
twenty-six of the signature amino acids identified in Table 86B, as
compared to an alignment with the relative sequence position
numbers of SEQID NO:1125; and a Cas endonuclease that is capable of
forming a complex with a guide polynucleotide comprising any one of
SEQID NOs: 426-510, 341-425, 141-255, or 256-340. In some aspects,
the Cas9 polynucleotide has a plurality of the previously listed
features.
[0194] The Cas9 ortholog or cas9 ortholog disclosed herein may
further comprise a heterologous component. In some aspects, said
heterologous component is selected from the group consisting of: a
heterologous polynucleotide, a heterologous polypeptide, a
particle, a solid matrix, and a Histidine tag. In some aspects,
said heterologous polynucleotide is a guide polynucleotide, or a
polynucleotide encoding a marker or purification tag, or a
heterologous noncoding regulatory element to which it is operably
linked.
[0195] In some aspects, the polynucleotide encoding the Cas9
endonuclease ortholog is comprised within a recombinant vector,
that may further comprise additional components, such as but not
limited to a heterologous promoter or other non-coding regulatory
element.
[0196] A Cas9 ortholog endonuclease, effector protein, or
functional fragment thereof, for use in the disclosed methods, can
be isolated from a native source, or from a recombinant source
where the genetically modified host cell is modified to express the
nucleic acid sequence encoding the protein. Alternatively, the Cas9
ortholog protein can be produced using cell free protein expression
systems, or be synthetically produced. Cas endonucleases may be
isolated and introduced into a heterologous cell, or may be
modified from its native form to exhibit a different type or
magnitude of activity than what it would exhibit in its native
source. Such modifications include but are not limited to:
fragments, variants, substitutions, deletions, and insertions.
[0197] Fragments and variants of Cas9 orthologs can be obtained via
methods such as site-directed mutagenesis and synthetic
construction. Methods for measuring endonuclease activity are well
known in the art such as, but not limiting to, WO2013166113
published 7 Nov. 2013, WO2016186953 published 24 Nov. 2016, and
WO2016186946 published 24 Nov. 2016.
[0198] The Cas9 ortholog can comprise a modified form of the Cas
polypeptide. The modified form of the Cas polypeptide can include
an amino acid change (e.g., deletion, insertion, or substitution)
that reduces the naturally-occurring nuclease activity of the Cas
protein. For example, in some instances, the modified form of the
Cas protein has less than 50%, less than 40%, less than 30%, less
than 20%, less than 10%, less than 5%, or less than 1% of the
nuclease activity of the corresponding wild-type Cas polypeptide
(US20140068797 published 6 Mar. 2014). In some cases, the modified
form of the Cas polypeptide has no substantial nuclease activity
and is referred to as catalytically "inactivated Cas" or
"deactivated Cas (dCas)." An inactivated Cas/deactivated Cas
includes a deactivated Cas endonuclease (dCas). A catalytically
inactive Cas endonuclease can be fused to a heterologous sequence
to induce or modify activity.
[0199] A Cas9 ortholog can be part of a fusion protein comprising
one or more heterologous protein domains (e.g., 1, 2, 3, or more
domains in addition to the Cas protein). Such a fusion protein may
comprise any additional protein sequence, and optionally a linker
sequence between any two domains, such as between Cas and a first
heterologous domain. Examples of protein domains that may be fused
to a Cas protein herein include, without limitation, epitope tags
(e.g., histidine [His], V5, FLAG, influenza hemagglutinin [HA],
myc, VSV-G, thioredoxin [Trx]), reporters (e.g.,
glutathione-5-transferase [GST], horseradish peroxidase [HRP],
chloramphenicol acetyltransferase [CAT], beta-galactosidase,
beta-glucuronidase [GUS], luciferase, green fluorescent protein
[GFP], HcRed, DsRed, cyan fluorescent protein [CFP], yellow
fluorescent protein [YFP], blue fluorescent protein [BFP]), and
domains having one or more of the following activities: methylase
activity, demethylase activity, transcription activation activity
(e.g., VP16 or VP64), transcription repression activity,
transcription release factor activity, histone modification
activity, RNA cleavage activity and nucleic acid binding activity.
A Cas9 ortholog can also be in fusion with a protein that binds DNA
molecules or other molecules, such as maltose binding protein
(MBP), S-tag, Lex A DNA binding domain (DBD), GAL4A DNA binding
domain, and herpes simplex virus (HSV) VP16.
[0200] A catalytically active and/or inactive Cas9 ortholog can be
fused to a heterologous sequence (US20140068797 published 6 Mar.
2014). Suitable fusion partners include, but are not limited to, a
polypeptide that provides an activity that indirectly increases
transcription by acting directly on the target DNA or on a
polypeptide (e.g., a histone or other DNA-binding protein)
associated with the target DNA. Additional suitable fusion partners
include, but are not limited to, a polypeptide that provides for
methyltransferase activity, demethylase activity, acetyltransferase
activity, deacetylase activity, kinase activity, phosphatase
activity, ubiquitin ligase activity, deubiquitinating activity,
adenylation activity, deadenylation activity, SUMOylating activity,
deSUMOylating activity, ribosylation activity, deribosylation
activity, myristoylation activity, or demyristoylation activity.
Further suitable fusion partners include, but are not limited to, a
polypeptide that directly provides for increased transcription of
the target nucleic acid (e.g., a transcription activator or a
fragment thereof, a protein or fragment thereof that recruits a
transcription activator, a small molecule/drug-responsive
transcription regulator, etc.). A catalytically inactive Cas can
also be fused to a FokI nuclease to generate double-strand breaks
(Guilinger et al. Nature Biotechnology, volume 32, number 6, June
2014). In some aspects, the Cas9 ortholog is a fusion protein
further comprising a nuclease domain, a transcriptional activator
domain, a transcriptional repressor domain, an epigenetic
modification domain, a cleavage domain, a nuclear localization
signal, a cell-penetrating domain, a translocation domain, a
marker, or a transgene that is heterologous to the target
polynucleotide sequence or to the cell from which said target
polynucleotide sequence is obtained or derived. In some aspects,
the nuclease fusion protein comprises Clo51 or Fok1.
[0201] The Cas9 orthologs described herein can be expressed and
purified by methods known in the art, for example as described in
WO/2016/186953 published 24 Nov. 2016.
[0202] A Cas endonuclease can comprise a heterologous nuclear
localization sequence (NLS). A heterologous NLS amino acid sequence
herein may be of sufficient strength to drive accumulation of a Cas
protein in a detectable amount in the nucleus of a yeast cell
herein, for example. An NLS may comprise one (monopartite) or more
(e.g., bipartite) short sequences (e.g., 2 to 20 residues) of
basic, positively charged residues (e.g., lysine and/or arginine),
and can be located anywhere in a Cas amino acid sequence but such
that it is exposed on the protein surface. An NLS may be operably
linked to the N-terminus or C-terminus of a Cas protein herein, for
example. Two or more NLS sequences can be linked to a Cas protein,
for example, such as on both the N- and C-termini of a Cas protein.
The Cas endonuclease gene can be operably linked to a SV40 nuclear
targeting signal upstream of the Cas codon region and a bipartite
VirD2 nuclear localization signal (Tinland et al. (1992) Proc.
Natl. Acad. Sci. USA 89:7442-6) downstream of the Cas codon region.
Non-limiting examples of suitable NLS sequences herein include
those disclosed in U.S. Pat. Nos. 6,660,830 and 7,309,576.
[0203] An artificial (non-naturally occurring) Cas endonuclease may
be produced from a native, or parental, Cas endonuclease molecule,
by any means known in the art. In some aspects, this is achieved
through mutagenesis of the gene encoding the endonuclease protein.
In some aspects, mutagenesis is achieved via a method selected from
the group consisting of: the use of a double-strand break inducing
agent acting on the endonuclease gene; radiation mutagenesis;
chemical mutagenesis; the addition, deletion, substitution,
insertion, or alteration of at least one polynucleotide in the gene
encoding the endonuclease; or the substitution of one or more
codons for an amino acid. In some aspects, directed evolution of
the endonuclease molecule may be employed to optimize the
expression or activity of the Cas endonuclease, and may be achieved
via stochastic or non-stochastic protein shuffling methods which
are known in the art.
Protospacer Adjacent Motif (PAM)
[0204] A "protospacer adjacent motif" (PAM) herein refers to a
short nucleotide sequence adjacent to a target sequence
(protospacer) that can be recognized (targeted) by a guide
polynucleotide/Cas endonuclease system. In some aspects, the Cas
endonuclease may not successfully recognize a target DNA sequence
if the target DNA sequence is not adjacent to, or near, a PAM
sequence. In some aspects, the PAM precedes the target sequence
(e.g. Cas12a). In some aspects, the PAM follows the target sequence
(e.g. S. pyogenes Cas9). The sequence and length of a PAM herein
can differ depending on the Cas protein or Cas protein complex
used. The PAM sequence can be of any length but is typically 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20
nucleotides long.
[0205] A "randomized PAM" and "randomized protospacer adjacent
motif" are used interchangeably herein, and refer to a random DNA
sequence adjacent to a target sequence (protospacer) that is
recognized (targeted) by a guide polynucleotide/Cas endonuclease
system. The randomized PAM sequence can be of any length but is
typically 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19 or 20 nucleotides long. A randomized nucleotide includes
anyone of the nucleotides A, C, G or T.
[0206] Many Cas endonucleases have been described to date that can
recognize specific PAM sequences (WO2016186953 published 24 Nov.
2016, WO2016186946 published 24 Nov. 2016, and Zetsche B et al.
2015. Cell 163, 1013) and cleave the target DNA at a specific
position. It is understood that based on the methods and
embodiments described herein utilizing a novel guided Cas system
one skilled in the art can now tailor these methods such that they
can utilize any guided endonuclease system.
[0207] PAM sequences that correspond to some of the Cas9 orthologs
of the instant invention are described in Tables 4-50.
Guide Polynucleotides
[0208] The guide polynucleotide enables target recognition,
binding, and optionally cleavage by the Cas endonuclease, and can
be a single molecule or a double molecule. The guide polynucleotide
sequence can be a RNA sequence, a DNA sequence, or a combination
thereof (a RNA-DNA combination sequence). Optionally, the guide
polynucleotide can comprise at least one nucleotide, phosphodiester
bond or linkage modification such as, but not limited, to Locked
Nucleic Acid (LNA), 5-methyl dC, 2,6-Diaminopurine, 2'-Fluoro A,
2'-Fluoro U, 2'-O-Methyl RNA, phosphorothioate bond, linkage to a
cholesterol molecule, linkage to a polyethylene glycol molecule,
linkage to a spacer 18 (hexaethylene glycol chain) molecule, or 5'
to 3' covalent linkage resulting in circularization. A guide
polynucleotide that solely comprises ribonucleic acids is also
referred to as a "guide RNA" or "gRNA" (US20150082478 published 19
Mar. 2015 and US20150059010 published 26 Feb. 2015). A guide
polynucleotide may be engineered or synthetic.
[0209] The guide polynucleotide includes a chimeric non-naturally
occurring guide RNA comprising regions that are not found together
in nature (i.e., they are heterologous with respect to each other).
For example, a chimeric non-naturally occurring guide RNA
comprising a first nucleotide sequence domain (referred to as
Variable Targeting domain or VT domain) that can hybridize to a
nucleotide sequence in a target DNA, linked to a second nucleotide
sequence that can recognize the Cas endonuclease, such that the
first and second nucleotide sequence are not found linked together
in nature.
[0210] The guide polynucleotide can be a double molecule (also
referred to as duplex guide polynucleotide) comprising a
crNucleotide sequence and a tracrNucleotide sequence. The
crNucleotide includes a first nucleotide sequence domain (referred
to as Variable Targeting domain or VT domain) that can hybridize to
a nucleotide sequence in a target DNA and a second nucleotide
sequence (also referred to as a tracr mate sequence) that is part
of a Cas endonuclease recognition (CER) domain. The tracr mate
sequence can hybridized to a tracrNucleotide along a region of
complementarity and together form the Cas endonuclease recognition
domain or CER domain. The CER domain is capable of interacting with
a Cas endonuclease polypeptide. The crNucleotide and the
tracrNucleotide of the duplex guide polynucleotide can be RNA, DNA,
and/or RNA-DNA-combination sequences.
[0211] In some embodiments, the crNucleotide molecule of the duplex
guide polynucleotide is referred to as "crDNA" (when composed of a
contiguous stretch of DNA nucleotides) or "crRNA" (when composed of
a contiguous stretch of RNA nucleotides), or "crDNA-RNA" (when
composed of a combination of DNA and RNA nucleotides). The
crNucleotide can comprise a fragment of the crRNA naturally
occurring in Bacteria and Archaea. The size of the fragment of the
crRNA naturally occurring in Bacteria and Archaea that can be
present in a crNucleotide disclosed herein can range from, but is
not limited to, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20 or more nucleotides.
[0212] The tracrRNA (trans-activating CRISPR RNA) comprises, in the
5'-to-3' direction, (i) an "anti-repeat" sequence that anneals with
the repeat region of CRISPR type II crRNA and (ii) a stem
loop-comprising portion (Deltcheva et al., Nature 471:602-607). The
duplex guide polynucleotide can form a complex with a Cas
endonuclease, wherein said guide polynucleotide/Cas endonuclease
complex (also referred to as a guide polynucleotide/Cas
endonuclease system) can direct the Cas endonuclease to a genomic
target site, enabling the Cas endonuclease to recognize, bind to,
and optionally nick or cleave (introduce a single or double-strand
break) into the target site. (US20150082478 published 19 Mar. 2015
and US20150059010 published 26 Feb. 2015). In some embodiments, the
tracrNucleotide is referred to as "tracrRNA" (when composed of a
contiguous stretch of RNA nucleotides) or "tracrDNA" (when composed
of a contiguous stretch of DNA nucleotides) or "tracrDNA-RNA" (when
composed of a combination of DNA and RNA nucleotides.
[0213] In one embodiment, the RNA that guides the RNA/Cas
endonuclease complex is a duplexed RNA comprising a duplex
crRNA-tracrRNA.
[0214] In one aspect, the guide polynucleotide is a guide
polynucleotide capable of forming a PGEN as described herein,
wherein said guide polynucleotide comprises a first nucleotide
sequence domain that is complementary to a nucleotide sequence in a
target DNA, and a second nucleotide sequence domain that interacts
with said Cas endonuclease polypeptide.
[0215] In one aspect, the guide polynucleotide is a guide
polynucleotide described herein, wherein the first nucleotide
sequence and the second nucleotide sequence domain is selected from
the group consisting of a DNA sequence, a RNA sequence, and a
combination thereof.
[0216] In one aspect, the guide polynucleotide is a guide
polynucleotide described herein, wherein the first nucleotide
sequence and the second nucleotide sequence domain is selected from
the group consisting of RNA backbone modifications that enhance
stability, DNA backbone modifications that enhance stability, and a
combination thereof (see Kanasty et al., 2013, Common RNA-backbone
modifications, Nature Materials 12:976-977; US20150082478 published
19 Mar. 2015 and US20150059010 published 26 Feb. 2015)
[0217] The guide RNA includes a dual molecule comprising a chimeric
non-naturally occurring crRNA linked to at least one tracrRNA. A
chimeric non-naturally occurring crRNA includes a crRNA that
comprises regions that are not found together in nature (i.e., they
are heterologous with each other. For example, a crRNA comprising a
first nucleotide sequence domain (referred to as Variable Targeting
domain or VT domain) that can hybridize to a nucleotide sequence in
a target DNA, linked to a second nucleotide sequence (also referred
to as a tracr mate sequence) such that the first and second
sequence are not found linked together in nature.
[0218] The guide polynucleotide can also be a single molecule (also
referred to as single guide polynucleotide) comprising a
crNucleotide sequence linked to a tracrNucleotide sequence. The
single guide polynucleotide comprises a first nucleotide sequence
domain (referred to as Variable Targeting domain or VT domain) that
can hybridize to a nucleotide sequence in a target DNA and a Cas
endonuclease recognition domain (CER domain), that interacts with a
Cas endonuclease polypeptide.
[0219] The term "variable targeting domain" or "VT domain" is used
interchangeably herein and includes a nucleotide sequence that can
hybridize (is complementary) to one strand (nucleotide sequence) of
a double strand DNA target site. The % complementation between the
first nucleotide sequence domain (VT domain) and the target
sequence can be at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%,
58%, 59%, 60%, 61%, 62%, 63%, 63%, 65%, 66%, 67%, 68%, 69%, 70%,
71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%,
84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, 99% or 100%. The variable targeting domain can be at
least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29 or 30 nucleotides in length.
[0220] The VT domain and/or the CER domain of a single guide
polynucleotide can comprise a RNA sequence, a DNA sequence, or a
RNA-DNA-combination sequence. The single guide polynucleotide being
comprised of sequences from the crNucleotide and the
tracrNucleotide may be referred to as "single guide RNA" (when
composed of a contiguous stretch of RNA nucleotides) or "single
guide DNA" (when composed of a contiguous stretch of DNA
nucleotides) or "single guide RNA-DNA" (when composed of a
combination of RNA and DNA nucleotides). The single guide
polynucleotide can form a complex with a Cas endonuclease, wherein
said guide polynucleotide/Cas endonuclease complex (also referred
to as a guide polynucleotide/Cas endonuclease system) can direct
the Cas endonuclease to a genomic target site, enabling the Cas
endonuclease to recognize, bind to, and optionally nick or cleave
(introduce a single or double-strand break) the target site.
(US20150082478 published 19 Mar. 2015 and US20150059010 published
26 Feb. 2015).
[0221] A chimeric non-naturally occurring single guide RNA (sgRNA)
includes a sgRNA that comprises regions that are not found together
in nature (i.e., they are heterologous with each other. For
example, a sgRNA comprising a first nucleotide sequence domain
(referred to as Variable Targeting domain or VT domain) that can
hybridize to a nucleotide sequence in a target DNA linked to a
second nucleotide sequence (also referred to as a tracr mate
sequence) that are not found linked together in nature.
[0222] The nucleotide sequence linking the crNucleotide and the
tracrNucleotide of a single guide polynucleotide can comprise a RNA
sequence, a DNA sequence, or a RNA-DNA combination sequence. In one
embodiment, the nucleotide sequence linking the crNucleotide and
the tracrNucleotide of a single guide polynucleotide (also referred
to as "loop") can be at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,
48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64,
65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 78, 79, 80,
81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,
98, 99 or 100 nucleotides in length. In another embodiment, the
nucleotide sequence linking the crNucleotide and the
tracrNucleotide of a single guide polynucleotide can comprise a
tetraloop sequence, such as, but not limiting to a GAAA tetraloop
sequence.
[0223] The guide polynucleotide can be produced by any method known
in the art, including chemically synthesizing guide polynucleotides
(such as but not limiting to Hendel et al. 2015, Nature
Biotechnology 33, 985-989), in vitro generated guide
polynucleotides, and/or self-splicing guide RNAs (such as but not
limited to Xie et al. 2015, PNAS 112:3570-3575).
[0224] A method of expressing RNA components such as gRNA in
eukaryotic cells for performing Cas9-mediated DNA targeting has
been to use RNA polymerase III (Pol III) promoters, which allow for
transcription of RNA with precisely defined, unmodified, 5'- and
3'-ends (DiCarlo et al., Nucleic Acids Res. 41: 4336-4343; Ma et
al., Mol. Ther. Nucleic Acids 3:e161). This strategy has been
successfully applied in cells of several different species
including maize and soybean (US 20150082478, published on Mar. 19,
2015). Methods for expressing RNA components that do not have a 5'
cap have been described (WO 2016/025131, published on Feb. 18,
2016).
[0225] A single guide RNA (sgRNA) molecule may comprise a VT
domain.
[0226] A single guide RNA (sgRNA) molecule may comprise a crRNA
repeat. In some aspects, the crRNA repeat is selected from the
group consisting of: SEQID NO:171-255.
[0227] A single guide RNA (sgRNA) molecule may comprise a loop.
[0228] A single guide RNA (sgRNA) molecule may comprise an
anti-repeat. In some aspects, the anti-repeat is selected from the
group consisting of: SEQID NO:256-340.
[0229] A single guide RNA (sgRNA) molecule may comprise A 3'
tracrRNA. In some aspects, the 3' tracrRNA is selected from the
group consisting of: SEQID NO:341-425.
[0230] The terms "single guide RNA" and "sgRNA" are used
interchangeably herein and relate to a synthetic fusion of two RNA
molecules, a crRNA (CRISPR RNA) comprising a variable targeting
domain (linked to a tracr mate sequence that hybridizes to a
tracrRNA), fused to a tracrRNA (trans-activating CRISPR RNA). The
single guide RNA can comprise a crRNA or crRNA fragment and a
tracrRNA or tracrRNA fragment of the type II CRISPR/Cas9 system
that can form a complex with a type II Cas9 endonuclease, wherein
said guide RNA/Cas9 endonuclease complex can direct the Cas9
endonuclease to a DNA target site, enabling the Cas9 endonuclease
to recognize, bind to, and optionally nick or cleave (introduce a
single or double strand break) the DNA target site.
[0231] In some aspects, the sgRNA is selected from the group
consisting of: SEQID NO: 426-510.
[0232] Single guide RNAs targeting a target site in the genome of
an organism can be designed by changing the Variable Targeting
Domain (VT) of any of the guide polynucleotides described herein,
with any random nucleotide that can hybridize to any desired target
sequence.
[0233] In some embodiments, a subject nucleic acid (e.g., a guide
polynucleotide, a nucleic acid comprising a nucleotide sequence
encoding a guide polynucleotide; a nucleic acid encoding Cas9
endonuclease of the present disclosure; a crRNA or a nucleotide
encoding a crRNA, a tracrRNA or a nucleotide encoding a tracrRNA, a
nucleotide encoding a VT domain, a nucleotide encoding a CER
domain, etc.) comprises a modification or sequence that provides
for an additional desirable feature (e.g., modified or regulated
stability; subcellular targeting; tracking, e.g., a fluorescent
label; a binding site for a protein or protein complex; etc.).
Nucleotide sequence modification of the guide polynucleotide, VT
domain and/or CER domain can be selected from, but not limited to,
the group consisting of a 5' cap, a 3' polyadenylated tail, a
riboswitch sequence, a stability control sequence, a sequence that
forms a dsRNA duplex, a modification or sequence that targets the
guide poly nucleotide to a subcellular location, a modification or
sequence that provides for tracking, a modification or sequence
that provides a binding site for proteins, a Locked Nucleic Acid
(LNA), a 5-methyl dC nucleotide, a 2,6-Diaminopurine nucleotide, a
2'-Fluoro A nucleotide, a 2'-Fluoro U nucleotide; a 2'-O-Methyl RNA
nucleotide, a phosphorothioate bond, linkage to a cholesterol
molecule, linkage to a polyethylene glycol molecule, linkage to a
spacer 18 molecule, a 5' to 3' covalent linkage, or any combination
thereof. These modifications can result in at least one additional
beneficial feature, wherein the additional beneficial feature is
selected from the group of a modified or regulated stability, a
subcellular targeting, tracking, a fluorescent label, a binding
site for a protein or protein complex, modified binding affinity to
complementary target sequence, modified resistance to cellular
degradation, and increased cellular permeability.
[0234] Functional variants of a guide polynucleotide of the present
disclosure can comprise a modified guide polynucleotide wherein the
modification comprises adding, removing, or otherwise altering
loops and/or hairpins in the single guide RNA.
[0235] Functional variants of a guide polynucleotide of the present
disclosure can comprise a modified guide polynucleotide wherein the
modification comprises one or more modified nucleotides in the
nucleotide sequence, wherein the one or more modified nucleotides
comprises at least one non-naturally-occurring nucleotide,
nucleotide mimetic (as described in US application US2014/0068797,
published Mar. 6, 2014), or analog thereof, or wherein the one or
more modified nucleotides are selected from the group consisting of
2'-O-methylanalogs, 2'-fluoro analogs 2-aminopurine,
5-bromo-uridine, pseudouridine, and 7-methylguanosine.
[0236] In one aspect, the functional variant of the guide RNA can
form a guide RNA/Cas9 endonuclease complex that can recognize, bind
to, and optionally nick or cleave a target sequence.
Guide Polynucleotide/Cas Endonuclease Complexes
[0237] A guide polynucleotide/Cas endonuclease complex described
herein is capable of recognizing, binding to, and optionally
nicking, unwinding, or cleaving all or part of a target
sequence.
[0238] A guide polynucleotide/Cas endonuclease complex that can
cleave both strands of a DNA target sequence typically comprises a
Cas protein that has all of its endonuclease domains in a
functional state (e.g., wild type endonuclease domains or variants
thereof retaining some or all activity in each endonuclease
domain). Thus, a wild type Cas protein (e.g., a Cas protein
disclosed herein), or a variant thereof retaining some or all
activity in each endonuclease domain of the Cas protein, is a
suitable example of a Cas endonuclease that can cleave both strands
of a DNA target sequence.
[0239] A guide polynucleotide/Cas endonuclease complex that can
cleave one strand of a DNA target sequence can be characterized
herein as having nickase activity (e.g., partial cleaving
capability). A Cas nickase typically comprises one functional
endonuclease domain that allows the Cas to cleave only one strand
(i.e., make a nick) of a DNA target sequence. For example, a Cas
nickase may comprise (i) a mutant, dysfunctional RuvC domain and
(ii) a functional HNH domain (e.g., wild type HNH domain). As
another example, a Cas nickase may comprise (i) a functional RuvC
domain (e.g., wild type RuvC domain) and (ii) a mutant,
dysfunctional HNH domain. Non-limiting examples of Cas nickases
suitable for use herein are disclosed in US20140189896 published on
3 Jul. 2014. A pair of Cas nickases can be used to increase the
specificity of DNA targeting. In general, this can be done by
providing two Cas nickases that, by virtue of being associated with
RNA components with different guide sequences, target and nick
nearby DNA sequences on opposite strands in the region for desired
targeting. Such nearby cleavage of each DNA strand creates a
double-strand break (i.e., a DSB with single-stranded overhangs),
which is then recognized as a substrate for
non-homologous-end-joining, NHEJ (prone to imperfect repair leading
to mutations) or homologous recombination, HR. Each nick in these
embodiments can be at least 5, between 5 and 10, at least 10,
between 10 and 15, at least 15, between 15 and 20, at least 20,
between 20 and 30, at least 30, between 30 and 40, at least 40,
between 40 and 50, at least 50, between 50 and 60, at least 60,
between 60 and 70, at least 70, between 70 and 80, at least 80,
between 80 and 90, at least 90, between 90 and 100, or 100 or
greater (or any number between 5 and 100) bases apart from each
other, for example. One or two Cas nickase proteins herein can be
used in a Cas nickase pair. For example, a Cas nickase with a
mutant RuvC domain, but functioning HNH domain (i.e., Cas
HNH+/RuvC-), can be used (e.g., Streptococcus pyogenes Cas
HNH+/RuvC-). Each Cas nickase (e.g., Cas HNH+/RuvC-) can be
directed to specific DNA sites nearby each other (up to 100 base
pairs apart) by using suitable RNA components herein with guide RNA
sequences targeting each nickase to each specific DNA site.
[0240] A guide polynucleotide/Cas endonuclease complex in certain
embodiments can bind to a DNA target site sequence, but does not
cleave any strand at the target site sequence. Such a complex may
comprise a Cas protein in which all of its nuclease domains are
mutant, dysfunctional. For example, a Cas protein that can bind to
a DNA target site sequence, but does not cleave any strand at the
target site sequence, may comprise both a mutant, dysfunctional
RuvC domain and a mutant, dysfunctional HNH domain. A Cas protein
herein that binds, but does not cleave, a target DNA sequence can
be used to modulate gene expression, for example, in which case the
Cas protein could be fused with a transcription factor (or portion
thereof) (e.g., a repressor or activator, such as any of those
disclosed herein).
[0241] In one embodiment of the disclosure, the guide
polynucleotide/Cas endonuclease complex is a guide
polynucleotide/Cas endonuclease complex (PGEN) comprising at least
one guide polynucleotide and at least one Cas endonuclease
polypeptide. In some aspects, the Cas endonuclease polypeptide
comprises at least one protein subunit of another Cas protein, or a
functional fragment thereof, wherein said guide polynucleotide is a
chimeric non-naturally occurring guide polynucleotide, wherein said
guide polynucleotide/Cas endonuclease complex is capable of
recognizing, binding to, and optionally nicking, unwinding, or
cleaving all or part of a target sequence.
[0242] In some aspects, the PGEN is a ribonucleoprotein complex
(RNP), wherein the Cas 9 ortholog is provided as a protein and the
guide polynucleotide is provided as a ribonucleotide.
[0243] The Cas endonuclease protein can be a Cas9 ortholog as
disclosed herein.
[0244] In one embodiment of the disclosure, the guide
polynucleotide/Cas effector complex is a guide polynucleotide/Cas
endonuclease complex (PGEN) comprising at least one guide
polynucleotide and a Cas9 ortholog endonuclease, wherein said guide
polynucleotide/Cas endonuclease complex is capable of recognizing,
binding to, and optionally nicking, unwinding, or cleaving all or
part of a target sequence.
[0245] The PGEN can be a guide polynucleotide/Cas endonuclease
complex, wherein said Cas endonuclease further comprises one copy
or multiple copies of at least one protein subunit, or a functional
fragment thereof, of an additional Cas protein.
[0246] In one aspect, the guide polynucleotide/Cas endonuclease
complex (PGEN) described herein is a PGEN, wherein said Cas
endonuclease is covalently or non-covalently linked to at least one
Cas protein subunit, or functional fragment thereof. The PGEN can
be a guide polynucleotide/Cas endonuclease complex, wherein said
Cas endonuclease polypeptide is covalently or non-covalently
linked, or assembled to one copy or multiple copies of at least one
protein subunit, or a functional fragment thereof, of a Cas protein
selected from the group consisting of a Cas1 protein subunit, a
Cas2 protein subunit, a Cas4 protein subunit, and any combination
thereof, in some aspects effectively forming a cleavage ready
Cascade. The PGEN can be a guide polynucleotide/Cas endonuclease
complex, wherein said Cas endonuclease is covalently or
non-covalently linked or assembled to at least two different
protein subunits of a Cas protein selected from the group
consisting of a Cas1, a Cas2, and Cas4. The PGEN can be a guide
polynucleotide/Cas endonuclease complex, wherein said Cas
endonuclease is covalently or non-covalently linked to at least
three different protein subunits, or functional fragments thereof,
of a Cas protein selected from the group consisting of a Cas1, a
Cas2, and Cas4, and any combination thereof.
[0247] Any component of the guide polynucleotide/Cas endonuclease
complex, the guide polynucleotide/Cas endonuclease complex itself,
as well as the polynucleotide modification template(s) and/or donor
DNA(s), can be introduced into a heterologous cell or organism by
any method known in the art.
[0248] Some uses for guide RNA/Cas9 endonuclease systems include
but are not limited to modifying or replacing nucleotide sequences
of interest (such as a regulatory elements), insertion of
polynucleotides of interest, gene knock-out, gene-knock in,
modification of splicing sites and/or introducing alternate
splicing sites, modifications of nucleotide sequences encoding a
protein of interest, amino acid and/or protein fusions, and gene
silencing by expressing an inverted repeat into a gene of
interest.
Recombinant Constructs for Transformation of Cells
[0249] The disclosed guide polynucleotides, Cas endonucleases,
polynucleotide modification templates, donor DNAs, guide
polynucleotide/Cas endonuclease systems disclosed herein, and any
one combination thereof, optionally further comprising one or more
polynucleotide(s) of interest, can be introduced into a cell. Cells
include, but are not limited to, human, non-human, animal,
bacterial, fungal, insect, yeast, non-conventional yeast, and plant
cells as well as plants and seeds produced by the methods described
herein.
[0250] Standard recombinant DNA and molecular cloning techniques
used herein are well known in the art and are described more fully
in Sambrook et al., Molecular Cloning: A Laboratory Manual; Cold
Spring Harbor Laboratory: Cold Spring Harbor, N.Y. (1989).
Transformation methods are well known to those skilled in the art
and are described infra.
[0251] Vectors and constructs include circular plasmids, and linear
polynucleotides, comprising a polynucleotide of interest and
optionally other components including linkers, adapters, regulatory
or analysis. In some examples a recognition site and/or target site
can be comprised within an intron, coding sequence, 5' UTRs, 3'
UTRs, and/or regulatory regions.
Components for Expression and Utilization of Novel CRISPR-Cas
Systems in Prokaryotic and Eukaryotic Cells
[0252] The invention further provides expression constructs for
expressing in a prokaryotic or eukaryotic cell/organism a guide
RNA/Cas system that is capable of recognizing, binding to, and
optionally nicking, unwinding, or cleaving all or part of a target
sequence.
[0253] In one embodiment, the expression constructs of the
disclosure comprise a promoter operably linked to a nucleotide
sequence encoding a Cas gene (or optimized sequence, including a
Cas endonuclease gene described herein) and a promoter operably
linked to a guide RNA of the present disclosure. The promoter is
capable of driving expression of an operably linked nucleotide
sequence in a prokaryotic or eukaryotic cell/organism.
[0254] Nucleotide sequence modification of the guide
polynucleotide, VT domain and/or CER domain can be selected from,
but not limited to, the group consisting of a 5' cap, a 3'
polyadenylated tail, a riboswitch sequence, a stability control
sequence, a sequence that forms a dsRNA duplex, a modification or
sequence that targets the guide poly nucleotide to a subcellular
location, a modification or sequence that provides for tracking, a
modification or sequence that provides a binding site for proteins,
a Locked Nucleic Acid (LNA), a 5-methyl dC nucleotide, a
2,6-Diaminopurine nucleotide, a 2'-Fluoro A nucleotide, a 2'-Fluoro
U nucleotide; a 2'-O-Methyl RNA nucleotide, a phosphorothioate
bond, linkage to a cholesterol molecule, linkage to a polyethylene
glycol molecule, linkage to a spacer 18 molecule, a 5' to 3'
covalent linkage, or any combination thereof. These modifications
can result in at least one additional beneficial feature, wherein
the additional beneficial feature is selected from the group of a
modified or regulated stability, a subcellular targeting, tracking,
a fluorescent label, a binding site for a protein or protein
complex, modified binding affinity to complementary target
sequence, modified resistance to cellular degradation, and
increased cellular permeability.
[0255] A method of expressing RNA components such as gRNA in
eukaryotic cells for performing Cas9-mediated DNA targeting has
been to use RNA polymerase III (Pol III) promoters, which allow for
transcription of RNA with precisely defined, unmodified, 5'- and
3'-ends (DiCarlo et al., Nucleic Acids Res. 41: 4336-4343; Ma et
al., Mol. Ther. Nucleic Acids 3:e161). This strategy has been
successfully applied in cells of several different species
including maize and soybean (US20150082478 published 19 Mar. 2015).
Methods for expressing RNA components that do not have a 5' cap
have been described (WO2016/025131 published 18 Feb. 2016).
[0256] Various methods and compositions can be employed to obtain a
cell or organism having a polynucleotide of interest inserted in a
target site for a Cas endonuclease. Such methods can employ
homologous recombination (HR) to provide integration of the
polynucleotide of interest at the target site. In one method
described herein, a polynucleotide of interest is introduced into
the organism cell via a donor DNA construct.
[0257] The donor DNA construct further comprises a first and a
second region of homology that flank the polynucleotide of
interest. The first and second regions of homology of the donor DNA
share homology to a first and a second genomic region,
respectively, present in or flanking the target site of the cell or
organism genome.
[0258] The donor DNA can be tethered to the guide polynucleotide.
Tethered donor DNAs can allow for co-localizing target and donor
DNA, useful in genome editing, gene insertion, and targeted genome
regulation, and can also be useful in targeting post-mitotic cells
where function of endogenous HR machinery is expected to be highly
diminished (Mali et al., 2013, Nature Methods Vol. 10:
957-963).
[0259] The amount of homology or sequence identity shared by a
target and a donor polynucleotide can vary and includes total
lengths and/or regions having unit integral values in the ranges of
about 1-20 bp, 20-50 bp, 50-100 bp, 75-150 bp, 100-250 bp, 150-300
bp, 200-400 bp, 250-500 bp, 300-600 bp, 350-750 bp, 400-800 bp,
450-900 bp, 500-1000 bp, 600-1250 bp, 700-1500 bp, 800-1750 bp,
900-2000 bp, 1-2.5 kb, 1.5-3 kb, 2-4 kb, 2.5-5 kb, 3-6 kb, 3.5-7
kb, 4-8 kb, 5-10 kb, or up to and including the total length of the
target site. These ranges include every integer within the range,
for example, the range of 1-20 bp includes 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 bps. The amount of
homology can also be described by percent sequence identity over
the full aligned length of the two polynucleotides which includes
percent sequence identity of about at least 50%, 55%, 60%, 65%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%,
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, between 98% and 99%, 99%, between 99% and 100%, or
100%. Sufficient homology includes any combination of
polynucleotide length, global percent sequence identity, and
optionally conserved regions of contiguous nucleotides or local
percent sequence identity, for example sufficient homology can be
described as a region of 75-150 bp having at least 80% sequence
identity to a region of the target locus. Sufficient homology can
also be described by the predicted ability of two polynucleotides
to specifically hybridize under high stringency conditions, see,
for example, Sambrook et al., (1989) Molecular Cloning: A
Laboratory Manual, (Cold Spring Harbor Laboratory Press, NY);
Current Protocols in Molecular Biology, Ausubel et al., Eds (1994)
Current Protocols, (Greene Publishing Associates, Inc. and John
Wiley & Sons, Inc.); and, Tijssen (1993) Laboratory Techniques
in Biochemistry and Molecular Biology--Hybridization with Nucleic
Acid Probes, (Elsevier, New York).
[0260] The structural similarity between a given genomic region and
the corresponding region of homology found on the donor DNA can be
any degree of sequence identity that allows for homologous
recombination to occur. For example, the amount of homology or
sequence identity shared by the "region of homology" of the donor
DNA and the "genomic region" of the organism genome can be at least
50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%,
87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or
100% sequence identity, such that the sequences undergo homologous
recombination
[0261] The region of homology on the donor DNA can have homology to
any sequence flanking the target site. While in some instances the
regions of homology share significant sequence homology to the
genomic sequence immediately flanking the target site, it is
recognized that the regions of homology can be designed to have
sufficient homology to regions that may be further 5' or 3' to the
target site. The regions of homology can also have homology with a
fragment of the target site along with downstream genomic
regions
[0262] In one embodiment, the first region of homology further
comprises a first fragment of the target site and the second region
of homology comprises a second fragment of the target site, wherein
the first and second fragments are dissimilar.
Polynucleotides of Interest
[0263] Polynucleotides of interest are further described herein and
include polynucleotides reflective of the commercial markets and
interests of those involved in the development of the crop. Crops
and markets of interest change, and as developing nations open up
world markets, new crops and technologies will emerge also. In
addition, as our understanding of agronomic traits and
characteristics such as yield and heterosis increase, the choice of
genes for genetic engineering will change accordingly.
[0264] General categories of polynucleotides of interest include,
for example, genes of interest involved in information, such as
zinc fingers, those involved in communication, such as kinases, and
those involved in housekeeping, such as heat shock proteins. More
specific polynucleotides of interest include, but are not limited
to, genes involved in crop yield, grain quality, crop nutrient
content, starch and carbohydrate quality and quantity as well as
those affecting kernel size, sucrose loading, protein quality and
quantity, nitrogen fixation and/or utilization, fatty acid and oil
composition, genes encoding proteins conferring resistance to
abiotic stress (such as drought, nitrogen, temperature, salinity,
toxic metals or trace elements, or those conferring resistance to
toxins such as pesticides and herbicides), genes encoding proteins
conferring resistance to biotic stress (such as attacks by fungi,
viruses, bacteria, insects, and nematodes, and development of
diseases associated with these organisms).
[0265] Agronomically important traits such as oil, starch, and
protein content can be genetically altered in addition to using
traditional breeding methods. Modifications include increasing
content of oleic acid, saturated and unsaturated oils, increasing
levels of lysine and sulfur, providing essential amino acids, and
also modification of starch. Hordothionin protein modifications are
described in U.S. Pat. Nos. 5,703,049, 5,885,801, 5,885,802, and
5,990,389.
[0266] Polynucleotide sequences of interest may encode proteins
involved in providing disease or pest resistance. By "disease
resistance" or "pest resistance" is intended that the plants avoid
the harmful symptoms that are the outcome of the plant-pathogen
interactions. Pest resistance genes may encode resistance to pests
that have great yield drag such as rootworm, cutworm, European Corn
Borer, and the like. Disease resistance and insect resistance genes
such as lysozymes or cecropins for antibacterial protection, or
proteins such as defensins, glucanases or chitinases for antifungal
protection, or Bacillus thuringiensis endotoxins, protease
inhibitors, collagenases, lectins, or glycosidases for controlling
nematodes or insects are all examples of useful gene products.
Genes encoding disease resistance traits include detoxification
genes, such as against fumonisin (U.S. Pat. No. 5,792,931);
avirulence (avr) and disease resistance (R) genes (Jones et al.
(1994) Science 266:789; Martin et al. (1993) Science 262:1432; and
Mindrinos et al. (1994) Cell 78:1089); and the like. Insect
resistance genes may encode resistance to pests that have great
yield drag such as rootworm, cutworm, European Corn Borer, and the
like. Such genes include, for example, Bacillus thuringiensis toxic
protein genes (U.S. Pat. Nos. 5,366,892; 5,747,450; 5,736,514;
5,723,756; 5,593,881; and Geiser et al. (1986) Gene 48:109); and
the like.
[0267] An "herbicide resistance protein" or a protein resulting
from expression of an "herbicide resistance-encoding nucleic acid
molecule" includes proteins that confer upon a cell the ability to
tolerate a higher concentration of an herbicide than cells that do
not express the protein, or to tolerate a certain concentration of
an herbicide for a longer period of time than cells that do not
express the protein. Herbicide resistance traits may be introduced
into plants by genes coding for resistance to herbicides that act
to inhibit the action of acetolactate synthase (ALS, also referred
to as acetohydroxyacid synthase, AHAS), in particular the
sulfonylurea (UK: sulphonylurea) type herbicides, genes coding for
resistance to herbicides that act to inhibit the action of
glutamine synthase, such as phosphinothricin or basta (e.g., the
bar gene), glyphosate (e.g., the EPSP synthase gene and the GAT
gene), HPPD inhibitors (e.g., the HPPD gene) or other such genes
known in the art. See, for example, U.S. Pat. Nos. 7,626,077,
5,310,667, 5,866,775, 6,225,114, 6,248,876, 7,169,970, 6,867,293,
and 9,187,762. The bar gene encodes resistance to the herbicide
basta, the nptII gene encodes resistance to the antibiotics
kanamycin and geneticin, and the ALS-gene mutants encode resistance
to the herbicide chlorsulfuron.
[0268] Furthermore, it is recognized that the polynucleotide of
interest may also comprise antisense sequences complementary to at
least a portion of the messenger RNA (mRNA) for a targeted gene
sequence of interest. Antisense nucleotides are constructed to
hybridize with the corresponding mRNA. Modifications of the
antisense sequences may be made as long as the sequences hybridize
to and interfere with expression of the corresponding mRNA. In this
manner, antisense constructions having 70%, 80%, or 85% sequence
identity to the corresponding antisense sequences may be used.
Furthermore, portions of the antisense nucleotides may be used to
disrupt the expression of the target gene. Generally, sequences of
at least 50 nucleotides, 100 nucleotides, 200 nucleotides, or
greater may be used.
[0269] In addition, the polynucleotide of interest may also be used
in the sense orientation to suppress the expression of endogenous
genes in plants. Methods for suppressing gene expression in plants
using polynucleotides in the sense orientation are known in the
art. The methods generally involve transforming plants with a DNA
construct comprising a promoter that drives expression in a plant
operably linked to at least a portion of a nucleotide sequence that
corresponds to the transcript of the endogenous gene. Typically,
such a nucleotide sequence has substantial sequence identity to the
sequence of the transcript of the endogenous gene, generally
greater than about 65% sequence identity, about 85% sequence
identity, or greater than about 95% sequence identity. See U.S.
Pat. Nos. 5,283,184 and 5,034,323.
[0270] The polynucleotide of interest can also be a phenotypic
marker. A phenotypic marker is screenable or a selectable marker
that includes visual markers and selectable markers whether it is a
positive or negative selectable marker. Any phenotypic marker can
be used. Specifically, a selectable or screenable marker comprises
a DNA segment that allows one to identify, or select for or against
a molecule or a cell that comprises it, often under particular
conditions. These markers can encode an activity, such as, but not
limited to, production of RNA, peptide, or protein, or can provide
a binding site for RNA, peptides, proteins, inorganic and organic
compounds or compositions and the like.
[0271] Examples of selectable markers include, but are not limited
to, DNA segments that comprise restriction enzyme sites; DNA
segments that encode products which provide resistance against
otherwise toxic compounds including antibiotics, such as,
spectinomycin, ampicillin, kanamycin, tetracycline, Basta, neomycin
phosphotransferase II (NEO) and hygromycin phosphotransferase
(HPT)); DNA segments that encode products which are otherwise
lacking in the recipient cell (e.g., tRNA genes, auxotrophic
markers); DNA segments that encode products which can be readily
identified (e.g., phenotypic markers such as .beta.-galactosidase,
GUS; fluorescent proteins such as green fluorescent protein (GFP),
cyan (CFP), yellow (YFP), red (RFP), and cell surface proteins);
the generation of new primer sites for PCR (e.g., the juxtaposition
of two DNA sequence not previously juxtaposed), the inclusion of
DNA sequences not acted upon or acted upon by a restriction
endonuclease or other DNA modifying enzyme, chemical, etc.; and,
the inclusion of a DNA sequences required for a specific
modification (e.g., methylation) that allows its
identification.
[0272] Additional selectable markers include genes that confer
resistance to herbicidal compounds, such as sulphonylureas,
glufosinate ammonium, bromoxynil, imidazolinones, and
2,4-dichlorophenoxyacetate (2,4-D). See for example, Acetolactase
synthase (ALS) for resistance to sulfonylureas, imidazolinones,
triazolopyrimidine sulfonamides, pyrimidinylsalicylates and
sulphonylaminocarbonyl-triazolinones (Shaner and Singh, 1997,
Herbicide Activity: Toxicol Biochem Mol Biol 69-110); glyphosate
resistant 5-enolpyruvylshikimate-3-phosphate (EPSPS) (Saroha et al.
1998, J. Plant Biochemistry & Biotechnology Vol 7:65-72);
[0273] Polynucleotides of interest includes genes that can be
stacked or used in combination with other traits, such as but not
limited to herbicide resistance or any other trait described
herein. Polynucleotides of interest and/or traits can be stacked
together in a complex trait locus as described in US20130263324
published 3 Oct. 2013 and in WO/2013/112686, published 1 Aug.
2013.
[0274] A polypeptide of interest includes any protein or
polypeptide that is encoded by a polynucleotide of interest
described herein.
[0275] Further provided are methods for identifying at least one
plant cell, comprising in its genome, a polynucleotide of interest
integrated at the target site. A variety of methods are available
for identifying those plant cells with insertion into the genome at
or near to the target site. Such methods can be viewed as directly
analyzing a target sequence to detect any change in the target
sequence, including but not limited to PCR methods, sequencing
methods, nuclease digestion, Southern blots, and any combination
thereof. See, for example, US20090133152 published 21 May 2009. The
method also comprises recovering a plant from the plant cell
comprising a polynucleotide of interest integrated into its genome.
The plant may be sterile or fertile. It is recognized that any
polynucleotide of interest can be provided, integrated into the
plant genome at the target site, and expressed in a plant.
Optimization of Sequences for Expression in Plants
[0276] Methods are available in the art for synthesizing
plant-preferred genes. See, for example, U.S. Pat. Nos. 5,380,831,
and 5,436,391, and Murray et al. (1989) Nucleic Acids Res.
17:477-498. Additional sequence modifications are known to enhance
gene expression in a plant host. These include, for example,
elimination of: one or more sequences encoding spurious
polyadenylation signals, one or more exon-intron splice site
signals, one or more transposon-like repeats, and other such
well-characterized sequences that may be deleterious to gene
expression. The G-C content of the sequence may be adjusted to
levels average for a given plant host, as calculated by reference
to known genes expressed in the host plant cell. When possible, the
sequence is modified to avoid one or more predicted hairpin
secondary mRNA structures. Thus, "a plant-optimized nucleotide
sequence" of the present disclosure comprises one or more of such
sequence modifications.
Expression Elements
[0277] Any polynucleotide encoding a Cas protein or other CRISPR
system component disclosed herein may be functionally linked to a
heterologous expression element, to facilitate transcription or
regulation in a host cell. Such expression elements include but are
not limited to: promoter, leader, intron, and terminator.
Expression elements may be "minimal"--meaning a shorter sequence
derived from a native source, that still functions as an expression
regulator or modifier. Alternatively, an expression element may be
"optimized"--meaning that its polynucleotide sequence has been
altered from its native state in order to function with a more
desirable characteristic in a particular host cell. Alternatively,
an expression element may be "synthetic"--meaning that it is
designed in silico and synthesized for use in a host cell.
Synthetic expression elements may be entirely synthetic, or
partially synthetic (comprising a fragment of a naturally-occurring
polynucleotide sequence).
[0278] It has been shown that certain promoters are able to direct
RNA synthesis at a higher rate than others. These are called
"strong promoters". Certain other promoters have been shown to
direct RNA synthesis at higher levels only in particular types of
cells or tissues and are often referred to as "tissue specific
promoters", or "tissue-preferred promoters" if the promoters direct
RNA synthesis preferably in certain tissues but also in other
tissues at reduced levels.
[0279] A plant promoter includes a promoter capable of initiating
transcription in a plant cell. For a review of plant promoters,
see, Potenza et al., 2004, In vitro Cell Dev Biol 40:1-22; Porto et
al., 2014, Molecular Biotechnology (2014), 56(1), 38-49.
[0280] Constitutive promoters include, for example, the core CaMV
35S promoter (Odell et al., (1985) Nature 313:810-2); rice actin
(McElroy et al., (1990) Plant Cell 2:163-71); ubiquitin
(Christensen et al., (1989) Plant Mol Biol 12:619-32; ALS promoter
(U.S. Pat. No. 5,659,026) and the like.
[0281] Tissue-preferred promoters can be utilized to target
enhanced expression within a particular plant tissue.
Tissue-preferred promoters include, for example, WO2013103367
published 11 Jul. 2013, Kawamata et al., (1997) Plant Cell Physiol
38:792-803; Hansen et al., (1997) Mol Gen Genet 254:337-43; Russell
et al., (1997) Transgenic Res 6:157-68; Rinehart et al., (1996)
Plant Physiol 112:1331-41; Van Camp et al., (1996) Plant Physiol
112:525-35; Canevascini et al., (1996) Plant Physiol 112:513-524;
Lam, (1994) Results Probl Cell Differ 20:181-96; and Guevara-Garcia
et al., (1993) Plant J 4:495-505. Leaf-preferred promoters include,
for example, Yamamoto et al., (1997) Plant J 12:255-65; Kwon et
al., (1994) Plant Physiol 105:357-67; Yamamoto et al., (1994) Plant
Cell Physiol 35:773-8; Gotor et al., (1993) Plant J 3:509-18;
Orozco et al., (1993) Plant Mol Biol 23:1129-38; Matsuoka et al.,
(1993) Proc. Natl. Acad. Sci. USA 90:9586-90; Simpson et al.,
(1958) EMBO J 4:2723-9; Timko et al., (1988) Nature 318:57-8.
Root-preferred promoters include, for example, Hire et al., (1992)
Plant Mol Biol 20:207-18 (soybean root-specific glutamine synthase
gene); Miao et al., (1991) Plant Cell 3:11-22 (cytosolic glutamine
synthase (GS)); Keller and Baumgartner, (1991) Plant Cell 3:1051-61
(root-specific control element in the GRP 1.8 gene of French bean);
Sanger et al., (1990) Plant Mol Biol 14:433-43 (root-specific
promoter of A. tumefaciens mannopine synthase (MAS)); Bogusz et
al., (1990) Plant Cell 2:633-41 (root-specific promoters isolated
from Parasponia andersonii and Trema tomentosa); Leach and Aoyagi,
(1991) Plant Sci 79:69-76 (A. rhizogenes rolC and rolD
root-inducing genes); Teeri et al., (1989) EMBO J 8:343-50
(Agrobacterium wound-induced TR1' and TR2' genes); VfENOD-GRP3 gene
promoter (Kuster et al., (1995) Plant Mol Biol 29:759-72); and rolB
promoter (Capana et al., (1994) Plant Mol Biol 25:681-91; phaseolin
gene (Murai et al., (1983) Science 23:476-82; Sengopta-Gopalen et
al., (1988) Proc. Natl. Acad. Sci. USA 82:3320-4). See also, U.S.
Pat. Nos. 5,837,876; 5,750,386; 5,633,363; 5,459,252; 5,401,836;
5,110,732 and 5,023,179.
[0282] Seed-preferred promoters include both seed-specific
promoters active during seed development, as well as
seed-germinating promoters active during seed germination. See,
Thompson et al., (1989) BioEssays 10:108. Seed-preferred promoters
include, but are not limited to, Cim1 (cytokinin-induced message);
cZ19B1 (maize 19 kDa zein); and milps (myo-inositol-1-phosphate
synthase); and for example, those disclosed in WO2000011177
published 2 Mar. 2000 and U.S. Pat. No. 6,225,529. For dicots,
seed-preferred promoters include, but are not limited to, bean
.beta.-phaseolin, napin, .beta.-conglycinin, soybean lectin,
cruciferin, and the like. For monocots, seed-preferred promoters
include, but are not limited to, maize 15 kDa zein, 22 kDa zein, 27
kDa gamma zein, waxy, shrunken 1, shrunken 2, globulin 1, oleosin,
and nuc1. See also, WO2000012733 published 9 Mar. 2000, where
seed-preferred promoters from END1 and END2 genes are
disclosed.
[0283] Chemical inducible (regulated) promoters can be used to
modulate the expression of a gene in a prokaryotic and eukaryotic
cell or organism through the application of an exogenous chemical
regulator. The promoter may be a chemical-inducible promoter, where
application of the chemical induces gene expression, or a
chemical-repressible promoter, where application of the chemical
represses gene expression. Chemical-inducible promoters include,
but are not limited to, the maize In2-2 promoter, activated by
benzene sulfonamide herbicide safeners (De Veylder et al., (1997)
Plant Cell Physiol 38:568-77), the maize GST promoter (GST-II-27,
WO1993001294 published 21 Jan. 1993), activated by hydrophobic
electrophilic compounds used as pre-emergent herbicides, and the
tobacco PR-la promoter (Ono et al., (2004) Biosci Biotechnol
Biochem 68:803-7) activated by salicylic acid. Other
chemical-regulated promoters include steroid-responsive promoters
(see, for example, the glucocorticoid-inducible promoter (Schena et
al., (1991) Proc. Natl. Acad. Sci. USA 88:10421-5; McNellis et al.,
(1998) Plant J 14:247-257); tetracycline-inducible and
tetracycline-repressible promoters (Gatz et al., (1991) Mol Gen
Genet 227:229-37; U.S. Pat. Nos. 5,814,618 and 5,789,156).
[0284] Pathogen inducible promoters induced following infection by
a pathogen include, but are not limited to those regulating
expression of PR proteins, SAR proteins, beta-1,3-glucanase,
chitinase, etc.
[0285] A stress-inducible promoter includes the RD29A promoter
(Kasuga et al. (1999) Nature Biotechnol. 17:287-91). One of
ordinary skill in the art is familiar with protocols for simulating
stress conditions such as drought, osmotic stress, salt stress and
temperature stress and for evaluating stress tolerance of plants
that have been subjected to simulated or naturally-occurring stress
conditions.
[0286] Another example of an inducible promoter useful in plant
cells, is the ZmCAS1 promoter, described in US20130312137 published
21 Nov. 2013.
[0287] New promoters of various types useful in plant cells are
constantly being discovered; numerous examples may be found in the
compilation by Okamuro and Goldberg, (1989) In The Biochemistry of
Plants, Vol. 115, Stumpf and Conn, eds (New York, N.Y.: Academic
Press), pp. 1-82.
Modification of Genomes with Novel CRISPR-Cas System Components
[0288] As described herein, a guided Cas endonuclease can
recognize, bind to a DNA target sequence and introduce a single
strand (nick) or double-strand break. Once a single or
double-strand break is induced in the DNA, the cell's DNA repair
mechanism is activated to repair the break. Error-prone DNA repair
mechanisms can produce mutations at double-strand break sites. The
most common repair mechanism to bring the broken ends together is
the nonhomologous end-joining (NHEJ) pathway (Bleuyard et al.,
(2006) DNA Repair 5:1-12). The structural integrity of chromosomes
is typically preserved by the repair, but deletions, insertions, or
other rearrangements (such as chromosomal translocations) are
possible (Siebert and Puchta, 2002, Plant Cell 14:1121-31; Pacher
et al., 2007, Genetics 175:21-9).
[0289] DNA double-strand breaks appear to be an effective factor to
stimulate homologous recombination pathways (Puchta et al., (1995)
Plant Mol Biol 28:281-92; Tzfira and White, (2005) Trends
Biotechnol 23:567-9; Puchta, (2005) J Exp Bot 56:1-14). Using
DNA-breaking agents, a two- to nine-fold increase of homologous
recombination was observed between artificially constructed
homologous DNA repeats in plants (Puchta et al., (1995) Plant Mot
Biol 28:281-92). In maize protoplasts, experiments with linear DNA
molecules demonstrated enhanced homologous recombination between
plasmids (Lyznik et al., (1991) Mol Gen Genet 230:209-18).
[0290] Homology-directed repair (HDR) is a mechanism in cells to
repair double-stranded and single stranded DNA breaks.
Homology-directed repair includes homologous recombination (HR) and
single-strand annealing (SSA) (Lieber. 2010 Annu. Rev. Biochem.
79:181-211). The most common form of HDR is called homologous
recombination (HR), which has the longest sequence homology
requirements between the donor and acceptor DNA. Other forms of HDR
include single-stranded annealing (SSA) and breakage-induced
replication, and these require shorter sequence homology relative
to HR. Homology-directed repair at nicks (single-stranded breaks)
can occur via a mechanism distinct from HDR at double-strand breaks
(Davis and Maizels. PNAS (0027-8424), 111 (10), p. E924-E932).
[0291] Alteration of the genome of a prokaryotic and eukaryotic
cell or organism cell, for example, through homologous
recombination (HR), is a powerful tool for genetic engineering.
Homologous recombination has been demonstrated in plants (Halfter
et al., (1992) Mol Gen Genet 231:186-93) and insects (Dray and
Gloor, 1997, Genetics 147:689-99). Homologous recombination has
also been accomplished in other organisms. For example, at least
150-200 bp of homology was required for homologous recombination in
the parasitic protozoan Leishmania (Papadopoulou and Dumas, (1997)
Nucleic Acids Res 25:4278-86). In the filamentous fungus
Aspergillus nidulans, gene replacement has been accomplished with
as little as 50 bp flanking homology (Chaveroche et al., (2000)
Nucleic Acids Res 28:e97). Targeted gene replacement has also been
demonstrated in the ciliate Tetrahymena thermophila (Gaertig et
al., (1994) Nucleic Acids Res 22:5391-8). In mammals, homologous
recombination has been most successful in the mouse using
pluripotent embryonic stem cell lines (ES) that can be grown in
culture, transformed, selected and introduced into a mouse embryo
(Watson et al., 1992, Recombinant DNA, 2nd Ed., Scientific American
Books distributed by WH Freeman & Co.).
Gene Targeting
[0292] The guide polynucleotide/Cas systems described herein can be
used for gene targeting.
[0293] In general, DNA targeting can be performed by cleaving one
or both strands at a specific polynucleotide sequence in a cell
with a Cas protein associated with a suitable polynucleotide
component. Once a single or double-strand break is induced in the
DNA, the cell's DNA repair mechanism is activated to repair the
break via nonhomologous end-joining (NHEJ) or Homology-Directed
Repair (HDR) processes which can lead to modifications at the
target site.
[0294] The length of the DNA sequence at the target site can vary,
and includes, for example, target sites that are at least 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
or more than 30 nucleotides in length. It is further possible that
the target site can be palindromic, that is, the sequence on one
strand reads the same in the opposite direction on the
complementary strand. The nick/cleavage site can be within the
target sequence or the nick/cleavage site could be outside of the
target sequence. In another variation, the cleavage could occur at
nucleotide positions immediately opposite each other to produce a
blunt end cut or, in other cases, the incisions could be staggered
to produce single-stranded overhangs, also called "sticky ends" or
"staggered end", which can be either 5' overhangs, or 3' overhangs.
Active variants of genomic target sites can also be used. Such
active variants can comprise at least 65%, 70%, 75%, 80%, 85%, 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence
identity to the given target site, wherein the active variants
retain biological activity and hence are capable of being
recognized and cleaved by a Cas endonuclease.
[0295] Assays to measure the single or double-strand break of a
target site by an endonuclease are known in the art and generally
measure the overall activity and specificity of the agent on DNA
substrates comprising recognition sites.
[0296] A targeting method herein can be performed in such a way
that two or more DNA target sites are targeted in the method, for
example. Such a method can optionally be characterized as a
multiplex method. Two, three, four, five, six, seven, eight, nine,
ten, or more target sites can be targeted at the same time in
certain embodiments. A multiplex method is typically performed by a
targeting method herein in which multiple different RNA components
are provided, each designed to guide a guide polynucleotide/Cas
endonuclease complex to a unique DNA target site.
Gene Editing
[0297] The process for editing a genomic sequence combining DSB and
modification templates generally comprises: introducing into a host
cell a DSB-inducing agent, or a nucleic acid encoding a
DSB-inducing agent, that recognizes a target sequence in the
chromosomal sequence and is able to induce a DSB in the genomic
sequence, and at least one polynucleotide modification template
comprising at least one nucleotide alteration when compared to the
nucleotide sequence to be edited. The polynucleotide modification
template can further comprise nucleotide sequences flanking the at
least one nucleotide alteration, in which the flanking sequences
are substantially homologous to the chromosomal region flanking the
DSB. Genome editing using DSB-inducing agents, such as Cas-gRNA
complexes, has been described, for example in US20150082478
published on 19 Mar. 2015, WO2015026886 published on 26 Feb. 2015,
WO2016007347 published 14 Jan. 2016, and WO/2016/025131 published
on 18 Feb. 2016.
[0298] Some uses for guide RNA/Cas endonuclease systems have been
described (see for example: US20150082478 A1 published 19 Mar.
2015, WO2015026886 published 26 Feb. 2015, and US20150059010
published 26 Feb. 2015) and include but are not limited to
modifying or replacing nucleotide sequences of interest (such as a
regulatory elements), insertion of polynucleotides of interest,
gene knock-out, gene-knock in, modification of splicing sites
and/or introducing alternate splicing sites, modifications of
nucleotide sequences encoding a protein of interest, amino acid
and/or protein fusions, and gene silencing by expressing an
inverted repeat into a gene of interest.
[0299] Proteins may be altered in various ways including amino acid
substitutions, deletions, truncations, and insertions. Methods for
such manipulations are generally known. For example, amino acid
sequence variants of the protein(s) can be prepared by mutations in
the DNA. Methods for mutagenesis and nucleotide sequence
alterations include, for example, Kunkel, (1985) Proc. Natl. Acad.
Sci. USA 82:488-92; Kunkel et al., (1987) Meth Enzymol 154:367-82;
U.S. Pat. No. 4,873,192; Walker and Gaastra, eds. (1983) Techniques
in Molecular Biology (MacMillan Publishing Company, New York) and
the references cited therein. Guidance regarding amino acid
substitutions not likely to affect biological activity of the
protein is found, for example, in the model of Dayhoff et al.,
(1978) Atlas of Protein Sequence and Structure (Natl Biomed Res
Found, Washington, D.C.). Conservative substitutions, such as
exchanging one amino acid with another having similar properties,
may be preferable. Conservative deletions, insertions, and amino
acid substitutions are not expected to produce radical changes in
the characteristics of the protein, and the effect of any
substitution, deletion, insertion, or combination thereof can be
evaluated by routine screening assays. Assays for
double-strand-break-inducing activity are known and generally
measure the overall activity and specificity of the agent on DNA
substrates comprising target sites.
[0300] Described herein are methods for genome editing with CRISPR
Associated (Cas) endonucleases. Following characterization of the
guide RNA (or guide polynucleotide) and PAM sequence, a
ribonucleoprotein (RNP) complex comprising the Cas endonuclease and
the guide RNA (or guide polynucleotide) may be utilized to modify a
target polynucleotide, including but not limited to: synthetic DNA,
isolated genomic DNA, or chromosomal DNA in other organisms,
including plants. To facilitate optimal expression and nuclear
localization (for eukaryotic cells), the gene comprising the Cas
endonuclease may be optimized, and then delivered into cells as DNA
expression cassettes by methods known in the art. The components
necessary to comprise an active RNP may also be delivered as RNA
with or without modifications that protect the RNA from degradation
or as mRNA capped or uncapped (Zhang, Y. et al., 2016, Nat. Commun.
7:12617) or Cas protein guide polynucleotide complexes
(WO2017070032 published 27 Apr. 2017), or any combination thereof.
Additionally, a part or part(s) of the complex may be expressed
from a DNA construct while other components are delivered as RNA
with or without modifications that protect the RNA from degradation
or as mRNA capped or uncapped (Zhang et al. 2016 Nat. Commun.
7:12617) or Cas protein guide polynucleotide complexes
(WO2017070032 published 27 Apr. 2017) or any combination thereof.
To produce crRNAs in-vivo, tRNA derived elements may also be used
to recruit endogenous RNAses to cleave crRNA transcripts into
mature forms capable of guiding the complex to its DNA target site,
as described, for example, in WO2017105991 published 22 Jun. 2017.
Furthermore, the cleavage activity of the Cas endonuclease may be
deactivated by altering key catalytic residues in its cleavage
domain (Sinkunas, T. et al., 2013, EMBO J. 32:385-394) resulting in
a RNA guided helicase that may be used to enhance homology directed
repair, induce transcriptional activation, or remodel local DNA
structures. Moreover, the activity of the Cas cleavage and helicase
domains may both be knocked-out and used in combination with other
DNA cutting, DNA nicking, DNA binding, transcriptional activation,
transcriptional repression, DNA remodeling, DNA deamination, DNA
unwinding, DNA recombination enhancing, DNA integration, DNA
inversion, and DNA repair agents.
[0301] The transcriptional direction of the tracrRNA for the
CRISPR-Cas system (if present) and other components of the
CRISPR-Cas system (such as variable targeting domain, crRNA repeat,
loop, anti-repeat) can be deduced as described in WO2016186946
published 24 Nov. 2016, and WO2016186953 published 24 Nov.
2016.
[0302] As described herein, once the appropriate guide RNA
requirement is established, the PAM preferences for each new system
disclosed herein may be examined. If the cleavage RNP complex
(comprising the Cas endonuclease and guide polynucleotide) results
in degradation of the randomized PAM library, the complex can be
converted into a nickase by disabling activity either through
mutagenesis of critical residues or by assembling the reaction in
the absence of ATP as described previously (Sinkunas, T. et al.,
2013, EMBO J. 32:385-394). Two regions of PAM randomization
separated by two protospacer targets may be utilized to generate a
double-stranded DNA break which may be captured and sequenced to
examine the PAM sequences that support cleavage by the complex.
[0303] In one embodiment, the invention describes a method for
modifying a target site in the genome of a cell, the method
comprising introducing into a cell at least one PGEN described
herein, and identifying at least one cell that has a modification
at said target, wherein the modification at said target site is
selected from the group consisting of (i) a replacement of at least
one nucleotide, (ii) a deletion of at least one nucleotide, (iii)
an insertion of at least one nucleotide, and (iv) any combination
of (i)-(iii).
[0304] The nucleotide to be edited can be located within or outside
a target site recognized and cleaved by a Cas endonuclease. In one
embodiment, the at least one nucleotide modification is not a
modification at a target site recognized and cleaved by a Cas
endonuclease. In another embodiment, there are at least 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 30, 40, 50, 100, 200, 300, 400, 500, 600, 700,
900 or 1000 nucleotides between the at least one nucleotide to be
edited and the genomic target site.
[0305] A knock-out may be produced by an indel (insertion or
deletion of nucleotide bases in a target DNA sequence through
NHEJ), or by specific removal of sequence that reduces or
completely destroys the function of sequence at or near the
targeting site.
[0306] A guide polynucleotide/Cas endonuclease induced targeted
mutation can occur in a nucleotide sequence that is located within
or outside a genomic target site that is recognized and cleaved by
the Cas endonuclease.
[0307] The method for editing a nucleotide sequence in the genome
of a cell can be a method without the use of an exogenous
selectable marker by restoring function to a non-functional gene
product.
[0308] In one embodiment, the invention describes a method for
modifying a target site in the genome of a cell, the method
comprising introducing into a cell at least one PGEN described
herein and at least one donor DNA, wherein said donor DNA comprises
a polynucleotide of interest, and optionally, further comprising
identifying at least one cell that said polynucleotide of interest
integrated in or near said target site.
[0309] In one aspect, the methods disclosed herein may employ
homologous recombination (HR) to provide integration of the
polynucleotide of interest at the target site.
[0310] Various methods and compositions can be employed to produce
a cell or organism having a polynucleotide of interest inserted in
a target site via activity of a CRISPR-Cas system component
described herein. In one method described herein, a polynucleotide
of interest is introduced into the organism cell via a donor DNA
construct. As used herein, "donor DNA" is a DNA construct that
comprises a polynucleotide of interest to be inserted into the
target site of a Cas endonuclease. The donor DNA construct further
comprises a first and a second region of homology that flank the
polynucleotide of interest. The first and second regions of
homology of the donor DNA share homology to a first and a second
genomic region, respectively, present in or flanking the target
site of the cell or organism genome.
[0311] The donor DNA can be tethered to the guide polynucleotide.
Tethered donor DNAs can allow for co-localizing target and donor
DNA, useful in genome editing, gene insertion, and targeted genome
regulation, and can also be useful in targeting post-mitotic cells
where function of endogenous HR machinery is expected to be highly
diminished (Mali et al., 2013, Nature Methods Vol. 10:
957-963).
[0312] The amount of homology or sequence identity shared by a
target and a donor polynucleotide can vary and includes total
lengths and/or regions having unit integral values in the ranges of
about 1-20 bp, 20-50 bp, 50-100 bp, 75-150 bp, 100-250 bp, 150-300
bp, 200-400 bp, 250-500 bp, 300-600 bp, 350-750 bp, 400-800 bp,
450-900 bp, 500-1000 bp, 600-1250 bp, 700-1500 bp, 800-1750 bp,
900-2000 bp, 1-2.5 kb, 1.5-3 kb, 2-4 kb, 2.5-5 kb, 3-6 kb, 3.5-7
kb, 4-8 kb, 5-10 kb, or up to and including the total length of the
target site. These ranges include every integer within the range,
for example, the range of 1-20 bp includes 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 bps. The amount of
homology can also be described by percent sequence identity over
the full aligned length of the two polynucleotides which includes
percent sequence identity of about at least 50%, 55%, 60%, 65%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%,
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99% or 100%. Sufficient homology includes any
combination of polynucleotide length, global percent sequence
identity, and optionally conserved regions of contiguous
nucleotides or local percent sequence identity, for example
sufficient homology can be described as a region of 75-150 bp
having at least 80% sequence identity to a region of the target
locus. Sufficient homology can also be described by the predicted
ability of two polynucleotides to specifically hybridize under high
stringency conditions, see, for example, Sambrook et al., (1989)
Molecular Cloning: A Laboratory Manual, (Cold Spring Harbor
Laboratory Press, NY); Current Protocols in Molecular Biology,
Ausubel et al., Eds (1994) Current Protocols, (Greene Publishing
Associates, Inc. and John Wiley & Sons, Inc.); and, Tijssen
(1993) Laboratory Techniques in Biochemistry and Molecular
Biology--Hybridization with Nucleic Acid Probes, (Elsevier, New
York).
[0313] Episomal DNA molecules can also be ligated into the
double-strand break, for example, integration of T-DNAs into
chromosomal double-strand breaks (Chilton and Que, (2003) Plant
Physiol 133:956-65; Salomon and Puchta, (1998) EMBO J. 17:6086-95).
Once the sequence around the double-strand breaks is altered, for
example, by exonuclease activities involved in the maturation of
double-strand breaks, gene conversion pathways can restore the
original structure if a homologous sequence is available, such as a
homologous chromosome in non-dividing somatic cells, or a sister
chromatid after DNA replication (Molinier et al., (2004) Plant Cell
16:342-52). Ectopic and/or epigenic DNA sequences may also serve as
a DNA repair template for homologous recombination (Puchta, (1999)
Genetics 152:1173-81).
[0314] In one embodiment, the disclosure comprises a method for
editing a nucleotide sequence in the genome of a cell, the method
comprising introducing into at least one PGEN described herein, and
a polynucleotide modification template, wherein said polynucleotide
modification template comprises at least one nucleotide
modification of said nucleotide sequence, and optionally further
comprising selecting at least one cell that comprises the edited
nucleotide sequence.
[0315] The guide polynucleotide/Cas endonuclease system can be used
in combination with at least one polynucleotide modification
template to allow for editing (modification) of a genomic
nucleotide sequence of interest. (See also US20150082478, published
19 Mar. 2015 and WO2015026886 published 26 Feb. 2015).
[0316] Polynucleotides of interest and/or traits can be stacked
together in a complex trait locus as described in WO2012129373
published 27 Sep. 2012, and in WO2013112686, published 1 Aug. 2013.
The guide polynucleotide/Cas endonuclease system described herein
provides for an efficient system to generate double-strand breaks
and allows for traits to be stacked in a complex trait locus.
[0317] A guide polynucleotide/Cas system as described herein,
mediating gene targeting, can be used in methods for directing
heterologous gene insertion and/or for producing complex trait loci
comprising multiple heterologous genes in a fashion similar as
disclosed in WO2012129373 published 27 Sep. 2012, where instead of
using a double-strand break inducing agent to introduce a gene of
interest, a guide polynucleotide/Cas system as disclosed herein is
used. By inserting independent transgenes within 0.1, 0.2, 0.3,
0.4, 0.5, 1.0, 2, or even 5 centimorgans (cM) from each other, the
transgenes can be bred as a single genetic locus (see, for example,
US20130263324 published 3 Oct. 2013 or WO2012129373 published 14
Mar. 2013). After selecting a plant comprising a transgene, plants
comprising (at least) one transgenes can be crossed to form an F1
that comprises both transgenes. In progeny from these F1 (F2 or
BC1) 1/500 progeny would have the two different transgenes
recombined onto the same chromosome. The complex locus can then be
bred as single genetic locus with both transgene traits. This
process can be repeated to stack as many traits as desired.
[0318] Further uses for guide RNA/Cas endonuclease systems have
been described (See for example: US20150082478 published 19 Mar.
2015, WO2015026886 published 26 Feb. 2015, US20150059010 published
26 Feb. 2015, WO2016007347 published 14 Jan. 2016, and PCT
application WO2016025131 published 18 Feb. 2016) and include but
are not limited to modifying or replacing nucleotide sequences of
interest (such as a regulatory elements), insertion of
polynucleotides of interest, gene knock-out, gene-knock in,
modification of splicing sites and/or introducing alternate
splicing sites, modifications of nucleotide sequences encoding a
protein of interest, amino acid and/or protein fusions, and gene
silencing by expressing an inverted repeat into a gene of
interest.
[0319] Resulting characteristics from the gene editing compositions
and methods described herein may be evaluated. Chromosomal
intervals that correlate with a phenotype or trait of interest can
be identified. A variety of methods well known in the art are
available for identifying chromosomal intervals. The boundaries of
such chromosomal intervals are drawn to encompass markers that will
be linked to the gene controlling the trait of interest. In other
words, the chromosomal interval is drawn such that any marker that
lies within that interval (including the terminal markers that
define the boundaries of the interval) can be used as a marker for
a particular trait. In one embodiment, the chromosomal interval
comprises at least one QTL, and furthermore, may indeed comprise
more than one QTL. Close proximity of multiple QTLs in the same
interval may obfuscate the correlation of a particular marker with
a particular QTL, as one marker may demonstrate linkage to more
than one QTL. Conversely, e.g., if two markers in close proximity
show co-segregation with the desired phenotypic trait, it is
sometimes unclear if each of those markers identifies the same QTL
or two different QTL. The term "quantitative trait locus" or "QTL"
refers to a region of DNA that is associated with the differential
expression of a quantitative phenotypic trait in at least one
genetic background, e.g., in at least one breeding population. The
region of the QTL encompasses or is closely linked to the gene or
genes that affect the trait in question. An "allele of a QTL" can
comprise multiple genes or other genetic factors within a
contiguous genomic region or linkage group, such as a haplotype. An
allele of a QTL can denote a haplotype within a specified window
wherein said window is a contiguous genomic region that can be
defined, and tracked, with a set of one or more polymorphic
markers. A haplotype can be defined by the unique fingerprint of
alleles at each marker within the specified window.
[0320] In addition to the double-strand break inducing agents,
site-specific base conversions can also be achieved to engineer one
or more nucleotide changes to create one or more edits into the
genome. These include for example, a site-specific base edit
mediated by an C G to T A or an A T to G C base editing deaminase
enzymes (Gaudelli et al., Programmable base editing of A T to G C
in genomic DNA without DNA cleavage." Nature (2017); Nishida et al.
"Targeted nucleotide editing using hybrid prokaryotic and
vertebrate adaptive immune systems." Science 353 (6305) (2016);
Komor et al. "Programmable editing of a target base in genomic DNA
without double-stranded DNA cleavage." Nature 533 (7603)
(2016):420-4. A catalytically "dead" or inactive Cas9 (dCas9), for
example a catalytically inactive "dead" version of a Cas9 ortholog
disclosed herein, fused to a cytidine deaminase or an adenine
deaminase protein becomes a specific base editor that can alter DNA
bases without inducing a DNA break. Base editors convert C->T
(or G->A on the opposite strand) or an adenine base editor that
would convert adenine to inosine, resulting in an A->G change
within an editing window specified by the gRNA.
Introduction of CRISPR-Cas System Components into a Cell
[0321] The methods and compositions described herein do not depend
on a particular method for introducing a sequence into an organism
or cell, only that the polynucleotide or polypeptide gains access
to the interior of at least one cell of the organism. Introducing
includes reference to the incorporation of a nucleic acid into a
eukaryotic or prokaryotic cell where the nucleic acid may be
incorporated into the genome of the cell, and includes reference to
the transient (direct) provision of a nucleic acid, protein or
polynucleotide-protein complex (PGEN, RGEN) to the cell.
[0322] Methods for introducing polynucleotides or polypeptides or a
polynucleotide-protein complex into cells or organisms are known in
the art including, but not limited to, microinjection,
electroporation, stable transformation methods, transient
transformation methods, ballistic particle acceleration (particle
bombardment), whiskers mediated transformation,
Agrobacterium-mediated transformation, direct gene transfer,
viral-mediated introduction, transfection, transduction,
cell-penetrating peptides, mesoporous silica nanoparticle
(MSN)-mediated direct protein delivery, topical applications,
sexual crossing, sexual breeding, and any combination thereof.
[0323] For example, the guide polynucleotide (guide RNA,
crNucleotide+tracrNucleotide, guide DNA and/or guide RNA-DNA
molecule) can be introduced into a cell directly (transiently) as a
single stranded or double stranded polynucleotide molecule. The
guide RNA (or crRNA+tracrRNA) can also be introduced into a cell
indirectly by introducing a recombinant DNA molecule comprising a
heterologous nucleic acid fragment encoding the guide RNA (or
crRNA+tracrRNA), operably linked to a specific promoter that is
capable of transcribing the guide RNA (crRNA+tracrRNA molecules) in
said cell. The specific promoter can be, but is not limited to, a
RNA polymerase III promoter, which allow for transcription of RNA
with precisely defined, unmodified, 5'- and 3'-ends (Ma et al.,
2014, Mol. Ther. Nucleic Acids 3:e161; DiCarlo et al., 2013,
Nucleic Acids Res. 41: 4336-4343; WO2015026887, published 26 Feb.
2015). Any promoter capable of transcribing the guide RNA in a cell
can be used and includes a heat shock/heat inducible promoter
operably linked to a nucleotide sequence encoding the guide
RNA.
[0324] The Cas endonuclease, such as the Cas endonuclease described
herein, can be introduced into a cell by directly introducing the
Cas polypeptide itself (referred to as direct delivery of Cas
endonuclease), the mRNA encoding the Cas protein, and/or the guide
polynucleotide/Cas endonuclease complex itself, using any method
known in the art. The Cas endonuclease can also be introduced into
a cell indirectly by introducing a recombinant DNA molecule that
encodes the Cas endonuclease. The endonuclease can be introduced
into a cell transiently or can be incorporated into the genome of
the host cell using any method known in the art. Uptake of the
endonuclease and/or the guided polynucleotide into the cell can be
facilitated with a Cell Penetrating Peptide (CPP) as described in
WO2016073433 published 12 May 2016. Any promoter capable of
expressing the Cas endonuclease in a cell can be used and includes
a heat shock/heat inducible promoter operably linked to a
nucleotide sequence encoding the Cas endonuclease.
[0325] Direct delivery of a polynucleotide modification template
into plant cells can be achieved through particle mediated
delivery, and any other direct method of delivery, such as but not
limiting to, polyethylene glycol (PEG)-mediated transfection to
protoplasts, whiskers mediated transformation, electroporation,
particle bombardment, cell-penetrating peptides, or mesoporous
silica nanoparticle (MSN)-mediated direct protein delivery can be
successfully used for delivering a polynucleotide modification
template in eukaryotic cells, such as plant cells.
[0326] The donor DNA can be introduced by any means known in the
art. The donor DNA may be provided by any transformation method
known in the art including, for example, Agrobacterium-mediated
transformation or biolistic particle bombardment. The donor DNA may
be present transiently in the cell or it could be introduced via a
viral replicon. In the presence of the Cas endonuclease and the
target site, the donor DNA is inserted into the transformed plant's
genome.
[0327] Direct delivery of any one of the guided Cas system
components can be accompanied by direct delivery (co-delivery) of
other mRNAs that can promote the enrichment and/or visualization of
cells receiving the guide polynucleotide/Cas endonuclease complex
components. For example, direct co-delivery of the guide
polynucleotide/Cas endonuclease components (and/or guide
polynucleotide/Cas endonuclease complex itself) together with mRNA
encoding phenotypic markers (such as but not limiting to
transcriptional activators such as CRC (Bruce et al. 2000 The Plant
Cell 12:65-79) can enable the selection and enrichment of cells
without the use of an exogenous selectable marker by restoring
function to a non-functional gene product as described in
WO2017070032 published 27 Apr. 2017.
[0328] Introducing a guide RNA/Cas endonuclease complex described
herein, into a cell includes introducing the individual components
of said complex either separately or combined into the cell, and
either directly (direct delivery as RNA for the guide and protein
for the Cas endonuclease and Cas protein subunits, or functional
fragments thereof) or via recombination constructs expressing the
components (guide RNA, Cas endonuclease, Cas protein subunits, or
functional fragments thereof). Introducing a guide RNA/Cas
endonuclease complex (RGEN) into a cell includes introducing the
guide RNA/Cas endonuclease complex as a ribonucleotide-protein into
the cell. The ribonucleotide-protein can be assembled prior to
being introduced into the cell as described herein. The components
comprising the guide RNA/Cas endonuclease ribonucleotide protein
(at least one Cas endonuclease, at least one guide RNA, at least
one Cas protein subunits) can be assembled in vitro or assembled by
any means known in the art prior to being introduced into a cell
(targeted for genome modification as described herein).
[0329] Plant cells differ from human and animal cells in that plant
cells comprise a plant cell wall which may act as a barrier to the
direct delivery of the RGEN ribonucleoproteins and/or of the direct
delivery of the RGEN components.
[0330] Direct delivery of the RGEN ribonucleoproteins into plant
cells can be achieved through particle mediated delivery (particle
bombardment. Based on the experiments described herein, a skilled
artesian can now envision that any other direct method of delivery,
such as but not limiting to, polyethylene glycol (PEG)-mediated
transfection to protoplasts, electroporation, cell-penetrating
peptides, or mesoporous silica nanoparticle (MSN)-mediated direct
protein delivery, can be successfully used for delivering RGEN
ribonucleoproteins into plant cells.
[0331] Direct delivery of the RGEN ribonucleoprotein, allows for
genome editing at a target site in the genome of a cell which can
be followed by rapid degradation of the complex, and only a
transient presence of the complex in the cell. This transient
presence of the RGEN complex may lead to reduced off-target
effects. In contrast, delivery of RGEN components (guide RNA, Cas
endonuclease) via plasmid DNA sequences can result in constant
expression of RGENs from these plasmids which can intensify off
target effects (Cradick, T. J. et al. (2013) Nucleic Acids Res
41:9584-9592; Fu, Y et al. (2014) Nat. Biotechnol. 31:822-826).
[0332] Direct delivery can be achieved by combining any one
component of the guide RNA/Cas endonuclease complex (RGEN) (such as
at least one guide RNA, at least one Cas protein, and at least one
Cas protein), with a particle delivery matrix comprising a
microparticle (such as but not limited to of a gold particle,
tungsten particle, and silicon carbide whisker particle) (see also
WO2017070032 published 27 Apr. 2017).
[0333] In one aspect, the guide polynucleotide/Cas endonuclease
complex is a complex wherein the guide RNA and Cas endonuclease
protein forming the guide RNA/Cas endonuclease complex are
introduced into the cell as RNA and protein, respectively.
[0334] In one aspect, the guide polynucleotide/Cas endonuclease
complex is a complex wherein the guide RNA and Cas endonuclease
protein and the at least one protein subunit of a Cas protein
forming the guide RNA/Cas endonuclease complex are introduced into
the cell as RNA and proteins, respectively.
[0335] In one aspect, the guide polynucleotide/Cas endonuclease
complex is a complex wherein the guide RNA and Cas endonuclease
protein and the at least one protein subunit of a Cascade forming
the guide RNA/Cas endonuclease complex (cleavage ready cascade) are
preassembled in vitro and introduced into the cell as a
ribonucleotide-protein complex.
[0336] Protocols for introducing polynucleotides, polypeptides or
polynucleotide-protein complexes (PGEN, RGEN) into eukaryotic
cells, such as plants or plant cells are known and include
microinjection (Crossway et al., (1986) Biotechniques 4:320-34 and
U.S. Pat. No. 6,300,543), meristem transformation (U.S. Pat. No.
5,736,369), electroporation (Riggs et al., (1986) Proc. Natl. Acad.
Sci. USA 83:5602-6, Agrobacterium-mediated transformation (U.S.
Pat. Nos. 5,563,055 and 5,981,840), whiskers mediated
transformation (Ainley et al. 2013, Plant Biotechnology Journal
11:1126-1134; Shaheen A. and M. Arshad 2011 Properties and
Applications of Silicon Carbide (2011), 345-358 Editor(s):
Gerhardt, Rosario. Publisher: InTech, Rijeka, Croatia. CODEN:
69PQBP; ISBN: 978-953-307-201-2), direct gene transfer (Paszkowski
et al., (1984) EMBO J 3:2717-22), and ballistic particle
acceleration (U.S. Pat. Nos. 4,945,050; 5,879,918; 5,886,244;
5,932,782; Tomes et al., (1995) "Direct DNA Transfer into Intact
Plant Cells via Microprojectile Bombardment" in Plant Cell, Tissue,
and Organ Culture: Fundamental Methods, ed. Gamborg & Phillips
(Springer-Verlag, Berlin); McCabe et al., (1988) Biotechnology
6:923-6; Weissinger et al., (1988) Ann Rev Genet 22:421-77; Sanford
et al., (1987) Particulate Science and Technology 5:27-37 (onion);
Christou et al., (1988) Plant Physiol 87:671-4 (soybean); Finer and
McMullen, (1991) In vitro Cell Dev Biol 27P:175-82 (soybean); Singh
et al., (1998) Theor Appl Genet 96:319-24 (soybean); Datta et al.,
(1990) Biotechnology 8:736-40 (rice); Klein et al., (1988) Proc.
Natl. Acad. Sci. USA 85:4305-9 (maize); Klein et al., (1988)
Biotechnology 6:559-63 (maize); U.S. Pat. Nos. 5,240,855; 5,322,783
and 5,324,646; Klein et al., (1988) Plant Physiol 91:440-4 (maize);
Fromm et al., (1990) Biotechnology 8:833-9 (maize); Hooykaas-Van
Slogteren et al., (1984) Nature 311:763-4; U.S. Pat. No. 5,736,369
(cereals); Bytebier et al., (1987) Proc. Natl. Acad. Sci. USA
84:5345-9 (Liliaceae); De Wet et al., (1985) in The Experimental
Manipulation of Ovule Tissues, ed. Chapman et al., (Longman, New
York), pp. 197-209 (pollen); Kaeppler et al., (1990) Plant Cell Rep
9:415-8) and Kaeppler et al., (1992) Theor Appl Genet 84:560-6
(whisker-mediated transformation); D'Halluin et al., (1992) Plant
Cell 4:1495-505 (electroporation); Li et al., (1993) Plant Cell Rep
12:250-5; Christou and Ford (1995) Annals Botany 75:407-13 (rice)
and Osjoda et al., (1996) Nat Biotechnol 14:745-50 (maize via
Agrobacterium tumefaciens).
[0337] Alternatively, polynucleotides may be introduced into plant
or plant cells by contacting cells or organisms with a virus or
viral nucleic acids. Generally, such methods involve incorporating
a polynucleotide within a viral DNA or RNA molecule. In some
examples a polypeptide of interest may be initially synthesized as
part of a viral polyprotein, which is later processed by
proteolysis in vivo or in vitro to produce the desired recombinant
protein. Methods for introducing polynucleotides into plants and
expressing a protein encoded therein, involving viral DNA or RNA
molecules, are known, see, for example, U.S. Pat. Nos. 5,889,191,
5,889,190, 5,866,785, 5,589,367 and 5,316,931.
[0338] The polynucleotide or recombinant DNA construct can be
provided to or introduced into a prokaryotic and eukaryotic cell or
organism using a variety of transient transformation methods. Such
transient transformation methods include, but are not limited to,
the introduction of the polynucleotide construct directly into the
plant.
[0339] Nucleic acids and proteins can be provided to a cell by any
method including methods using molecules to facilitate the uptake
of anyone or all components of a guided Cas system (protein and/or
nucleic acids), such as cell-penetrating peptides and nanocarriers.
See also US20110035836 published 10 Feb. 2011, and EP2821486A1
published 7 Jan. 2015.
[0340] Other methods of introducing polynucleotides into a
prokaryotic and eukaryotic cell or organism or plant part can be
used, including plastid transformation methods, and the methods for
introducing polynucleotides into tissues from seedlings or mature
seeds.
[0341] Stable transformation is intended to mean that the
nucleotide construct introduced into an organism integrates into a
genome of the organism and is capable of being inherited by the
progeny thereof. Transient transformation is intended to mean that
a polynucleotide is introduced into the organism and does not
integrate into a genome of the organism or a polypeptide is
introduced into an organism. Transient transformation indicates
that the introduced composition is only temporarily expressed or
present in the organism.
[0342] A variety of methods are available to identify those cells
having an altered genome at or near a target site without using a
screenable marker phenotype. Such methods can be viewed as directly
analyzing a target sequence to detect any change in the target
sequence, including but not limited to PCR methods, sequencing
methods, nuclease digestion, Southern blots, and any combination
thereof.
[0343] The presently disclosed polynucleotides and polypeptides can
be introduced into a cell. Cells include, but are not limited to,
human, non-human, animal, mammalian, bacterial, protist, fungal,
insect, yeast, non-conventional yeast, and plant cells, as well as
plants and seeds produced by the methods described herein. In some
aspects, the cell of the organism is a reproductive cell, a somatic
cell, a meiotic cell, a mitotic cell, a stem cell, or a pluripotent
stem cell.
Cells and Plants
[0344] The presently disclosed polynucleotides and polypeptides can
be introduced into a plant cell. Plant cells include, well as
plants and seeds produced by the methods described herein. Any
plant can be used with the compositions and methods described
herein, including monocot and dicot plants, and plant elements.
[0345] The novel Cas9 orthologs disclosed may be used to edit the
genome of a plant cell in various ways. In one aspect, it may be
desirable to delete one or more nucleotides. In another aspect, it
may be desirable to insert one or more nucleotides. In one aspect,
it may be desirable to replace one or more nucleotides. In another
aspect, it may be desirable to modify one or more nucleotides via a
covalent or non-covalent interaction with another atom or molecule.
In some aspects, the cell is diploid. In some aspects, the cell is
haploid.
[0346] Genome modification via a Cas9 ortholog may be used to
effect a genotypic and/or phenotypic change on the target organism.
Such a change is preferably related to an improved trait of
interest or an agronomically-important characteristic, the
correction of an endogenous defect, or the expression of some type
of expression marker. In some aspects, the trait of interest or
agronomically-important characteristic is related to the overall
health, fitness, or fertility of the plant, the yield of a plant
product, the ecological fitness of the plant, or the environmental
stability of the plant. In some aspects, the trait of interest or
agronomically-important characteristic is selected from the group
consisting of: agronomics, herbicide resistance, insecticide
resistance, disease resistance, nematode resistance, microbial
resistance, fungal resistance, viral resistance, fertility or
sterility, grain characteristics, commercial product production. In
some aspects, the trait of interest or agronomically-important
characteristic is selected from the group consisting of: disease
resistance, drought tolerance, heat tolerance, cold tolerance,
salinity tolerance, metal tolerance, herbicide tolerance, improved
water use efficiency, improved nitrogen utilization, improved
nitrogen fixation, pest resistance, herbivore resistance, pathogen
resistance, yield improvement, health enhancement, vigor
improvement, growth improvement, photosynthetic capability
improvement, nutrition enhancement, altered protein content,
altered starch content, altered carbohydrate content, altered sugar
content, altered fiber content, altered oil content, increased
biomass, increased shoot length, increased root length, improved
root architecture, modulation of a metabolite, modulation of the
proteome, increased seed weight, altered seed carbohydrate
composition, altered seed oil composition, altered seed protein
composition, altered seed nutrient composition, as compared to an
isoline plant not comprising a modification derived from the
methods or compositions herein.
[0347] Examples of monocot plants that can be used include, but are
not limited to, corn (Zea mays), rice (Oryza sativa), rye (Secale
cereale), sorghum (Sorghum bicolor, Sorghum vulgare), millet (e.g.,
pearl millet (Pennisetum glaucum), proso millet (Panicum
miliaceum), foxtail millet (Setaria italica), finger millet
(Eleusine coracana)), wheat (Triticum species, for example Triticum
aestivum, Triticum monococcum), sugarcane (Saccharum spp.), oats
(Avena), barley (Hordeum), switchgrass (Panicum virgatum),
pineapple (Ananas comosus), banana (Musa spp.), palm, ornamentals,
turfgrasses, and other grasses.
[0348] Examples of dicot plants that can be used include, but are
not limited to, soybean (Glycine max), Brassica species (for
example but not limited to: oilseed rape or Canola) (Brassica
napus, B. campestris, Brassica rapa, Brassica juncea), alfalfa
(Medicago sativa), tobacco (Nicotiana tabacum), Arabidopsis
(Arabidopsis thaliana), sunflower (Helianthus annuus), cotton
(Gossypium arboreum, Gossypium barbadense), and peanut (Arachis
hypogaea), tomato (Solanum lycopersicum), potato (Solanum
tuberosum).
[0349] Additional plants that can be used include safflower
(Carthamus tinctorius), sweet potato (Ipomoea batatus), cassava
(Manihot esculenta), coffee (Coffea spp.), coconut (Cocos
nucifera), citrus trees (Citrus spp.), cocoa (Theobroma cacao), tea
(Camellia sinensis), banana (Musa spp.), avocado (Persea
americana), fig (Ficus casica), guava (Psidium guajava), mango
(Mangifera indica), olive (Olea europaea), papaya (Carica papaya),
cashew (Anacardium occidentale), macadamia (Macadamia
integrifolia), almond (Prunus amygdalus), sugar beets (Beta
vulgaris), vegetables, ornamentals, and conifers.
[0350] Vegetables that can be used include tomatoes (Lycopersicon
esculentum), lettuce (e.g., Lactuca sativa), green beans (Phaseolus
vulgaris), lima beans (Phaseolus limensis), peas (Lathyrus spp.),
and members of the genus Cucumis such as cucumber (C. sativus),
cantaloupe (C. cantalupensis), and musk melon (C. melo).
Ornamentals include azalea (Rhododendron spp.), hydrangea
(Macrophylla hydrangea), hibiscus (Hibiscus rosasanensis), roses
(Rosa spp.), tulips (Tulipa spp.), daffodils (Narcissus spp.),
petunias (Petunia hybrida), carnation (Dianthus caryophyllus),
poinsettia (Euphorbia pulcherrima), and chrysanthemum.
[0351] Conifers that may be used include pines such as loblolly
pine (Pinus taeda), slash pine (Pinus elliotii), ponderosa pine
(Pinus ponderosa), lodgepole pine (Pinus contorta), and Monterey
pine (Pinus radiata); Douglas fir (Pseudotsuga menziesii); Western
hemlock (Tsuga canadensis); Sitka spruce (Picea glauca); redwood
(Sequoia sempervirens); true firs such as silver fir (Abies
amabilis) and balsam fir (Abies balsamea); and cedars such as
Western red cedar (Thuja plicata) and Alaska yellow cedar
(Chamaecyparis nootkatensis).
[0352] In certain embodiments of the disclosure, a fertile plant is
a plant that produces viable male and female gametes and is
self-fertile. Such a self-fertile plant can produce a progeny plant
without the contribution from any other plant of a gamete and the
genetic material comprised therein. Other embodiments of the
disclosure can involve the use of a plant that is not self-fertile
because the plant does not produce male gametes, or female gametes,
or both, that are viable or otherwise capable of fertilization.
[0353] The present disclosure finds use in the breeding of plants
comprising one or more introduced traits, or edited genomes.
[0354] A non-limiting example of how two traits can be stacked into
the genome at a genetic distance of, for example, 5 cM from each
other is described as follows: A first plant comprising a first
transgenic target site integrated into a first DSB target site
within the genomic window and not having the first genomic locus of
interest is crossed to a second transgenic plant, comprising a
genomic locus of interest at a different genomic insertion site
within the genomic window and the second plant does not comprise
the first transgenic target site. About 5% of the plant progeny
from this cross will have both the first transgenic target site
integrated into a first DSB target site and the first genomic locus
of interest integrated at different genomic insertion sites within
the genomic window. Progeny plants having both sites in the defined
genomic window can be further crossed with a third transgenic plant
comprising a second transgenic target site integrated into a second
DSB target site and/or a second genomic locus of interest within
the defined genomic window and lacking the first transgenic target
site and the first genomic locus of interest. Progeny are then
selected having the first transgenic target site, the first genomic
locus of interest and the second genomic locus of interest
integrated at different genomic insertion sites within the genomic
window. Such methods can be used to produce a transgenic plant
comprising a complex trait locus having at least 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29, 30, 31 or more transgenic target sites
integrated into DSB target sites and/or genomic loci of interest
integrated at different sites within the genomic window. In such a
manner, various complex trait loci can be generated.
Cells and Animals
[0355] The presently disclosed polynucleotides and polypeptides can
be introduced into an animal cell. Animal cells can include, but
are not limited to: an organism of a phylum including chordates,
arthropods, mollusks, annelids, cnidarians, or echinoderms; or an
organism of a class including mammals, insects, birds, amphibians,
reptiles, or fishes. In some aspects, the animal is human, mouse,
C. elegans, rat, fruit fly (Drosophila spp.), zebrafish, chicken,
dog, cat, guinea pig, hamster, chicken, Japanese ricefish, sea
lamprey, pufferfish, tree frog (e.g., Xenopus spp.), monkey, or
chimpanzee. Particular cell types that are contemplated include
haploid cells, diploid cells, reproductive cells, neurons, muscle
cells, endocrine or exocrine cells, epithelial cells, muscle cells,
tumor cells, embryonic cells, hematopoietic cells, bone cells, germ
cells, somatic cells, stem cells, pluripotent stem cells, induced
pluripotent stem cells, progenitor cells, meiotic cells, and
mitotic cells. In some aspects, a plurality of cells from an
organism may be used.
[0356] The novel Cas9 orthologs disclosed may be used to edit the
genome of an animal cell in various ways. In one aspect, it may be
desirable to delete one or more nucleotides. In another aspect, it
may be desirable to insert one or more nucleotides. In one aspect,
it may be desirable to replace one or more nucleotides. In another
aspect, it may be desirable to modify one or more nucleotides via a
covalent or non-covalent interaction with another atom or
molecule.
[0357] Genome modification via a Cas9 ortholog may be used to
effect a genotypic and/or phenotypic change on the target organism.
Such a change is preferably related to an improved phenotype of
interest or a physiologically-important characteristic, the
correction of an endogenous defect, or the expression of some type
of expression marker. In some aspects, the phenotype of interest or
physiologically-important characteristic is related to the overall
health, fitness, or fertility of the animal, the ecological fitness
of the animal, or the relationship or interaction of the animal
with other organisms in its environment. In some aspects, the
phenotype of interest or physiologically-important characteristic
is selected from the group consisting of: improved general health,
disease reversal, disease modification, disease stabilization,
disease prevention, treatment of parasitic infections, treatment of
viral infections, treatment of retroviral infections, treatment of
bacterial infections, treatment of neurological disorders (for
example but not limited to: multiple sclerosis), correction of
endogenous genetic defects (for example but not limited to:
metabolic disorders, Achondroplasia, Alpha-1 Antitrypsin
Deficiency, Antiphospholipid Syndrome, Autism, Autosomal Dominant
Polycystic Kidney Disease, Barth syndrome, Breast cancer,
Charcot-Marie-Tooth, Colon cancer, Cri du chat, Crohn's Disease,
Cystic fibrosis, Dercum Disease, Down Syndrome, Duane Syndrome,
Duchenne Muscular Dystrophy, Factor V Leiden Thrombophilia,
Familial Hypercholesterolemia, Familial Mediterranean Fever,
Fragile X Syndrome, Gaucher Disease, Hemochromatosis, Hemophilia,
Holoprosencephaly, Huntington's disease, Klinefelter syndrome,
Marfan syndrome, Myotonic Dystrophy, Neurofibromatosis, Noonan
Syndrome, Osteogenesis Imperfecta, Parkinson's disease,
Phenylketonuria, Poland Anomaly, Porphyria, Progeria, Prostate
Cancer, Retinitis Pigmentosa, Severe Combined Immunodeficiency
(SCID), Sickle cell disease, Skin Cancer, Spinal Muscular Atrophy,
Tay-Sachs, Thalassemia, Trimethylaminuria, Turner Syndrome,
Velocardiofacial Syndrome, WAGR Syndrome, and Wilson Disease),
treatment of innate immune disorders (for example but not limited
to: immunoglobulin subclass deficiencies), treatment of acquired
immune disorders (for example but not limited to: AIDS and other
HIV-related disorders), treatment of cancer, as well as treatment
of diseases, including rare or "orphan" conditions, that have
eluded effective treatment options with other methods.
[0358] Cells that have been genetically modified using the
compositions or methods disclosed herein may be transplanted to a
subject for purposes such as gene therapy, e.g. to treat a disease,
or as an antiviral, antipathogenic, or anticancer therapeutic, for
the production of genetically modified organisms in agriculture, or
for biological research.
In Vitro Polynucleotide Detection, Binding, and Modification
[0359] The compositions disclosed herein may further be used as
compositions for use in in vitro methods, in some aspects with
isolated polynucleotide sequence(s). Said isolated polynucleotide
sequence(s) may comprise one or more target sequence(s) for
modification. In some aspects, said isolated polynucleotide
sequence(s) may be genomic DNA, a PCR product, or a synthesized
oligonucleotide.
Compositions
[0360] Modification of a target sequence may be in the form of a
nucleotide insertion, a nucleotide deletion, a nucleotide
substitution, the addition of an atom molecule to an existing
nucleotide, a nucleotide modification, or the binding of a
heterologous polynucleotide or polypeptide to said target sequence.
The insertion of one or more nucleotides may be accomplished by the
inclusion of a donor polynucleotide in the reaction mixture: said
donor polynucleotide is inserted into a double-strand break created
by said Cas9 ortholog polypeptide. The insertion may be via
non-homologous end joining or via homologous recombination.
[0361] In one aspect, the sequence of the target polynucleotide is
known prior to modification, and compared to the sequence(s) of
polynucleotide(s) that result from treatment with the Cas9
ortholog. In one aspect, the sequence of the target polynucleotide
is not known prior to modification, and the treatment with the Cas9
ortholog is used as part of a method to determine the sequence of
said target polynucleotide.
[0362] Polynucleotide modification with a Cas9 ortholog may be
accomplished by usage of a full-length polypeptide identified from
a Cas locus, or from a fragment, modification, or variant of a
polypeptide identified from a Cas locus. In some aspects, said Cas9
ortholog is obtained or derived from an organism listed in Table 1.
In some aspects, said Cas9 ortholog is a polypeptide sharing at
least 80% identity with any of SEQID NOs:86-170 or 511-1135. In
some aspects, said Cas9 ortholog is a functional variant of any of
SEQID NOs:86-170 or 511-1135. In some aspects, said Cas9 ortholog
is a functional fragment of any of SEQID NOs:86-170 or 511-1135. In
some aspects, said Cas9 ortholog is a Cas9 polypeptide encoded by a
polynucleotide selected from the group consisting of: SEQID
NO:86-170 or 511-1135. In some aspects, said Cas9 ortholog is a
Cas9 polypeptide that recognizes a PAM sequence listed in any of
Tables 4-83. In some aspects, said Cas9 ortholog is a Cas9
polypeptide identified from an organism listed in the sequence
listing.
[0363] In some aspects, the Cas9 ortholog is provided as a cas9
polynucleotide. In some aspects, said cas9 polynucleotide is
selected from the group consisting of: SEQID NO:1-85, or a sequence
sharing at least 80%, 85%, 90%, 95%, 97%, 99%, or 100% with any one
of SEQID NO:1-85.
[0364] In some aspects, the Cas9 ortholog may be selected from the
group consisting of: an unmodified wild type Cas9 ortholog, a
functional Cas9 ortholog variant, a functional Cas9 ortholog
fragment, a fusion protein comprising an active or deactivated Cas9
ortholog, a Cas9 ortholog further comprising one or more nuclear
localization sequences (NLS) on the C-terminus or on the N-terminus
or on both the N- and C-termini, a biotinylated Cas9 ortholog, a
Cas9 ortholog nickase, a Cas9 ortholog endonuclease, a Cas9
ortholog further comprising a Histidine tag, and a mixture of any
two or more of the preceding.
[0365] In some aspects, the Cas9 ortholog is a fusion protein
further comprising a nuclease domain, a transcriptional activator
domain, a transcriptional repressor domain, an epigenetic
modification domain, a cleavage domain, a nuclear localization
signal, a cell-penetrating domain, a translocation domain, a
marker, or a transgene that is heterologous to the target
polynucleotide sequence or to the cell from which said target
polynucleotide sequence is obtained or derived.
[0366] In some aspects, a plurality of Cas9 orthologs may be
desired. In some aspects, said plurality may comprise Cas9
orthologs derived from different source organisms or from different
loci within the same organism. In some aspects, said plurality may
comprise Cas9 orthologs with different binding specificities to the
target polynucleotide. In some aspects, said plurality may comprise
Cas9 orthologs with different cleavage efficiencies. In some
aspects, said plurality may comprise Cas9 orthologs with different
PAM specificities. In some aspects, said plurality may comprise
orthologs of different molecular compositions, i.e., a
polynucleotide cas9 ortholog and a polypeptide Cas9 ortholog.
[0367] The guide polynucleotide may be provided as a single guide
RNA (sgRNA), a chimeric molecule comprising a tracrRNA, a chimeric
molecule comprising a crRNA, a chimeric RNA-DNA molecule, a DNA
molecule, or a polynucleotide comprising one or more chemically
modified nucleotides.
[0368] The storage conditions of the Cas9 ortholog and/or the guide
polynucleotide include parameters for temperature, state of matter,
and time. In some aspects, the Cas9 ortholog and/or the guide
polynucleotide is stored at about -80 degrees Celsius, at about -20
degrees Celsius, at about 4 degrees Celsius, at about 20-25 degrees
Celsius, or at about 37 degrees Celsius. In some aspects, the Cas9
ortholog and/or the guide polynucleotide is stored as a liquid, a
frozen liquid, or as a lyophilized powder. In some aspects, the
Cas9 ortholog and/or the guide polynucleotide is stable for at
least one day, at least one week, at least one month, at least one
year, or even greater than one year.
[0369] Any or all of the possible polynucleotide components of the
reaction (e.g., guide polynucleotide, donor polynucleotide,
optionally a cas9 polynucleotide) may be provided as part of a
vector, a construct, a linearized or circularized plasmid, or as
part of a chimeric molecule. Each component may be provided to the
reaction mixture separately or together. In some aspects, one or
more of the polynucleotide components are operably linked to a
heterologous noncoding regulatory element that regulates its
expression.
[0370] The method for modification of a target polynucleotide
comprises combining the minimal elements into a reaction mixture
comprising: a Cas9 ortholog (or variant, fragment, or other related
molecule as described above), a guide polynucleotide comprising a
sequence that is substantially complementary to, or selectively
hybridizes to, the target polynucleotide sequence of the target
polynucleotide, and a target polynucleotide for modification. In
some aspects, the Cas9 ortholog is provided as a polypeptide. In
some aspects, the Cas9 ortholog is provided as a cas9 ortholog
polynucleotide. In some aspects, the guide polynucleotide is
provided as an RNA molecule, a DNA molecule, an RNA:DNA hybrid, or
a polynucleotide molecule comprising a chemically-modified
nucleotide.
[0371] The storage buffer of any one of the components, or the
reaction mixture, may be optimized for stability, efficacy, or
other parameters. Additional components of the storage buffer or
the reaction mixture may include a buffer composition, Tris, EDTA,
dithiothreitol (DTT), phosphate-buffered saline (PBS), sodium
chloride, magnesium chloride, HEPES, glycerol, BSA, a salt, an
emulsifier, a detergent, a chelating agent, a redox reagent, an
antibody, nuclease-free water, a proteinase, and/or a viscosity
agent. In some aspects, the storage buffer or reaction mixture
further comprises a buffer solution with at least one of the
following components: HEPES, MgCl2, NaCl, EDTA, a proteinase,
Proteinase K, glycerol, nuclease-free water.
[0372] Incubation conditions will vary according to desired
outcome. The temperature is preferably at least 10 degrees Celsius,
between 10 and 15, at least 15, between 15 and 17, at least 17,
between 17 and 20, at least 20, between 20 and 22, at least 22,
between 22 and 25, at least 25, between 25 and 27, at least 27,
between 27 and 30, at least 30, between 30 and 32, at least 32,
between 32 and 35, at least 35, at least 36, at least 37, at least
38, at least 39, at least 40, or even greater than 40 degrees
Celsius. The time of incubation is at least 1 minute, at least 2
minutes, at least 3 minutes, at least 4 minutes, at least 5
minutes, at least 6 minutes, at least 7 minutes, at least 8
minutes, at least 9 minutes, at least 10 minutes, or even greater
than 10 minutes.
[0373] The sequence(s) of the polynucleotide(s) in the reaction
mixture prior to, during, or after incubation may be determined by
any method known in the art. In one aspect, modification of a
target polynucleotide may be ascertained by comparing the
sequence(s) of the polynucleotide(s) purified from the reaction
mixture to the sequence of the target polynucleotide prior to
combining with the Cas9 ortholog.
[0374] Any one or more of the compositions disclosed herein, useful
for in vitro or in vivo polynucleotide detection, binding, and/or
modification, may be comprised within a kit. A kit comprises a Cas9
ortholog or a polynucleotide cas9 ortholog encoding such,
optionally further comprising buffer components to enable efficient
storage, and one or more additional compositions that enable the
introduction of said Cas9 ortholog or cas9 ortholog to a
heterologous polynucleotide, wherein said Cas9 ortholog or cas9
ortholog is capable of effecting a modification, addition,
deletion, or substitution of at least one nucleotide of said
heterologous polynucleotide. In an additional aspect, a Cas9
ortholog disclosed herein may be used for the enrichment of one or
more polynucleotide target sequences from a mixed pool. In an
additional aspect, a Cas9 ortholog disclosed herein may be
immobilized on a matrix for use in in vitro target polynucleotide
detection, binding, and/or modification.
Methods of Detection
[0375] Methods of detecting the Cas9:guide polynucleotide complex
bound to the target polynucleotide may include any known in the
art, including but not limited to microscopy, chromatographic
separation, electrophoresis, immunoprecipitation, filtration,
nanopore separation, microarrays, as well as those described
below.
[0376] A DNA Electrophoretic Mobility Shift Assay (EMSA): studies
proteins binding to known DNA oligonucleotide probes and assesses
the specificity of the interaction. The technique is based on the
principle that protein-DNA complexes migrate more slowly than free
DNA molecules when subjected to polyacrylamide or agarose gel
electrophoresis. Because the rate of DNA migration is retarded upon
protein binding, the assay is also called a gel retardation assay.
Adding a protein-specific antibody to the binding components
creates an even larger complex (antibody-protein-DNA) which
migrates even slower during electrophoresis, this is known as a
supershift and can be used to confirm protein identities.
[0377] DNA Pull-down Assays use a DNA probe labelled with a high
affinity tag, such as biotin, which allows the probe to be
recovered or immobilized. A DNA probe can be complexed with a
protein from a cell lysate in a reaction similar to that used in
the EMSA and then used to purify the complex using agarose or
magnetic beads. The proteins are then eluted from the DNA and
detected by Western blot or identified by mass spectrometry.
Alternatively, the protein may be labelled with an affinity tag or
the DNA-protein complex may be isolated using an antibody against
the protein of interest (similar to a supershift assay). In this
case, the unknown DNA sequence bound by the protein is detected by
Southern blotting or through PCR analysis.
[0378] Reporter assays provide a real-time in vivo read-out of
translational activity for a promoter of interest. Reporter genes
are fusions of a target promoter DNA sequence and a reporter gene
DNA sequence which is customized by the researcher and the DNA
sequence codes for a protein with detectable properties like
firefly/Renilla luciferase or alkaline phosphatase. These genes
produce enzymes only when the promoter of interest is activated.
The enzyme, in turn, catalyses a substrate to produce either light
or a colour change that can be detected by spectroscopic
instrumentation. The signal from the reporter gene is used as an
indirect determinant for the translation of endogenous proteins
driven from the same promoter.
[0379] Microplate Capture and Detection Assays use immobilized DNA
probes to capture specific protein-DNA interactions and confirm
protein identities and relative amounts with target specific
antibodies. Typically, a DNA probe is immobilized on the surface of
96- or 384-well microplates coated with streptavidin. A cellular
extract is prepared and added to allow the binding protein to bind
to the oligonucleotide. The extract is then removed and each well
is washed several times to remove non-specifically bound proteins.
Finally, the protein is detected using a specific antibody labelled
for detection. This method can be extremely sensitive, detecting
less than 0.2 pg of the target protein per well. This method may
also be utilized for oligonucleotides labelled with other tags,
such as primary amines that can be immobilized on microplates
coated with an amine-reactive surface chemistry.
[0380] DNA Footprinting is one of the most widely used methods for
obtaining detailed information on the individual nucleotides in
protein--DNA complexes, even inside living cells. In such an
experiment, chemicals or enzymes are used to modify or digest the
DNA molecules. When sequence specific proteins bind to DNA they can
protect the binding sites from modification or digestion. This can
subsequently be visualized by denaturing gel electrophoresis, where
unprotected DNA is cleaved more or less at random. Therefore it
appears as a `ladder` of bands and the sites protected by proteins
have no corresponding bands and look like foot prints in the
pattern of bands. The foot prints there by identify specific
nucleosides at the protein--DNA binding sites.
[0381] Microscopic techniques include optical, fluorescence,
electron, and atomic force microscopy (AFM).
[0382] Chromatin immunoprecipitation analysis (ChIP) causes
proteins to bind covalently to their DNA targets, after which they
are unlinked and characterized separately.
[0383] Systematic Evolution of Ligands by EXponential enrichment
(SELEX) exposes target proteins to a random library of
oligonucleotides. Those genes that bind are separated and amplified
by PCR.
Non-Limiting Aspects
[0384] Aspect 1: A synthetic composition comprising a cas9
polynucleotide selected from the group consisting of: (a) a
polynucleotide sharing at least 80% identity with any of: SEQID
NOS:86-170 or 511-1135, (b) a functional variant of any of SEQID
NOS:86-170 or 511-1135, (c) a functional fragment of any of SEQID
NOS:86-170 or 511-1135, (d) a cas9 gene encoding a Cas9 polypeptide
selected from the group consisting of: SEQID NO:86-170, (e) a cas9
gene encoding a Cas9 polypeptide that recognizes a PAM sequence
listed in any of Tables 4-83, and (f) a cas9 gene identified from
an organism listed in Table 1; and a heterologous component.
[0385] Aspect 2: A synthetic composition comprising a Cas9
polypeptide selected from the group consisting of: (a) a
polypeptide sharing at least 80% identity with any of: SEQID
NO:86-170 or 511-1135, (b) a functional variant of any of SEQID
NO:86-170 or 511-1135, (c) a functional fragment of any of SEQID
NO:86-170, (d) a Cas9 polypeptide encoded by a polynucleotide
selected from the group consisting of: SEQID NOS:86-170 or
511-1135, (e) a Cas9 polypeptide that recognizes a PAM sequence
listed in any of Tables 4-83, and (f) a Cas9 polypeptide identified
from an organism listed in Table 1 or in the sequence listing; and
a heterologous component.
[0386] Aspect 3: A deactivated Cas9 polypeptide wherein said
deactivated Cas9 polypeptide is capable of binding to a target
polynucleotide but lacks at least one domain responsible for
nucleotide cleavage.
[0387] Aspect 4: A synthetic fusion protein comprising a Cas9
polypeptide and a heterologous polypeptide, wherein said Cas9
polypeptide is selected from the group consisting of:
[0388] Aspect 5: A synthetic composition comprising a single guide
RNA selected from the group consisting of: (a) a polynucleotide
sharing at least 80% identity with any of: SEQID NO:426-510, (b) a
functional variant of any of: SEQID NO:426-510, (c) a functional
fragment of any of: SEQID NO:426-510, and (d) a single guide RNA
molecule identified or derived from an organism listed in Table 1;
and a heterologous component.
[0389] Aspect 6: A synthetic composition comprising a tracrRNA
selected from the group consisting of: (a) a polynucleotide sharing
at least 80% identity with any of: SEQID NO:341-425, (b) a
functional variant of any of: SEQID NO:341-425, (c) a functional
fragment of any of: SEQID NO:341-425, and (d) a tracrRNA molecule
identified from an organism listed in Table 1; and a heterologous
component.
[0390] Aspect 7: A synthetic composition comprising a crRNA repeat
sequence selected from the group consisting of: (a) a
polynucleotide sharing at least 80% identity with any of: SEQID
NO:171-255, (b) a functional variant of any of: SEQID NO:171-255,
(c) a functional fragment of any of: SEQID NO:171-255, and (d) a
crRNA repeat sequence molecule identified from an organism listed
in Table 1; and a heterologous component.
[0391] Aspect 8: A synthetic composition comprising an anti-repeat
sequence selected from the group consisting of: (a) a
polynucleotide sharing at least 80% identity with any of: SEQID
NO:256-340, (b) a functional variant of any of: SEQID NO:256-340,
(c) a functional fragment of any of: SEQID NO:256-340, and (d) an
anti-repeat sequence molecule identified from an organism listed in
Table 1; and a heterologous component.
[0392] Aspect 9: A synthetic composition comprising a polypeptide
sharing at least 80% identity with a polypeptide selected from the
group consisting of SEQID NO:86-170 and a polynucleotide selected
from the group consisting of: (a) a polynucleotide sharing at least
80% identity with a polynucleotide selected from the group
consisting of SEQID NO: 171-255, (b) a polynucleotide sharing at
least 80% identity with a polynucleotide selected from the group
consisting of SEQID NO: 341-425, and (c) a polynucleotide sharing
at least 80% identity with a polynucleotide selected from the group
consisting of SEQID NO: 426-510; wherein said synthetic composition
further comprises a heterologous component.
[0393] Aspect 10: A synthetic composition comprising a guide
polynucleotide and Cas9 ortholog, wherein said Cas9 ortholog is
selected from the group consisting of: (a) the deactivated Cas9
polypeptide of Aspect 3, (b) a polypeptide sharing at least 80%
identity with any of: SEQID NO:86-170 or 511-1135, (c) a functional
variant of any of SEQID NO:86-170 or 511-1135, (d) a functional
fragment of any of SEQID NO:86-170 or 511-1135, (e) a Cas9
polypeptide that recognizes a PAM sequence listed in any of Tables
4-83, (f) a Cas9 polypeptide identified from an organism listed in
Table 1, (g) a cas9 polynucleotide selected from the group
consisting of: SEQID NOS:86-170 or 511-1135, and (h) a cas9
polynucleotide encoding any of the polypeptides of (a) through (f);
and said guide polynucleotide is selected from the group consisting
of: (i) a single guide RNA sharing at least 80% identity with a
sequence selected from the group consisting of SEQ ID NOs:426-510,
(j) a single guide RNA comprising a functional fragment of SEQ ID
NOs:426-510, (k) a single guide RNA comprising a functional variant
of SEQ ID NOs:426-510, (1) a single guide RNA comprising a chimeric
non-naturally occurring crRNA linked to a tracrRNA, wherein said
tracrRNA comprises a nucleotide sequence selected from the group
consisting of SEQ ID NOs:341-425, a functional fragment of SEQ ID
NOs:341-425, and a functional variant of SEQ ID NOs:341-425, (m) a
single guide RNA comprises a chimeric non-naturally occurring crRNA
linked to a tracrRNA, wherein said chimeric non-naturally occurring
crRNA comprises a nucleotide sequence selected from the group
consisting of SEQ ID NOs:171-255, a functional fragment of SEQ ID
NOs:171-255, and a functional variant of SEQ ID NOs:171-255, (n) a
guide RNA that is a duplex molecule comprising a chimeric
non-naturally occurring crRNA and a tracrRNA, wherein said chimeric
non-naturally occurring crRNA comprises a variable targeting domain
capable of hybridizing to said target sequence, wherein said
tracrRNA comprises a nucleotide sequence selected from the group
consisting of SEQ ID NOs:341-425, a functional fragment of SEQ ID
NOs:341-425, and a functional variant of SEQ ID NOs:341-425,
wherein said chimeric non-naturally occurring crRNA comprises a
variable targeting domain capable of hybridizing to said target
sequence, (o) a guide RNA that is a duplex molecule comprising a
chimeric non-naturally occurring crRNA and a tracrRNA, wherein said
chimeric non-naturally occurring crRNA comprises a nucleotide
sequence selected from the group consisting of SEQ ID NOs:171-255,
a functional fragment of SEQ ID NOs:171-255, and a functional
variant of SEQ ID NOs:171-255, wherein said chimeric non-naturally
occurring crRNA comprises a variable targeting domain capable of
hybridizing to said target sequence, (p) a polynucleotide
comprising both DNA and RNA, (q) a polynucleotide comprising at
least one chemically-modified nucleotide, and (r) a DNA molecule
encoding any of the RNA molecules of (h) through (n); wherein said
guide polynucleotide and said Cas 9 ortholog are capable of forming
a complex that is capable of recognizing, binding to, and
optionally nicking or cleaving a target polynucleotide sequence;
further comprising at least one heterologous component.
[0394] Aspect 11: The guide polynucleotide/Cas9 endonuclease
complex of Aspect 10, wherein said target polynucleotide sequence
is located in the genome of a cell.
[0395] Aspect 12: The guide polynucleotide/Cas9 endonuclease
complex of Aspect 10, wherein said target polynucleotide sequence
is isolated from a genomic environment.
[0396] Aspect 13: The guide polynucleotide/Cas9 endonuclease
complex of Aspect 10, wherein said target polynucleotide sequence
is synthetic.
[0397] Aspect 14: The synthetic composition of any of Aspects 1-10,
wherein said heterologous component is selected from the group
consisting of: a heterologous polynucleotide, a heterologous
polypeptide, a particle, a solid matrix, an antibody, a buffer
composition, Tris, EDTA, dithiothreitol (DTT), phosphate-buffered
saline (PBS), sodium chloride, magnesium chloride, HEPES, glycerol,
bovine serum albumin (BSA), a salt, an emulsifier, a detergent, a
chelating agent, a redox reagent, an antibody, nuclease-free water,
a viscosity agent, and a Histidine tag.
[0398] Aspect 15: The synthetic composition of Aspect 14, wherein
said heterologous polypeptide comprises a nuclease domain, a
transcriptional activator domain, a transcriptional repressor
domain, an epigenetic modification domain, a cleavage domain, a
nuclear localization signal, a cell-penetrating domain, a deaminase
domain, a base editing domain, a translocation domain, a marker,
and a transgene.
[0399] Aspect 16: The synthetic composition of Aspect 14, wherein
said heterologous polynucleotide is selected from the group
consisting of: a guide polynucleotide, a chimeric guide
polynucleotide, a chemically modified guide polynucleotide, a guide
polynucleotide comprising both DNA and RNA, a noncoding expression
element, a gene, a marker, and a polynucleotide encoding a
plurality of Histidine residues.
[0400] Aspect 17: The synthetic composition of Aspect 14,
comprising at least two different said heterologous components.
[0401] Aspect 18: The synthetic composition of Aspect 14, wherein
the pH is between 1.0 and 14.0, between 2.0 and 13.0, between 3.0
and 12.0, between 4.0 and 11.0, between 5.0 and 10.0, between 6.0
and 9.0, between 7.0 and 8.0, between 4.5 and 6.5, between 5.5 and
7.5, or between 6.5 and 7.5.
[0402] Aspect 19: The synthetic composition of Aspect 14, wherein
said Cas9 ortholog has an activity optimum at a pH between 1.0 and
14.0, between 2.0 and 13.0, between 3.0 and 12.0, between 4.0 and
11.0, between 5.0 and 10.0, between 6.0 and 9.0, between 7.0 and
8.0, between 4.5 and 6.5, between 5.5 and 7.5, or between 6.5 and
7.5.
[0403] Aspect 20: The synthetic composition of Aspect 14, wherein
said Cas9 ortholog has an activity optimum at a temperature between
0 degrees Celsius and 100 degrees Celsius, between at least 0
degrees Celsius and 10 degrees Celsius, between at least 10 degrees
Celsius and 20 degrees Celsius, between at least 20 degrees Celsius
and 25 degrees Celsius, between at least 25 degrees Celsius and 30
degrees Celsius, between at least 30 degrees Celsius and 40 degrees
Celsius, between at least 40 degrees Celsius and 50 degrees
Celsius, between at least 50 degrees Celsius and 60 degrees
Celsius, between at least 60 degrees Celsius and 70 degrees
Celsius, between at least 70 degrees Celsius and 80 degrees
Celsius, between at least 80 degrees Celsius and 90 degrees
Celsius, between at least 90 degrees Celsius and 100 degrees
Celsius, or 100 degrees Celsius.
[0404] Aspect 21: The synthetic composition of Aspect 14, stored or
incubated at a temperature of at least minus 200 degrees Celsius,
at least minus 150 degrees Celsius, at least minus 135 degrees
Celsius, at least minus 90 degrees Celsius, at least minus 80
degrees Celsius, at least minus 20 degrees Celsius, at least 4
degrees Celsius, at least 17 degrees Celsius, at least 25 degrees
Celsius, at least 30 degrees Celsius, at least 35 degrees Celsius,
at least 37 degrees Celsius, at least 39 degrees Celsius, or
greater than 39 degrees Celsius.
[0405] Aspect 22: A substantially nuclease-free, endotoxin-free
composition comprising the synthetic composition of any of Aspects
1-10.
[0406] Aspect 23: A lyophilized composition comprising the
synthetic composition of Aspect 10 or Aspect 15.
[0407] Aspect 24: A cell comprising the synthetic composition of
any of Aspects 1-10.
[0408] Aspect 25: A progeny cell of the cell of Aspect 23, wherein
said progeny cell comprises at least one modification of its genome
compared to the target polynucleotide site of the parental
cell.
[0409] Aspect 26: The cell of Aspect 24, selected from the group
consisting of: human, non-human primate, mammal, animal, archaeal,
bacterial, protist, fungal, insect, yeast, non-conventional yeast,
and plant.
[0410] Aspect 27: The human cell of Aspect 26, wherein said human
cell is selected from the group consisting of: haploid cells,
diploid cells, reproductive cells, neurons, muscle cells, endocrine
or exocrine cells, epithelial cells, muscle cells, tumor cells,
embryonic cells, hematopoietic cells, bone cells, germ cells,
somatic cells, stem cells, pluripotent stem cells, induced
pluripotent stem cells, progenitor cells, meiotic cells, and
mitotic cells.
[0411] Aspect 28: The plant cell of Aspect 26, wherein the plant
cell is selected from the group consisting of a monocot and dicot
cell.
[0412] Aspect 29: The plant cell of Aspect 26, wherein the plant
cell is selected from the group consisting of maize, rice, sorghum,
rye, barley, wheat, millet, oats, sugarcane, turfgrass,
switchgrass, soybean, canola, alfalfa, sunflower, cotton, tobacco,
peanut, potato, tobacco, Arabidopsis, vegetable, and safflower
cell.
[0413] Aspect 30: The synthetic composition of Aspect 2, wherein
said Cas9 endonuclease has been modified to lack at least one
nuclease domain.
[0414] Aspect 31: The synthetic composition of Aspect 2, wherein
said Cas9 endonuclease has been modified to lack endonuclease
activity.
[0415] Aspect 32: A kit comprising the lyophilized composition of
Aspect 23 or the synthetic composition of Aspect 22.
[0416] Aspect 33: An in vitro method of detecting a target
polynucleotide sequence, comprising: (a) obtaining said target
polynucleotide, (b) combining a Cas9 ortholog polypeptide, a guide
polynucleotide, and said target polynucleotide in a reaction
vessel, (c) incubating the components of step (b) at a temperature
of at least 10 degrees Celsius for at least 1 minute, (d)
sequencing the resulting polynucleotide(s) in the reaction mixture,
and (e) characterizing the sequence of the target polynucleotide of
step (a) that was identified by the Cas9 ortholog polypeptide and
the guide polynucleotide; wherein said guide polynucleotide
comprises a polynucleotide sequence that is substantially
complementary to the sequence of the target polynucleotide.
[0417] Aspect 34: An in vitro method of binding a Cas9 ortholog and
guide polynucleotide complex to a target polynucleotide,
comprising: (a) obtaining the sequence of said target
polynucleotide, (b) combining a Cas9 ortholog polypeptide, a guide
polynucleotide, and said target polynucleotide in a reaction
vessel, (c) incubating the components of step (b) at a temperature
of at least 10 degrees Celsius for at least 1 minute; wherein said
guide polynucleotide comprises a polynucleotide sequence that is
substantially complementary to the target polynucleotide sequence
of the target polynucleotide; further comprising detecting the Cas9
ortholog and guide polynucleotide complex bound to the target
polynucleotide.
[0418] Aspect 35: The method of Aspect 34, wherein said Cas9
ortholog further comprises a detectable fusion protein domain, a
histidine tag, or a chemical marker.
[0419] Aspect 36: The method of Aspect 34, wherein detecting said
Cas9 ortholog and guide polynucleotide complex bound to the target
polynucleotide further comprises a step comprising an enzyme-linked
immunosorbent assay, a radioimmunoassay, affinity chromatography,
size exclusion chromatography, ion exchange chromatography,
hydrophobic interaction chromatography, electrophoretic mobility
shift assay, chromatin immunoprecipitation assay, yeast one-hybrid
system, bacterial one-hybrid system, x-ray crystallography,
pull-down assay, reporter assay, marker expression assay,
microplate capture assay, and DNA footprinting.
[0420] Aspect 37: An in vitro method of modifying a target
polynucleotide, comprising: (a) obtaining the sequence of said
target polynucleotide, (b) combining a Cas9 ortholog polypeptide, a
guide polynucleotide, and said target polynucleotide in a reaction
vessel, (c) incubating the components of step (b) at a temperature
of at least 10 degrees Celsius for at least 1 minute, (d)
sequencing the resulting polynucleotide(s) in the reaction mixture,
and (e) identifying at least one sequence modification of said
resulting polynucleotide(s) as compared to the sequence of the
target polynucleotide obtained in step (a); wherein said guide
polynucleotide comprises a polynucleotide sequence that is
substantially complementary to the target polynucleotide sequence
of the target polynucleotide.
[0421] Aspect 38: The method of any of Aspects 33, 34, or 37,
wherein said target polynucleotide was obtained or derived from a
host organism prior to the incubation of step (c), and
re-introduced back into the same host organism after the incubation
of step (c).
[0422] Aspect 39: The method of any of Aspects 33, 34, or 37,
wherein said Cas9 ortholog polypeptide is adhered to a solid
matrix.
[0423] Aspect 40: The method of any of Aspects 33, 34, or 37,
wherein said Cas9 ortholog polypeptide is a nuclease, a nickase, or
lacks either nuclease or nickase activity.
[0424] Aspect 41: The method of Aspect 33, wherein said target
polynucleotide was obtained or derived from a host organism prior
to the incubation of step (c), and introduced into a different
organism after the incubation of step (c).
[0425] Aspect 42: The method of Aspect 33, wherein said Cas9
ortholog polypeptide is selected from the group consisting of: an
unmodified wild type Cas9 ortholog, a functional Cas9 ortholog
variant, a functional Cas9 ortholog fragment, a fusion protein
comprising an active or deactivated Cas9 ortholog, a Cas9 ortholog
further comprising one or more nuclear localization sequences (NLS)
on the C-terminus or on the N-terminus or on both the N- and
C-termini, a biotinylated Cas9 ortholog, a Cas9 ortholog nickase, a
Cas9 ortholog endonuclease, a Cas9 ortholog further comprising a
Histidine tag, a plurality of Cas9 orthologs, and a mixture of any
two or more of the preceding.
[0426] Aspect 43: The method of Aspect 33, wherein said Cas9
ortholog polypeptide is selected from the group consisting of: (a)
a polypeptide sharing at least 80% identity with any of: SEQID
NO:86-170, (b) a functional variant of any of SEQID NO:86-170, (c)
a functional fragment of any of SEQID NO:86-170, (d) a Cas9
polypeptide encoded by a polynucleotide selected from the group
consisting of: SEQID NOS:86-170 or 511-1135, (e) a Cas9 polypeptide
that recognizes a PAM sequence listed in any of Tables 4-83, and
(f) a Cas9 polypeptide identified from an organism listed in Table
1.
[0427] Aspect 44: The method of Aspect 33, further comprising a
composition selected from the group consisting of: 200 mM HEPES, 50
mM MgCl2, 1M NaCl, and 1 mM EDTA, a proteinase, Proteinase K, and
nuclease-free water.
[0428] Aspect 45: The method of Aspect 33, wherein said
modification is selected from the group consisting of: an
insertion, a deletion, a substitution, and the addition or
association of an atom or molecule to an existing nucleotide.
[0429] Aspect 46: The method of Aspect 33, further comprising a
donor polynucleotide, wherein said donor polynucleotide is inserted
into a double-strand break created by said Cas9 ortholog
polypeptide.
[0430] Aspect 47: An in vivo method of modifying a target
polynucleotide sequence, comprising providing to a cell a
composition comprising the synthetic composition of any one of
Aspects 1-10, wherein said cell comprises in its genome a
polynucleotide sequence capable of being recognized, bound to, and
cleaved said composition.
[0431] Aspect 48: A method for modifying a target site in the
genome of a cell, the method comprising providing to said cell at
least one Cas9 ortholog selected from the group consisting of: (a)
the deactivated Cas9 polypeptide of Aspect 3, (b) a polypeptide
sharing at least 80% identity with any of: SEQID NO:86-170, (c) a
functional variant of any of SEQID NO:86-170, (d) a functional
fragment of any of SEQID NO:86-170, (e) a Cas9 polypeptide that
recognizes a PAM sequence listed in any of Tables 4-83, (f) a Cas9
polypeptide identified from an organism listed in Table 1, (g) a
Cas9 polypeptide encoded by a cas9 polynucleotide selected from the
group consisting of: SEQID NOS:86-170 or 511-1135, and (h) a Cas9
polypeptide encoding any of the polypeptides of (a) through (g);
and said guide polynucleotide is selected from the group consisting
of: (i) a single guide RNA sharing at least 80% identity with a
sequence selected from the group consisting of SEQ ID NOs:426-510,
(j) a single guide RNA comprising a functional fragment of SEQ ID
NOs:426-510, (k) a single guide RNA comprising a functional variant
of SEQ ID NOs:426-510, (1) a single guide RNA comprising a chimeric
non-naturally occurring crRNA linked to a tracrRNA, wherein said
tracrRNA comprises a nucleotide sequence selected from the group
consisting of SEQ ID NOs:341-425, a functional fragment of SEQ ID
NOs:341-425, and a functional variant of SEQ ID NOs:341-425, (m) a
single guide RNA comprises a chimeric non-naturally occurring crRNA
linked to a tracrRNA, wherein said chimeric non-naturally occurring
crRNA comprises a nucleotide sequence selected from the group
consisting of SEQ ID NOs:171-255, a functional fragment of SEQ ID
NOs:171-255, and a functional variant of SEQ ID NOs:171-255, (n) a
guide RNA that is a duplex molecule comprising a chimeric
non-naturally occurring crRNA and a tracrRNA, wherein said chimeric
non-naturally occurring crRNA comprises a fragment capable of
hybridizing to said target sequence, wherein said tracrRNA
comprises a nucleotide sequence selected from the group consisting
of: SEQ ID NOs:341-425, a functional fragment of SEQ ID
NOs:341-425, and a functional variant of SEQ ID NOs:341-425, (o) a
guide RNA that is a duplex molecule comprising a chimeric
non-naturally occurring crRNA and a tracrRNA, wherein said chimeric
non-naturally occurring crRNA comprises a nucleotide sequence
selected from the group consisting of SEQ ID NOs:171-255, a
functional fragment of SEQ ID NOs:171-255, and a functional variant
of SEQ ID NOs:171-255, wherein said chimeric non-naturally
occurring crRNA comprises a variable targeting domain capable of
hybridizing to said target sequence, (p) a polynucleotide
comprising both DNA and RNA, (q) a polynucleotide comprising at
least one chemically-modified nucleotide, and (r) a DNA molecule
capable of being transcribed into any of the RNA molecules of (i)
through (q); wherein said guide polynucleotide and said Cas9
ortholog are capable of forming a complex that is capable of
recognizing, binding to, and optionally nicking or cleaving a
target polynucleotide sequence; and identifying at least one cell
that has a modification at the target site of said cell, wherein
the modification at said target site is selected from the group
consisting of (i) a replacement of at least one nucleotide, (ii) a
deletion of at least one nucleotide, (iii) an insertion of at least
one nucleotide, (iv) modification of at least one nucleotide, and
(v) any combination of (i)-(iv).
[0432] Aspect 49: The method of Aspect 48, comprising providing to
said cell a plurality of Cas9 polypeptides that each recognize a
different PAM sequence listed in any of Tables 4-83.
[0433] Aspect 50: The method of Aspect 48, wherein the
concentration of the Cas9 ortholog is provided to said cell at a
concentration of less than 100 micromolar.
[0434] Aspect 51: The method of Aspect 48, further comprising
providing to said cell a polynucleotide modification template,
wherein the polynucleotide modification template comprises at least
one nucleotide modification as compared to the target nucleotide
sequence of said cell.
[0435] Aspect 52: The method of Aspect 49, wherein said donor DNA
comprises a polynucleotide of interest.
[0436] Aspect 53: The method of Aspect 52, further comprising
identifying at least one cell that has the polynucleotide of
interest integrated in or near the target site.
[0437] Aspect 54: The method of Aspect 52, wherein the
polynucleotide of interest confers a benefit to said cell or to the
organism that comprises said cell.
[0438] Aspect 55: The method of Aspect 54, wherein the
polynucleotide modification or benefit is conferred to a subsequent
generation of said cell or said organism that comprises said
cell.
[0439] Aspect 56: The method of Aspect 54 or Aspect 55, wherein
said benefit is selected from the group consisting of: improved
health, improved growth, improved fertility, improved fecundity,
improved environmental tolerance, improved vigor, improved disease
resistance, improved disease tolerance, improved tolerance to a
heterologous molecule, improved fitness, improved physical
characteristic, greater mass, increased production of a biochemical
molecule, decreased production of a biochemical molecule,
upregulation of a gene, downregulation of a gene, upregulation of a
biochemical pathway, downregulation of a biochemical pathway,
stimulation of cell reproduction, and suppression of cell
reproduction.
[0440] Aspect 57: The method of any one of Aspects 51-56, wherein
the cell is selected from the group consisting of: a human,
non-human primate, mammal, animal, archaeal, bacterial, protist,
fungal, insect, yeast, non-conventional yeast, and plant cell.
[0441] Aspect 58: The method of any one of Aspects 51-56, wherein
the cell is heterologous to the organism from which the Cas9
ortholog was derived.
[0442] Aspect 59: The method of Aspect 57, wherein the plant cell
is selected from the group consisting of a monocot and dicot
cell.
[0443] Aspect 60: The method of Aspect 57, wherein the plant cell
is selected from the group consisting of maize, rice, sorghum, rye,
barley, wheat, millet, oats, sugarcane, turfgrass, switchgrass,
soybean, canola, alfalfa, sunflower, cotton, tobacco, peanut,
potato, tobacco, Arabidopsis, vegetable, and safflower cell.
[0444] Aspect 61: The method of any one of Aspects 51-56, wherein
the cell is a plant cell, and wherein the modification of said
target site results in the modulation of a trait of agronomic
interest of a plant comprising said cell or a progeny cell thereof,
selected from the group consisting of: disease resistance, drought
tolerance, heat tolerance, cold tolerance, salinity tolerance,
metal tolerance, herbicide tolerance, improved water use
efficiency, improved nitrogen utilization, improved nitrogen
fixation, pest resistance, herbivore resistance, pathogen
resistance, yield improvement, health enhancement, improved
fertility, vigor improvement, growth improvement, photosynthetic
capability improvement, nutrition enhancement, altered protein
content, altered oil content, increased biomass, increased shoot
length, increased root length, improved root architecture,
modulation of a metabolite, modulation of the proteome, increased
seed weight, altered seed carbohydrate composition, altered seed
oil composition, altered seed protein composition, altered seed
nutrient composition; as compared to an isoline plant not
comprising said target site modification or as compared to the
plant prior to the modification of said target site in said plant
cell.
[0445] Aspect 62: The method of Aspect 57, wherein the human cell
is selected from the group consisting of: haploid cells, diploid
cells, reproductive cells, neurons, muscle cells, endocrine or
exocrine cells, epithelial cells, muscle cells, tumor cells,
embryonic cells, hematopoietic cells, bone cells, germ cells,
somatic cells, stem cells, pluripotent stem cells, induced
pluripotent stem cells, progenitor cells, meiotic cells, and
mitotic cells.
[0446] Aspect 63: The method of any one of Aspects 51-56, wherein
the cell is an animal cell, and wherein the modification of said
target site results in the modulation of a phenotype of
physiological interest of an organism comprising said animal cell
or a progeny cell thereof, selected from the group consisting of:
improved health, improved nutritional status, reduced disease
impact, disease stasis, disease reversal, improved fertility,
improved vigor, improved mental capacity, improved organism growth,
improved weight gain, weight loss, modulation of an endocrine
system, modulation of an exocrine system, reduced tumor size,
reduced tumor mass, stimulated cell growth, reduced cell growth,
production of a metabolite, production of a hormone, production of
an immune cell, stimulation of cell production,
[0447] Aspect 64: The method of Aspect 50, wherein said animal cell
is a human cell.
[0448] Aspect 65: A plant comprising a modified target site,
wherein said plant originates from a plant cell comprising a
modified target site produced by the method of any of Aspects
51-56.
[0449] Aspect 66: A plant comprising an edited nucleotide, wherein
said plant originates from a plant cell comprising an edited
nucleotide produced by the method of Aspect 49.
[0450] Aspect 67: A method of editing a plurality of polynucleotide
target sequences, comprising providing to said plurality of
polynucleotide target sequences a plurality of Cas9 polypeptides
that each recognizes a different PAM sequence listed in any of
Tables 4-83.
[0451] Aspect 68: A method of modulating target polynucleotide
specificity of a Cas9 ortholog/guide polynucleotide complex as
compared to its wild type activity, by changing a parameter
selected from the group consisting of(a) guide polynucleotide
length, (b) guide polynucleotide composition, (c) length of PAM
sequence, (d) composition of the PAM sequence, and (e) affinity of
the Cas9 molecule with the target polynucleotide backbone; and
assessing the target polynucleotide specificity of the complex with
the changed parameter, and comparing it to the activity of a
complex with wild type parameters.
[0452] Aspect 69: A method of optimizing the activity of a Cas9
molecule, comprising introducing at least one nucleotide
modification to a sequence selected from the group consisting of
SEQID NO:86-170, and identifying at least one improved
characteristic as compared to that of SEQID NO:86-170.
[0453] Aspect 70: A method of optimizing the activity of a Cas9
molecule by subjecting a parental Cas9 molecule to at least one
round of stochastic protein shuffling, and selecting a resultant
molecule that has at least one characteristic not present in the
parental Cas9 molecule.
[0454] Aspect 71: A method of optimizing the activity of a Cas9
molecule by subjecting a parental Cas9 molecule to at least one
round of non-stochastic protein shuffling, and selecting a
resultant molecule that has at least one characteristic not present
in the parental Cas9 molecule.
[0455] Aspect 72: A synthetic composition comprising a Cas9
ortholog endonuclease and a heterologous polynucleotide that is
capable of selective hybridization with a PAM consensus sequence of
a target polynucleotide, wherein said PAM consensus sequence has a
length of at least 3 nucleotides, at least 4 nucleotides, at least
5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, or
greater than 7 nucleotides.
[0456] Aspect 73: A method of effecting a single-strand nick or a
double-strand break of a target polynucleotide, wherein said target
polynucleotide comprises a PAM consensus sequence that is capable
of being recognized by a guide polynucleotide, comprising
introducing said guide polynucleotide and a Cas9 ortholog to said
target polynucleotide, wherein said single-strand nick or double
strand break occurs within said target polynucleotide.
[0457] Aspect 74: A synthetic composition comprising a Cas9
ortholog endonuclease and a heterologous polynucleotide that is
capable of selective hybridization with a PAM consensus nucleotide
sequence selected from the group consisting of: (a) AAA, (b) AAAA,
(c) AAAAA, (d) AAAC, (e) AAAT, (f) AGA, (g) AGRG, (h) AHAC, (i)
ANGG, (j) ARHHG, (k) ARNAT, (1) ATAA, (m) ATTTTT, (n) BAVMAR, (o)
BGGAT, (p) CAA, (q) CAHGGDD (r) CC, (s) CCA, (t) CCH, (u) CDA, (v)
CNA, (w) CNAVGAC, (x) CNG, (y) CT (z) CTA, (aa) CVG, (bb) DGGD (cc)
GAAA, (dd) GG, (ee) GGAH, (ff) GGDG, (gg) GGN, (hh) GHAAA, (ii)
GNA, (jj) GNAC, (kk) GNAY, (11) GNG, (mm) GTAMY, (nn) GTGA, (oo)
HAR (pp) NDGGD (qq) RNCAC, (rr) RTAA (ss) TC, (tt) TGAR, (uu)
TTTTT, (vv) VNCC, (ww) VRACC, (xx) VRNTT, and (yy) VRTTT; wherein
A=Adenine, C=Cytosine, G=Guanine, T=Thymine, R=A or G, Y=C or T,
S=G or C, W=A or T, K=G or T, M=A or C, B=C or G or T, D=A or G or
T, H=A or C or T, V=A or C or G, and N=any base; optionally wherein
any nucleotide may flank said PAM consensus nucleotide
sequence.
[0458] Aspect 75: A synthetic composition comprising a heterologous
component and a Cas endonuclease, wherein the Cas endonuclease
comprises at least one amino acid feature selected from the group
consisting of: (a) Isoleucine (I) at position 13, (b) Isoleucine
(I) at position 21, (c) Leucine (L) at position 71, (d) Leucine (L)
at position 149, (e) Serine (S) at position 150, (f) Leucine (L) at
position 444, (g) Threonine (T) at position 445, (h) Proline (P) at
position 503, (i) F (Phenylalanine) at position 587, (j) A
(Alanine) at position 620, (k) L (Leucine) at position 623, (l) T
(Threonine) at position 624, (m) I (Isoleucine) at position 632,
(n) Q (Glutamine) at position 692, (o) L (Leucine) at position 702,
(p) I (Isoleucine) at position 781, (q) K (Lysine) at position 810,
(r) L (Leucine) at position 908, (s) V (Valine) at position 931,
(t) N/Q (Asparagine or Glutamine) at position 933, (u) K (Lysine)
at position 954, (v) V (Valine) at position 955, (w) K (Lysine) at
position 1000, (x) V (Valine) at position 1100, (y) Y (Tyrosine) at
position 1232, and (z) I (Isoleucine) at position 1236; wherein the
position numbers are determined by sequence alignment against SEQID
NO: 1125.
[0459] Aspect 76: The synthetic composition of Aspect 1, wherein
the Cas endonuclease shares at least 90% identity with a sequence
selected from the group consisting of: SEQID NOs:86-170 and
511-1135.
[0460] Aspect 77: The synthetic composition of Aspect 1, wherein
the Cas endonuclease has a total score greater than 3.14, as
calculated from the amino acid position scores of Table 86A.
[0461] Aspect 78: The synthetic composition of Aspect 1, wherein
the Cas endonuclease has been modified.
[0462] Aspect 79: The synthetic composition of Aspect 4, wherein
the Cas endonuclease has been modified to lack endonuclease
activity.
[0463] Aspect 80: The synthetic composition of Aspect 4, wherein
the Cas endonuclease has been modified to nick a single strand of
the target polynucleotide.
[0464] Aspect 81: The synthetic composition of Aspect 4, wherein
the Cas endonuclease has been modified to further comprise a
heterologous nuclease domain, a transcriptional activator domain, a
transcriptional repressor domain, an epigenetic modification
domain, a cleavage domain, a nuclear localization signal, a
cell-penetrating domain, a deaminase domain, a base editing domain,
or a translocation domain.
[0465] Aspect 82: A polynucleotide encoding the polypeptide of
Aspect 1.
[0466] Aspect 83: A plasmid comprising the polynucleotide of Aspect
8.
[0467] Aspect 84: The plasmid of Aspect 9, further comprising an
expression element operably linked to the polynucleotide encoding
the Cas endonuclease.
[0468] Aspect 85: The plasmid of Aspect 9, further comprising a
gene encoding a selectable marker or a transgene.
[0469] Aspect 86: The synthetic composition of Aspect 1, wherein
the heterologous component is selected from the group consisting
of: a heterologous polynucleotide, a heterologous polypeptide, a
particle, a solid matrix, an antibody, Tris, EDTA, dithiothreitol
(DTT), phosphate-buffered saline (PBS), sodium chloride, magnesium
chloride, HEPES, glycerol, bovine serum albumin (BSA), a salt, an
emulsifier, a detergent, a chelating agent, a proteinase,
Proteinase K, a redox reagent, an antibody, nuclease-free water, a
viscosity agent, and a Histidine tag
[0470] Aspect 87: The synthetic composition of Aspect 1, wherein
the Cas endonuclease is in a liquid formulation.
[0471] Aspect 88: The synthetic composition of Aspect 1, wherein
the Cas endonuclease is in a lyophilized formulation.
[0472] Aspect 89: The synthetic composition of Aspect 1, wherein
the Cas endonuclease is in a substantially endotoxin-free
formulation.
[0473] Aspect 90: The synthetic composition of Aspect 1, wherein
the Cas endonuclease is in a formulation with a pH of between 1.0
and 14.0, between 2.0 and 13.0, between 3.0 and 12.0, between 4.0
and 11.0, between 5.0 and 10.0, between 6.0 and 9.0, between 7.0
and 8.0, between 4.5 and 6.5, between 5.5 and 7.5, or between 6.5
and 7.5.
[0474] Aspect 91: The synthetic composition of Aspect 1, wherein
the Cas endonuclease is stored or incubated at a temperature of at
least minus 200 degrees Celsius, at least minus 150 degrees
Celsius, at least minus 135 degrees Celsius, at least minus 90
degrees Celsius, at least minus 80 degrees Celsius, at least minus
20 degrees Celsius, at least 4 degrees Celsius, at least 17 degrees
Celsius, at least 20 degrees Celsius, at least 25 degrees Celsius,
at least 30 degrees Celsius, at least 35 degrees Celsius, at least
37 degrees Celsius, at least 39 degrees Celsius, at least 40
degrees Celsius, at least 45 degrees Celsius, at least 50 degrees
Celsius, at least 55 degrees Celsius, at least 60 degrees Celsius,
at least 65 degrees Celsius, at least 70 degrees Celsius, or
greater than 70 degrees Celsius.
[0475] Aspect 92: The synthetic composition of Aspect 1, wherein
the Cas endonuclease is attached to a solid matrix.
[0476] Aspect 93: The synthetic composition of Aspect 1, wherein
the solid matrix is a particle.
[0477] Aspect 94: A kit comprising the synthetic composition of
Aspect 1.
[0478] Aspect 95: The synthetic composition of Aspect 1, further
comprising a guide polynucleotide.
[0479] Aspect 96: The synthetic composition of Aspect 1, further
comprising a heterologous cell.
[0480] Aspect 97: The synthetic composition of Aspect 22, wherein
the cell is obtained from a eukaryotic, prokaryotic, plant, or
animal organism.
[0481] Aspect 98: A method of creating a double strand break in a
target polynucleotide, the method comprising contacting the target
polynucleotide with a guide polynucleotide that shares
complementarity with the target nucleotide, and a Cas endonuclease
selected from the group consisting of: (a) a polypeptide comprising
at least one amino acid feature selected from the group consisting
of: (i) Isoleucine (I) at position 13, (ii) Isoleucine (I) at
position 21, (iii) Leucine (L) at position 71, (iv) Leucine (L) at
position 149, (v) Serine (S) at position 150, (vi) Leucine (L) at
position 444, (vii) Threonine (T) at position 445, (viii) Proline
(P) at position 503, (ix) F (Phenylalanine) at position 587, (x) A
(Alanine) at position 620, (xi) L (Leucine) at position 623, (xii)
T (Threonine) at position 624, (xiii) I (Isoleucine) at position
632, (xiv) Q (Glutamine) at position 692, (xv) L (Leucine) at
position 702, (xvi) I (Isoleucine) at position 781, (xvii) K
(Lysine) at position 810, (xviii) L (Leucine) at position 908,
(xix) V (Valine) at position 931, (xx) N/Q (Asparagine or
Glutamine) at position 933, (xxi) K (Lysine) at position 954,
(xxii) V (Valine) at position 955, (xxiii) K (Lysine) at position
1000, (xxiv) V (Valine) at position 1100, (xxv) Y (Tyrosine) at
position 1232, and (xxvi) I (Isoleucine) at position 1236; wherein
the position numbers are determined by sequence alignment against
SEQID NO: 1125; and (b) a polypeptide comprising a domain at least
90% identical to a sequence selected from the group consisting of:
SEQID NOs: 1136-1730; wherein the Cas endonuclease and the guide
RNA form a complex that recognizes, binds to, and cleaves the
target polynucleotide.
[0482] Aspect 99: The method of Aspect 24, wherein the polypeptide
shares at least 90% identity with any of: SEQID NOs:86-170 and
511-1135.
[0483] Aspect 100: The method of Aspect 24, wherein the double
strand break comprises a sticky end overhang.
[0484] Aspect 101: The method of Aspect 25, wherein the Cas
endonuclease comprises a polypeptide at least 80% identical to a
sequence selected from the group consisting of SEQID NOs: 46, 68,
63, 70, 102, 108, 119, and 131.
[0485] Aspect 102: The method of Aspect 24, wherein the double
strand break comprises a blunt end.
[0486] Aspect 103: The method of Aspect 25, wherein the Cas
endonuclease comprises a polypeptide at least 80% identical to a
sequence selected from the group consisting of SEQ ID NOs: 33, 50,
56, 64, 79, 2, 3, 4, 5, 6, 8, 9, 12, 13, 16, 17, 18, 19, 27, 28,
29, 30, 32, 35, 41, 44, 47, 48, 51, 52, 60, 61, 65, 66, 67, 71, 77,
78, 80, 81, 85, 87, 94, and 97.
[0487] Aspect 104: A method of modifying a DNA target site, the
method comprising: (a) contacting a polynucleotide comprising the
DNA target site with a Cas endonuclease comprising a polypeptide
selected from the group consisting of: (i) a polypeptide comprising
at least one amino acid feature selected from the group consisting
of: (1) Isoleucine (I) at position 13, (2) Isoleucine (I) at
position 21, (3) Leucine (L) at position 71, (4) Leucine (L) at
position 149, (5) Serine (S) at position 150, (6) Leucine (L) at
position 444, (7) Threonine (T) at position 445, (8) Proline (P) at
position 503, (9) F (Phenylalanine) at position 587, (10) A
(Alanine) at position 620, (11) L (Leucine) at position 623, (12) T
(Threonine) at position 624, (13) I (Isoleucine) at position 632,
(14) Q (Glutamine) at position 692, (15) L (Leucine) at position
702, (16) I (Isoleucine) at position 781, (17) K (Lysine) at
position 810, (18) L (Leucine) at position 908, (19) V (Valine) at
position 931, (20) N/Q (Asparagine or Glutamine) at position 933,
(21) K (Lysine) at position 954, (22) V (Valine) at position 955,
(23) K (Lysine) at position 1000, (24) V (Valine) at position 1100,
(25) Y (Tyrosine) at position 1232, and (26) I (Isoleucine) at
position 1236; wherein the position numbers are determined by
sequence alignment against SEQID NO: 1125; and (ii) a polypeptide
comprising a domain at least 90% identical to a sequence selected
from the group consisting of: SEQID NOs: 1136-1730; and (b) a guide
polynucleotide that shares complementarity with a sequence in or
near the DNA target site, wherein the Cas endonuclease and the
guide RNA form a complex that recognizes, binds to, and nicks or
cleaves the DNA target site; and (c) detecting at least one
modification at the DNA target site.
[0488] Aspect 105: The method of Aspect 30, wherein the Case
endonuclease is a polypeptide sharing at least 90% identity with
any of: SEQID NOs:86-170 and 511-1135.
[0489] Aspect 106: The method of Aspect 30, further comprising
introducing a donor DNA molecule in step (a), wherein the donor DNA
molecule is integrated into the target site.
[0490] Aspect 107: The method of Aspect 30, further comprising
introducing a template DNA molecule in step (a), wherein the
template DNA molecule directs the repair outcome of the cleavage
site.
[0491] Aspect 108: A method of editing at least one base of a
target polynucleotide, comprising: (a) contacting the target
polynucleotide with: (i) a deaminase, (ii) a Cas endonuclease
comprising a polypeptide sharing at least 90% identity with any of:
SEQID NOs:1136-1730, wherein the Cas endonuclease has been modified
to lack nuclease activity, and (iii) a guide polynucleotide that
shares complementarity with a sequence of the target
polynucleotide, wherein the Cas endonuclease and the guide RNA form
a complex that recognizes and binds to the target polynucleotide;
and (b) detecting at least one modification at the DNA target
site.
[0492] Aspect 109: The method of Aspect 34, wherein the Cas
endonuclease has been modified to lack endonuclease activity.
[0493] Aspect 110: A method of modifying the genome of a cell, the
method comprising:
[0494] (a) introducing into the cell a guide polynucleotide that
shares complementarity with a sequence in or near a DNA target site
in the cell, and a heterologous Cas endonuclease comprising a
polypeptide selected from the group consisting of: (i) a
polypeptide comprising at least one amino acid feature selected
from the group consisting of: Isoleucine (I) at position 13,
Isoleucine (I) at position 21, Leucine (L) at position 71, Leucine
(L) at position 149, Serine (S) at position 150, Leucine (L) at
position 444, Threonine (T) at position 445, Proline (P) at
position 503, F (Phenylalanine) at position 587, A (Alanine) at
position 620, L (Leucine) at position 623, T (Threonine) at
position 624, I (Isoleucine) at position 632, Q (Glutamine) at
position 692, L (Leucine) at position 702, I (Isoleucine) at
position 781, K (Lysine) at position 810, L (Leucine) at position
908, V (Valine) at position 931, N/Q (Asparagine or Glutamine) at
position 933, K (Lysine) at position 954, V (Valine) at position
955, K (Lysine) at position 1000, V (Valine) at position 1100, Y
(Tyrosine) at position 1232, and I (Isoleucine) at position 1236;
wherein the position numbers are determined by sequence alignment
against SEQID NO: 1125; and (ii) a polypeptide comprising a domain
at least 90% identical to a sequence selected from the group
consisting of: SEQID NOs: 1136-1730; and wherein the Cas
endonuclease and the guide RNA form a complex that recognizes,
binds to, and nicks or cleaves the DNA target site; and (b)
identifying at least one modification, as compared to an isoline
cell not introduced to the Cas endonuclease and guide
polynucleotide.
[0495] Aspect 111: The method of Aspect 35, further comprising
introducing a heterologous polynucleotide in step (a), wherein the
heterologous polynucleotide is a donor DNA or a template DNA.
[0496] Aspect 112: The method of Aspect 35, wherein the cell is
removed from a source organism prior to step (a) and re-introduced
into either the source organism or introduced into a new organism
after step (a).
[0497] Aspect 113: The method of Aspect 35, wherein the cell is
placed in a medium that supports growth, and a tissue or organism
is regenerated from the cell
[0498] Aspect 114: The method of Aspect 35, wherein the method of
modifying the genome of the cell results in a benefit to an
organism obtained or derived from the cell.
[0499] Aspect 115: The method of Aspect 35, wherein the cell is
selected from the group consisting of: a human, non-human primate,
mammal, animal, archaeal, bacterial, protist, fungal, insect,
yeast, non-conventional yeast, and plant cell.
[0500] Aspect 116: The method of Aspect 40, wherein the organism is
a plant.
[0501] Aspect 117: The method of Aspect 42, wherein the plant is
selected from the group consisting of maize, rice, sorghum, rye,
barley, wheat, millet, oats, sugarcane, turfgrass, switchgrass,
soybean, canola, alfalfa, sunflower, cotton, tobacco, peanut,
potato, tobacco, Arabidopsis, vegetable, and safflower.
[0502] Aspect 118: The method of Aspect 42, wherein the benefit is
selected from the group consisting of: disease resistance, drought
tolerance, heat tolerance, cold tolerance, salinity tolerance,
metal tolerance, herbicide tolerance, improved water use
efficiency, improved nitrogen utilization, improved nitrogen
fixation, pest resistance, herbivore resistance, pathogen
resistance, yield improvement, health enhancement, improved
fertility, vigor improvement, growth improvement, photosynthetic
capability improvement, nutrition enhancement, altered protein
content, altered oil content, increased biomass, increased shoot
length, increased root length, improved root architecture,
modulation of a metabolite, modulation of the proteome, increased
seed weight, altered seed carbohydrate composition, altered seed
oil composition, altered seed protein composition, altered seed
nutrient composition; as compared to an isoline plant not
comprising said target site modification or as compared to the
plant prior to the modification of said target site in said plant
cell.
[0503] Aspect 119: The method of Aspect 40, wherein the organism is
an animal.
[0504] Aspect 120: The method of Aspect 45, wherein the animal is a
human.
[0505] Aspect 121: The method of Aspect 45, wherein the animal cell
is selected from the group consisting of: haploid cells, diploid
cells, reproductive cells, neurons, muscle cells, endocrine or
exocrine cells, epithelial cells, muscle cells, kidney cells,
ovarian cells, tumor cells, embryonic cells, hematopoietic cells,
bone cells, germ cells, somatic cells, stem cells, pluripotent stem
cells, induced pluripotent stem cells, progenitor cells, meiotic
cells, and mitotic cells.
[0506] Aspect 122: The method of Aspect 45, wherein the
modification of said target site results in the modulation of a
phenotype of physiological interest of an organism comprising said
animal cell or a progeny cell thereof, selected from the group
consisting of: improved health, improved nutritional status,
reduced disease impact, disease stasis, disease reversal, improved
fertility, improved vigor, improved mental capacity, improved
organism growth, improved weight gain, weight loss, modulation of
an endocrine system, modulation of an exocrine system, reduced
tumor size, reduced tumor mass, stimulated cell growth, reduced
cell growth, production of a metabolite, production of a hormone,
production of an immune cell, and stimulation of cell
production.
[0507] Aspect 123: A Cas endonuclease that recognizes a PAM
selected from the group consisting of: NAR (G>A)WH
(A>T>C)GN (C>T>R), N (C>D)V (A>S)R (G>A)TTTN
(T>V), NV (A>G>C)TTTTT, NATTTTT, NN (H>G)AAAN
(G>A>Y)N, N (T>V)NAAATN, NAV (A>G>C)TCNN, NN
(A>S>T)NN (W>G>C)CCN (Y>R), NNAH (T>M)ACN,
NGTGANN, NARN (A>K>C)ATN, NV (G>A>C)RNTTN, NN
(A>B)RN (A>G>T>C)CCN, NN (A>B)NN (T>V)CCH
(A>Y), NNN (H>G)NCDAA, NN (H>G)D (A>K)GGDN (A>B),
NNNNCCAG, NNNNCTAA, NNNNCVGANN, N (C>D)NNTCCN, NNNNCTA,
NNNNCYAA, NAGRGNY, NNGH (W>C)AAA, NNGAAAN, NNAAAAA, NTGAR
(G>A)N(A>Y>G)N(Y>R), N (C>D)H (C>W)GH
(Y>A)N(A>B)AN(A>T>S), NNAAACN, NNGTAM (A>C)Y, NH
(A>Y)ARNN (C>W>G)N, B (C>K)GGN(A>Y>G)N NN, N
(T>C>R)AGAN (A>K>C)NN, NGGN (A>T>G>C)NNN, NGGD
(A>T>G)TNN, NGGAN(T>A>C>G)NN, CGGWN (T>R>C)NN,
NGGWGNN, N (B>A)GGNN (T>V)NN, NNGD (A>T>G)AY (T>C)N,
N (T>V)H(T>C>A)AAAAN, NRTAANN, N (H>G)CAAH
(Y>A)N(Y>R)N, NATAAN (A>T>S)N, NV (A>G>C)R
(A>G)ACCN, CN (C>W>G)AV (A>S)GAC, NNRNCAC, N(A>B)GGD
(W>G)D (G>W)NN, BGD (G>W)GTCN(A>K>C), NAANACN,
NRTHAN(A>B)N, BHN (H>G)NGN(T>M)H(Y>A),
NMRN(A>Y>G)AH(C>T>A)N, NNNCACN, NARN(T>A>S)ACN,
NNNNATW, NGCNGCN, NNNCATN, NAGNGCN, NARN(T>M>G)CCN, NATCCTN,
NRTAAN(T>A>S)N, N(C>T>G>A)AAD (A>G>T)CNN,
NAAAGNN, NNGACNN, N(T>V)NTAAD (A>T>G)N, NNGAD (G>W)NN,
NGGN(W>S)NNN, N(T>V)GGD(W>G)GNN,
NGGD(A>T>G)N(T>M>G)NN, NNAAAGN,
N(G>H)GGDN(T>M>G)NN, NNAGAAA, NN(T>M>G)AAAAA,
N(C>D)N(C>W>G)GW(T>C)D(A>G>T)AA, NAAAAYN,
NRGNNNN, NATGN (H>G)TN, NNDATTT, and
NATARCN(C>T>A>G).
[0508] Aspect 124: A synthetic composition comprising a
heterologous component and a Cas endonuclease, wherein the Cas
endonuclease comprises at least one amino acid feature selected
from the group consisting of: (a) Isoleucine (I) at position 13,
(b) Isoleucine (I) at position 21, (c) Leucine (L) at position 71,
(d) Leucine (L) at position 149, (e) Serine (S) at position 150,
(f) Leucine (L) at position 444, (g) Threonine (T) at position 445,
(h) Proline (P) at position 503, (i) F (Phenylalanine) at position
587, (j) A (Alanine) at position 620, (k) L (Leucine) at position
623, (1) T (Threonine) at position 624, (m) I (Isoleucine) at
position 632, (n) Q (Glutamine) at position 692, (o) L (Leucine) at
position 702, (p) I (Isoleucine) at position 781, (q) K (Lysine) at
position 810, (r) L (Leucine) at position 908, (s) V (Valine) at
position 931, (t) N/Q (Asparagine or Glutamine) at position 933,
(u) K (Lysine) at position 954, (v) V (Valine) at position 955, (w)
K (Lysine) at position 1000, (x) V (Valine) at position 1100, (y) Y
(Tyrosine) at position 1232, and (z) I (Isoleucine) at position
1236; wherein the position numbers are determined by sequence
alignment against SEQID NO: 1125.
[0509] Aspect 125: The synthetic composition of Aspect 1, wherein
the Cas endonuclease shares at least 90% identity with a sequence
selected from the group consisting of: SEQID NOs:86-170 and
511-1135.
[0510] Aspect 126: The synthetic composition of Aspect 1, wherein
the Cas endonuclease comprises a domain sharing 90% or greater
identity with any of SEQID NOs: 1136-1730.
[0511] Aspect 127: The synthetic composition of Aspect 1, wherein
the Cas endonuclease is fused to a heterologous polypeptide.
[0512] Aspect 128: The synthetic composition of Aspect 4, wherein
the heterologous polypeptide comprises nuclease activity.
[0513] Aspect 129: The synthetic composition of Aspect 4, wherein
the heterologous polypeptide is a deaminase.
[0514] Aspect 130: The synthetic composition of Aspect 1, further
comprising a guide polynucleotide with which the polypeptide forms
a complex.
[0515] Aspect 131: The synthetic composition of Aspect 2, wherein
the guide polynucleotide is a single guide comprising a sequence
selected from the group consisting of SEQID NOs: 426-510.
[0516] Aspect 132: The synthetic composition of Aspect 2, wherein
the guide polynucleotide comprises a tracrRNA comprising a sequence
selected from the group consisting of SEQID NOs: 341-425.
[0517] Aspect 133: The synthetic composition of Aspect 2, wherein
the guide polynucleotide comprises a crRNA comprising a sequence
selected from the group consisting of SEQID NOs: 171-255.
[0518] Aspect 134: The synthetic composition of Aspect 2, wherein
the guide polynucleotide comprises an anti-repeat sequence
comprising a sequence selected from the group consisting of SEQID
NOs: 256-340.
[0519] Aspect 135: The synthetic composition of Aspect 2, wherein
the guide polynucleotide guide comprises DNA.
[0520] Aspect 136: The synthetic composition of Aspect 1 that
selectively hybridizes with a PAM sequence consensus listed in
Tables 4-83.
[0521] Aspect 137: A Cas endonuclease or deactivated Cas
endonuclease that recognizes a PAM selected from the group
consisting of: NAR (G>A)WH (A>T>C)GN (C>T>R), N
(C>D)V (A>S)R (G>A)TTTN (T>V), NV (A>G>C)TTTTT,
NATTTTT, NN (H>G)AAAN (G>A>Y)N, N (T>V)NAAATN, NAV
(A>G>C)TCNN, NN (A>S>T)NN (W>G>C)CCN (Y>R),
NNAH (T>M)ACN, NGTGANN, NARN (A>K>C)ATN, NV
(G>A>C)RNTTN, NN (A>B)RN (A>G>T>C)CCN, NN
(A>B)NN (T>V)CCH (A>Y), NNN (H>G)NCDAA, NN (H>G)D
(A>K)GGDN (A>B), NNNNCCAG, NNNNCTAA, NNNNCVGANN, N
(C>D)NNTCCN, NNNNCTA, NNNNCYAA, NAGRGNY, NNGH (W>C)AAA,
NNGAAAN, NNAAAAA, NTGAR (G>A)N(A>Y>G)N(Y>R), N
(C>D)H (C>W)GH (Y>A)N(A>B)AN(A>T>S), NNAAACN,
NNGTAM (A>C)Y, NH (A>Y)ARNN (C>W>G)N, B
(C>K)GGN(A>Y>G)N NN, N (T>C>R)AGAN (A>K>C)NN,
NGGN (A>T>G>C)NNN, NGGD (A>T>G)TNN,
NGGAN(T>A>C>G)NN, CGGWN (T>R>C)NN, NGGWGNN, N
(B>A)GGNN (T>V)NN, NNGD (A>T>G)AY (T>C)N, N
(T>V)H(T>C>A)AAAAN, NRTAANN, N (H>G)CAAH
(Y>A)N(Y>R)N, NATAAN (A>T>S)N, NV (A>G>C)R
(A>G)ACCN, CN (C>W>G)AV (A>S)GAC, NNRNCAC, N(A>B)GGD
(W>G)D (G>W)NN, BGD (G>W)GTCN(A>K>C), NAANACN,
NRTHAN(A>B)N, BHN (H>G)NGN(T>M)H(Y>A),
NMRN(A>Y>G)AH(C>T>A)N, NNNCACN, NARN(T>A>S)ACN,
NNNNATW, NGCNGCN, NNNCATN, NAGNGCN, NARN(T>M>G)CCN, NATCCTN,
NRTAAN(T>A>S)N, N(C>T>G>A)AAD (A>G>T)CNN,
NAAAGNN, NNGACNN, N(T>V)NTAAD (A>T>G)N, NNGAD (G>W)NN,
NGGN(W>S)NNN, N(T>V)GGD(W>G)GNN,
NGGD(A>T>G)N(T>M>G)NN, NNAAAGN,
N(G>H)GGDN(T>M>G)NN, NNAGAAA, NN(T>M>G)AAAAA,
N(C>D)N(C>W>G)GW(T>C)D(A>G>T)AA, NAAAAYN,
NRGNNNN, NATGN (H>G)TN, NNDATTT, and
NATARCN(C>T>A>G).
[0522] Aspect 138: The synthetic composition of Aspect 1 that is
identified from an organism listed in Table 1.
[0523] Aspect 139: The synthetic composition of Aspect 1, selected
from the group consisting of SEQID NOs: 86-170.
[0524] Aspect 140: The synthetic composition of Aspect 1, wherein
the target cell-optimized polypeptide lacks endonuclease
activity.
[0525] Aspect 141: The synthetic composition of Aspect 1, wherein
the target cell-optimized polypeptide is capable of nicking a
single stranded target polynucleotide.
[0526] Aspect 142: The synthetic composition of Aspect 1, wherein
the target cell-optimized polypeptide is capable of cleaving a
double stranded target polynucleotide.
[0527] Aspect 143: The synthetic composition of Aspect 1, further
comprising a donor DNA molecule.
[0528] Aspect 144: The synthetic composition of Aspect 1, further
comprising repair template DNA molecule.
[0529] Aspect 145: The synthetic composition of Aspect 1, wherein
the heterologous composition is selected from the group consisting
of: a heterologous polynucleotide, a heterologous polypeptide, a
particle, a solid matrix, an antibody, a buffer composition, Tris,
EDTA, dithiothreitol (DTT), phosphate-buffered saline (PBS), sodium
chloride, magnesium chloride, HEPES, glycerol, bovine serum albumin
(BSA), a salt, an emulsifier, a detergent, a chelating agent, a
redox reagent, an antibody, nuclease-free water, a viscosity agent,
and a Histidine tag.
[0530] Aspect 146: The synthetic composition of Aspect 19, further
comprising an additional heterologous composition.
[0531] Aspect 147: The synthetic composition of Aspect 1, further
comprising a cell.
[0532] Aspect 148: The synthetic composition of Aspect 21, wherein
the cell is obtained or derived from an organism selected from the
group consisting of: human, non-human primate, mammal, animal,
archaeal, bacterial, protist, fungal, insect, yeast,
non-conventional yeast, and plant.
[0533] Aspect 149: The synthetic composition of Aspect 22, wherein
the plant cell is obtained or derived from maize, rice, sorghum,
rye, barley, wheat, millet, oats, sugarcane, turfgrass,
switchgrass, soybean, canola, alfalfa, sunflower, cotton, tobacco,
peanut, potato, tobacco, Arabidopsis, vegetable, or safflower.
[0534] Aspect 150: The synthetic composition of Aspect 22, wherein
the animal cell is selected from the group consisting of: haploid
cells, diploid cells, reproductive cells, neurons, muscle cells,
endocrine or exocrine cells, epithelial cells, muscle cells, tumor
cells, embryonic cells, hematopoietic cells, bone cells, germ
cells, somatic cells, stem cells, pluripotent stem cells, induced
pluripotent stem cells, progenitor cells, meiotic cells, and
mitotic cells.
[0535] Aspect 151: A polynucleotide encoding the polypeptide of
Aspect 1.
[0536] Aspect 152: The polynucleotide of Aspect 25, wherein in the
polynucleotide is comprised within a vector that further comprises
at least one heterologous polynucleotide.
[0537] Aspect 153: A kit comprising the synthetic composition of
Aspect 1 or the polynucleotide of Aspect 25.
[0538] Aspect 154: The synthetic composition of Aspect 1, wherein
the polypeptide is in a liquid formulation.
[0539] Aspect 155: The synthetic composition of Aspect 1, wherein
the polypeptide is in a lyophilized composition.
[0540] Aspect 156: The synthetic composition of Aspect 1, wherein
the polypeptide is in a substantially endotoxin-free
formulation.
[0541] Aspect 157: The synthetic composition of Aspect 1, wherein
the polypeptide is in a formulation with a pH of between 1.0 and
14.0, between 2.0 and 13.0, between 3.0 and 12.0, between 4.0 and
11.0, between 5.0 and 10.0, between 6.0 and 9.0, between 7.0 and
8.0, between 4.5 and 6.5, between 5.5 and 7.5, or between 6.5 and
7.5.
[0542] Aspect 158: The synthetic composition of Aspect 1, wherein
the polypeptide is stored or incubated at a temperature of at least
minus 200 degrees Celsius, at least minus 150 degrees Celsius, at
least minus 135 degrees Celsius, at least minus 90 degrees Celsius,
at least minus 80 degrees Celsius, at least minus 20 degrees
Celsius, at least 4 degrees Celsius, at least 17 degrees Celsius,
at least 20 degrees Celsius, at least 25 degrees Celsius, at least
30 degrees Celsius, at least 35 degrees Celsius, at least 37
degrees Celsius, at least 39 degrees Celsius, at least 40 degrees
Celsius, at least 45 degrees Celsius, at least 50 degrees Celsius,
at least 55 degrees Celsius, at least 60 degrees Celsius, at least
65 degrees Celsius, at least 70 degrees Celsius, or greater than 70
degrees Celsius.
[0543] Aspect 159: The synthetic composition of Aspect 1, wherein
the polypeptide is attached to a solid matrix.
[0544] Aspect 160: The synthetic composition of Aspect 33, wherein
the solid matrix is a particle.
[0545] Aspect 161: A method of detecting a target polynucleotide
sequence, comprising: (a) obtaining the target polynucleotide, (b)
combining a Cas endonuclease, a guide polynucleotide, and said
target polynucleotide in a reaction vessel, (c) incubating the
components of step (b) at a temperature of at least 10 degrees
Celsius for at least 1 minute, (d) sequencing the resulting
polynucleotide(s) in the reaction mixture, and (e) characterizing
the sequence of the target polynucleotide of step (a) that was
identified by the Cas endonuclease and the guide polynucleotide;
(f) wherein said guide polynucleotide comprises a polynucleotide
sequence that is substantially complementary to the sequence of the
target polynucleotide; wherein the Cas endonuclease comprises at
least one amino acid feature selected from the group consisting of:
(a) Isoleucine (I) at position 13, (b) Isoleucine (I) at position
21, (c) Leucine (L) at position 71, (d) Leucine (L) at position
149, (e) Serine (S) at position 150, (f) Leucine (L) at position
444, (g) Threonine (T) at position 445, (h) Proline (P) at position
503, (i) F (Phenylalanine) at position 587, (j) A (Alanine) at
position 620, (k) L (Leucine) at position 623, (1) T (Threonine) at
position 624, (m) I (Isoleucine) at position 632, (n) Q (Glutamine)
at position 692, (o) L (Leucine) at position 702, (p) I
(Isoleucine) at position 781, (q) K (Lysine) at position 810, (r) L
(Leucine) at position 908, (s) V (Valine) at position 931, (t) N/Q
(Asparagine or Glutamine) at position 933, (u) K (Lysine) at
position 954, (v) V (Valine) at position 955, (w) K (Lysine) at
position 1000, (x) V (Valine) at position 1100, (y) Y (Tyrosine) at
position 1232, and (z) I (Isoleucine) at position 1236; wherein the
position numbers are determined by sequence alignment against SEQID
NO: 1125.
[0546] Aspect 162: A method of binding a Cas endonuclease and guide
polynucleotide complex to a target polynucleotide, comprising: (a)
obtaining the sequence of said target polynucleotide, (b) combining
a Cas endonuclease, a guide polynucleotide, and said target
polynucleotide in a reaction vessel, (c) incubating the components
of step (b) at a temperature of at least 10 degrees Celsius for at
least 1 minute; wherein said guide polynucleotide comprises a
polynucleotide sequence that is substantially complementary to the
target polynucleotide sequence of the target polynucleotide;
further comprising detecting the Cas endonuclease and guide
polynucleotide complex bound to the target polynucleotide; and
wherein the Cas endonuclease comprises at least one amino acid
feature selected from the group consisting of: (a) Isoleucine (I)
at position 13, (b) Isoleucine (I) at position 21, (c) Leucine (L)
at position 71, (d) Leucine (L) at position 149, (e) Serine (S) at
position 150, (f) Leucine (L) at position 444, (g) Threonine (T) at
position 445, (h) Proline (P) at position 503, (i) F
(Phenylalanine) at position 587, (j) A (Alanine) at position 620,
(k) L (Leucine) at position 623, (l) T (Threonine) at position 624,
(m) I (Isoleucine) at position 632, (n) Q (Glutamine) at position
692, (o) L (Leucine) at position 702, (p) I (Isoleucine) at
position 781, (q) K (Lysine) at position 810, (r) L (Leucine) at
position 908, (s) V (Valine) at position 931, (t) N/Q (Asparagine
or Glutamine) at position 933, (u) K (Lysine) at position 954, (v)
V (Valine) at position 955, (w) K (Lysine) at position 1000, (x) V
(Valine) at position 1100, (y) Y (Tyrosine) at position 1232, and
(z) I (Isoleucine) at position 1236; wherein the position numbers
are determined by sequence alignment against SEQID NO: 1125.
[0547] Aspect 163: A method of creating a double strand break in a
target polynucleotide, comprising: (d) obtaining the sequence of
said target polynucleotide, (e) combining a Cas endonuclease
polypeptide, a guide polynucleotide, and said target polynucleotide
in a reaction vessel, (f) incubating the components of step (b) at
a temperature of at least 10 degrees Celsius for at least 1 minute;
wherein said guide polynucleotide comprises a polynucleotide
sequence that is substantially complementary to the target
polynucleotide sequence of the target polynucleotide; further
comprising detecting the Cas endonuclease and guide polynucleotide
complex bound to the target polynucleotide; and wherein the Cas
endonuclease comprises at least one amino acid feature selected
from the group consisting of: (a) Isoleucine (I) at position 13,
(b) Isoleucine (I) at position 21, (c) Leucine (L) at position 71,
(d) Leucine (L) at position 149, (e) Serine (S) at position 150,
(f) Leucine (L) at position 444, (g) Threonine (T) at position 445,
(h) Proline (P) at position 503, (i) F (Phenylalanine) at position
587, (j) A (Alanine) at position 620, (k) L (Leucine) at position
623, (1) T (Threonine) at position 624, (m) I (Isoleucine) at
position 632, (n) Q (Glutamine) at position 692, (o) L (Leucine) at
position 702, (p) I (Isoleucine) at position 781, (q) K (Lysine) at
position 810, (r) L (Leucine) at position 908, (s) V (Valine) at
position 931, (t) N/Q (Asparagine or Glutamine) at position 933,
(u) K (Lysine) at position 954, (v) V (Valine) at position 955, (w)
K (Lysine) at position 1000, (x) V (Valine) at position 1100, (y) Y
(Tyrosine) at position 1232, and (z) I (Isoleucine) at position
1236; wherein the position numbers are determined by sequence
alignment against SEQID NO: 1125.
[0548] Aspect 164: The method of Aspect 36 or Aspect 37, further
comprising at least one additional target site.
[0549] Aspect 165: A method for editing the genome of a cell, the
method comprising providing to the cell: (a) at least one Cas
endonuclease comprises at least one amino acid feature selected
from the group consisting of: (i) Isoleucine (I) at position 13,
(ii) Isoleucine (I) at position 21, (iii) Leucine (L) at position
71, (iv) Leucine (L) at position 149, (v) Serine (S) at position
150, (vi) Leucine (L) at position 444, (vii) Threonine (T) at
position 445, (viii) Proline (P) at position 503, (ix) F
(Phenylalanine) at position 587, (x) A (Alanine) at position 620,
(xi) L (Leucine) at position 623, (xii) T (Threonine) at position
624, (xiii) I (Isoleucine) at position 632, (xiv) Q (Glutamine) at
position 692, (xv) L (Leucine) at position 702, (xvi) I
(Isoleucine) at position 781, (xvii) K (Lysine) at position 810,
(xviii) L (Leucine) at position 908, (xix) V (Valine) at position
931, (xx) N/Q (Asparagine or Glutamine) at position 933, (xxi) K
(Lysine) at position 954, (xxii) V (Valine) at position 955,
(xxiii) K (Lysine) at position 1000, (xxiv) V (Valine) at position
1100, (xxv) Y (Tyrosine) at position 1232, and (xxvi) I
(Isoleucine) at position 1236; wherein the position numbers are
determined by sequence alignment against SEQID NO: 1125; and (b) a
guide polynucleotide with which the Cas endonuclease forms a
complex; wherein the complex is capable of recognizing, binding to,
and optionally nicking or cleaving a target polynucleotide
sequence; and identifying at least one cell that has a modification
in a genomic DNA sequence of the cell, wherein the modification is
selected from the group consisting of: an insertion, a deletion, a
substitution, and the addition or association of an atom or
molecule to an existing nucleotide.
[0550] Aspect 166: A method of modulating the expression of a gene
in a cell, the method comprising providing to the cell: (a) at
least one Cas endonuclease comprises at least one amino acid
feature selected from the group consisting of: (i) Isoleucine (I)
at position 13, (ii) Isoleucine (I) at position 21, (iii) Leucine
(L) at position 71, (iv) Leucine (L) at position 149, (v) Serine
(S) at position 150, (vi) Leucine (L) at position 444, (vii)
Threonine (T) at position 445, (viii) Proline (P) at position 503,
(ix) F (Phenylalanine) at position 587, (x) A (Alanine) at position
620, (xi) L (Leucine) at position 623, (xii) T (Threonine) at
position 624, (xiii) I (Isoleucine) at position 632, (xiv) Q
(Glutamine) at position 692, (xv) L (Leucine) at position 702,
(xvi) I (Isoleucine) at position 781, (xvii) K (Lysine) at position
810, (xviii) L (Leucine) at position 908, (xix) V (Valine) at
position 931, (xx) N/Q (Asparagine or Glutamine) at position 933,
(xxi) K (Lysine) at position 954, (xxii) V (Valine) at position
955, (xxiii) K (Lysine) at position 1000, (xxiv) V (Valine) at
position 1100, (xxv) Y (Tyrosine) at position 1232, and (xxvi) I
(Isoleucine) at position 1236; wherein the position numbers are
determined by sequence alignment against SEQID NO: 1125, and (b) a
guide polynucleotide with which the Cas endonuclease forms a
complex; wherein the complex is capable of recognizing, binding to,
and optionally nicking or cleaving a target polynucleotide sequence
in the cell; and identifying at least one cell that has a modulated
gene expression as compared to a cell that did not have the Cas
endonuclease introduced.
[0551] Aspect 167: The method of Aspect 39 or Aspect 40, further
comprising providing to the cell a donor DNA molecule.
[0552] Aspect 168: The method of Aspect 39 or Aspect 40, further
comprising providing to the cell a template DNA molecule.
[0553] Aspect 169: The method of Aspect 39 or Aspect 40, wherein
the method confers a benefit to the cell or to an organism that
comprises the cell.
[0554] Aspect 170: The method of Aspect 41, wherein the benefit is
selected from the group consisting of: improved health, improved
growth, improved fertility, improved fecundity, improved
environmental tolerance, improved vigor, improved disease
resistance, improved disease tolerance, improved tolerance to a
heterologous molecule, improved fitness, improved physical
characteristic, greater mass, increased production of a biochemical
molecule, decreased production of a biochemical molecule,
upregulation of a gene, downregulation of a gene, upregulation of a
biochemical pathway, downregulation of a biochemical pathway,
stimulation of cell reproduction, and suppression of cell
reproduction.
[0555] Aspect 171: The method of Aspect 39 or Aspect 40, wherein
the cell is heterologous to the organism from which the Cas
endonuclease was derived, and is selected from the group consisting
of: a human, non-human primate, mammal, animal, archaeal,
bacterial, protist, fungal, insect, yeast, non-conventional yeast,
and plant cell.
[0556] Aspect 172: The method of Aspect 45, wherein the plant cell
is obtained or derived from maize, rice, sorghum, rye, barley,
wheat, millet, oats, sugarcane, turfgrass, switchgrass, soybean,
canola, alfalfa, sunflower, cotton, tobacco, peanut, potato,
tobacco, Arabidopsis, vegetable, or safflower.
[0557] Aspect 173: The method of Aspect 45, wherein the cell is a
plant cell, and the benefit is the modulation of a trait of
agronomic interest of a plant comprising said cell or a progeny
cell thereof, selected from the group consisting of: disease
resistance, drought tolerance, heat tolerance, cold tolerance,
salinity tolerance, metal tolerance, herbicide tolerance, improved
water use efficiency, improved nitrogen utilization, improved
nitrogen fixation, pest resistance, herbivore resistance, pathogen
resistance, yield improvement, health enhancement, improved
fertility, vigor improvement, growth improvement, photosynthetic
capability improvement, nutrition enhancement, altered protein
content, altered oil content, increased biomass, increased shoot
length, increased root length, improved root architecture,
modulation of a metabolite, modulation of the proteome, increased
seed weight, altered seed carbohydrate composition, altered seed
oil composition, altered seed protein composition, altered seed
nutrient composition; as compared to an isoline plant not
comprising said target site modification or as compared to the
plant prior to the modification of said target site in said plant
cell.
[0558] Aspect 174: The method of Aspect 45, wherein the animal cell
is selected from the group consisting of: haploid cells, diploid
cells, reproductive cells, neurons, muscle cells, endocrine or
exocrine cells, epithelial cells, muscle cells, tumor cells,
embryonic cells, hematopoietic cells, bone cells, germ cells,
somatic cells, stem cells, pluripotent stem cells, induced
pluripotent stem cells, progenitor cells, meiotic cells, and
mitotic cells.
[0559] Aspect 175: The method of Aspect 45, wherein the cell is an
animal cell, and the benefit is the modulation of a phenotype of
physiological interest of an organism comprising the animal cell,
or a progeny cell thereof, selected from the group consisting of:
improved health, improved nutritional status, reduced disease
impact, disease stasis, disease reversal, improved fertility,
improved vigor, improved mental capacity, improved organism growth,
improved weight gain, weight loss, modulation of an endocrine
system, modulation of an exocrine system, reduced tumor size,
reduced tumor mass, stimulated cell growth, reduced cell growth,
production of a metabolite, production of a hormone, production of
an immune cell, and stimulation of cell production.
[0560] Aspect 176: A method of editing at least one base of a
target polynucleotide, comprising: (a) contacting the target
polynucleotide with: i. a deaminase, ii. a Cas endonuclease capable
of selective hybridization with a PAM sequence consensus listed in
Tables 4-83, wherein the Cas endonuclease has been modified to lack
nuclease activity, and iii. a guide polynucleotide that shares
complementarity with a sequence of the target polynucleotide,
wherein the Cas endonuclease and the guide RNA form a complex that
recognizes and binds to the target polynucleotide; and (b)
detecting at least one modification at the DNA target site.
[0561] Aspect 177: A method of editing a plurality of bases of a
target polynucleotide, comprising: (a) contacting the target
polynucleotide with: i. at least one deaminase, ii. a plurality of
Cas endonucleases, each capable of selective hybridization with a
PAM sequence consensus listed in Tables 4-83, wherein the Cas
endonucleases have been modified to lack nuclease activity, and
iii. a guide polynucleotide that shares complementarity with a
sequence of the target polynucleotide, wherein the Cas endonuclease
and the guide RNA form a complex that recognizes and binds to the
target polynucleotide; and (b) detecting at least one modification
at the DNA target site.
[0562] Aspect 178: A method of optimizing the activity of a Cas
molecule comprising introducing at least one nucleotide
modification to a sequence that comprises at least one amino acid
feature selected from the group consisting of: (a) Isoleucine (I)
at position 13, (b) Isoleucine (I) at position 21, (c) Leucine (L)
at position 71, (d) Leucine (L) at position 149, (e) Serine (S) at
position 150, (f) Leucine (L) at position 444, (g) Threonine (T) at
position 445, (h) Proline (P) at position 503, (i) F
(Phenylalanine) at position 587, (j) A (Alanine) at position 620,
(k) L (Leucine) at position 623, (l) T (Threonine) at position 624,
(m) I (Isoleucine) at position 632, (n) Q (Glutamine) at position
692, (o) L (Leucine) at position 702, (p) I (Isoleucine) at
position 781, (q) K (Lysine) at position 810, (r) L (Leucine) at
position 908, (s) V (Valine) at position 931, (t) N/Q (Asparagine
or Glutamine) at position 933, (u) K (Lysine) at position 954, (v)
V (Valine) at position 955, (w) K (Lysine) at position 1000, (x) V
(Valine) at position 1100, (y) Y (Tyrosine) at position 1232, and
(z) I (Isoleucine) at position 1236; wherein the position numbers
are determined by sequence alignment against SEQID NO: 1125; and
identifying at least one improved characteristic as compared to the
molecule prior to nucleotide modification.
[0563] Aspect 179: A method of optimizing the activity of a Cas9
molecule by subjecting a parental Cas9 molecule to at least one
round of stochastic protein shuffling, and selecting a resultant
molecule that has at least one characteristic not present in the
parental Cas9 molecule; wherein the parental Cas9 molecule
comprises at least one amino acid feature selected from the group
consisting of: (a) Isoleucine (I) at position 13, (b) Isoleucine
(I) at position 21, (c) Leucine (L) at position 71, (d) Leucine (L)
at position 149, (e) Serine (S) at position 150, (f) Leucine (L) at
position 444, (g) Threonine (T) at position 445, (h) Proline (P) at
position 503, (i) F (Phenylalanine) at position 587, (j) A
(Alanine) at position 620, (k) L (Leucine) at position 623, (1) T
(Threonine) at position 624, (m) I (Isoleucine) at position 632,
(n) Q (Glutamine) at position 692, (o) L (Leucine) at position 702,
(p) I (Isoleucine) at position 781, (q) K (Lysine) at position 810,
(r) L (Leucine) at position 908, (s) V (Valine) at position 931,
(t) N/Q (Asparagine or Glutamine) at position 933, (u) K (Lysine)
at position 954, (v) V (Valine) at position 955, (w) K (Lysine) at
position 1000, (x) V (Valine) at position 1100, (y) Y (Tyrosine) at
position 1232, and (z) I (Isoleucine) at position 1236; wherein the
position numbers are determined by sequence alignment against SEQID
NO: 1125.
[0564] Aspect 180: A method of optimizing the activity of a Cas9
molecule by subjecting a parental Cas9 molecule to at least one
round of non-stochastic protein shuffling, and selecting a
resultant molecule that has at least one characteristic not present
in the parental Cas9 molecule; wherein the parental Cas9 molecule
comprises a motif selected from the group consisting of comprises
at least one amino acid feature selected from the group consisting
of: (a) Isoleucine (I) at position 13, (b) Isoleucine (I) at
position 21, (c) Leucine (L) at position 71, (d) Leucine (L) at
position 149, (e) Serine (S) at position 150, (f) Leucine (L) at
position 444, (g) Threonine (T) at position 445, (h) Proline (P) at
position 503, (i) F (Phenylalanine) at position 587, (j) A
(Alanine) at position 620, (k) L (Leucine) at position 623, (1) T
(Threonine) at position 624, (m) I (Isoleucine) at position 632,
(n) Q (Glutamine) at position 692, (o) L (Leucine) at position 702,
(p) I (Isoleucine) at position 781, (q) K (Lysine) at position 810,
(r) L (Leucine) at position 908, (s) V (Valine) at position 931,
(t) N/Q (Asparagine or Glutamine) at position 933, (u) K (Lysine)
at position 954, (v) V (Valine) at position 955, (w) K (Lysine) at
position 1000, (x) V (Valine) at position 1100, (y) Y (Tyrosine) at
position 1232, and (z) I (Isoleucine) at position 1236; wherein the
position numbers are determined by sequence alignment against SEQID
NO: 1125.
[0565] While the invention has been particularly shown and
described with reference to a preferred embodiment and various
alternate embodiments, it will be understood by persons skilled in
the relevant art that various changes in form and details can be
made therein without departing from the spirit and scope of the
invention. For instance, while the particular examples below may
illustrate the methods and embodiments described herein using a
specific plant, the principles in these examples may be applied to
any plant. Therefore, it will be appreciated that the scope of this
invention is encompassed by the embodiments of the inventions
recited herein and in the specification rather than the specific
examples that are exemplified below. All cited patents and
publications referred to in this application are herein
incorporated by reference in their entirety, for all purposes, to
the same extent as if each were individually and specifically
incorporated by reference.
EXAMPLES
[0566] The following are examples of specific embodiments of some
aspects of the invention. The examples are offered for illustrative
purposes only, and are not intended to limit the scope of the
invention in any way. Efforts have been made to ensure accuracy
with respect to numbers used (e.g., amounts, temperatures, etc.),
but some experimental error and deviation should, of course, be
allowed for.
[0567] The meaning of abbreviations is as follows: "sec" means
second(s), "min" means minute(s), "h" means hour(s), "d" means
day(s), ".mu.L" or "uL" or ".mu.l" or "ul" means microliter(s),
"mL" means milliliter(s), "L" means liter(s), ".mu.M" means
micromolar, "mM" means millimolar, "M" means molar, "mmol" means
millimole(s), ".mu.mole" or "umole" mean micromole(s), "g" means
gram(s), ".mu.g" or "ug" means microgram(s), "ng" means
nanogram(s), "U" means unit(s), "bp" means base pair(s) and "kB"
means kilobase(s).
Example 1: Identification of Cas9 Orthologs and their Guide
RNAs
[0568] In this example, methods for identifying Cas9 proteins and
their associated guide RNA(s) from Type II CRISPR (Clustered
Regularly Interspaced Short Palindromic Repeats)-Cas (CRISPR
associated) loci are described.
Cas9 Identification
[0569] Type II Cas9 endonucleases were identified by first
searching for the presence of clustered regularly interspaced short
palindromic repeats (CRISPRs) indicative of the CRISPR-Cas nucleic
acid based adaptive immune systems of bacteria and archaea (Bhaya,
D. et al. (2011) Annu. Rev. Genet. 45: 273-97) in public sequence
collections using PILER-CR (Edgar, R. C. (2007) BMC Bioinformatics.
8: 18). Following the identification of CRISPR arrays, the DNA
regions surrounding the CRISPR array (about 20 kb 5' and 3' of the
CRISPR array) were examined for the presence of open-reading frames
(ORFs) encoding proteins greater than 750 amino acids. Next, to
identify CRISPR associated genes homologous to Cas9, multiple
sequence alignment of protein sequences from a diverse collection
of Cas9 endonucleases was performed using MUSCLE (Edgar, R. C.
(2004) Nucleic Acids Res. 32: 1792-97) and used to build profile
hidden Markov models (HMMs) for Cas9 sub-families as described
previously (Fonfara, I. et al. (2014) Nucleic Acids Res. 42:
2577-2590) using HMMER (Eddy, S. R. (1998) Bioinformatics. 14:
755-63 and Eddy, S. R. (2011) PLoS Comput. Biol. 7: e1002195). The
resulting HMMs were then utilized to search protein sequences
translated from the CRISPR associated ORFs for the presence of cas
genes with homology to Cas9. Only proteins comprising the key HNH
and RuvC nucleolytic domains and catalytic residues defining a Type
II Cas9 protein (Nishimasu, H. et al. (2014) Cell. 156: 935-49)
were selected. Through comparative analyses, Cas9 proteins were
parsed into distinct families and representative members of each
family used to construct a phylogenetic tree with MEGA7 (Kumar, S.
et al. (2016) Mol. Biol. Evol. 33: 1870-74) utilizing the
Neighbor-Joining (Saitou, N. et al. (1987) Mol. Biol. Evol. 4:
406-25) and Poisson correction (Zuckerkandl, E. et al. (1965) Evol.
genes proteins. 97: 97-166) methods to compute the evolutionary
history.
[0570] The resulting phylogenetic tree, representing 675 Type II
Cas9 sequences (SEQ ID NOs: 86-170 and 511-1135), was divided into
12 clades based on phylogenetic distance. Proteins were then
selected to capture the diversity presented by Cas9 orthologs (FIG.
1). Clades giving rise to previously characterized Cas9 proteins
with positive attributes (e.g. activity in eukaryotic cells or
interesting protospacer adjacent motif (PAM) recognition) were
mined at a rate of approximately 20% while all others were surveyed
at a rate of approximately 10%. In total, 85 Cas9 proteins were
selected for further characterization (Table 1).
[0571] Next, structural analyses were performed to further confirm
the candidate proteins as Cas9 orthologs. First, whole sequences
were aligned using Ssearch36 (Smith, T. F. and Waterman, M. S.
(1981) J. Mol. Biol. 147: 195-97 and Pearson, W. R. (1991) Genomics
11: 635-50) with known Cas9 structures from the Protein Data Bank
(PDB, The Protein Data Bank H. M. Berman, J. Westbrook, Z. Feng, G.
Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, P. E. Bourne
(2000) Nucleic Acids Research, 28: 235-242). Then, the best
matching structure was utilized as a template to assign functional
domain boundaries according to structural domains defined in the
known Cas9s. The resulting structural alignment produced six
distinct groups, based on the similarity to modelling templates
with largest variation at REC subdomain.
[0572] REC Group I Cas9 orthologs (SEQ ID NOs: 93, 97, 98, 99, 100,
101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113,
114, 115, 116, 117, 118, 136, 137, 138, 139, 140, 141, 143, 144,
145, 146, 148, 158, 160, 161, 162, 142, 168, and 169) were aligned
against the Staphylococcus aureus Cas9 structure PDB ID 5CZZ_A
("Crystal structure of Staphylococcus aureus Cas9", Nishimasu, H.,
Cong, L., Yan, W. X., Ran, F. A., Zetsche, B., Li, Y., Kurabayashi,
A., Ishitani, R., Zhang, F., Nureki, O., (2015) Cell 162:
1113-1126). The consensus sequence is shown in FIG. 4, with
conserved residues depicted in bold, underlined text (X).
[0573] REC Group II (represented by a single Cas9 ortholog, SEQID
NO: 96) aligned with PDB:5czz in full length, but comprised a novel
insertion of approximately 312 amino acid residues prior to the
RuvCIII domain signature helix. This was a unique feature of this
group.
[0574] REC Group III Cas9 orthologs (86, 87, 88, 89, 90, 91, 92,
94, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130,
131, 132, 147, 149, 150, 151, 152, 153, 154, 155, 156, 157, 159,
163, 164, 165, 166, 167, and 170) were aligned against the
Streptococcus pyogenes serotype M1 structure PDB ID 4UN3_B
("Structural Basis of Pam-Dependent Target DNA Recognition by the
Cas9 Endonuclease", Anders, C., Niewoehner, O., Duerst, A., Jinek,
M., (2014) Nature 513: 569-73). The consensus sequence is shown in
FIG. 5, with conserved residues depicted in bold, underlined text
(X).
[0575] REC Group IV Cas9 orthologs (SEQ ID NOs: 133 and 134) were
aligned against the Actinomyces naeslundii structure PDB ID 4OGE_A
("Structures of Cas9 endonucleases reveal RNA-mediated
conformational activation", Jinek, M., Jiang, F., Taylor, D. W.,
Sternberg, S. H., Kaya, E., Ma, E., Anders, C., Hauer, M., Zhou,
K., Lin, S., Kaplan, M., Iavarone, A. T., Charpentier, E., Nogales,
E., Doudna, J. A., (2014) Science 343: 1247997). The consensus
sequence is shown in FIG. 6, with conserved residues depicted in
bold, underlined text (X). The consensus sequence for Group IV
featured multiple tryptophan residues, which was a unique feature
among the Cas9s examined.
[0576] SEQ ID NOs: 95, 96, and 135 aligned with a known structural
template only partially. Therefore, HHsearch (Soding, J. (2005)
Bioinformatics. 21: 951-60), a profile-profile search program, was
used to extend candidate-template alignment. SEQID NO: 95 (REC
Group V) aligned with PDB:4oge fully, and SEQID NO: 135 (REC Group
VI) aligned with Francisella novicida Cas9 (PDB:5b2o) from
beginning to end.
[0577] In all, sequences belonged to the Cas9 family and comprise
all of the major functional domains in this order: RuvCI, bridge
helix, REC, RuvCII, HNH, RuvCIII, WED, and PI (Table 2A). Like
other known Cas9 proteins, there was sequence length variation,
ranging from .about.1,000 to .about.1,600 residues. Table 2B lists
the SEQ IDs for each domain of each Cas9 ortholog.
[0578] Compared to the phylogenic analysis, the template-based
approach clustered sequences into groups coincident with their
length: for example, Group I of .about.1,100 aa and Group III of
.about.1,350 aa. The major sequence length variation occurred at
the REC domain responsible for nucleotide-chain binding.
Consistently, REC domain was also the least conserved sequence
segment in Cas9 protein superfamily. Clade I-X and Group I-II-III-V
were very similar to one another, forming a family, while Clade XI
corresponding to Group IV and Clade XII corresponding to Group VI
showed more divergence.
Guide RNA Identification
[0579] Next, the small RNA(s) capable of complexing with and
guiding the Cas9 orthologs described herein (Table 1) to recognize
a DNA target sequence adjacent to an appropriate PAM (protospacer
adjacent motif) were predicted. First, the trans-activating RNA
(tracrRNA) essential for CRISPR RNA (crRNA) maturation (Deltcheva,
E. et al. (2011) Nature. 471: 602-7) and Cas9 directed target site
cleavage in Type II systems (Jinek, M. et al. (2012) Science. 337:
816-21 and Karvelis, T. et al. (2013) RNA Biol. 10: 20-19) was
identified by searching for a region in the vicinity of the cas9
gene, the anti-repeat, which may base-pair with the CRISPR repeat
and was distinct from the CRISPR array(s). Once identified, the
possible transcriptional directions of the putative tracrRNA(s) for
each new system were established by examining the secondary
structures using UNAfold (Markham, N. R. et al. (2008) Methods Mol.
Biol. 453: 3-31) and possible termination signals present in RNA
versions corresponding to the sense and anti-sense transcription
scenarios surrounding the anti-repeat as described in Karvelis, T.
et al. (2015) Genome Biology. 16:253. Once the tracrRNA was
predicted, the transcriptional direction of the crRNA could also be
deduced (since the tracrRNA must hybridize to the crRNA with 5' to
3' directionality). Following guide RNA predictions, single guide
RNAs (sgRNAs) representing a non-natural artificial linkage of the
crRNA and tracrRNA (Jinek, M. et al. (2012) Science. 337: 816-21),
were designed and are listed in Table 3.
[0580] All sgRNA molecules used in this study were synthesized by
in vitro transcription using TranscriptAid T7 High Yield
Transcription Kit (Thermo Fisher Scientific) or transcribed
directly in the in vitro translation (IVT) reaction. Templates for
sgRNA transcription were generated by PCR amplifying synthesized
fragments (IDT and Genscript).
Example 2: Determination of the Protospacer Adjacent Motif
Requirement and Target Cleavage Pattern for Cas9 Orthologs
[0581] In this example, methods for the rapid characterization of
the protospacer adjacent motif (PAM) requirement and the position
and type (e.g. blunt, 5' overhang, or 3' overhang) of
double-stranded DNA target cleavage for orthologous Cas9 proteins
are described.
[0582] To determine the PAM sequences that support DNA target
recognition and cleavage, Cas9 protein was produced using either a
continuous exchange 1-Step Human Coupled IVT Kit (Thermo Fisher
Scientific) or a PURExpress bacterial IVT kit (New England
Biolabs), following the manufacturer's recommended protocol. This
was accomplished by first generating a plasmid DNA encoding the
Cas9 otholog. For the Human Coupled kit, genes were human codon
optimized and synthesized (Genescript, Inc. and Twist Bioscience)
into pT7-N-His-GST (Thermo Fisher Scientific). For the bacterial
IVT kit, genes were E. coli codon optimized, synthesized
(Genescript, Inc. and Twist Bioscience), and cloned into the pET28a
(New England Biolabs) expression cassette.
[0583] Following in vitro expression, Cas9 ribonucleoprotein (RNP)
complexes were generated. This was carried-out by first clearing
the reactions of debris centrifugation at 14,000 g for 30 min at
4.degree. C. Next, 20 .mu.l of supernatant containing the soluble
Cas9 protein was immediately combined with 2 .mu.g of the T7
transcribed guide RNA(s) in the presence of 1 .mu.l (40 U) of
RiboLock RNase Inhibitor (Thermo Fisher Scientific, USA) and
incubated for 15 min. at room temperature. In some instances, the
sgRNA was transcribed directly in the IVT reaction by supplying a
DNA template containing a T7 promoter and sequence encoding the
respective sgRNA. In this case, Cas9-guide RNA ribonucleoprotein
(RNP) complexes were not processed any further but used directly in
the next step.
[0584] Next, digestion of a randomized PAM library was then
performed by gently combining 10 .mu.l of the Cas9-guide RNA lysate
mixture with 90 .mu.l of reaction buffer (10 mM Tris-HCl, pH 7.5 at
37.degree. C., 100 mM NaCl and 1 mM DTT, 10 mM MgCl2) and 1 .mu.g
of the 7 bp randomized PAM library from Karvelis et al. 2015
containing a T1 target sequence. After 1 h at 37.degree. C.,
reactions were subject to DNA end-repaired by incubating them with
1 .mu.l (5 U) of T4 DNA polymerase and 1 .mu.l of 10 mM dNTP mix
(Thermo Fisher Scientific, USA) for 20 min at 11.degree. C. The
reaction was then inactivated by heating it to 75.degree. C. for 10
min. To efficiently capture free DNA ends by adapter ligation, a
3'-dA overhang was added by incubating the reaction mixture with 1
.mu.l (5 U) of DreamTaq polymerase (Thermo Fisher Scientific,
EP0701) for 30 min. at 72.degree. C. Excess RNA was then removed
from the reaction by incubating 1 .mu.l of RNase A/T1 (Thermo
Fisher Scientific, USA) for 30 min at 37.degree. C. The resulting
DNA was then purified using a Monarch PCR & DNA Cleanup
purification column (New England Biolabs, USA).
[0585] Following digestion and end repair, the PAM sequences
supporting cleavage were then captured by adapter ligation. This
was accomplished by first preparing an adapter with a 3'-dT
overhang by annealing A1 (5'-CGGCATTCCTGCTGAACCGCTCTTCCGATCT-3'
(SEQ ID NO:1731)) and phosphorylated A2
(5'-GATCGGAAGAGCGGTTCAGCAGGAATGCCG-3' (SEQ ID NO:1732)
oligonucleotides by heating an equimolar mixture of the two for 5
min at 95.degree. C. and slowly cooling (.about.0.1.degree. C./s)
to room temperature in Annealing (A) buffer (10 mM Tris-HCl, pH 7.5
at 37.degree. C., 50 mM NaCl). The adapter was then ligated to the
end repaired 3'-dA overhanging cleavage products by combining 100
ng of it and the adapter with 5 U of T4 Ligase (Thermo Fisher
Scientific, USA) in 25 .mu.l of ligation buffer (40 mM Tris-HCl, pH
7.8 at 25.degree. C., 10 mM MgCl2, 10 mM DTT, 0.5 mM ATP, 5% (w/v)
PEG 4000) and allowing the reaction to proceed for 1 h at room
temperature.
[0586] Next, the cleaved products containing the PAM sequence were
enriched using R0 (5'-GCCAGGGTTTTCCCAGTCACGA-3' (SEQ ID NO:1733))
and the A1 oligonucleotide specific to the 7 bp PAM library and
adapter, respectively. PCR was performed with Phusion High-Fidelity
PCR Master Mix with high fidelity (HF) Buffer (Thermo Fisher
Scientific, USA) or Q5 DNA polymerase (New England Biolabs, USA)
using 10 .mu.l of the ligation reaction as template. A two-step
amplification protocol (98.degree. C.--30 s initial denaturation,
98.degree. C.--15 s, 72.degree. C.-30 s denaturation, annealing and
synthesis for 15 cycles and 72.degree. C.--5 min for final
extension) was used. For the samples assembled in the absence of a
Cas9, PCR was performed using the R0 and the C0 primer
(5'-GAAATTCTAAACGCTAAAGAGGAAGAGG-3' (SEQ ID NO:1734)) pair with C0
being complementary to protospacer sequence. Next, the
amplification products (148 bp and 145 bp for A1/R0 and C0/R0
primer pairs, respectively) were purified using a Monarch PCR &
DNA Cleanup purification column (New England Biolabs, USA).
[0587] Next, the sequences and indexes required for Illumina deep
sequencing were incorporated onto the ends of the Cas9 cleaved DNA
fragments and the resulting products deep sequenced. This was
accomplished through two rounds of PCR using Phusion High-Fidelity
PCR Master Mix in HF buffer (New England Biolabs, USA) per the
manufacturer's instruction. The primary PCR was assembled using 20
ng of Cas9 cleaved adapter ligated PAM-sided template and allowed
to proceed for 10 cycles. The reaction uses a forward primer, F1
(5'-CTACACTCTTTCCCTACACGACGCTCTTCCGATCTAAGGCGGCATTCCTGCTGAAC-3'
(SEQ ID NO:1735)) that can hybridize to the adapter and a reverse
primer, R1 (5'-CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTCGGCGACGTTGGGTC-3'
(SEQ ID NO:1736)), that binds to a site 3' of the region of PAM
randomization. In addition to hybridizing to the adapter ligated
PAM fragment, the primers also contain Illumina sequences extending
off their 5' ends. For the forward primer, the extra sequence
includes a portion of the sequence required for bridge
amplification (5'-CTACACTCTTTCCCTACACGACGCTCTTCCGATCT-3' (SEQ ID
NO:1737)) followed by an interchangeable unique index sequence
(5'-AAGG-3') that permits multiple amplicons to be deconvoluted if
sequenced simultaneously. For the reverse primer, the additional
sequence is comprised only of that required for bridge
amplification at the 3' end of the amplicon
(5'-CAAGCAGAAGACGGCATACGAGCTCTTCCGATCT-3' (SEQ ID NO:1738)). The
following PCR cycling conditions were used: 95.degree. C.--30 s
initial denaturation, 95.degree. C.--10 s, 60.degree. C.--15 s,
72.degree. C.--5 s denaturation, annealing and synthesis for 10
cycles and 72.degree. C.--5 min for final extension. Following
primary PCR, a second round of PCR amplification was performed
using 2 .mu.l (in total volume of 50 .mu.l) of the first round PCR
as template. The forward primer, F2
(5'-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACG-3' (SEQ ID
NO:1739)), used in the secondary PCR hybridizes to the 5' region of
F1 further extending the sequences required for Illumina deep
sequencing. The reverse primer, R2 (5'-CAAGCAGAAGACGGCATA-3' (SEQ
ID NO:1740)), used in the secondary PCR simply binds to the 3' end
of the primary PCR amplicon. The following PCR cycling conditions
were used: 95.degree. C.--30 s initial denaturation, 95.degree.
C.--10 s, 58.degree. C.--15 s, 72.degree. C.--5 s denaturation,
annealing and synthesis for 10 cycles and 72.degree. C.--5 min for
final extension. Following library creation, amplifications were
purified with a QIAquick PCR Purification Kit (Qiagen, USA) per the
manufacturer's instruction and combined into a single sample in an
equimolar concentration. Next, the libraries were single-read deep
sequenced on a MiSeq Personal Sequencer (Illumina, USA) with a 25%
(v/v) spike of PhiX control v3 (Illumina, USA) and sequences
post-processed and deconvoluted per the manufacture's instruction.
Note the original PAM library was also sequenced as a control to
account for inherent bias that would affect downstream PAM
analyses. This is carried out as described above except the forward
primer in the primary PCR, C1
(5'-CTACACTCTTTCCCTACACGACGCTCTTCCGATCTGGAATAAACGCTAAAGAGGAAGAGG-3'
(SEQ ID NO:1741)), is used instead of F1 as it hybridizes directly
to the protospacer region in the uncut PAM library.
[0588] Next, PAM recognition was evaluated. This was accomplished
by first generating a collection of sequences representing all
possible outcomes of double stranded DNA cleavage and adapter
ligation within the target region. For example, cleavage and
adapter ligation at just after the third position of the target
would produce the following sequence (5'-CTTCCGATCTACA-3' (SEQ ID
NO:1742)) where the adapter and target sequences comprise
5'-CTTCCGATCT-3' (SEQ ID NO:1743) and 5'-ACA-3', respectively.
Next, these sequences were searched for in the sequence datasets
along with a 10 bp sequence 5' of the 7 bp PAM region
(5'-AGTTGACCCA-3' (SEQ ID NO:1744)). Protospacer-adapter ligation
positions where Illumina sequences were recovered in excess
resulting in a peak or spike of read coverage over negative
controls were denoted as the cleavage position (FIG. 9). Those Cas9
proteins that produced dominant cleavage at a protospacer position
other than just after 3 were then re-examined by also capturing the
cleavage product resulting from cleavage, end-repair, 3' adenine
addition, and adapter ligation of protospacer side of the cleaved
library target (FIG. 10A). Finally, the resulting frequencies were
then compared for both the protospacer and PAM sides of cleavage
and used to determine the position and type of cleavage taking T4
DNA polymerase end-repair into consideration (FIG. 10B).
[0589] Next, the sequences comprised of the dominant cleavage point
were examined for PAM preferences. This was accomplished by
isolating the PAM sequence from these reads and trimming away the
5' and 3' flanking sequences. Next, the frequency of the extracted
PAM sequences was normalized to the original PAM library to account
for bias inherent to the initial library. First, identical PAM
sequences were enumerated, and frequency calculated versus the
total reads in the dataset. Then, normalization was performed for
each PAM using the following equation such that PAM sequences that
were under- or over-represented in the initially library were
accounted for:
Normalized Frequency=(Treatment Frequency)/(((Control
Frequency)/(Average Control Frequency)))
[0590] After normalization, a position frequency matrix (PFM) was
calculated. This was done by weighting each nucleotide at each
position based on the frequency (normalized) associated with each
PAM. For example, if a PAM of 5'-CGGTAGC-3' had a normalized
frequency of 0.15%, then the C at first position would be given a
frequency of 0.15% when determining the nucleotide frequency for
the first PAM position. Next, the overall contribution of each
nucleotide at each position in the dataset was summed and organized
into a table with the most abundant nucleotides indicating Cas9 PAM
preferences (Tables 4-83, wherein: A=Adenine, C=Cytosine,
G=Guanine, T=Thymine, R=A or G, Y=C or T, S=G or C, W=A or T, D=A
or G or T, H=A or C or T, K=G or T, M=A or C, N=any base, B=C or G
or T, V=A or C or G) and displayed as a WebLogo (FIG. 3).
[0591] IVT method results were confirmed with purified
ribonucleoprotein (RNP), at several different concentrations. The
WebLogo comparisons for selected Cas9 orthologs are shown in FIG.
8.
[0592] In all, a diverse range of PAM sequence preferences were
obtained. These included novel G-rich, C-rich, A-rich, and T-rich
PAM recognition. Additionally, approximately 10% of the Cas9
orthologs surveyed exhibited 5' staggered overhanging cleavage (1-3
nt) as opposed to a blunt DNA target cleavage pattern typified by
other Cas9s. Taken together, this diversity presented by Cas9
orthologs provides a wealth of DNA target recognition and
biophysical properties that may be harnessed for genome editing
applications.
Example 3: Expression Analysis in E. coli Cells
[0593] Upon determination of the PAM requirements and functional
sgRNA sequence, candidates of interest were selected for expression
analysis in and purification from E. coli cells. Primary selection
criteria include desirable or other interesting PAMs, genome
editing activity, unusual cleavage patterns, and protein size.
Candidate Cas9 nuclease encoding genes were sub-cloned into E. coli
expression vectors, to yield constructs encoding fusion proteins
comprising a C-terminal 6-His-tag. In some instances, sequences
encoding nuclear localization sequences (SV40 origin) were
incorporated onto the 5' and 3' ends of the Cas9 gene as well. The
expression analysis may be performed in different E. coli strains
under various growth conditions (media, temperature, induction) and
detected by SDS-PAGE and Western blot analysis. At least some Cas9
proteins were soluble when expressed in E. coli, and soluble and
stable when purified. Optimized conditions can be chosen for
purification. Proteins were purified from cell lysate using
standard IMAC and ion-exchange chromatography.
[0594] Cas9 proteins that were successfully purified at flask scale
were advanced to expression trials in high-density bioreactors.
Scalable purification schemes amenable to GMP (Good Manufacturing
Practices) manufacture are determined. Optimal storage conditions
and the stability of purified protein are determined using a
combination of nano differential scanning fluorimetry (nanoDSF) and
in vitro DNA endonuclease assays. DNA endonuclease assays are
performed on fluorescently end-labeled DNA fragments and detected
and quantified using capillary electrophoresis in 96-well
plates.
Example 4: In Vitro Method for Modification of a Target
Polynucleotide with Cas9 Ortholog Nuclease
[0595] The compositions disclosed herein may be utilized outside of
a typical cellular environment for in vitro modification of one or
more target polynucleotides. In some aspects, the target
polynucleotide is isolated and purified from a genomic source. In
some aspects, the target polynucleotide is on a circularized or
linearized plasmid. In some aspects, the target polynucleotide is a
PCR product. In some aspects, the target polynucleotide is a
synthesized oligonucleotide.
[0596] In some aspects, said modification includes binding to,
nicking, or cleaving a target polynucleotide.
Materials
[0597] The following materials were used: [0598] a. a Cas9 ortholog
polypeptide, a cas9 ortholog polynucleotide, a functional Cas9
ortholog variant, a functional Cas9 ortholog fragment, a fusion
protein comprising an active or deactivated Cas9 ortholog, a Cas9
ortholog further comprising one or more nuclear localization
sequences (NLS) on the C-terminus or on the N-terminus or on both
the N- and C-termini, a biotinylated Cas9 ortholog, a Cas9 ortholog
nickase, a Cas9 ortholog endonuclease, a Cas9 ortholog further
comprising a Histidine tag, a mixture of Cas9 orthologs with
different PAM specificities, or a mixture of any two or more of the
preceding. [0599] b. 10.times. reaction buffer at pH 6.5: 200 mM
HEPES, 50 mM MgCl2, 1M NaCl, 1 mM EDTA or equivalent buffer that
supports activity [0600] c. a proteinase (e.g., Proteinase K,
molecular biology grade, New England BioLabs product #P8107S)
[0601] d. nuclease-free water [0602] e. a sgRNA or other guide
polynucleotide comprising the targeting sequence in the region of
interest on the target (substrate) polynucleotide, wherein the
targeting sequence is substantially complementary to a fragment of
the target sequence of the target (substrate) polynucleotide [0603]
f. a target (substrate) polynucleotide, comprising the target
sequence [0604] g. It is preferred to keep the molar ratio of Cas9
and the sgRNA/guide polynucleotide per target site at a 1:1:1 or
higher, to obtain the best cleavage efficiency.
Method
[0605] Each 30 ul reaction was assembled at room temperature:
[0606] 1. 20 ul nuclease-free water [0607] 2. 3 ul 10.times.
reaction buffer [0608] 3. sgRNA or other polypeptide [0609] 4. Cas9
ortholog or other molecule described in part a. of the Materials
section
[0610] The mixture was incubated at 25 degrees Celsius (or other
temperature which supports ribonucleoprotein complex formation) for
1 or more minutes. Substrate polynucleotide was added. The mixture
was mixed thoroughly and pulse-spun in a microfuge. The sample was
incubated at 37 degrees Celsius (or other temperature that supports
optimal activity) for 5 or more minutes. 1 ul of proteinase was
added to each sample, which was then mixed thoroughly and
pulse-spun in a microfuge. The sample was incubated at room
temperature for 10 minutes, and prepared for subsequent
analysis.
Example 5: In Vitro Characterization of Purified Proteins
[0611] Purified Cas9 proteins that were amenable to manufacturing
(those that include desired stability, solubility, and/or other
properties) were further characterized in vitro. First, the PAM
sequences determined by the aforementioned assay were confirmed by
standard plasmid DNA cleavage (Karvelis et al., 2015). The cleavage
patterns of each Cas9 were tested using plasmid with optimal PAM
and at least three different targets (different CG content). Next
cleavage conditions and optimal sgRNA structure were determined
using in vitro DNA endonuclease assays, and cell-based genome
editing assays.
[0612] Data for some of the Cas9 orthologs tested with two
different lengths of spacers (20 nucleotides and 24 nucleotides) is
shown in FIG. 11.
[0613] Variants that showed similar or better in vitro cleavage
efficiency than SpCas9 were selected for additional testing. Table
84 summarizes the in vitro and in vivo cleavage data obtained for a
representative number of Cas9 orthologs.
Example 6: Evaluation of Homology-Directed Repair (HDR)
Activity
[0614] Cleavage activity of novel Cas9 orthologs for certain
target/targets in vitro, in cultured human cells, and in plant
cells is determined. A cell line-based gain-of-function fluorescent
reporter system is engineered for evaluation of HDR efficiency
induced by a Cas9 protein. Briefly, the eGFP gene is inactivated by
inserting region containing multiple STOP codons and PAMs for
various novel Cas9s. Two approaches (FIG. 7) may be tested: i) the
homology arms for repair (.about.500 bp) is duplicated in eGFP
gene; ii) repair template is introduced into the cell together with
Cas9. For direct comparison of different Cas9 proteins, the
transfection efficiency and Cas9 expression are normalized.
[0615] Direct counting of green cells allows scoring for the HDR
frequency, whereas subsequently performed T7 endonuclease assay (or
deep sequencing) enables evaluation of the cleavage- and NHEJ
efficiency in the same cells. These experiments lead to selection
of novel Cas9 proteins with cleavage reparation output shifted to
HDR. This system has the advantage of allowing for the direct
comparison of HDR efficiency between Cas9 nuclease systems. The
biophysical properties of the Cas9 orthologs is assessed,
including: blunt-end or sticky overhang DNA cleavage, target site
release, and frequency of recurrent target site cleavage. HDR
analysis coupled with detailed characterization of in vitro DNA
cleavage assists with connecting biophysical properties of Cas9
nucleases with desirable HDR outcomes.
Example 7: In Vivo Modification of a Plant Cell Target
Polynucleotide with Cas9 Ortholog Nucleases
[0616] In some aspects, the compositions disclosed herein may be
utilized to modify a target polynucleotide in the genome of a cell.
In some aspects, said cell is a eukaryotic cell. In one example of
a eukaryotic cell, a plant cell is used. Transformation of a
eukaryotic cell with a Cas9 ortholog to effect genomic
polynucleotide editing can be accomplished by various methods known
to be effective in plants, including particle-mediated delivery,
Agrobacterium-mediated transformation, PEG-mediated delivery, and
electroporation. It is appreciated that any method known in the art
may be utilized. Example methods are described below.
[0617] To confer efficient expression, the novel Cas9 endonuclease
gene, was optimized per standard techniques known in the art and
the potato ST-LS1 intron 2 introduced in order to eliminate its
expression in E. coli and Agrobacterium. To facilitate nuclear
localization in maize cells, a nucleotide sequence encoding two
versions of Simian virus 40 (SV40) monopartite nuclear localization
signal was added to either the 5 prime, 3 prime, or both 5 prime
and 3 prime ends. The resulting sequences encoding the different
optimized Cas9 endonuclease gene and nuclear localization signal
variants, were then operably linked to a promoter, for example a
maize ubiquitin promoter, maize ubiquitin 5' untranslated region
(UTR), maize ubiquitin intron 1, and suitable terminator, by
standard molecular biological techniques.
[0618] The Cas9 endonuclease is directed by small RNAs (referred to
herein as guide RNAs) to cleave double-stranded DNA. These guide
RNAs comprise a sequence that aids recognition by Cas9 (referred to
as Cas9 recognition domain) and a sequence that serves to direct
Cas9 cleavage by base pairing with one strand of the DNA target
site (Cas9 variable targeting domain). To transcribe small RNAs
necessary for directing Cas9 endonuclease cleavage activity in
maize cells, a U6 polymerase III promoter and terminator are
isolated from maize and operably fused to the ends of DNA sequences
that upon transcription would result in a suitable guide RNA for a
Cas9 nuclease. To promote optimal transcription of the guide RNA
from the maize U6 polymerase III promoter a G nucleotide was added
to the 5' end of the sequence to be transcribed.
Particle-Mediated Delivery
[0619] Transformation of maize immature embryos using particle
delivery is performed as follows. Media recipes follow below.
[0620] The ears are husked and surface sterilized in 30% Clorox
bleach plus 0.5% Micro detergent for 20 minutes, and rinsed two
times with sterile water. The immature embryos are isolated and
placed embryo axis side down (scutellum side up), 25 embryos per
plate, on 560Y medium for 4 hours and then aligned within the
2.5-cm target zone in preparation for bombardment. Alternatively,
isolated embryos are placed on 560L (Initiation medium) and placed
in the dark at temperatures ranging from 26.degree. C. to
37.degree. C. for 8 to 24 hours prior to placing on 560Y for 4
hours at 26.degree. C. prior to bombardment as described above.
[0621] Plasmids comprising the Cas9 ortholog and donor DNA are
constructed using standard molecular biology techniques and
co-bombarded with plasmids containing the developmental genes ODP2
(AP2 domain transcription factor ODP2 (Ovule development protein
2); US20090328252 A1) and Wushel (US2011/0167516).
[0622] The plasmids and DNA of interest are precipitated onto 0.6
micrometer (average diameter) gold pellets using a water-soluble
cationic lipid transfection reagent as follows. DNA solution is
prepared on ice using 1 ug of plasmid DNA and optionally other
constructs for co-bombardment such as 50 ng (0.5 ul) of each
plasmid containing the developmental genes ODP2 (AP2 domain
transcription factor ODP2 (Ovule development protein 2);
US20090328252 A1) and Wushel. To the pre-mixed DNA, 20 ul of
prepared gold particles (15 mg/ml) and 5 ul of a water-soluble
cationic lipid transfection reagent is added in water and mixed
carefully. Gold particles are pelleted in a microfuge at 10,000 rpm
for 1 min and supernatant is removed. The resulting pellet is
carefully rinsed with 100 ml of 100% EtOH without resuspending the
pellet and the EtOH rinse is carefully removed. 105 ul of 100% EtOH
is added and the particles are resuspended by brief sonication.
Then, 10 ul is spotted onto the center of each macrocarrier and
allowed to dry about 2 minutes before bombardment.
[0623] Alternatively, the plasmids and DNA of interest are
precipitated onto 1.1 um (average diameter) tungsten pellets using
a calcium chloride (CaCl2) precipitation procedure by mixing 100 ul
prepared tungsten particles in water, 10 ul (1 ug) DNA in Tris EDTA
buffer (1 ug total DNA), 100 ul 2.5 M CaCl2, and 10 ul 0.1 M
spermidine. Each reagent is added sequentially to the tungsten
particle suspension, with mixing. The final mixture is sonicated
briefly and allowed to incubate under constant vortexing for 10
minutes. After the precipitation period, the tubes are centrifuged
briefly, liquid is removed, and the particles are washed with 500
ml 100% ethanol, followed by a 30 second centrifugation. Again, the
liquid is removed, and 105 ul of 100% ethanol is added to the final
tungsten particle pellet. For particle gun bombardment, the
tungsten/DNA particles are briefly sonicated. 10 ul of the
tungsten/DNA particles is spotted onto the center of each
macrocarrier, after which the spotted particles are allowed to dry
about 2 minutes before bombardment.
[0624] The sample plates are bombarded at level #4 with a Biorad
Helium Gun. All samples receive a single shot at 450 PSI, with a
total of ten aliquots taken from each tube of prepared
particles/DNA.
[0625] Following bombardment, the embryos are incubated on 560P
(maintenance medium) for 12 to 48 hours at temperatures ranging
from 26 C to 37 C, and then placed at 26 C. After 5 to 7 days the
embryos are transferred to 560R selection medium containing 3
mg/liter Bialaphos, and subcultured every 2 weeks at 26 C. After
approximately 10 weeks of selection, selection-resistant callus
clones are transferred to 288J medium to initiate plant
regeneration. Following somatic embryo maturation (2-4 weeks),
well-developed somatic embryos are transferred to medium for
germination and transferred to a lighted culture room.
Approximately 7-10 days later, developing plantlets are transferred
to 272V hormone-free medium in tubes for 7-10 days until plantlets
are well established. Plants are then transferred to inserts in
flats (equivalent to a 2.5'' pot) containing potting soil and grown
for 1 week in a growth chamber, subsequently grown an additional
1-2 weeks in the greenhouse, then transferred to Classic 600 pots
(1.6 gallon) and grown to maturity. Plants are monitored and scored
for transformation efficiency, and/or modification of regenerative
capabilities.
[0626] Initiation medium (560L) comprises 4.0 g/l N6 basal salts
(SIGMA C-1416), 1.0 ml/l Eriksson's Vitamin Mix
(1000.times.SIGMA-1511), 0.5 mg/l thiamine HCl, 20.0 g/l sucrose,
1.0 mg/l 2,4-D, and 2.88 g/l L-proline (brought to volume with D-I
H.sub.2O following adjustment to pH 5.8 with KOH); 2.0 g/l Gelrite
(added after bringing to volume with D-I H2O); and 8.5 mg/l silver
nitrate (added after sterilizing the medium and cooling to room
temperature).
[0627] Maintenance medium (560P) comprises 4.0 g/l N6 basal salts
(SIGMA C-1416), 1.0 ml/l Eriksson's Vitamin Mix
(1000.times.SIGMA-1511), 0.5 mg/l thiamine HCl, 30.0 g/l sucrose,
2.0 mg/l 2,4-D, and 0.69 g/l L-proline (brought to volume with D-I
H.sub.2O following adjustment to pH 5.8 with KOH); 3.0 g/l Gelrite
(added after bringing to volume with D-I H2O); and 0.85 mg/l silver
nitrate (added after sterilizing the medium and cooling to room
temperature).
[0628] Bombardment medium (560Y) comprises 4.0 g/l N6 basal salts
(SIGMA C-1416), 1.0 ml/l Eriksson's Vitamin Mix
(1000.times.SIGMA-1511), 0.5 mg/l thiamine HCl, 120.0 g/l sucrose,
1.0 mg/l 2,4-D, and 2.88 g/l L-proline (brought to volume with D-I
H.sub.2O following adjustment to pH 5.8 with KOH); 2.0 g/l Gelrite
(added after bringing to volume with D-I H2O); and 8.5 mg/l silver
nitrate (added after sterilizing the medium and cooling to room
temperature).
[0629] Selection medium (560R) comprises 4.0 g/l N6 basal salts
(SIGMA C-1416), 1.0 ml/l Eriksson's Vitamin Mix
(1000.times.SIGMA-1511), 0.5 mg/l thiamine HCl, 30.0 g/l sucrose,
and 2.0 mg/l 2,4-D (brought to volume with D-I H.sub.2O following
adjustment to pH 5.8 with KOH); 3.0 g/l Gelrite (added after
bringing to volume with D-I H2O); and 0.85 mg/l silver nitrate and
3.0 mg/l bialaphos (both added after sterilizing the medium and
cooling to room temperature).
[0630] Plant regeneration medium (288J) comprises 4.3 g/l MS salts
(GIBCO 11117-074), 5.0 ml/l MS vitamins stock solution (0.100 g
nicotinic acid, 0.02 g/l thiamine HCL, 0.10 g/l pyridoxine HCL, and
0.40 g/l glycine brought to volume with polished D-I H.sub.2O)
(Murashige and Skoog (1962) Physiol. Plant. 15:473), 100 mg/l
myo-inositol, 0.5 mg/l zeatin, 60 g/l sucrose, and 1.0 ml/l of 0.1
mM abscisic acid (brought to volume with polished D-I H.sub.2O
after adjusting to pH 5.6); 3.0 g/l Gelrite (added after bringing
to volume with D-I H2O); and 1.0 mg/l indoleacetic acid and 3.0
mg/l bialaphos (added after sterilizing the medium and cooling to
60.degree. C.).
[0631] Hormone-free medium (272V) comprises 4.3 g/l MS salts (GIBCO
11117-074), 5.0 ml/l MS vitamins stock solution (0.100 g/l
nicotinic acid, 0.02 g/l thiamine HCL, 0.10 g/l pyridoxine HCL, and
0.40 g/l glycine brought to volume with polished D-I H2O), 0.1 g/l
myo-inositol, and 40.0 g/l sucrose (brought to volume with polished
D-I H.sub.2O after adjusting pH to 5.6); and 6 g/l bacto-agar
(added after bringing to volume with polished D-I H2O), sterilized
and cooled to 60.degree. C.
[0632] The delivery of RNP (ribonucleoprotein) in to cells,
including plant or animal cells, has several advantages compared to
plasmid or RNA. When intact complex is delivered in to cell, the
DNA may be modified faster and with higher efficiency. In addition,
the concentration of Cas9 may be controlled more strictly in this
case, potentially lowering the rate of off-targets.
[0633] For maize transformation, particle gun transformation of
Hi-Type II 8 to 10-day-old immature embryos (IEs) was carried-out
similar to that described previously (Svitashev et al. 2015 and
Karvelis et al. 2015). Briefly, DNA expression cassettes were
co-precipitated onto 0.6 .mu.M (average size) gold particles
utilizing TransIT-2020, pelleted by centrifugation, washed with
absolute ethanol and re-dispersed by sonication. Following
sonication, 10 .mu.l of the DNA coated gold particles were loaded
onto a macrocarrier and air dried. Next, biolistic transformation
was performed using a PDS-1000/He Gun (Bio-Rad) with a 425 lb per
square inch rupture disc. Since particle gun transformation can be
highly variable, a visual marker DNA expression cassette encoding a
cyan fluorescent protein (CFP) was also co-delivered to aid in the
selection of evenly transformed IEs and each treatment was
performed in triplicate.
Agrobacterium-Mediated Transformation
[0634] Agrobacterium-mediated transformation is performed
essentially as described in Djukanovic et al. (2006) Plant Biotech
J 4:345-57. Briefly, 10-12 day old immature embryos (0.8-2.5 mm in
size) are dissected from sterilized kernels and placed into liquid
medium (4.0 g/L N6 Basal Salts (Sigma C-1416), 1.0 ml/L Eriksson's
Vitamin Mix (Sigma E-1511), 1.0 mg/L thiamine HCl, 1.5 mg/L 2, 4-D,
0.690 g/L L-proline, 68.5 g/L sucrose, 36.0 g/L glucose, pH 5.2).
After embryo collection, the medium is replaced with 1 ml
Agrobacterium at a concentration of 0.35-0.45 OD550. Maize embryos
are incubated with Agrobacterium for 5 min at room temperature,
then the mixture is poured onto a media plate containing 4.0 g/L N6
Basal Salts (Sigma C-1416), 1.0 ml/L Eriksson's Vitamin Mix (Sigma
E-1511), 1.0 mg/L thiamine HCl, 1.5 mg/L 2, 4-D, 0.690 g/L
L-proline, 30.0 g/L sucrose, 0.85 mg/L silver nitrate, 0.1 nM
acetosyringone, and 3.0 g/L Gelrite, pH 5.8. Embryos are incubated
axis down, in the dark for 3 days at 20.degree. C., then incubated
4 days in the dark at 28.degree. C., then transferred onto new
media plates containing 4.0 g/L N6 Basal Salts (Sigma C-1416), 1.0
ml/L Eriksson's Vitamin Mix (Sigma E-1511), 1.0 mg/L thiamine HCl,
1.5 mg/L 2, 4-D, 0.69 g/L L-proline, 30.0 g/L sucrose, 0.5 g/L
IVIES buffer, 0.85 mg/L silver nitrate, 3.0 mg/L Bialaphos, 100
mg/L carbenicillin, and 6.0 g/L agar, pH 5.8. Embryos are
subcultured every three weeks until transgenic events are
identified. Somatic embryogenesis are induced by transferring a
small amount of tissue onto regeneration medium (4.3 g/L MS salts
(Gibco 11117), 5.0 ml/L MS Vitamins Stock Solution, 100 mg/L
myo-inositol, 0.1 .mu.M ABA, 1 mg/L IAA, 0.5 mg/L zeatin, 60.0 g/L
sucrose, 1.5 mg/L Bialaphos, 100 mg/L carbenicillin, 3.0 g/L
Gelrite, pH 5.6) and incubation in the dark for two weeks at
28.degree. C. All material with visible shoots and roots are
transferred onto media containing 4.3 g/L MS salts (Gibco 11117),
5.0 ml/L MS Vitamins Stock Solution, 100 mg/L myo-inositol, 40.0
g/L sucrose, 1.5 g/L Gelrite, pH 5.6, and incubated under
artificial light at 28.degree. C. One week later, plantlets are
moved into glass tubes containing the same medium and grown until
they were sampled and/or transplanted into soil.
Ribonucleoprotein Transformation
[0635] A Cas9 and associated guide polynucleotide(s)
ribonucleoprotein (RNP) complex can be recombinantly expressed and
purified. RNP complex assembly can be carried-out directly in the
cell recombinantly expressing the components or in vitro. Following
purification, the RNP complex(es) can be delivered by particle gun
transformation as described in Svitashev, S. et al. (2016) Nat.
Commun. 7:13274. Briefly, RNPs (and optionally DNA expression) are
precipitated onto 0.6 mm (average diameter) gold particles
(Bio-Rad, USA) using a water soluble cationic lipid TransIT-2020
(Minis, USA) as follows: 50 ml of gold particles (water suspension
of 10 mg/ml) and 2 ml of TransIT-2020 water solution are added to
the premixed RNPs (and optionally DNA expression vectors), mixed
gently, and incubated on ice for 10 min. RNP/DNA-coated gold
particles are then pelleted in a microfuge at 8,000 g for 30 s and
supernatant is removed. The pellet is then resuspended in 50 ml of
sterile water by brief sonication. Immediately after sonication,
coated gold particles are loaded onto a microcarrier (10 ml each)
and allowed to air dry. Immature maize embryos, 8-10 days after
pollination, are then bombarded using a PDS-1000/He Gun (Bio-Rad,
USA) with a rupture pressure of 425 pounds per inch square.
Post-bombardment culture, selection, and plant regeneration are
performed as previously described above.
Variations in Delivery
[0636] Cas9 and guide polynucleotide can be delivered as DNA
expression cassettes, RNA, messenger RNA (5'-capped and
polyadenylated), or protein or combinations thereof. Cell lines or
transformants can also be established stably expressing all but one
or more of the components needed to form a functional guide
polynucleotide/Cas complex so that upon delivery of the missing
component(s) a functional guide polynucleotide/Cas complex can
form.
[0637] Sequence Verification of Genomic Polynucleotide
Modification
[0638] Samples of a transformed plant are obtained and sequenced
via any method known in the art, and compared to the genomic
sequences of an isoline plant not transformed with the Cas9 and/or
guide polynucleotide. The presence of non-homologous end-joining
(NHEJ) insertion and/or deletion (indel) mutations resulting from
DNA repair can also be used as a signature to detect cleavage
activity.
[0639] This can be performed 2 days or longer after transformation.
A variety of tissues can be samples, included but not limited to
callus and leaf tissue. Total genomic DNA can be extracted and the
region surrounding the intended target site can be PCR amplified
with Phusion.RTM. HighFidelity PCR Master Mix (New England Biolabs,
M0531L) adding on the sequences necessary for amplicon-specific
barcodes and Illumina sequencing using "tailed" primers through two
rounds of PCR and deep sequenced. The resulting reads can then
examined for the presence of mutations at the expected site of
cleavage by comparison to control experiments where the small RNA
transcriptional cassette is omitted from the transformation.
Sequence Verification of Genomic Polynucleotide Modification
[0640] The cellular cleavage activity of Cas9 orthologs was
assessed in Zea mays using a rapid transient assay as described
previously (Svitashev et al. 2015 and Karvelis et al. 2015).
Briefly, after 2 days, the 20-30 most evenly transformed IEs were
harvested based on their fluorescence. Total genomic DNA was
extracted and the region surrounding the intended target site was
PCR amplified with Phusion.RTM. HighFidelity PCR Master Mix (New
England Biolabs, M0531L) adding on the sequences necessary for
amplicon-specific barcodes and Illumina sequencing using "tailed"
primers through two rounds of PCR and deep sequenced. The resulting
reads were then examined for the presence of mutations at the
expected site of cleavage by comparison to control experiments
where the small RNA transcriptional cassette is omitted from the
transformation.
[0641] FIG. 16 shows the results of two different Cas9 orthologs
(ID33 and ID64) across three different target sites (MS45, MS26,
and LIG) in maize T0 plants, as compared to control plants modified
with S. pyogenes Cas9. FIGS. 15 and 19 show the mutant read results
of Cas9 orthologs ID33 (FIG. 15A), ID64 (FIG. 15B), ID46 (FIG.
19A), and ID56 (FIG. 19B), in maize cells.
Example 8: In Vivo Modification of a Human Cell Target
Polynucleotide with Cas9 Ortholog Nucleases
[0642] The genome editing activity of selected Cas9 proteins is
measured in the human model cell line HEK293. Cells are
co-transfected with plasmids encoding Cas9 candidates together with
U6-driven dsDNA encoding their cognate sgRNA. This approach does
not require purified protein and is initiated once the PAM
preferences and sgRNA(s) supportive of cleavage activity are
determined. Targeting endogenous genes allows evaluation of the
activity of the selected Cas9s on chromosomal DNA. The targeting
frequencies of endogenous human genes is tested using a T7
endonuclease assay and then evaluated by deep sequencing PCR
amplicons spanning the targeted regions. Wild-type and mutant
amplicons are counted to derive editing scores. Editing scores for
each target are combined to obtain an aggregate score. Three to
five different targets for each Cas9 protein are tested. Genome
editing activity for selected Cas9 candidates are compared to
activity for SpCas9 in parallel transfections. For candidate Cas9
nucleases, nearby or overlapping (if possible) target locations are
targeted, matching target GC content as closely as possible to
SpCas9 targets.
[0643] Deep sequencing not only allows comparison of cleavage
efficiencies of investigated Cas9 proteins, but also provides
valuable information about dominant NHEJ repair outcomes for dsDNA
breaks generated with each of the novel Cas9 orthologs. The
delivery of RNP (ribonucleoprotein) in to cells, including plant or
animal cells, has several advantages compared to plasmid or RNA.
When intact complex is delivered in to cell, the DNA may be
modified faster and with higher efficiency. In addition, the
concentration of Cas9 may be controlled more strictly in this case,
potentially lowering the rate of off-targets. To validate the
functional activity of novel Cas9 nucleases in human cells, RNP
complexes are assembled using purified proteins and in vitro
transcribed sgRNAs. RNPs are introduced into HEK293 cells by
electroporation. Genome editing activity is assessed as described
above using T7 endonuclease I assays and deep sequencing of
amplicons corresponding to genomic targets. Genome editing
efficiency of novel Cas9 variants are compared to that of SpCas9.
Variants that show similar or better genome editing efficiency than
SpCas9 bearing the same NLS and His-tag sequences are selected.
This approach allows prediction of the functional activity of new
Cas9 nucleases when introduced as RNP into model cells, which is
useful for the development of new methods for delivery of gene
editing tools.
Cell Culture Electroporation
[0644] Cas9 RNPs were electroporated into HEK293 (ATCC Cat
#CRL-1573) cells using the Lonza 4D-Nucleofector System and the SF
Cell Line 4D-Nucleofector.RTM. X Kit (Lonza). For each
electroporation, RNPs were formed by incubating 100 pmoles of sgRNA
with 50 pmoles of Cas9 protein in nucleofector solution in a volume
of 17 .mu.L at room temperature for 20 minutes. HEK293 cells were
released from culture vessels using TrypLE.TM. Express Enzyme
1.times. (ThermoFisher) washed with 1.times.PBS without Ca++ or
Mg++ (ThermoFisher) and counted using a XXX LUNA.TM. Automated Cell
Counter (Logos Biosystems)XXX. For each electroporation,
1.times.10{circumflex over ( )}5 live cells were resuspended in 9
.mu.L electroporation solution. Cells and RNP were mixed and
transferred to one well of a 16-well strip and electroporated using
the CM-130 program. 75 .mu.L of pre-warmed culture was added to
each well and 10 .mu.L of the resultant resuspended cells were
dispensed into a well of a 96-well culture vessel containing 125
.mu.L of pre-warmed culture medium. Electroporated cells were
incubated at 37.degree. C., 5% CO2 in a humidified incubator for 48
hours before analysis of genome editing.
Cell Culture Lipofection
[0645] Human embryonic kidney (HEK) cell line 293 (ATCC-CRL-1573)
was maintained in Dulbecco's modified Eagle's Medium (DMEM) with
GlutaMAX (Thermo Fisher Scientific), supplemented with 10% fetal
bovine serum (Thermo Fisher Scientific) and 10,000 units/mL
penicillin, and 10,000 .mu.g/mL streptomycin (Thermo Fisher
Scientific) at 37.degree. C. with 5% CO2 incubation.
[0646] HEK293 cells were seeded into 96-well plates (Thermo Fisher
Scientific) one day prior to transfection at a density of 18,000
cells per well. Cells were transfected using Lipofectamine 3000
(Thermo Fisher Scientific) following the manufacturer's recommended
protocol. For each well of a 96-well plate a total amount of 200 ng
DNA containing 30 fmol of plasmid Cas9 encoding plasmid and 27 fmol
of PCR fragment with appropriate U6-gRNA template was used.
[0647] Cells were incubated at 37.degree. C. for 48 hours post
transfection in 5% CO2 before genomic DNA extraction. The cells
were washed twice with 200 .mu.l 1.times.DPBS (Thermo Fisher
Scientific) and resuspended in 25 .mu.l 50 mM Tris-HCl, 150 mM
NaCl, 0.05% Tween 20, pH 7.6 (Sigma Aldrich) and 0.2 mg/ml
Proteinase K (Thermo Fisher Scientific) lysis buffer. Resuspended
cells were incubated at 55.degree. C. for 30 minutes and 98.degree.
C. for 20 minutes. Genomic region surrounding each Cas9 target site
was PCR amplified using primers X and Y and analyzed with T7
endonuclease as described above.
Sequence Verification of Genomic Polynucleotide Modification
[0648] For genome editing analysis, genomic DNA was extracted 48 h
post electroporation using 50 .mu.L of Epicentre QuickExtract.TM.
DNA Extraction Solution for each well of a 96-well culture vessel
according the to the manufacturer's recommendations. Regions
surrounding the intended target sites were PCR amplified using
Q5.RTM. Hot Start High-Fidelity 2.times. Master Mix (NEB) according
to the manufacturer's suggestion, and using 2 .mu.L of genomic DNA
(diluted 1:5 in water) in 25 .mu.L reactions.
[0649] Genome editing was estimated using T7 Endonuclease I assays.
5 .mu.L of each PCR reaction was combined with 2 .mu.L NEBuffer 2
(NEB) and 12 .mu.L of water before denaturation at 95.degree. C.
for 5 minutes and re-annealing by temperature ramping from
95-85.degree. C. at -2.degree. C./s followed by ramping from
85-25.degree. C. at -0.1.degree. C./s. 1 .mu.L of T7 Endonuclease I
(NEB) was added to each re-annealed sample and cleavage reactions
were incubated at 37.degree. C. for 15 min. Reactions were stopped
by adding 1 .mu.L of Proteinase K (NEB) per sample and incubation
at 25.degree. C. for 5 min. Fragments were analysed on an AATI
Fragment Analyzer (AATI) using the CRISPR Discovery Gel Kit
reagents (AATI).
[0650] Genome editing outcomes were characterized by deep
sequencing of PCR amplicons from targeted loci. Illumina sequencing
libraries were constructed using the NEBNext.RTM. Ultra.TM. II DNA
Library Prep Kit for Illumina.RTM. and NEBNext.RTM. Multiplex
Oligos for Illumina.RTM. (96 Index Primers) (NEB) according to the
manufacturer's suggestion. After sequencing, reads were examined
for the presence of mutations at the expected site of cleavage by
comparison to control experiments where RNPs targeted a different
region of the genome.
[0651] FIG. 17 shows the results of selected Cas9 orthologs at the
HEK cell WTAP locus, as compared to the activity of S. pyogenes
Cas9, in cells transformed with a recombinant construct comprising
a DNA sequence encoding the respective Cas9 ortholog.
[0652] FIG. 18 shows the results of selected Cas9 orthologs at the
HEK cell RunX1 locus, as compared to the activity of S. pyogenes
Cas9, in cells transformed with a recombinant construct comprising
a DNA sequence encoding the respective Cas9 ortholog.
[0653] FIG. 20 shows the results of selected Cas9 orthologs at the
HEK cell WTAP locus, as compared to the activity of S. pyogenes
Cas9, in cells transformed with ribonucleoprotein comprising the
respective Cas9 ortholog and its appropriate guide RNA.
Example 9: Analysis of Cas9 Orthologs to Identify Key Residues,
Predict Ortholog Activity, and Methods for Design of Variants
[0654] Amino acid residues that were conserved in active Cas9s and
under-represented in non-active Cas9s were identified. This was
accomplished by first aligning orthologs using MUSCLE (default
parameters). Next, each position was parsed and the frequency of
each amino acid at each position was assessed. Next, the overall
fraction of each amino acid at each position in the active and
non-active datasets were defined by summing and dividing by the
total number in each dataset, respectively. Then, the non-active
dataset was subtracted from the active with positive values
indicating conserved amino acids in the active Cas9s that were
under-represented in the non-active collection. Finally, key
positions defining an active Cas9 were hand curated by selecting
only those locations with a score greater than or equal to +0.4
where at least 5 of the 7 active Cas9s exhibited the conserved and
under-represented amino acid (FIG. 21 and Table 86A).
[0655] After defining a set of structural features ("fingerprints")
for active Cas9s (all identified fingerprint positions listed in
Table 86B), Cas9 orthologs were scored as summations of position
scores. The maximum score of the method described herein was 12.52
and the minimum score was 0. After evaluating a diverse collection
of Cas9s, scores ranged from 11.64 to 0.4. Many of the Cas9s
experimentally determined to be active in eukaryotic cells were
found to be in the top 8-10% of activity scores. All active Cas9
orthologs had at least one of the identified structural features.
Table 86C shows the calculated activity categories for each of the
Cas9 orthologs disclosed herein (by SEQID). Orthologs with a score
greater than the median score (3.14) are predicted to have positive
cutting activity in a eukaryotic cell. Other orthologs may have
activity as well.
[0656] Using the methods described herein, the activity score,
structural fingerprint, and category may be determined for any Cas9
ortholog. These or similar methods can be used to predict the
activity of Cas9 orthologs, define key amino acids and structural
features required for an active Cas9, define the residues
responsible for sticky or blunt cleavage activity, and provide
residues and regions for the generation of engineered variants.
[0657] Cas9 ortholog variants with different desired properties
such as but not limited to: altered PAM recognition sequence,
modified specificity, and/or altered cleavage activity may be
engineered by analyzing the sequence-structure-function
relationships of the Cas9 orthologs described herein. In some
aspects, the evolution of functionally important domains (e.g., PI
domains) is analyzed. In some aspects, information about conserved
and non-conserved amino acids or amino acid motifs is utilized to
predict activity of Cas9 orthologs and to design possible mutations
in a Cas9 protein that may modulate activity or a molecular
property. In some aspects, rational design is used. In some
aspects, random mutagenesis is used. In some aspects, directed
evolution is used. In some aspects, a combination of rational
design, random mutagenesis, and directed evolution are used.
[0658] Following generation of variants, Cas9 ortholog variants are
selected and tested to determine the PAM sequence, activity in
cultured cells (e.g., human or plant), purified, and/or further
characterized.
Tables
TABLE-US-00001 [0659] TABLE 1 Cas9 orthologs selected for
characterization SEQ IDs of the gene ORF and translated encoded
protein, whole Cas9 protein phylogenetic clade, unique ID#, and
source organism are listed. NT PRT Ortholog SEQID SEQID ID# Clade
Source Organism 1 86 2 1 Prevotella histicola 2 87 3 1
Chryseobacterium gallinarum 3 88 4 1 Parabacteroides sp. 4 89 5 1
Capnocytophaga canis 5 90 6 1 Ornithobacterium rhinotracheale 6 91
8 1 Weeksella virosa 7 92 9 1 Flavobacterium frigidarium 8 93 12 2
Rikenellaceae sp. 9 94 13 2 Jejuia pallidilutea 10 95 16 3
Caenispirillum salinarum 11 96 17 3 Salinispira pacifica 12 97 18 3
Sulfitobacter donghicola 13 98 19 3 Mucispirillum schaedleri 14 99
21 3 Mesorhizobium sp. 15 100 27 5 Neisseria meningitidis 16 101 28
5 Geobacillus sp. 17 102 29 5 Bacillus okhensis 18 103 30 5
Tistrella mobilis 19 104 32 5 Kingella kingae 20 105 33 5
Clostridium perfringens 21 106 35 5 Neisseria sp. 22 107 41 5
Campylobacter coli 23 108 43 5 Sulfurospirillum sp. 24 109 44 5
Dechloromonas denitnficans 25 110 46 6 Nitratifractor salsuginis 26
111 47 7 Enterococcus cecorum 27 112 48 7 Facklamia hominis 28 113
50 7 Streptococcus sinensis 29 114 51 7 Eubacterium dolichum 30 115
52 7 Streptococcus macedonicus 31 116 56 7 Turicibacter sp. 32 117
60 7 Bacillus niameyensis 33 118 61 7 Massilibacterium senegalense
34 119 63 8 Kurthia huakuii 35 120 64 9 Streptococcus equinus 36
121 65 9 Streptococcus equi 37 122 66 9 Enterococcus faecium 38 123
67 9 Enterococcus italicus 39 124 68 9 Streptococcus agalactiae 40
125 70 9 Streptococcus ratti 41 126 71 9 Listeria monocytogenes 42
127 77 10 Lactobacillus sp. 43 128 78 10 Pediococcus acidilactici
44 129 79 10 Acidaminococcus sp. 45 130 80 10 Lactobacillus sp. 46
131 81 10 Treponema putidum 47 132 87 10 Eubacterium sp. 48 133 94
11 Bifidobacterium bombi 49 134 97 11 Corynebacterium
camporealensis 50 135 102 12 Legionella pneumophila 51 136 83 1
Environmental metagenome 52 137 84 1 Environmental metagenome 53
138 85 5 Environmental metagenome 54 139 88 5 Environmental
metagenome 55 140 91 3 Environmental metagenome 56 141 93 3
Environmental metagenome 57 142 139 3 Environmental metagenome 58
143 96 5 Environmental metagenome 59 144 98 3 Environmental
metagenome 60 145 101 3 Environmental metagenome 61 146 103 2
Environmental metagenome 62 147 104 1 Environmental metagenome 63
148 105 2 Environmental metagenome 64 149 106 10
Acidaminococcus_intestini_RyC-MR95 65 150 107 8
Coriobacterium_glomerans_PW2 66 151 108 8 Eggerthella_sp._YY7918 67
152 109 10 Finegoldia_magna_ATCC_29328 68 153 112 10
Lactobacillus_rhamnosus_LOCK900 69 154 116 7
Mycoplasma_gallisepticum_CA06 70 155 119 9
Streptococcus_agalactiae_NEM316 71 156 120 9
Streptococcus_dysgalactiae_subsp._equisimilis_AC-2713 72 157 121 9
Streptococcus_gallolyticus_subsp._gallolyticus_ATCC_43143 73 158
122 7 Streptococcus_gordonii_str_Challis_substr_CH1 74 159 123 9
Streptococcus_mutans_GS-5] 75 160 124 7
Streptococcus_salivarius_JIM8777 76 161 125 7 Streptococcus_suis_D9
77 162 126 7 Streptococcus_thermophilus_LMG_18311 78 163 127 10
Treponema_denticola_ATCC_35405 79 164 131 9 Lactobacillus animalis
KCTC 3501 80 165 132 10 Lactobacillus ceti DSM 22408 81 166 136 9
Tissierellia bacterium KA00581 82 167 138 10 Veillonella parvula
ATCC 17745 83 168 141 7 Streptococcus gallolyticus 84 169 142 7
Staphylococcus pasteuri 85 170 140 9 Enterococcus faecalis
OG1RF
TABLE-US-00002 TABLE 2A Amino acid positions of Cas9 ortholog
domains The Cas9 orthologs were grouped by sequence similarities
with the largest variation at the REC domain. To determine the
functional domain boundary, the Cas9 candidate sequences of Group
I, II, III, IV, V, and VI were aligned with their closest
homologous sequences of known high resolution 3D structures,
including PDBID: 5czz, 5czz, 4un3, 4oge, 4oge and 5b2o,
respectively. Based on these alignments, each candidate sequence
was threaded into its corresponding structural template for
modeling, and the domain boundaries were assigned according to the
template's domain definition in the associated publication
references. PRT RuvCI RUVC1 BH BH REC REC RuvCII RUVCII HNH HNH
RUVCIII RUVCIII WED WED PI PI ID # SEQID start end start end strat
end start end start end start end strat end start end Group 1 12 93
1 41 42 81 82 518 519 622 623 758 759 929 930 1035 1036 1053 18 97
1 40 41 78 79 458 459 558 559 681 682 824 825 925 926 1071 19 98 1
48 49 86 87 448 449 548 549 680 681 813 814 895 896 1044 21 99 1 51
52 89 90 503 504 605 606 743 744 887 888 946 947 1118 27 100 1 51
52 89 90 458 459 538 539 660 661 831 832 950 951 1082 28 101 1 39
40 77 78 456 457 534 535 656 657 804 805 925 926 1087 29 102 1 50
51 88 89 462 463 541 542 670 671 814 815 932 933 1074 30 103 1 47
48 85 86 450 451 538 539 662 663 819 820 900 901 1049 32 104 1 48
49 86 87 457 458 537 538 659 660 814 815 924 925 1060 33 105 1 43
44 81 82 455 456 535 536 655 656 823 824 938 839 1065 35 106 1 48
49 86 87 461 462 541 542 666 667 816 817 931 932 1069 41 107 1 36
37 74 75 439 440 521 522 638 639 784 785 837 838 1001 43 108 1 45
46 82 83 453 454 537 538 657 658 796 797 853 854 1048 44 109 1 39
40 77 78 474 475 570 571 697 698 863 864 981 982 1115 46 110 1 46
47 85 86 487 488 572 573 689 690 836 837 967 968 1137 47 111 1 42
43 76 77 462 463 543 544 683 684 824 825 973 974 1134 48 112 1 37
38 71 72 466 467 549 550 681 682 830 831 991 992 1142 50 113 1 39
40 73 74 462 463 542 543 677 678 822 823 966 967 1122 51 114 1 39
40 73 74 434 435 513 514 646 647 783 784 933 934 1091 52 115 1 40
41 74 75 461 462 542 543 677 678 823 824 968 969 1130 56 116 1 38
39 72 73 449 450 530 531 667 668 806 807 950 951 1107 60 117 1 41
42 75 76 451 452 530 531 662 663 799 800 926 927 1064 61 118 1 40
41 73 74 437 438 518 519 643 644 787 788 913 914 1063 83 136 1 58
59 100 101 456 457 515 516 679 680 792 793 905 906 1039 84 137 1 44
45 88 89 622 623 674 675 834 835 978 979 1200 1201 1354 85 138 1 42
43 83 84 456 457 515 516 677 678 791 792 830 831 972 88 139 1 39 40
77 78 447 448 502 503 662 663 788 789 899 900 1046 91 140 1 43 44
87 88 482 483 558 559 715 716 842 843 964 965 1094 93 141 1 43 44
81 82 463 464 526 527 688 689 806 807 919 920 1037 139 142 1 39 40
82 83 600 601 653 654 822 *1150 1228 1229 1392 1393 1525 96 143 1
45 46 83 84 450 451 508 509 670 671 788 789 843 844 978 98 144 1 47
48 85 86 472 473 549 550 718 719 831 832 903 904 1037 101 145 1 42
43 80 81 448 449 505 506 674 675 789 780 908 909 1028 103 146 1 41
42 79 80 451 452 502 503 658 659 770 771 884 885 1008 105 148 1 45
46 87 88 511 512 571 572 735 736 846 847 997 998 1124 122 158 1 40
41 73 74 459 460 514 515 687 688 814 815 963 964 1136 124 160 1 40
41 73 74 466 467 521 522 694 695 819 820 969 970 1127 125 161 1 41
42 74 75 460 461 515 516 688 689 816 817 963 964 1122 126 162 1 40
41 73 74 460 461 515 516 688 689 813 814 964 965 1122 141 168 1 41
42 74 75 460 461 515 516 688 689 816 817 967 968 1130 142 169 1 41
42 74 75 430 431 485 486 652 653 774 775 909 910 1054 GROUP II 17
96 1 40 41 86 87 538 539 629 630 751 752 1208 1209 1322 1323 1458
GROUP III 2 86 1 58 59 94 95 637 638 692 693 852 853 1053 1054 1126
1127 1380 3 87 1 59 60 96 97 653 654 707 708 866 867 1014 1015 1147
1148 1403 4 88 1 58 59 94 95 669 670 724 725 881 882 1082 1083 1155
1156 1424 5 89 1 58 59 94 95 672 673 733 734 893 894 1099 1100 1172
1173 1430 6 90 1 59 60 94 95 695 696 755 756 962 963 1190 1191 1268
1269 1535 8 91 1 58 59 92 93 703 704 763 764 967 968 1189 1190 1208
1209 1440 9 92 1 58 59 93 94 612 613 674 675 829 830 1027 1028 1100
1101 1345 13 94 1 47 48 82 83 722 723 783 784 937 938 1104 1105
1167 1168 1459 63 119 1 44 45 77 78 719 720 774 775 930 931 1070
1071 1090 1091 1368 64 120 1 59 60 94 95 716 717 772 773 930 931
1112 1113 1156 1157 1375 65 121 1 59 60 94 95 715 716 771 772 922
923 1083 1084 1120 1121 1348 66 122 1 59 60 94 95 728 729 784 785
932 933 1090 1091 1127 1128 1340 67 123 1 59 60 94 95 720 721 776
777 924 925 1078 1079 1115 1116 1330 68 124 1 59 60 94 95 731 732
787 788 942 943 1078 1079 1115 1116 1330 70 125 1 59 60 94 95 720
721 776 777 928 929 1101 1102 1138 1139 1370 71 126 1 76 77 105 106
730 731 786 787 928 929 1101 1102 1132 1133 1345 77 127 1 50 51 85
86 729 730 785 786 939 940 1081 1082 1124 1125 1365 78 128 1 48 49
83 84 729 730 784 785 938 939 1088 1089 1125 1126 1366 79 129 1 47
48 82 83 725 726 781 782 939 940 1068 1069 1103 1104 1358 80 130 1
50 51 85 86 747 748 804 805 967 968 1126 1127 1168 1169 1396 81 131
1 50 51 85 86 744 745 800 801 961 962 1096 1097 1159 1160 1395 87
132 1 53 54 88 89 727 728 784 785 946 947 1079 1080 1130 1131 1345
104 147 1 44 45 88 89 646 647 713 714 881 882 1039 1040 1253 1254
1399 106 149 1 46 47 77 78 715 716 777 778 941 942 1062 1063 1104
1105 1358 107 150 1 51 52 82 83 757 758 817 818 977 978 1124 1125
1169 1170 1384 108 151 1 50 51 81 82 754 755 813 814 970 971 1120
1121 1165 1166 1380 109 152 1 48 49 79 80 726 727 786 787 954 955
1079 1080 1129 1130 1348 112 153 1 49 50 80 81 720 721 782 783 941
942 1075 1076 1125 1126 1361 116 154 1 49 50 78 79 529 530 588 589
766 767 913 914 1102 1103 1269 119 155 1 47 48 89 90 707 708 766
767 930 931 1102 1103 1149 1150 1377 120 156 1 58 59 89 90 708 709
767 768 924 925 1096 1097 1140 1141 1371 121 157 1 59 60 91 92 710
711 769 770 933 934 1102 1103 1149 1150 1371 123 159 1 58 59 89 90
709 710 768 769 925 926 1076 1077 1123 1124 1345 127 163 1 49 50 80
81 733 734 796 797 963 964 1091 1090 1135 1136 1395 131 164 1 63 64
94 95 708 709 767 768 921 922 1065 1066 1109 1110 1318 132 165 1 51
52 82 83 743 744 806 807 968 969 1099 1100 1150 1151 1395 136 166 1
50 51 81 82 725 726 786 787 952 953 1089 1090 1149 1150 1400 138
167 1 63 64 94 95 747 748 809 810 979 980 1105 1106 1158 1159 1398
140 170 1 58 59 89 90 720 721 779 780 936 937 1081 1082 1125 1126
1137 GROUP IV 94 133 1 49 50 96 97 532 533 579 580 726 727 909 910
1025 1026 1239 97 134 1 41 42 88 89 470 471 517 518 672 673 820 821
913 914 1095 GROUP V 16 95 1 44 45 96 97 606 607 661 662 844 845
1000 1001 1103 1104 1442 GROUP VI 102 135 1 52 53 86 87 626 627 685
686 842 843 954 955 1184 1185 1372 * indicates an unstructured
insertion between HNH and RuvCIII domains.
TABLE-US-00003 TABLE 2B SEQ IDs for domains of selected Cas9
orthologs Cas9 REC RUVC1 RUVC2 RUVC3 HNH WED PI Ortholog domain
domain domain domain domain domain domain ID SEQID SEQID SEQID
SEQID SEQID SEQID SEQID 2 1136 1221 1306 1391 1476 1561 1646 3 1137
1222 1307 1392 1477 1562 1647 4 1138 1223 1308 1393 1478 1563 1648
5 1139 1224 1309 1394 1479 1564 1649 6 1140 1225 1310 1395 1480
1565 1650 8 1141 1226 1311 1396 1481 1566 1651 9 1142 1227 1312
1397 1482 1567 1652 12 1143 1228 1313 1398 1483 1568 1653 13 1144
1229 1314 1399 1484 1569 1654 16 1145 1230 1315 1400 1485 1570 1655
17 1146 1231 1316 1401 1486 1571 1656 18 1147 1232 1317 1402 1487
1572 1657 19 1148 1233 1318 1403 1488 1573 1658 21 1149 1234 1319
1404 1489 1574 1659 27 1150 1235 1320 1405 1490 1575 1660 28 1151
1236 1321 1406 1491 1576 1661 29 1152 1237 1322 1407 1492 1577 1662
30 1153 1238 1323 1408 1493 1578 1663 32 1154 1239 1324 1409 1494
1579 1664 33 1155 1240 1325 1410 1495 1580 1665 35 1156 1241 1326
1411 1496 1581 1666 41 1157 1242 1327 1412 1497 1582 1667 43 1158
1243 1328 1413 1498 1583 1668 44 1159 1244 1329 1414 1499 1584 1669
46 1160 1245 1330 1415 1500 1585 1670 47 1161 1246 1331 1416 1501
1586 1671 48 1162 1247 1332 1417 1502 1587 1672 50 1163 1248 1333
1418 1503 1588 1673 51 1164 1249 1334 1419 1504 1589 1674 52 1165
1250 1335 1420 1505 1590 1675 56 1166 1251 1336 1421 1506 1591 1676
60 1167 1252 1337 1422 1507 1592 1677 61 1168 1253 1338 1423 1508
1593 1678 63 1169 1254 1339 1424 1509 1594 1679 64 1170 1255 1340
1425 1510 1595 1680 65 1171 1256 1341 1426 1511 1596 1681 66 1172
1257 1342 1427 1512 1597 1682 67 1173 1258 1343 1428 1513 1598 1683
68 1174 1259 1344 1429 1514 1599 1684 70 1175 1260 1345 1430 1515
1600 1685 71 1176 1261 1346 1431 1516 1601 1686 77 1177 1262 1347
1432 1517 1602 1687 78 1178 1263 1348 1433 1518 1603 1688 79 1179
1264 1349 1434 1519 1604 1689 80 1180 1265 1350 1435 1520 1605 1690
81 1181 1266 1351 1436 1521 1606 1691 83 1182 1267 1352 1437 1522
1607 1692 84 1183 1268 1353 1438 1523 1608 1693 85 1184 1269 1354
1439 1524 1609 1694 87 1185 1270 1355 1440 1525 1610 1695 88 1186
1271 1356 1441 1526 1611 1696 91 1187 1272 1357 1442 1527 1612 1697
93 1188 1273 1358 1443 1528 1613 1698 94 1189 1274 1359 1444 1529
1614 1699 96 1190 1275 1360 1445 1530 1615 1700 97 1191 1276 1361
1446 1531 1616 1701 98 1192 1277 1362 1447 1532 1617 1702 101 1193
1278 1363 1448 1533 1618 1703 102 1194 1279 1364 1449 1534 1619
1704 103 1195 1280 1365 1450 1535 1620 1705 104 1196 1281 1366 1451
1536 1621 1706 105 1197 1282 1367 1452 1537 1622 1707 106 1198 1283
1368 1453 1538 1623 1708 107 1199 1284 1369 1454 1539 1624 1709 108
1200 1285 1370 1455 1540 1625 1710 109 1201 1286 1371 1456 1541
1626 1711 112 1202 1287 1372 1457 1542 1627 1712 116 1203 1288 1373
1458 1543 1628 1713 119 1204 1289 1374 1459 1544 1629 1714 120 1205
1290 1375 1460 1545 1630 1715 121 1206 1291 1376 1461 1546 1631
1716 122 1207 1292 1377 1462 1547 1632 1717 123 1208 1293 1378 1463
1548 1633 1718 124 1209 1294 1379 1464 1549 1634 1719 125 1210 1295
1380 1465 1550 1635 1720 126 1211 1296 1381 1466 1551 1636 1721 127
1212 1297 1382 1467 1552 1637 1722 131 1213 1298 1383 1468 1553
1638 1723 132 1214 1299 1384 1469 1554 1639 1724 136 1215 1300 1385
1470 1555 1640 1725 138 1216 1301 1386 1471 1556 1641 1726 139 1217
1302 1387 1472 1557 1642 1727 140 1218 1303 1388 1473 1558 1643
1728 141 1219 1304 1389 1474 1559 1644 1729 142 1220 1305 1390 1475
1560 1645 1730
TABLE-US-00004 TABLE 3 Examples of sgRNA solutions and their
components (VT, crRNA repeat, loop, anti-repeat and 3' tracrRNA)
for some of the Cas9 orthologs described herein As described
herein, the variable targeting domain of a sgRNA can vary for
example, but not limiting from at least 12 to 30 nucleotides. As
described herein, the length of the loop between the crRNA and the
anti-repeat can vary from at least 3 nucleotides to 100
nucleotides. sgRNA ORF crRNA anti- 3' (CER DNA PRT repeat repeat
tracrRNA domain) ID # Clade SEQID SEQID SEQID SEQID SEQID SEQID 2 1
1 86 171 256 341 426 3 1 2 87 172 257 342 427 4 1 3 88 173 258 343
428 5 1 4 89 174 259 344 429 6 1 5 90 175 260 345 430 8 1 6 91 176
261 346 431 9 1 7 92 177 262 347 432 12 2 8 93 178 263 348 433 13 2
9 94 179 264 349 434 16 3 10 95 180 265 350 435 17 3 11 96 181 266
351 436 18 3 12 97 182 267 352 437 19 3 13 98 183 268 353 438 21 3
14 99 184 269 354 439 27 5 15 100 185 270 355 440 28 5 16 101 186
271 356 441 29 5 17 102 187 272 357 442 30 5 18 103 188 273 358 443
32 5 19 104 189 274 359 444 33 5 20 105 190 275 360 445 35 5 21 106
191 276 361 446 41 5 22 107 192 277 362 447 43 5 23 108 193 278 363
448 44 5 24 109 194 279 364 449 46 6 25 110 195 280 365 450 47 7 26
111 196 281 366 451 48 7 27 112 197 282 367 452 50 7 28 113 198 283
368 453 51 7 29 114 199 284 369 454 52 7 30 115 200 285 370 455 56
7 31 116 201 286 371 456 60 7 32 117 202 287 372 457 61 7 33 118
203 288 373 458 63 8 34 119 204 289 374 459 64 9 35 120 205 290 375
460 65 9 36 121 206 291 376 461 66 9 37 122 207 292 377 462 67 9 38
123 208 293 378 463 68 9 39 124 209 294 379 464 70 9 40 125 210 295
380 465 71 9 41 126 211 296 381 466 77 10 42 127 212 297 382 467 78
10 43 128 213 298 383 468 79 10 44 129 214 299 384 469 80 10 45 130
215 300 385 470 81 10 46 131 216 301 386 471 87 10 47 132 217 302
387 472 94 11 48 133 218 303 388 473 97 11 49 134 219 304 389 474
102 12 50 135 220 305 390 475 83 1 51 136 221 306 391 476 84 1 52
137 222 307 392 477 85 5 53 138 223 308 393 478 88 5 54 139 224 309
394 479 91 3 55 140 225 310 395 480 93 3 56 141 226 311 396 481 139
3 57 142 227 312 397 482 96 5 58 143 228 313 398 483 98 3 59 144
229 314 399 484 101 3 60 145 230 315 400 485 103 2 61 146 231 316
401 486 104 1 62 147 232 317 402 487 105 2 63 148 233 318 403 488
106 10 64 149 234 319 404 489 107 8 65 150 235 320 405 490 108 8 66
151 236 321 406 491 109 10 67 152 237 322 407 492 112 10 68 153 238
323 408 493 116 7 69 154 239 324 409 494 119 9 70 155 240 325 410
495 120 9 71 156 241 326 411 496 121 9 72 157 242 327 412 497 122 7
73 158 243 328 413 498 123 9 74 159 244 329 414 499 124 7 75 160
245 330 415 500 125 7 76 161 246 331 416 501 126 7 77 162 247 332
417 502 127 10 78 163 248 333 418 503 131 9 79 164 249 334 419 504
132 10 80 165 250 335 420 505 136 9 81 166 251 336 421 506 138 10
82 167 252 337 422 507 141 7 83 168 253 338 423 508 142 7 84 169
254 339 424 509 140 9 85 170 255 340 425 510
TABLE-US-00005 TABLE 4 Protospacer adjacent motif (PAM) preferences
for ID2 Clade 1 Displayed as a position frequency matrix (PFM).
Numbers in brackets [x] represent strong PAM preferences, numbers
in slashes /x/ represent weak PAM preferences. PAM Position 1 2 3 4
5 6 7 Nucleotide G 36.14% 21.25% [54.36%] 0.16% 0% [91.52%] 7.65% A
7.44% [78.48%] /45.64%/ /46.12%/ /48.14%/ 3.33% 6.68% T 24.12% 0%
0% /46.68%/ 34.78% 3.08% 28.66% C 32.30% 0.27% 0% 7.04% 17.07%
2.07% /57.01%/ Consensus N A R W H G N (G > A) (A > T > C)
(C > T > R)
TABLE-US-00006 TABLE 5 Protospacer adjacent motif (PAM) preferences
for ID3 Clade 1 Displayed as a position frequency matrix (PFM).
Numbers in brackets [x] represent strong PAM preferences, numbers
in slashes /x/ represent weak PAM preferences. PAM Position 1 2 3 4
5 6 7 Nucleotide G 28.58% 23.58% [55.97%] 1.33% 0.02% 1.83% 16.89%
A 10.31% /57.81%/ /40.56%/ 11.2% 2.37% 0.26% 24.79% T 13.88% 2.88%
0% [77.09%] [81.69%] [85.73%] /42.4%/ C /47.23%/ 15.73% 3.47%
10.38% 15.93% 12.18% 15.92% Consensus N V R T T T N (C > D) (A
> S) (G > A) (T > V)
TABLE-US-00007 TABLE 6 Protospacer adjacent motif (PAM) preferences
for ID4 Clade 1 Displayed as a position frequency matrix (PFM).
Numbers in brackets [x] represent strong PAM preferences, numbers
in slashes /x/ represent weak PAM preferences. PAM Position 1 2 3 4
5 6 7 Nucleotide G 30.63% 33.91% 9.17% 0.12% 0.19% 0.08% 8.43% A
15.52% /53.21%/ 20.43% 5.77% 4.39% 0.43% 6.52% T 22.02% 3.04%
[60.65%] [85.47%] [72.35%] [90.08%] [73.38%] C 31.83% 9.84% 9.75%
8.64% 23.07% 9.4% 11.67% Consensus N V T T T T T (A > G >
C)
TABLE-US-00008 TABLE 7 Protospacer adjacent motif (PAM) preferences
for ID5 Clade 1 Displayed as a position frequency matrix (PFM).
Numbers in brackets [x] represent strong PAM preferences, numbers
in slashes /x/ represent weak PAM preferences. PAM Position 1 2 3 4
5 6 7 Nucleotide G 30.31% 31.67% 7.44% 0.01% 0.01% 0% 4.94% A
17.59% [60.32%] 19.98% 2.08% 1.74% 0.09% 4.29% T 28.33% 1.01%
[63.72%] [93.23%] [90.31%] [97.29%] [83.28%] C 23.77% 7% 8.86%
4.68% 7.94% 2.62% 7.48% Consensus N A T T T T T
TABLE-US-00009 TABLE 8 Protospacer adjacent motif (PAM) preferences
for ID6 Clade 1 Displayed as a position frequency matrix (PFM).
Numbers in brackets [x] represent strong PAM preferences, numbers
in slashes /x/ represent weak PAM preferences. PAM Position 1 2 3 4
5 6 7 Nucleotide G 24.08% 8.85% 9.57% 6.63% 10.8% /52.38%/ 26.21% A
20.44% 33.32% [89.83%] [82.42%] [61.84%] 35.19% 25.1% T 18.01%
26.95% 0.56% 0% 8.44% 5.22% 22.01% C 37.48% 30.88% 0.05% 10.95%
18.91% 7.21% 26.68% Consensus N N A A A N N (H > G) (G > A
> Y)
TABLE-US-00010 TABLE 9 Protospacer adjacent motif (PAM) preferences
for ID8 Clade 1 Displayed as a position frequency matrix (PFM).
Numbers in brackets [x] represent strong PAM preferences, numbers
in slashes /x/ represent weak PAM preferences. PAM Position 1 2 3 4
5 6 7 Nucleotide G 10.17% 6.73% 0.89% 1.22% 2.56% 3.05% 22.15% A
23.01% 27.71% [99.11%] [98.51%] [94.16%] 4.91% 37.94% T /42.68%/
33.86% 0% 0.24% 0.13% [86.66%] 26.05% C 24.14% 31.70% 0% 0.03%
3.15% 5.37% 13.85% Consensus N N A A A T N (T > V)
TABLE-US-00011 TABLE 10 Protospacer adjacent motif (PAM)
preferences for ID9 Clade 1 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 27.23% 12.35% 35.91% 5.65%
0% 29.72% 31.39% A 9.6% [83.2%] /48.04%/ 19.98% 0% 21.22% 9.29% T
24.91% 0.73% 4.92% [70.58%] 0% 12.79% 30.15% C 38.26% 3.72% 11.13%
3.79% [100%] 36.27% 29.17% Consensus N A V T C N N (A > G >
C)
TABLE-US-00012 TABLE 11 Protospacer adjacent motif (PAM)
preferences for ID12 Clade 2 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 21.92% 20.6% 14.54% 21.79%
0% 0% 6.48% A 21.26% /46.96%/ 26.87% 38.08% 0% 0% 8.92% T 23.77%
8.06% 27.05% 34.31% 0% 0% /44.69%/ C 33.04% 24.38% 31.54% 5.82%
[100%] [100%] 39.92% Consensus N N N N C C N (A > S > T) (W
> G > C) (Y > R)
TABLE-US-00013 TABLE 12 Protospacer adjacent motif (PAM)
preferences for ID13 Clade 2 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 25.31% 23.72% 2.93% 3.87%
0% 0% 25.89% A 15.05% 37.23% [97.02%] 24.57% [93.86%] 0% 28.74% T
30.05% 12.64% 0% /45.21%/ 3.67% 12.01% 23.85% C 29.59% 26.41% 0.05%
26.35% 2.48% [87.99%] 21.52% Consensus N N A H (T > M) A C N
TABLE-US-00014 TABLE 13 Protospacer adjacent motif (PAM)
preferences for ID16 Clade 3 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 14.16% [93.5%] 1.83%
[85.98%] 0.16% 33.41% 26.87% A 26.12% 3.56% 13.32% 11.24% [86.61%]
11.29% 23.92% T 24.65% 0.3% [64.11%] 2.68% 2.69% 33.07% 30.21% C
35.07% 2.65% 20.73% 0.1% 10.54% 22.23% 19.01% Consensus N G T G A N
N
TABLE-US-00015 TABLE 14 Protospacer adjacent motif (PAM)
preferences for ID17 Clade 3 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 31.01% 1.81% [48.09%]
20.51% 0.22% 1.27% 24.04% A 10.3% [97.24%] [51.62%] /41.94%/
[96.02%] 1.54% 35.49% T 37.06% 0.42% 0% 29.98% 0.04% [92.67%]
16.87% C 21.62% 0.54% 0.29% 7.58% 3.73% 4.52% 23.59% Consensus N A
R N (A > K > C) A T N
TABLE-US-00016 TABLE 15 Protospacer adjacent motif (PAM)
preferences for ID18 Clade 3 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 22.25% /53.26%/ [53.02%]
22.86% 0% 7.32% 23% A 18.57% 35.41% [46.92%] 28.78% 0.45% 0.12%
34.66% T 26.14% 0% 0 25.08% [98.68%] [92.53%] 27.46% C 33.04%
11.33% 0.06 23.27% 0.87% 0.03% 14.88% Consensus N V (G > A >
C) R N T T N
TABLE-US-00017 TABLE 16 Protospacer adjacent motif (PAM)
preferences for ID19 Clade 3 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 24.51% 6.95% /42.48%/
34.06% 0% 0% 35.8% A 14.06% /50.32%/ /48.28%/ /43.01%/ 6.8% 0%
31.95% T 29.38% 17.63% 1% 16.44% 0% 3.89% 16.29% C 32.06% 25.1%
8.24% 6.5% [93.2%] [96.11%] 15.95% Consensus N N (A > B) R N C C
N (A > G > T > C)
TABLE-US-00018 TABLE 17 Protospacer adjacent motif (PAM)
preferences for ID27 Clade 5 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 27.54% 12.25% 24.63% 11.40%
0% 0% 3.11% A 19.03% /41.8%/ 37.36% 19.92% 0% 0% /55.4%/ T 20.49%
27.98% 24.88% /54.55%/ 0% 0.30% 23.50% C 32.95% 17.97% 13.13%
14.13% [100%] [99.7%] 18% Consensus N N (A > B) N N (T > V) C
C H (A > Y)
TABLE-US-00019 TABLE 18 Protospacer adjacent motif (PAM)
preferences for ID28 Clade 5 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 8 Nucleotide G 20.1% 13.69% 8.1% 10.23%
0.5% 27.01% 0.38% 0.52% A 24.09% 26.66% 25.49% 29.16% 0.1% 32.22%
[95.74%] [99.03%] T 24.69% 26.9% 32.15% 26.02% 0% 39.55% 0.44%
0.39% C 31.12% 32.76% 34.25% 34.59% [99.39%] 1.22% 3.44% 0.07%
Consensus N N N (H > G) N C D A A
TABLE-US-00020 TABLE 19 Protospacer adjacent motif (PAM)
preferences for ID29 Clade 5 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 20.24% 6.48% 32.16%
[91.37%] [93.46%] 24.58% 15.75% A 16.76% 26.36% /40.8%/ 5.83% 6.54%
30.98% /48.29%/ T 24.40% 31.57% 25.32% 2.70% 0% 39.92% 24.16% C
38.60% 35.58% 1.71% 0.09% 0% 4.52% 11.80% Consensus N N (H > G)
D (A > K) G G D N (A > B)
TABLE-US-00021 TABLE 20 Protospacer adjacent motif (PAM)
preferences for ID30 Clade 5 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 8 Nucleotide G 17.53% 11.24% 16.65%
15.25% 0.00% 0.00% 0.00% [97.99%] A 21.12% 26.13% 29.25% 29.16%
30.95% 2.88% [100.00%] 0.84% T 28.26% 30.76% 36.33% 33.24% 0.00%
3.18% 0.00% 0.35% C 33.09% 31.88% 17.77% 22.36% [69.05%] [93.94%]
0.00% 0.82% Consensus N N N N C C A G
TABLE-US-00022 TABLE 21 Protospacer adjacent motif (PAM)
preferences for ID32 Clade 5 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 8 Nucleotide G 21.46% 5.68% 11.12%
13.79% 0.00% 0.93% 1.59% 5.92% A 14.73% 36.25% 29.20% 26.40% 0.00%
2.40% [64.92%] [80.85%] T 25.36% 27.28% 34.96% 28.56% 0.00%
[60.92%] 33.49% 5.07% C 38.45% 30.79% 24.71% 31.25% [100.00%]
35.76% 0.00% 8.16% Consensus N N N N C T A A
TABLE-US-00023 TABLE 22 Protospacer adjacent motif (PAM)
preferences for ID33 Clade 5 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 8 9 10 Nucleotide G 22.09% 7.14% 14.13%
11.46% 0.00% 29.62% [98.54%] 8.83% 14.01% 19.37% A 5.88% 31.83%
30.44% 34.78% 0.00% 39.89% 1.32% [72.61%] /51.42%/ 31.58% T 29.82%
32.90% 29.77% 22.67% 0.00% 0.02% 0.14% 13.59% 16.89% 26.71% C
/42.21%/ 28.12% 25.67% 31.08% [100.00%] 30.47% 0.00% 4.96% 17.68%
22.34% Consensus N N N N C V G A N N
TABLE-US-00024 TABLE 23 Protospacer adjacent motif (PAM)
preferences for ID35 Clade 5 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 22.03% 9.34% 25.15% 17.12%
0% 0% 22.47% A 14.56% 39.21% 35.63% 9.50% 0% 0% 25.37% T 22.33%
24.30% 21.03% [71.71%] 0% 0% 36.60% C /41.08%/ 27.15% 18.19% 1.66%
[100%] [100%] 15.57% Consensus N (C > D) N N T C C N
TABLE-US-00025 TABLE 24 Protospacer adjacent motif (PAM)
preferences for ID41 Clade 5 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 19.6% 16.88% 11.98% 35.91%
0.2% 0.23% 0.8% A 26.01% 25.05% 30.09% 23.09% 1.17% 0.01% [97.57%]
T 25.84% 26.95% 35.06% 9.22% 0% [97.83%] 0.23% C 28.54% 31.12%
22.86% 31.78% [98.63%] 1.93% 1.4% Consensus N N N N C T A
TABLE-US-00026 TABLE 25 Protospacer adjacent motif (PAM)
preferences for ID44 Clade 5 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 8 Nucleotide G 19.80% 7.57% 11.08%
15.61% [98.54%] 0.00% 0.00% 0.16% A 17.69% 38.78% 29.27% 22.89%
1.46% 0.00% [93.02%] [98.91%] T 23.27% 23.76% 27.37% 30.29% 0.00%
[45.31%] 6.98% 0.83% C 39.24% 29.90% 32.27% 31.22% 0.00% [54.69%]
0.00% 0.10% Consensus N N N N C Y A A
TABLE-US-00027 TABLE 26 Protospacer adjacent motif (PAM)
preferences for ID46 Clade 6 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 26.51% 25.76% [97.21%]
[37.66%] [73.44%] 28.66% 8.28% A 16.02% [70.60%] 2.08% [44.79%]
16.96% 24.92% 2.22% T 12.28% 0.00% 0.01% 0.60% 8.66% 31.22%
[47.73%] C /45.19%/ 3.64% 0.70% 16.96% 0.94% 15.20% [41.77%]
Consensus N A G R G N Y
TABLE-US-00028 TABLE 27 Protospacer adjacent motif (PAM)
preferences for ID47 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 21.09% 14.51% [96.97%]
1.68% 0.47% 1.22% 6.41% A 21.36% 31.40% 2.71% /46.42%/ [91.5%]
[98.06%] [80.67%] T 25.16% 29.52% 0.13% /39.18%/ 0.91% 0.56% 7.71%
C 32.39% 24.57% 0.19% 12.72% 7.12% 0.16% 5.21% Consensus N N G H (W
> C) A A A
TABLE-US-00029 TABLE 28 Protospacer adjacent motif (PAM)
preferences for ID48 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 25.12% 13.23% [96.52%]
2.72% 1.12% 2.51% 27.13% A 19.76% 37.09% 1.57% [95.9%] [90.8%]
[95.87%] 31.21% T 27.23% 32.68% 1.52% 0.02% 0.04% 0.52% 22.90% C
27.89% 17% 0.39% 1.36% 8.04% 1.11% 18.75% Consensus N N G A A A
N
TABLE-US-00030 TABLE 29 Protospacer adjacent motif (PAM)
preferences for ID50 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 18.16% 9.71% 2.12% 1.86%
0.48% 0.87% 19.56% A 15.19% 25.57% [97.47%] [97.38%] [98.98%]
[98.68%] [61.85%] T 36.44% 35.35% 0.03% 0% 0% 0.13% 11.97% C 30.21%
29.37% 0.38% 0.76% 0.54% 0.32% 6.62% Consensus N N A A A A A
TABLE-US-00031 TABLE 30 Protospacer adjacent motif (PAM)
preferences for ID51 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 23.52% 1.72% [99.37%] 9.50%
/39.07%/ 5.89% 7.91% A 21.33% 6.50% 0.58% [89.72%] [59.06%]
/45.26%/ 9.79% T 25.10% [65.77%] 0.01% 0% 1.05% 23.46% /39.29%/ C
30.05% 26.02% 0.04% 0.78% 0.82% 25.40% /43.01%/ Consensus N T G A R
N N (G > A) (A > Y > G) (Y > R)
TABLE-US-00032 TABLE 31 Protospacer adjacent motif (PAM)
preferences for ID52 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 18.00% 4.92% [87.99%] 1.61%
18.62% 13.60% 12.07% A 20.27% 34.84% 11.02% 6.15% /53.71%/ [69.84%]
/52.19%/ T 18.20% 20.00% 0.00% /55.44%/ 13.96% 12.71% 21.31% C
/43.53%/ /40.24%/ 0.99% 36.80% 13.72% 3.85% 14.44% Consensus N H G
H N A N (C > D) (C > W) (Y > A) (A > B) (A > T >
S)
TABLE-US-00033 TABLE 32 Protospacer adjacent motif (PAM)
preferences for ID56 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 18.78% 15.33% 4.88% 11.14%
18.77% 0.21% 20.14% A 23.55% 25.44% [91.9%] [82.72%] [76.54%] 8.37%
33.96% T 27.99% 29.19% 0.46% 0.26% 0% 2.49% 24.76% C 29.68% 30.04%
2.77% 5.89% 4.69% [88.93%] 21.15% Consensus N N A A A C N
TABLE-US-00034 TABLE 33 Protospacer adjacent motif (PAM)
preferences for ID60 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 24.17% 15.28% [97.1%] 0.41%
0.09% 0.18% 4.03% A 29.63% 27.87% 2.34% 7.16% [96.54%] [55.4%]
3.18% T 19.14% 31.83% 0.31% [80.64%] 0.09% 2.32% [47.41%] C 27.07%
25.02% 0.25% 11.79% 3.28% /42.09%/ [45.38%] Consensus N N G T A M
(A > C) Y
TABLE-US-00035 TABLE 34 Protospacer adjacent motif (PAM)
preferences for ID61 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 16.33% 2.30% 10.45%
[49.71%] 10.27% 5.21% 15.67% A 22.71% /40.64%/ [82.63%] [48.82%]
31.37% 24.51% 24.47% T 24.79% 27.85% 1.16% 0.10% 20.68% 18.23%
26.59% C 36.17% 29.22% 5.76% 1.37% 37.68% /52.04%/ 33.27% Consensus
N H A R N N N (A > Y) (C > W > G)
TABLE-US-00036 TABLE 35 Protospacer adjacent motif (PAM)
preferences for ID63 Clade 8 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 18.02% [100.00%] [100.00%]
5.80% 13.04% 11.96% 23.28% A 1.58% 0.00% 0.00% /44.96%/ 33.20%
37.33% 28.59% T 16.39% 0.00% 0.00% 26.50% /42.62%/ 23.30% 26.37% C
[64.01%] 0.00% 0.00% 22.73% 11.14% 27.41% 21.77% Consensus B G G N
N N N (C > K) (A > Y > G)
TABLE-US-00037 TABLE 36 Protospacer adjacent motif (PAM)
preferences for ID64 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 12.01% 0% [100%] 0.07%
19.95% 26.33% 24.20% A 8.86% [99.63%] 0% [94.81%] /50.21%/ 29.24%
25.36% T /48.83%/ 0.37% 0% 3.02% 24.39% 34.46% 24.57% C 30.30% 0%
0% 2.11% 5.45% 9.97% 25.87% Consensus N A G A N N N (T > C >
R) (A > K > C)
TABLE-US-00038 TABLE 37 Protospacer adjacent motif (PAM)
preferences for ID65 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 29.95% [98.81%] [100%]
20.33% 11.57% 20.52% 21.23% A 22.13% 1.11% 0% /40.36%/ 28.8% 25.49%
21.63% T 23.24% 0% 0% 32.01% 39.99% 27.35% 28.24% C 24.68% 0.08% 0%
7.31% 19.64% 26.64% 28.91% Consensus N G G N N N N (A > T > G
> C)
TABLE-US-00039 TABLE 38 Protospacer adjacent motif (PAM)
preferences for ID66 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 29.95% [100.00%] [100.00%]
8.51% 3.40% 24.99% 26.27% A 9.78% 0.00% 0.00% /50.57%/ 20.08%
30.56% 20.09% T /42.89%/ 0.00% 0.00% 38.92% [62.19%] 20.92% 25.07%
C 17.38% 0.00% 0.00% 2.01% 14.32% 23.53% 28.56% Consensus N G G D T
N N (A > T > G)
TABLE-US-00040 TABLE 39 Protospacer adjacent motif (PAM)
preferences for ID67 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G /42.62%/ [100.00%]
[100.00%] 4.86% 5.70% 18.40% 25.58% A 9.95% 0.00% 0.00% [60.99%]
25.61% /40.20%/ 26.75% T 30.10% 0.00% 0.00% 30.95% /54.61%/ 19.59%
22.24% C 17.33% 0.00% 0.00% 3.20% 14.08% 21.81% 25.42% Consensus N
G G A N N N (T > A > C > G)
TABLE-US-00041 TABLE 40 Protospacer adjacent motif (PAM)
preferences for ID68 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, number in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 14.54% [100.00%] [100.00%]
4.29% 28.33% 26.60% 19.02% A [74.70%] 0.00% 0.00% [41.25%] 22.57%
18.82% 23.93% T 5.28% 0.00% 0.00% [50.74%] /42.19%/ 26.56% 33.25% C
5.47% 0.00% 0.00% 3.72% 6.91% 28.02% 23.80% Consensus C G G W N N N
(T > R > C)
TABLE-US-00042 TABLE 41 Protospacer adjacent motif (PAM)
preferences for ID70 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 24.91% [99.98%] [100.00%]
5.34% [94.33%] 19.93% 29.84% A 26.13% 0.02% 0.00% [46.68%] 1.55%
23.48% 30.32% T 18.33% 0.00% 0.00% [40.21%] 4.09% 37.54% 28.07% C
30.63% 0.00% 0.00% 7.78% 0.04% 19.05% 11.76% Consensus N G G W G N
N
TABLE-US-00043 TABLE 42 Protospacer adjacent motif (PAM)
preferences for ID71 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 33.94% [96.51%] [100%]
21.22% 10.39% 17.04% 21.07% A 8.38% 3.38% 0% 38.2% 21.19% 25.41%
19.39% T 24.58% 0.02% 0% 30% /45.92%/ 28.63% 27.51% C 33.09% 0.09%
0% 10.57% 22.5% 28.92% 32.03% Consensus N (B > A) G G N N (T
> V) N N
TABLE-US-00044 TABLE 43 Protospacer adjacent motif (PAM)
preferences for ID77 Clade 10 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 20.44% 16.02% [100%] 5.88%
0.49% 0.4% 34.54% A 22.94% 33.83% 0% /50.41%/ [97.92%] 0.01% 16.29%
T 17.07% 16.73% 0% /39.08%/ 1.45% [58.62%] 33.89% C 39.56% 33.41%
0% 4.63% 0.14% /40.98%/ 15.27% Consensus N N G D (A > T > G)
A Y (T > C) N
TABLE-US-00045 TABLE 44 Protospacer adjacent motif (PAM)
preferences for ID78 Clade 10 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 10.68% 2.39% 15.41% 0%
3.57% 9.44% 22.67% A 23.8% 16.85% [84.22%] [99.64%] [93.98%]
[70.52%] 29.29% T /44.87%/ /51.64%/ 0.03% 0% 0.99% 14.92% 29.54% C
20.65% 29.11% 0.34% 0.36% 1.46% 5.12% 18.5% Consensus N (T > V)
H(T > C > A) A A A A N
TABLE-US-00046 TABLE 45 Protospacer adjacent motif (PAM)
preferences for ID79 Clade 10 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 17.96% [49.6%] 0.33% 0.12%
23.37% 14.15% 25.08% A 19.51% [50.11%] 0% [99.66%] [67.06%] 30.69%
24.04% T 39.37% 0.03% [99.45%] 0% 0.49% 39.64% 32.45% C 23.16%
0.26% 0.22% 0.22% 9.08% 15.51% 18.43% Consensus N R T A A N N
TABLE-US-00047 TABLE 46 Protospacer adjacent motif (PAM)
preferences for ID80 Clade 10 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 8.42% 0.03% 0.44% 0.06%
4.62% 15.47% 29.89% A 33.01% 0.61% [99.2%] [98.11%] 17.78% 6.43%
23.57% T 30.66% 8.58% 0% 0.26% 35.06% 38.25% 24.99% C 27.91%
[90.78%] 0.35% 1.57% /42.53%/ 39.84% 21.55% Consensus N (H > G)
C A A H (Y > A) N (Y > R) N
TABLE-US-00048 TABLE 47 Protospacer adjacent motif (PAM)
preferences for ID81 Clade 10 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 29.96% 27.29% 0.34% 1.38%
2.24% 11.3% 22.57% A 14.59% [65.08%] 1.88% [97.76%] [67.48%]
/48.92%/ 35.93% T 27.33% 0% [88.08%] 0% 28.63% 30.55% 23.15% C
28.12% 7.63% 9.7% 0.86% 1.66% 9.23% 18.35% Consensus N A T A A N N
(A > T > S)
TABLE-US-00049 TABLE 48 Protospacer adjacent motif (PAM)
preferences for ID87 Clade 10 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 25.83% 31.80% 38.79% 12.23%
0.08% 0% 20.01% A 25.90% /50.88%/ /55.74%/ [87.6%] 2.01% 3.30%
30.63% T 25.64% 4.20% 3.18% 0% 6.79% 25.75% 26.88% C 22.64% 13.12%
2.29% 0.18% [91.12%] [70.96%] 22.49% Consensus N V (A > G >
C) R (A > G) A C C N
TABLE-US-00050 TABLE 49 Protospacer adjacent motif (PAM)
preferences for ID94 Clade 11 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 13.46% 6.70% 13.39% 28.71%
[99.1%] 25.66% 0% A 3.38% 24.93% [59.5%] /48.9%/ 0.90% [69.36%] 0%
T 22.26% 25.44% 16.06% 4.46% 0% 2.51% 33.08% C [60.9%] /42.94%/
11.05% 17.93% 0% 2.46% [66.92%] Consensus C N A V (A > S) G A C
(C > W > G)
TABLE-US-00051 TABLE 50 Protospacer adjacent motif (PAM)
preferences for ID97 Clade 11 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 19.77% 7.13% /49.18%/
19.04% 0% 0.55% 0.51% A 15.06% 31.96% /50.58%/ 39.67% 0.51%
[82.96%] 0.16% T 29.42% 26.91% 0.04% 23.74% 14.81% 3.03% 38.27% C
35.75% 33.99% 0.20% 17.55% [84.68%] 13.46% [61.06%] Consensus N N R
N C A C
TABLE-US-00052 TABLE 51 Protospacer adjacent motif (PAM)
preferences for ID102 Clade 12 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 16.73% [99.91%] [100.00%]
13.17% /43.25%/ 23.63% 18.92% A /55.36%/ 0.09% 0.00% [36.82%]
23.17% 28.78% 33.64% T 16.66% 0.00% 0.00% [46.75%] 29.00% 23.22%
29.38% C 11.26% 0.00% 0.00% 3.26% 4.58% 24.37% 18.06% Consensus N(A
> B) G G D (W > G) D (G > W) N N
TABLE-US-00053 TABLE 52 Protospacer adjacent motif (PAM)
preferences for ID83 Clade 1 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 21.29% [69.99%] /55.33%/
[96.57%] 3.91% 0.03% 27.00% A 4.07% 30.01% 26.95% 3.43% 11.82%
0.09% /42.82%/ T 36.48% 0.00% 16.30% 0.00% [78.79%] 0.36% 24.52% C
38.16% 0.00% 1.42% 0.00% 5.47% [99.52%] 5.66% Consensus B G D (G
> W) G T C N(A > K > C)
TABLE-US-00054 TABLE 53 Protospacer adjacent motif (PAM)
preferences for ID84 Clade 1 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 26.80% 23.57% 28.47% 9.76%
29.69% 0.00% 22.61% A 17.55% [68.75%] [71.16%] /46.84%/ [70.25%]
0.00% 36.36% T 25.16% 0.05% 0.00% 30.92% 0.00% 0.00% 17.25% C
30.49% 7.63% 0.36% 12.47% 0.06% [100.00%] 23.78% Consensus N A A N
A C N
TABLE-US-00055 TABLE 54 Protospacer adjacent motif (PAM)
preferences for ID85 Clade 5 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 17.42% [53.62%] 4.73% 0.45%
2.01% 18.15% 15.99% A 30.45% [43.97%] 0.06% /49.54%/ [92.82%]
/53.05%/ 36.07% T 30.96% 1.11% [92.25%] 31.86% 4.44% 16.94% 29.85%
C 21.16% 1.30% 2.96% 18.15% 0.73% 11.85% 18.09% Consensus N R T H A
N(A > B) N
TABLE-US-00056 TABLE 55 Protospacer adjacent motif (PAM)
preferences for ID88 Clade 5 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 15.23% 3.65% 6.39% 28.21%
[100.00%] 10.46% 3.68% A 1.33% 35.26% 34.29% 22.17% 0.00% 19.54%
16.19% T 31.94% 23.85% 24.91% 35.52% 0.00% /48.96%/ 37.01% C
/51.50%/ 37.23% 34.40% 14.10% 0.00% 21.04% /43.11%/ Consensus B H N
(H > G) N G N(T > M) H(Y > A)
TABLE-US-00057 TABLE 56 Protospacer adjacent motif (PAM)
preferences for ID91 Clade 3 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 17.45% 9.96% [47.08%]
12.89% 0.08% 3.20% 15.05% A 18.82% [48.84%] [48.45%] /42.75%/
[90.63%] 10.35% 28.37% T 23.00% 1.78% 0.00% 21.97% 1.91% 33.16%
28.30% C /40.72%/ [39.42%] 4.47% 22.39% 7.38% /53.30%/ 28.28%
Consensus N M R N(A > Y > G) A H(C > T > A) N
TABLE-US-00058 TABLE 57 Protospacer adjacent motif (PAM)
preferences for ID93 Clade 3 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 25.77% 12.84% 17.81% 0.00%
0.01% 0.00% 32.43% A 13.74% 33.00% 26.81% 5.22% [96.69%] 0.01%
28.00% T 23.55% 27.15% 31.60% 7.76% 2.97% 0.00% 21.13% C 36.95%
27.01% 23.78% [87.03%] 0.33% [99.99%] 18.44% Consensus N N N C A C
N
TABLE-US-00059 TABLE 58 Protospacer adjacent motif (PAM)
preferences for ID94 Clade 3 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 33.90% 3.24% [40.55%]
10.77% 0.40% 0.01% 35.20% A 24.40% [96.24%] [56.77%] 32.74%
[92.08%] 1.03% 24.78% T 19.50% 0.30% 0.10% /47.78%/ 0.33% 0.13%
17.92% C 22.20% 0.22% 2.59% 8.71% 7.19% [98.83%] 22.10% Consensus N
A R N(T > A > S) A C N
TABLE-US-00060 TABLE 59 Protospacer adjacent motif (PAM)
preferences for ID96 Clade 5 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 24.38% 17.48% 26.35% 30.52%
0.04% 0.00% 0.29% A 22.39% 27.59% 34.39% 23.04% [99.96%] 0.00%
[55.85%] T 30.35% 32.34% 21.12% 32.84% 0.00% [89.28%] [43.70%] C
22.89% 22.59% 18.14% 13.60% 0.00% 10.72% 0.17% Consensus N N N N A
T W
TABLE-US-00061 TABLE 60 Protospacer adjacent motif (PAM)
preferences for ID98 Clade 3 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 8.87% [89.17%] 1.36% 21.49%
[84.56%] 0.17% 32.45% A 21.23% 7.29% 1.95% 24.66% 3.76% 3.87%
/40.20%/ T 28.78% 0.01% 9.16% 15.83% 9.76% 7.63% 12.82% C 41.12%
3.53% [87.53%] 38.01% 1.92% [88.33%] 14.54% Consensus N G C N G C
N
TABLE-US-00062 TABLE 61 Protospacer adjacent motif (PAM)
preferences for ID101 Clade 3 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 20.01% 11.34% 23.82% 0.00%
0.00% 0.00% 20.18% A 20.55% 26.03% 24.66% 12.82% [98.81%] 8.54%
35.07% T 19.48% 23.24% 32.59% 0.45% 1.00% [91.33%] 26.49% C 39.96%
39.39% 18.94% [86.73%] 0.19% 0.13% 18.26% Consensus N N N C A T
N
TABLE-US-00063 TABLE 62 Protospacer adjacent motif (PAM)
preferences for ID103 Clade 2 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 16.15% 18.90% [65.15%]
31.12% [75.29%] 0.00% 14.10% A 32.93% [74.24%] 34.60% 35.43% 24.71%
2.54% 26.89% T 22.28% 0.00% 0.00% 17.78% 0.00% 0.00% 32.85% C
28.64% 6.86% 0.25% 15.67% 0.00% [97.46%] 26.16% Consensus N A G N G
C N
TABLE-US-00064 TABLE 63 Protospacer adjacent motif (PAM)
preferences for ID104 Clade 1 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 26.47% 23.57% [49.94%]
5.78% 0.00% 0.00% 32.11% A 21.51% [64.48%] [47.51%] 19.40% 1.31%
1.41% 28.90% T 20.60% 0.07% 1.15% /43.06%/ 0.00% 1.64% 20.22% C
31.41% 11.88% 1.39% 31.76% [98.69%] [96.95%] 18.77% Consensus N A R
N(T > M > G) C C N
TABLE-US-00065 TABLE 64 Protospacer adjacent motif (PAM)
preferences for ID105 Clade 2 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 26.70% 11.24% 3.62% 0.48%
0.00% 5.98% 25.19% A 25.30% [60.72%] 14.33% 10.21% 2.18% 0.15%
22.86% T 23.50% 22.59% [64.96%] 8.66% 0.00% [81.78%] 16.31% C
24.51% 5.45% 17.09% [80.65%] [97.82%] 12.09% 35.64% Consensus N A T
C C T N
TABLE-US-00066 TABLE 65 Protospacer adjacent motif (PAM)
preferences for ID106 Clade 6 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 19.69% [46.70%] 0.00% 0.00%
24.29% 11.63% 24.06% A 16.38% [53.30%] 0.00% [100.00%] [71.30%]
29.64% 23.15% T 38.91% 0.00% [100.00%] 0.00% 0.00% /46.72%/ 33.44%
C 25.02% 0.00% 0.00% 0.00% 4.41% 12.01% 19.35% Consensus N R T A A
N(T > A > S) N
TABLE-US-00067 TABLE 66 Protospacer adjacent motif (PAM)
preferences for ID107 Clade 8 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 19.44% 0.54% 1.45% 32.87%
0.50% 13.62% 20.21% A 7.49% [98.74%] [98.05%] /58.52%/ 14.45%
33.94% 20.81% T 32.50% 0.18% 0.00% 8.48% 3.05% 31.30% 34.38% C
/40.56%/ 0.54% 0.50% 0.13% [81.99%] 21.14% 24.59% Consensus N(C
> T > G > A A D (A > G > T) C N N A)
TABLE-US-00068 TABLE 67 Protospacer adjacent motif (PAM)
preferences for ID108 Clade 8 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 12.41% 5.35% 0.46% 21.00%
[75.85%] 28.22% 19.32% A 13.28% [87.06%] [99.54%] [79.00%] 20.68%
29.04% 30.07% T 37.38% 1.04% 0.00% 0.00% 2.60% 29.23% 33.21% C
36.93% 6.54% 0.00% 0.00% 0.87% 13.51% 17.40% Consensus N A A A G N
N
TABLE-US-00069 TABLE 68 Protospacer adjacent motif (PAM)
preferences for ID109 Clade 10 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 19.23% 24.61% [99.54%]
0.00% 0.00% 16.90% 32.02% A 24.52% 38.19% 0.46% [91.30%] 2.36%
28.36% 27.48% T 25.09% 23.78% 0.00% 0.00% 6.53% 35.06% 24.12% C
31.16% 13.42% 0.00% 8.70% [91.11%] 19.68% 16.37% Consensus N N G A
C N N
TABLE-US-00070 TABLE 69 Protospacer adjacent motif (PAM)
preferences for ID112 Clade 10 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 16.33% 14.11% 0.00% 0.00%
2.17% 8.84% 25.79% A 19.13% 25.38% 6.25% [100.00%] [97.22%]
/54.51%/ 23.51% T /42.09%/ 38.68% [93.65%] 0.00% 0.61% 34.03%
34.56% C 22.44% 21.83% 0.09% 0.00% 0.00% 2.61% 16.13% Consensus N(T
> V) N T A A D (A > T > G) N
TABLE-US-00071 TABLE 70 Protospacer adjacent motif (PAM)
preferences for ID116 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 28.10% 11.55% [100.00%]
16.07% /41.26%/ 28.27% 25.86% A 21.76% 32.90% 0.00% [83.93%] 29.91%
23.75% 24.55% T 12.65% 37.58% 0.00% 0.00% 27.98% 29.78% 28.58% C
37.49% 17.98% 0.00% 0.00% 0.85% 18.21% 21.01% Consensus N N G A D
(G > W) N N
TABLE-US-00072 TABLE 71 Protospacer adjacent motif (PAM)
preferences for ID119 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 28.50% [99.98%] [99.96%]
8.85% 15.49% 22.77% 23.35% A 32.03% 0.01% 0.02% 34.59% 30.04%
26.82% 22.36% T 17.95% 0.02% 0.00% /42.56%/ 33.76% 25.64% 27.82% C
21.52% 0.00% 0.02% 14.00% 20.72% 24.77% 26.48% Consensus N G G N(W
> S) N N N
TABLE-US-00073 TABLE 72 Protospacer adjacent motif (PAM)
preferences for ID120 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 24.68% [97.47%] [100.00%]
15.48% [80.56%] 34.49% 27.40% A 20.40% 1.49% 0.00% /46.59%/ 2.72%
19.17% 33.53% T /40.19%/ 0.40% 0.00% 36.15% 16.69% 36.64% 29.09% C
14.72% 0.65% 0.00% 1.79% 0.03% 9.70% 9.98% Consensus N(T>V) G G
D(W>G) G N N
TABLE-US-00074 TABLE 73 Protospacer adjacent motif (PAM)
preferences for ID121 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 21.64% [99.88%] [100.00%]
18.79% 8.85% 18.07% 23.75% A 23.84% 0.12% 0.00% /46.56%/ 23.04%
25.24% 18.83% T 29.96% 0.00% 0.00% 30.30% /50.13%/ 30.47% 30.07% C
24.56% 0.00% 0.00% 4.35% 17.98% 26.23% 27.36% Consensus N G G
D(A>T>G) N(T>M>G) N N
TABLE-US-00075 TABLE 74 Protospacer adjacent motif (PAM)
preferences for ID122 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 24.43% 19.65% 0.02% 1.20%
5.14% [98.14%] 29.37% A 20.98% 28.14% [99.98%] [98.35%] [94.63%]
1.63% 25.64% T 35.18% 31.89% 0.00% 0.00% 0.00% 0.23% 24.28% C
19.40% 20.32% 0.00% 0.44% 0.23% 0.00% 20.70% Consensus N N A A A G
N
TABLE-US-00076 TABLE 75 Protospacer adjacent motif (PAM)
preferences for ID123 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 39.61% [99.95%] [100.00%]
17.78% 6.15% 16.45% 24.04% A 19.53% 0.05% 0.00% /41.69%/ 20.33%
29.55% 23.86% T 23.46% 0.00% 0.00% 36.41% /56.54%/ 26.96% 28.20% C
17.40% 0.00% 0.00% 4.12% 16.99% 27.04% 23.91% Consensus N(G>H) G
G D N(T>M>G) N N
TABLE-US-00077 TABLE 76 Protospacer adjacent motif (PAM)
preferences for ID124 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 16.86% 16.49% 20.40%
[88.50%] 2.70% 1.11% 13.86% A 32.84% 30.59% [78.18%] 2.07% [94.36%]
[95.77%] [67.88%] T 22.62% 26.74% 0.08% 8.07% 0.54% 2.89% 10.86% C
27.68% 26.18% 1.34% 1.36% 2.40% 0.23% 7.40% Consensus N N A G A A
A
TABLE-US-00078 TABLE 77 Protospacer adjacent motif (PAM)
preferences for ID125 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 16.14% 6.88% 0.92% 0.35%
0.31% 0.81% 21.38% A 23.49% 21.94% [98.19%] [99.39%] [99.27%]
[97.69%] [64.31%] T 32.76% /43.27%/ 0.17% 0.09% 0.09% 0.89% 9.87% C
27.61% 27.90% 0.72% 0.17% 0.33% 0.61% 4.43% Consensus N
N(T>M>G) A A A A A
TABLE-US-00079 TABLE 78 Protospacer adjacent motif (PAM)
preferences for ID126 Clade 7 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 19.49% 7.57% [95.84%] 2.21%
27.10% 8.72% 10.45% A 20.71% 23.44% 4.12% 8.27% /56.45%/ [83.93%]
[68.27%] T 16.90% 25.97% 0.00% [57.84%] 12.18% 6.62% 14.06% C
/42.90%/ /43.02%/ 0.04% 31.68% 4.27% 0.73% 7.22% Consensus
N(C>D) N(C>W>G) G W(T>C) D(A>G>T) A A
TABLE-US-00080 TABLE 79 Protospacer adjacent motif (PAM)
preferences for ID127 Clade 10 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 25.25% 26.55% 8.71% 3.98%
1.52% 1.10% 22.96% A 12.91% [69.11%] [82.08%] [95.92%] [77.80%]
0.09% 27.92% T 34.16% 0.04% 2.68% 0.00% 1.28% [50.31%] 24.96% C
27.68% 4.30% 6.54% 0.10% 19.39% [48.50%] 24.16% Consensus N A A A A
Y N
TABLE-US-00081 TABLE 80 Protospacer adjacent motif (PAM)
preferences for ID131 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 32.38% [45.99%] [94.38%]
10.89% 11.50% 22.57% 17.71% A 28.22% [52.41%] 4.24% 33.95% 26.70%
26.58% 27.18% T 11.53% 0.96% 0.52% 34.44% /45.50%/ 24.63% 26.27% C
27.87% 0.64% 0.86% 20.73% 16.30% 26.22% 28.85% Consensus N R G N N
N N
TABLE-US-00082 TABLE 81 Protospacer adjacent motif (PAM)
preferences for ID132 Clade 10 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 17.77% 6.33% 0.80% [65.36%]
5.70% 11.21% 14.11% A 14.33% [71.50%] 6.90% 26.81% 33.68% 4.99%
37.97% T 32.59% 3.73% [63.88%] 0.00% 34.29% [68.57%] 29.70% C
35.31% 18.44% 28.42% 7.83% 26.34% 15.22% 18.21% Consensus N A T G N
(H>G) T N
TABLE-US-00083 TABLE 82 Protospacer adjacent motif (PAM)
preferences for ID136 Clade 9 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 17.84% 25.26% 38.64% 3.86%
0.06% 0.44% 15.50% A 31.37% 37.18% 39.78% [95.11%] 0.49% 0.16%
12.36% T 34.07% 28.69% 19.79% 0.00% [98.97%] [98.40%] [65.48%] C
16.73% 8.86% 1.79% 1.02% 0.48% 1.01% 6.66% Consensus N N D A T T
T
TABLE-US-00084 TABLE 83 Protospacer adjacent motif (PAM)
preferences for ID138 Clade 10 Displayed as a position frequency
matrix (PFM). Numbers in brackets [x] represent strong PAM
preferences, numbers in slashes /x/ represent weak PAM preferences.
PAM Position 1 2 3 4 5 6 7 Nucleotide G 22.46% 20.19% 0.68% 8.49%
[43.74%] 0.00% 9.78% A 18.76% [78.12%] 10.48% [91.44%] [53.85%]
18.32% 19.57% T 34.94% 0.00% [83.47%] 0.00% 1.09% 11.13% 30.01% C
23.84% 1.69% 5.38% 0.07% 1.31% [70.54%] /40.64%/ Consensus N A T A
R C N(C>T>A>G)
TABLE-US-00085 TABLE 84 Summary of cutting data for some of the
Cas9 orthologs Cas9 blunt sticky Ortholog NT PRT end end in plant
HEK ID# SEQID SEQ ID cut cut vitro cell cell 2 1 86 X X 3 2 87 X X
4 3 88 X X 5 4 89 X X 6 5 90 X X X 8 6 91 X X X 9 7 92 X X 12 8 93
X X 13 9 94 X X 16 10 95 X X 17 11 96 X X X 18 12 97 X X 19 13 98 X
X 21 14 99 27 15 100 X X X 28 16 101 X X 29 17 102 X X 30 18 103 X
X 32 19 104 X X 33 20 105 X X X X 35 21 106 X X 41 22 107 X X 43 23
108 44 24 109 X X 46 25 110 X X X 47 26 111 X X 48 27 112 X X X X
50 28 113 X X X 51 29 114 X X 52 30 115 X X 56 31 116 X X X 60 32
117 X X 61 33 118 X X X 63 34 119 X X X 64 35 120 X X X X 65 36 121
X X 66 37 122 X X 67 38 123 X X 68 39 124 X X X 70 40 125 X X X 71
41 126 X X 77 42 127 X X 78 43 128 X X X 79 44 129 X X X 80 45 130
X X X 81 46 131 X X 83 51 136 X X 84 52 137 X X 85 53 138 X X 87 47
132 X X 88 54 139 X X 91 55 140 X X 93 56 141 X X 94 48 133 X X 96
58 143 X X 97 49 134 X X 98 59 144 X X 101 60 145 X X 102 50 135 X
X 103 61 146 X X 104 62 147 X X 105 63 148 X X 106 64 149 X X 107
65 150 X X 108 66 151 X X 109 67 152 X X 112 68 153 X X 116 69 154
X X 119 70 155 X X 120 71 156 X X 121 72 157 X X 122 73 158 X X 123
74 159 X X 124 75 160 X X 125 76 161 X X 126 77 162 X X 127 78 163
X X 131 79 164 X X 132 80 165 X X 136 81 166 X X 138 82 167 X X 139
57 142 X X
TABLE-US-00086 TABLE 85 Summary of eukaryotic cell data for some of
the Cas9 orthologs % NHEJ mutant alleles for transient and stably
transformed plants (averaged across one to three loci: MS26, MS45,
and Lig), HEK293 cells transformed with DNA expression cassettes
(averaged across two loci: WTAP and RunX1), and HEK293 cells
transformed with RNP (ribonucleoprotein comprising Cas9 protein and
sgRNA polyribonucleotide) for one locus (WTAP). S. pyogenes Cas9
was tested in parallel as a comparator. % NHEJ Mutant Alleles Cas9
HEK293 Ortholog Zea mays Expression ID# Transient Stables Cassette
RNP 3 0.00% 0.06% 0.00% 4 0.00% 0.00% 0.00% 5 0.00% 0.00% 0.00% 6
0.00% 0.29% 3.02% 8 0.00% 3.32% 0.00% 12 0.00% 0.00% 0.00% 13 0.00%
0.00% 0.00% 17 0.00% 1.52% 0.00% 18 0.00% 0.00% 0.00% 19 0.00%
0.07% 0.00% 27 0.00% 1.34% 0.62% 30 0.00% 0.00% 0.00% 33 1.20%
43.75% 5.32% 28.40% 35 0.00% 0.30% 0.00% 41 0.00% 0.00% 0.00% 46 *
30.36% 9.22% 48 0.30% 4.05% 0.00% 50 0.22% 0.88% 0.00% 56 0.00%
17.13% 0.00% 61 0.18% 0.20% 0.00% 63 0.23% 0.00% 0.00% 64 0.43%
50.39% 4.00% 6.45% 67 0.00% 0.00% 0.33% 68 0.00% 2.67% 0.85% 70
0.24% 0.00% 0.00% 77 0.00% 0.26% 0.00% 78 0.00% 1.27% 0.00% 79
0.00% 3.34% 0.92% 80 0.07% 0.00% 0.00% 81 0.00% 0.00% 0.00% 87
0.00% 0.00% 0.00% 94 0.00% 0.00% 0.00% SpCas9 0.58% 41.13% 21.57%
87.45% * indicates that heat shock is likely required for optimal
activity in plants.
TABLE-US-00087 TABLE 86A Cas9 Ortholog Amino Acid Position Scoring
SpCas9 Posi- Amino Acid tion .ANG. R N D C Q E G H I 13 0.00 0.00
0.00 0.00 0.00 0.00 0.00 -0.03 0.00 0.51 21 0.00 0.00 -0.03 0.00
0.00 0.00 0.00 0.00 0.00 0.47 71 0.00 -0.16 -0.17 0.00 0.00 -0.03
0.00 0.00 0.00 0.00 149 0.15 0.00 0.00 0.00 0.00 0.00 -0.03 0.00
0.00 -0.24 150 -0.07 0.00 0.00 -0.09 0.00 0.00 -0.14 0.00 -0.03
0.00 444 -0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.24 445
-0.03 -0.03 0.11 0.00 0.00 0.00 0.11 0.00 0.00 -0.03 503 0.00 0.00
0.00 -0.03 0.00 -0.03 -0.08 0.00 0.00 -0.07 587 0.00 0.00 0.00 0.00
-0.03 0.00 0.00 0.00 -0.03 0.07 620 0.54 -0.03 0.00 -0.10 0.00
-0.07 0.00 -0.07 0.00 -0.24 623 -0.07 0.00 0.03 0.00 0.00 0.00 0.00
0.00 0.00 -0.10 624 0.00 -0.03 0.00 -0.03 0.00 0.14 0.00 0.00 0.03
-0.07 632 0.11 0.00 0.00 0.00 0.00 0.00 0.00 -0.07 0.00 0.55 692
0.00 -0.17 -0.09 -0.07 0.00 0.50 0.00 0.00 0.00 0.00 702 -0.10 0.00
0.00 -0.03 0.00 0.00 0.00 -0.07 0.00 0.00 781 0.00 -0.07 0.00 0.00
0.00 -0.03 -0.03 -0.03 -0.03 0.44 810 -0.03 -0.24 -0.03 -0.03 0.00
0.00 0.00 0.00 0.00 0.00 908 0.00 0.00 0.11 0.00 0.00 -0.08 -0.03
0.00 0.00 -0.17 931 -0.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.04 933 -0.03 -0.07 0.40 -0.03 0.00 0.86 -0.17 -0.03 0.00 -0.07
954 0.00 -0.24 -0.10 0.00 0.00 -0.07 -0.14 0.14 -0.03 0.00 955 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.10 -0.48 1000 -0.08 0.04 0.00
0.00 -0.03 -0.08 0.07 0.05 0.00 -0.03 1100 -0.17 0.00 0.00 0.00
0.00 -0.10 0.00 0.00 0.00 0.00 1232 0.00 0.00 0.11 -0.09 0.00 0.00
-0.03 -0.03 -0.14 0.00 1236 -0.03 0.00 -0.03 0.00 -0.03 0.00 0.00
0.00 0.00 0.51 Cas9 Ortholog Amino Acid Position Scoring SpCas9
Posi- Amino Acid tion L K M F P S T W Y V 13 -0.03 0.00 0.00 0.00
0.00 -0.14 -0.23 0.00 0.00 -0.07 21 0.18 0.00 0.00 0.00 0.00 -0.03
-0.14 0.00 -0.03 -0.41 71 0.44 0.00 0.00 0.10 0.00 0.00 0.00 0.00
0.00 -0.03 149 0.40 0.00 0.00 -0.00 0.00 0.00 0.00 0.00 0.00 -0.07
150 0.00 0.00 0.00 0.00 0.00 0.51 -0.21 0.00 0.00 0.00 444 0.44
-0.03 -0.03 0.04 0.00 0.00 0.00 0.00 0.00 -0.07 445 0.00 -0.07
-0.07 -0.34 0.00 -0.03 0.51 0.00 -0.07 0.00 503 -0.07 0.11 0.00
-0.03 0.40 -0.03 0.00 0.00 0.00 0.00 587 -0.17 0.00 -0.03 0.41 0.00
-0.03 0.00 -0.07 -0.07 -0.03 620 0.00 0.00 0.00 0.00 0.00 -0.07
0.00 0.00 0.00 0.08 623 0.69 0.00 -0.07 -0.07 0.00 -0.14 0.00 0.00
0.00 0.00 624 -0.14 -0.03 0.00 0.00 0.00 -0.17 0.44 0.00 -0.03
-0.07 632 -0.24 -0.03 0.00 -0.14 0.00 0.00 -0.03 0.00 0.00 -0.03
692 -0.10 -0.07 0.00 0.00 -0.03 0.00 0.00 0.00 -0.07 0.00 702 0.62
0.00 -0.03 -0.03 0.00 -0.03 0.00 0.00 -0.10 0.00 781 -0.10 -0.03
0.07 0.00 0.00 0.00 0.00 -0.03 -0.10 -0.07 810 0.00 0.41 -0.03 0.00
0.00 0.00 0.00 0.00 0.00 -0.03 908 0.48 0.00 -0.07 -0.14 0.00 0.00
-0.03 0.00 0.00 0.00 931 -0.06 0.00 0.00 0.00 0.00 0.00 -0.07 0.00
0.00 0.40 933 -0.03 -0.10 0.00 0.00 0.00 -0.03 -0.07 0.00 0.00
-0.07 954 0.00 0.47 0.00 0.00 0.00 -0.03 0.11 0.00 0.00 0.00 955
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.48 1000 -0.07 0.44
0.00 -0.03 0.00 -0.03 0.00 0.00 0.00 -0.41 1100 -0.03 -0.07 0.00
0.11 -0.21 -0.03 -0.10 -0.00 0.00 0.62 1232 0.00 -0.06 0.00 -0.10
-0.03 -0.07 0.00 -0.03 0.44 0.00 1256 0.11 0.00 0.00 -0.21 0.00
0.00 0.00 0.00 0.00 -0.31 Scoring of specific amino acid positions
of individual Cas9 orthologs (referenced versus the position in the
SpyCas9 sequence SEQID NO:1125). The overall fraction of each amino
acid at each position in the active and non-active datasets was
defined by summing and dividing by the total number in each
dataset, respectively. Then, the non-active dataset was subtracted
from the active with positive values indicating conserved amino
acids in the active Cas9s that were under-represented in the
non-active collection. Final scores >= 0.25 are indicated with a
.cndot. (circular) symbol, and were used to create "fingerprints"
to identify active Cas9 orthologs.
TABLE-US-00088 TABLE 86B Active Cas9 ortholog fingerprints
Signature amino acid residues for orthologs possessing a higher
probability of activity in eukaryotic cells. Position numbers are
with respect to the analogous amino acid position number sof S.
pyogenes Cas9 (SEQID NO: 1125). Orthologs with positive cutting
activity in eukaryotic cells comprise one or more of these
structural features. Relative Amino Position Acid 13 I 21 I 71 L
149 L 150 S 444 L 445 T 503 P 587 F 620 A 623 L 624 T 632 I 692 Q
702 L 781 I 810 K 908 L 931 V 933 N or Q 954 K 955 V 1000 K 1100 V
1232 Y 1236 I
TABLE-US-00089 TABLE 86C Cas9 ortholog amino acid position total
score (sums) Cas9 orthologs scoring, with total scores per ortholog
PRT SEQID, based on sums of scores of positions identified in Table
86A. PRT PRT PRT PRT PRT PRT PRT PRT PRT PRT PRT PRT PRT PRT PRT
SEQ SEQ Total SEQ Total SEQ Total SEQ Total SEQ Total SEQ Total SEQ
Total SEQ Total SEQ Total SEQ Total SEQ Total SEQ Total SEQ Total
SEQ Total ID Score ID Score ID Score ID Score ID Score ID Score ID
Score ID Score ID Score ID Score ID Score ID Score ID Score ID
Score ID Score 527 11.64 1005 8.46 1126 6.97 708 5.85 1078 5.05 998
4.17 772 3.72 714 3.29 574 3.09 671 2.76 738 2.58 763 2.23 973 1.86
798 1.64 585 0.99 116 11.43 885 8.39 841 6.90 855 5.84 564 5.02 152
4.16 892 3.71 859 3.29 694 3.09 771 2.75 549 2.51 894 2.23 149 1.85
140 1.57 597 0.99 860 11.19 110 8.37 546 6.89 138 5.74 1133 5.02
656 4.16 723 3.70 1081 3.29 662 3.07 889 2.74 921 2.48 1095 2.23
778 1.84 675 1.54 670 0.99 868 11.09 125 8.36 1059 6.86 512 5.70
103 5.01 888 4.13 789 3.69 712 3.28 535 3.07 920 2.74 917 2.44 886
2.22 1109 1.84 739 1.53 700 0.99 115 10.69 157 8.32 1028 6.83 932
5.67 1016 5.01 1036 4.13 515 3.69 736 3.28 561 3.07 1098 2.74 135
2.42 146 2.20 547 1.84 704 1.51 746 0.99 160 10.66 691 8.32 981
6.80 143 5.66 1047 4.98 839 4.10 853 3.69 1009 3.28 621 3.07 131
2.74 154 2.42 643 2.20 761 1.84 1104 1.49 783 0.99 162 10.65 697
8.32 1042 6.76 980 5.64 1114 4.96 1082 4.10 926 3.69 1097 3.27 629
3.06 1046 2.74 524 2.42 838 2.20 857 1.84 595 1.47 615 0.96 666
10.25 801 8.32 939 6.76 648 5.64 970 4.89 543 4.09 1130 3.69 525
3.26 900 3.06 545 2.71 677 2.42 130 2.20 1110 1.84 92 1.46 642 0.96
821 10.25 1121 8.32 678 6.75 856 5.62 684 4.87 513 4.08 551 3.68
717 3.25 1017 3.05 550 2.71 136 2.41 974 2.19 94 1.83 529 1.46 733
0.96 633 10.21 1122 8.32 754 6.71 680 5.61 108 4.85 706 4.07 907
3.68 837 3.25 1073 3.05 805 2.71 914 2.41 992 2.19 584 1.83 959
1.46 956 0.96 514 10.18 1123 8.28 913 6.68 661 5.56 1015 4.82 1041
4.07 530 3.66 730 3.25 994 3.03 984 2.71 968 2.41 1012 2.18 1052
1.83 768 1.45 652 0.95 105 10.15 953 8.25 999 6.67 664 5.53 102
4.79 1077 4.07 1010 3.66 803 3.25 563 3.03 166 2.71 988 2.41 1096
2.17 672 1.83 91 1.43 766 0.95 922 10.07 793 8.11 751 6.59 735 5.51
1068 4.78 1106 4.07 852 3.64 899 3.24 1003 3.02 915 2.70 743 2.37
573 2.16 523 1.82 1018 1.42 925 0.95 169 9.85 877 7.97 159 6.53 727
5.48 123 4.71 1061 4.06 1131 3.64 607 3.23 905 3.00 1040 2.70 825
2.37 625 2.16 682 1.82 86 1.40 0184 0.95 526 9.85 1076 7.89 570
6.53 679 5.47 750 4.69 532 4.06 711 3.63 645 3.22 635 3.00 875 2.69
950 2.37 647 2.16 844 1.81 88 1.40 1111 0.95 168 8.73 1064 7.18 795
6.02 164 5.15 788 4.24 1115 3.81 640 3.36 1024 3.12 165 2.81 687
2.63 137 2.24 1022 1.90 740 1.80 516 1.40 836 0.94 660 8.73 916
7.18 972 5.95 883 5.15 901 4.24 890 3.80 781 3.36 705 3.12 1011
2.81 908 2.63 831 2.24 887 1.89 823 1.80 609 1.40 1029 0.92 1102
8.71 688 7.16 106 5.93 1044 5.13 958 4.24 854 3.80 1080 3.34 996
3.11 909 2.80 930 2.63 605 2.24 562 1.87 610 1.80 689 1.40 1075
0.92 756 8.71 725 7.14 587 5.92 904 5.13 1135 4.24 520 3.79 599
3.33 879 3.11 829 2.79 1027 2.63 608 2.24 576 1.87 620 1.80 1132
1.40 933 0.91 978 8.71 934 7.00 731 5.91 782 5.12 674 4.22 542 3.79
871 3.33 521 3.10 692 2.78 744 2.61 728 2.24 581 1.87 1088 1.80 537
1.39 809 0.88 589 8.60 628 6.99 100 5.90 851 5.09 540 4.21 710 3.79
1058 3.33 758 3.10 1060 2.78 128 2.60 1021 2.24 654 1.87 1101 1.80
560 1.39 919 0.88 726 9.30 1039 7.84 849 6.34 590 5.40 884 4.57 119
3.94 923 3.56 1066 3.19 685 2.88 1116 2.67 616 2.31 957 2.14 611
1.79 567 1.39 1054 0.88 1038 9.30 1048 7.80 759 6.33 592 5.40 552
4.54 614 3.91 720 3.55 141 3.19 1006 2.88 555 2.66 1053 2.31 827
2.13 847 1.79 818 1.39 1079 0.88 942 9.26 741 7.77 716 6.33 1117
5.40 987 4.53 572 3.88 873 3.55 707 3.18 618 2.88 639 2.66 816 2.31
870 2.13 843 1.77 830 1.39 87 0.48 113 9.26 121 7.75 941 6.32 539
5.39 947 4.50 815 3.87 134 3.54 878 3.18 699 2.86 724 2.66 1070
2.31 686 2.09 676 1.76 1108 1.38 554 0.48 161 9.26 624 7.71 848
6.32 729 5.38 603 4.50 850 3.87 902 3.53 127 3.17 1112 2.86 931
2.66 557 2.30 702 2.09 1083 1.76 594 1.36 627 0.48 681 9.26 112
7.58 117 6.31 797 5.37 693 4.42 602 3.85 1085 3.49 153 3.17 822
2.85 977 2.66 979 2.30 553 2.05 863 1.76 622 1.36 775 0.48 1049
9.16 101 7.50 553 6.29 780 5.37 765 4.42 745 3.85 876 3.48 600 3.17
912 2.84 1033 2.66 601 2.27 99 2.01 142 1.75 753 1.36 817 0.48 938
9.09 114 7.50 835 6.28 654 5.34 668 4.41 757 3.85 810 3.47 644 3.17
144 2.83 785 2.66 632 2.27 565 1.98 906 1.75 1113 1.36 824 0.48 898
8.98 966 7.48 1045 6.27 104 5.32 794 4.39 634 3.85 989 3.46 657
3.17 1055 2.83 872 2.66 846 2.27 828 1.98 1069 1.75 1129 1.36 1063
0.48 158 8.90 586 7.44 808 6.27 927 5.30 882 4.35 579 3.84 955 3.45
945 3.17 150 2.82 1090 2.66 538 2.27 1065 1.98 964 1.74 577 1.33
1100 0.48 777 8.90 124 7.44 118 6.23 139 5.30 1099 4.33 804 3.84
961 3.45 874 3.15 528 2.82 869 2.65 596 2.27 534 1.97 760 1.73 1119
1.33 1103 0.48 891 8.86 155 7.44 598 6.17 918 5.30 820 4.32 895
3.84 107 3.44 569 3.15 591 2.82 963 2.65 578 2.26 1020 1.96 940
1.73 95 1.32 928 0.40 120 8.83 690 7.44 604 6.17 1050 5.23 881 4.31
109 3.83 145 3.44 132 3.14 703 2.82 1091 2.65 951 2.26 971 1.94 975
1.73 97 1.32 960 0.40 946 8.83 636 7.40 1134 6.10 619 5.20 653 4.30
695 3.83 976 3.44 606 3.14 779 2.82 929 2.64 986 2.26 133 1.91 1000
1.73 752 1.32 937 8.79 623 7.36 790 6.09 1074 5.17 1056 4.28 1008
3.83 612 3.43 767 3.14 1051 2.82 541 2.64 96 2.25 568 1.91 1057
1.73 786 1.32 944 8.79 1072 7.31 519 6.08 812 5.16 924 4.27 696
3.81 701 3.39 784 3.14 649 2.81 617 2.64 522 2.25 834 1.91 583 1.72
1071 1.32 1031 8.79 713 7.29 140 6.06 764 5.16 811 4.26 1001 3.81
167 3.37 148 3.13 880 2.81 787 2.64 965 2.25 588 1.90 721 1.72 650
1.31 865 8.75 722 7.22 774 6.06 1043 5.16 903 4.26 637 3.81 582
3.37 791 3.12 954 2.81 1118 2.64 995 2.25 991 1.90 673 1.69 734
1.31 156 8.73 1064 7.18 795 6.02 164 5.15 788 4.24 1115 3.81 640
3.36 1024 3.12 165 2.81 687 2.63 137 2.24 1022 1.90 1094 1.68 9.83
1.31 762 8.73 916 7.18 972 5.95 883 5.15 901 4.24 890 3.80 781 3.36
705 3.12 1011 2.81 908 2.63 831 2.24 887 1.89 698 1.66 147 1.29 833
8.71 688 7.16 106 5.93 1044 5.13 958 4.24 854 3.80 1080 3.34 996
3.11 909 2.80 930 2.63 605 2.24 562 1.87 536 1.66 517 1.29 747 8.71
725 7.14 587 5.92 904 5.13 1135 4.24 520 3.79 599 3.33 879 3.11 829
2.79 1027 2.63 608 2.24 576 1.87 943 1.66 814 1.29 842 8.71 934
7.00 731 5.91 782 5.12 674 4.22 542 3.79 871 3.33 521 3.10 692 2.78
744 2.61 728 2.24 581 1.87 961 1.66 867 1.28 732 8.60 628 6.99 100
5.90 851 5.09 540 4.21 710 3.79 1058 3.33 758 3.10 1060 2.78 128
2.60 1021 2.24 654 1.87 1062 1.66 864 1.10 935 8.57 1120 6.99 1023
5.90 683 5.09 1086 4.21 749 3.76 896 3.32 1019 3.10 858 2.78 800
2.60 566 2.23 1013 1.87 819 1.65 982 1.06 967 8.54 861 6.97 592
5.90 1026 5.05 1025 4.19 1067 3.74 98 3.32 575 3.10 163 2.77 832
2.60 638 2.23 1124 1.87 556 1.64 89 0.99 893 8.47 862 6.97 122 5.88
1037 5.05 658 4.17 737 3.72 151 3.30 813 3.10 663 2.77 952 2.58 667
2.23 776 1.86 742 1.64 548 0.99
Sequence CWU 0 SQTB SEQUENCE LISTING The patent application
contains a lengthy "Sequence Listing" section. A copy of the
"Sequence Listing" is available in electronic form from the USPTO
web site
(https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20220010293A1).
An electronic copy of the "Sequence Listing" will also be available
from the USPTO upon request and payment of the fee set forth in 37
CFR 1.19(b)(3).
0 SQTB SEQUENCE LISTING The patent application contains a lengthy
"Sequence Listing" section. A copy of the "Sequence Listing" is
available in electronic form from the USPTO web site
(https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20220010293A1).
An electronic copy of the "Sequence Listing" will also be available
from the USPTO upon request and payment of the fee set forth in 37
CFR 1.19(b)(3).
* * * * *
References